U.S. patent application number 13/131203 was filed with the patent office on 2011-09-15 for pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto.
This patent application is currently assigned to ARENA PHARMACEUTICALS, INC.. Invention is credited to Jason B. Ibarra, Young-Jun Shin, Thuy-Anh Tran, Brett Ullman, Xi Zeng, Ning Zou.
Application Number | 20110224262 13/131203 |
Document ID | / |
Family ID | 41718771 |
Filed Date | 2011-09-15 |
United States Patent
Application |
20110224262 |
Kind Code |
A1 |
Tran; Thuy-Anh ; et
al. |
September 15, 2011 |
PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF
THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF
DISORDERS RELATED THERETO
Abstract
Pyrazole derivatives of Formula Ia and pharmaceutical
compositions thereof that modulate the activity of the PGI2
receptor. Compounds of the present invention and pharmaceutical
compositions thereof are directed to methods useful in the
treatment of: pulmonary arterial hypertension (PAH) and related
disorders; platelet aggregation; coronary artery disease;
myocardial infarction; transient ischemic attack; angina; stroke;
ischemia-reperfusion injury; restenosis; atrial fibrillation; blood
clot formation in an angioplasty or coronary bypass surgery
individual or in an individual suffering from atrial fibrillation;
atherosclerosis; atherothrombosis; asthma or a symptom thereof; a
diabetic-related disorder such as diabetic peripheral neuropathy,
diabetic nephropathy or diabetic retinopathy; glaucoma or other
disease of the eye with abnormal intraocular pressure;
hypertension; inflammation; psoriasis; psoriatic arthritis;
rheumatoid arthritis; Crohn's disease; transplant rejection;
multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative
colitis; ischemia-reperfusion injury; restenosis; atherosclerosis;
acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic
obstructive pulmonary disorder (COPD). ##STR00001##
Inventors: |
Tran; Thuy-Anh; (San Diego,
CA) ; Ibarra; Jason B.; (Las Vegas, NV) ;
Shin; Young-Jun; (San Diego, CA) ; Ullman; Brett;
(San Diego, CA) ; Zou; Ning; (San Diego, CA)
; Zeng; Xi; (San Diego, CA) |
Assignee: |
ARENA PHARMACEUTICALS, INC.
San Diego
CA
|
Family ID: |
41718771 |
Appl. No.: |
13/131203 |
Filed: |
November 24, 2009 |
PCT Filed: |
November 24, 2009 |
PCT NO: |
PCT/US2009/006251 |
371 Date: |
May 25, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61200393 |
Nov 26, 2008 |
|
|
|
Current U.S.
Class: |
514/341 ;
514/406; 546/275.4; 548/359.1; 548/365.7; 548/376.1 |
Current CPC
Class: |
C07D 231/12 20130101;
C07D 401/04 20130101; C07D 409/04 20130101; C07D 231/54 20130101;
C07D 231/18 20130101; A61P 9/00 20180101; C07D 231/56 20130101;
A61P 11/00 20180101; C07D 405/04 20130101 |
Class at
Publication: |
514/341 ;
548/359.1; 548/376.1; 514/406; 546/275.4; 548/365.7 |
International
Class: |
A61K 31/4439 20060101
A61K031/4439; C07D 231/54 20060101 C07D231/54; A61K 31/416 20060101
A61K031/416; C07D 231/10 20060101 C07D231/10; A61K 31/415 20060101
A61K031/415; C07D 401/04 20060101 C07D401/04; C07D 405/04 20060101
C07D405/04; C07D 409/04 20060101 C07D409/04; A61K 31/4155 20060101
A61K031/4155; A61P 9/00 20060101 A61P009/00; A61P 7/02 20060101
A61P007/02; A61P 11/06 20060101 A61P011/06; A61P 3/10 20060101
A61P003/10; A61P 27/06 20060101 A61P027/06; A61P 27/02 20060101
A61P027/02; A61P 29/00 20060101 A61P029/00; A61P 17/06 20060101
A61P017/06; A61P 9/12 20060101 A61P009/12; A61P 19/02 20060101
A61P019/02; A61P 41/00 20060101 A61P041/00; A61P 21/00 20060101
A61P021/00; A61P 1/00 20060101 A61P001/00 |
Claims
1. A compound selected from compounds of Formula Ia and
pharmaceutically acceptable salts, solvates and hydrates thereof:
##STR00324## wherein: R.sup.1 is selected from: H and
C.sub.1-C.sub.6 alkyl; and R.sup.2, R.sup.3, and R.sup.4 are each
independently selected from: H, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, aryl,
C.sub.3-C.sub.7 cycloalkyl and heteroaryl; wherein said
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl, C.sub.3-C.sub.7 cycloalkyl and heteroaryl are each
optionally substituted with one or more groups selected from:
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, amino, aryl, carboxamide, cyano, C.sub.1-C.sub.6
haloalkyl, halogen and hydroxy; or R.sup.2 and R.sup.3 together
with the pyrazole ring to which they are both attached to form a
tricyclic heteroaryl; and R.sup.4 is selected from: H,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl, C.sub.3-C.sub.7 cycloalkyl and heteroaryl; wherein
said C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl, C.sub.3-C.sub.7 cycloalkyl and heteroaryl are each
optionally substituted with one or more groups selected from:
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, amino, aryl, cyano, C.sub.1-C.sub.6 haloalkyl, halogen
and hydroxy.
2. The compound according to claim 1, wherein R.sup.1 is H.
3. The compound according to claim 1, wherein R.sup.1 is
C.sub.1-C.sub.6 alkyl.
4. The compound according to claim 3, wherein R.sup.1 is
methyl.
5. The compound according to claim 1, wherein R.sup.2, R.sup.3, and
R.sup.4 are each independently selected from: H, C.sub.1-C.sub.6
alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, aryl,
C.sub.3-C.sub.7 cycloalkyl and heteroaryl; wherein said
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl, C.sub.3-C.sub.7 cycloalkyl and heteroaryl are each
optionally substituted with one or more groups selected from:
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, amino, aryl, carboxamide, cyano, C.sub.1-C.sub.6
haloalkyl, halogen and hydroxy.
6. The compound according to claim 1, wherein R.sup.2, R.sup.3, and
R.sup.4 are each independently selected from: H,
2-(methylsulfinyl)ethyl, 2-(methylsulfonyl)ethyl,
2-(methylthio)ethyl, 2,3-difluorophenyl, 2,4-difluorophenyl,
2,5-difluorophenyl, 2-aminoethylthio, 2-amino-2-oxoethoxy,
2-chlorophenyl, 2-cyanoethyl, 2-ethoxyethylthio,
2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl,
2-fluoro-3-methylphenyl, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl,
2-hydroxyethylsulfinyl, 2-hydroxyethylthio, 2-methoxyethyl,
2-methoxyethylthio, 2-methoxyphenyl, 2-methoxypyridin-4-yl,
3-(trifluoromethyl)phenyl, 3,4-difluorophenyl, 3,4-dihydroxybutyl,
3-chloro-2-fluorophenyl, 3-chloro-4-fluorophenyl, 3-chlorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluoro-5-methylphenyl, 3-fluorophenyl,
3-hydroxyphenyl, 3-hydroxypropyl, 3-hydroxypropylthio,
3-isopropoxyphenyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl,
4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-hydroxyphenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl,
5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl,
6-methoxypyridin-3-yl, benzhydryl, cyanomethoxy, cyanomethylthio,
cyclopropyl, ethoxy, ethyl, ethylthio, furan-2-yl, isopropyl,
methyl, methylsulfinyl, methylsulfonyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl, thiophen-2-yl, thiophen-3-yl and
trifluoromethyl.
7. The compound according to claim 1, wherein R.sup.2 is selected
from: H, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl,
C.sub.1-C.sub.6 alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl;
wherein said C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl,
C.sub.1-C.sub.6 alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl are
each optionally substituted with one or more groups selected from:
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, amino, carboxamide, cyano, halogen and hydroxy.
8. The compound according to claim 1, wherein R.sup.2 is selected
from: H, 2-(methylsulfinyl)ethyl, 2-(methylsulfonyl)ethyl,
2-(methylthio)ethyl, 2,3-difluorophenyl, 2-aminoethylthio,
2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio,
2-fluoro-4-methoxyphenyl, 2-fluorophenyl, 2-hydroxyethyl,
2-hydroxyethylsulfinyl, 2-hydroxyethylthio, 2-methoxyethyl,
2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl,
3-chloro-2-fluorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl,
3-hydroxypropyl, 3-hydroxypropylthio, 3-methoxyphenyl,
4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-methoxyphenyl, cyanomethoxy, cyanomethylthio, cyclopropyl,
ethoxy, ethyl, ethylthio, isopropyl, methyl, methylsulfinyl,
methylsulfonyl, methylthio, m-tolyl, n-propyl, phenyl, p-tolyl and
trifluoromethyl.
9. The compound according to claim 1, wherein R.sup.3 is selected
from: C.sub.1-C.sub.6 alkyl, aryl and heteroaryl; wherein said
C.sub.1-C.sub.6 alkyl, aryl and heteroaryl are each optionally
substituted with one or more groups selected from: C.sub.1-C.sub.6
alkoxy, C.sub.1-C.sub.6 alkyl, aryl, cyano, C.sub.1-C.sub.6
haloalkyl, halogen and hydroxy.
10. The compound according to claim 1, wherein R.sup.3 is selected
from: 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl,
2-chlorophenyl, 2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl,
2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-methoxyphenyl, 2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl,
3,4-difluorophenyl, 3-chloro-2-fluorophenyl,
3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl,
3-isopropoxyphenyl, 3-methoxyphenyl, 4-chlorophenyl,
4-fluorophenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl,
5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl,
6-methoxypyridin-3-yl, benzhydryl, furan-2-yl, m-tolyl, phenyl,
p-tolyl, thiophen-2-yl and thiophen-3-yl.
11. The compound according to claim 1, wherein R.sup.4 is selected
from: H, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl;
wherein said C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl are
each optionally substituted with one or more groups selected from:
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, carboxamide, cyano,
halogen and hydroxy.
12. The compound according to claim 1, wherein R.sup.4 is selected
from: H, 2,3-difluorophenyl, 2,4-difluorophenyl,
2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio,
2-fluoro-4-methoxyphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-hydroxyethyl, 2-hydroxyethylthio, 2-methoxyethyl,
2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl,
3-chloro-2-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluorophenyl, 3-hydroxypropyl, 3-methoxyphenyl,
4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl,
4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio,
cyclopropyl, ethyl, isopropyl, methyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl.
13. The compound according to claim 1, wherein R.sup.2 and R.sup.3
together with the pyrazole ring to which they are both attached to
form a tricyclic heteroaryl.
14. The compound according to claim 1, wherein R.sup.2 and R.sup.3
together with the pyrazole ring to which they are both attached to
form 4,5-dihydro-3H-benzo[e]indazol-3-yl or
indeno[2,1-c]pyrazol-1(8H)-yl.
15. The compound according to claim 1, selected from compounds of
Formula Ic and pharmaceutically acceptable salts, solvates and
hydrates thereof: ##STR00325## wherein: R.sup.1 is selected from: H
and C.sub.1-C.sub.6 alkyl; R.sup.2 is selected from: H,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl; wherein said
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl are each optionally
substituted with one or more groups selected from: C.sub.1-C.sub.6
alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, amino,
carboxamide, cyano, halogen and hydroxy; R.sup.3 is selected from:
C.sub.1-C.sub.6 alkyl, aryl and heteroaryl; wherein said
C.sub.1-C.sub.6 alkyl, aryl and heteroaryl are each optionally
substituted with one or more groups selected from: C.sub.1-C.sub.6
alkoxy, C.sub.1-C.sub.6 alkyl, aryl, cyano, C.sub.1-C.sub.6
haloalkyl, halogen and hydroxy; and R.sup.4 is selected from: H,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl; wherein said
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl are each optionally
substituted with one or more groups selected from: C.sub.1-C.sub.6
alkoxy, C.sub.1-C.sub.6 alkyl, carboxamide, cyano, halogen and
hydroxy.
16. The compound according to claim 1, selected from compounds of
Formula Ic and pharmaceutically acceptable salts, solvates and
hydrates thereof: ##STR00326## wherein: R.sup.1 is selected from: H
and methyl; R.sup.2 is selected from: H, 2-(methylsulfinyl)ethyl,
2-(methylsulfonyl)ethyl, 2-(methylthio)ethyl, 2,3-difluorophenyl,
2-aminoethylthio, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluorophenyl,
2-hydroxyethyl, 2-hydroxyethylsulfinyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl,
3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl,
3-hydroxypropylthio, 3-methoxyphenyl, 4-chloro-3-fluorophenyl,
4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, cyanomethoxy,
cyanomethylthio, cyclopropyl, ethoxy, ethyl, ethylthio, isopropyl,
methyl, methylsulfinyl, methylsulfonyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl; R.sup.3 is selected
from: 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl,
2-chlorophenyl, 2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl,
2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-methoxyphenyl, 2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl,
3,4-difluorophenyl, 3-chloro-2-fluorophenyl,
3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl,
3-isopropoxyphenyl, 3-methoxyphenyl, 4-chlorophenyl,
4-fluorophenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl,
5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl,
6-methoxypyridin-3-yl, benzhydryl, furan-2-yl, m-tolyl, phenyl,
p-tolyl, thiophen-2-yl and thiophen-3-yl; and R.sup.4 is selected
from: H, 2,3-difluorophenyl, 2,4-difluorophenyl,
2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio,
2-fluoro-4-methoxyphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-hydroxyethyl, 2-hydroxyethylthio, 2-methoxyethyl,
2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl,
3-chloro-2-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluorophenyl, 3-hydroxypropyl, 3-methoxyphenyl,
4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl,
4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio,
cyclopropyl, ethyl, isopropyl, methyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl.
17. The compound according to claim 1, selected from compounds of
Formula Ic and pharmaceutically acceptable salts, solvates and
hydrates thereof: ##STR00327## wherein: R.sup.1 is selected from: H
and methyl; R.sup.2 and R.sup.3 together with the pyrazole ring to
which they are both attached to form
4,5-dihydro-3H-benzo[e]indazol-3-yl or
indeno[2,1-c]pyrazol-1(8H)-yl; and R.sup.4 is selected from: H,
2,3-difluorophenyl, 2,4-difluorophenyl, 2-amino-2-oxoethoxy,
2-cyanoethyl, 2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl,
2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio,
3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl,
3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl,
4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl,
ethyl, isopropyl, methyl, methylthio, m-tolyl, n-propyl, phenyl,
p-tolyl and trifluoromethyl.
18. The compound according to claim 1, selected from compounds of
Formula Ie and pharmaceutically acceptable salts, solvates and
hydrates thereof: ##STR00328## wherein: R.sup.1 is selected from: H
and C.sub.1-C.sub.6 alkyl; R.sup.2 is selected from: H,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl; wherein said
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl are each optionally
substituted with one or more groups selected from: C.sub.1-C.sub.6
alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, amino,
carboxamide, cyano, halogen and hydroxy; R.sup.3 is selected from:
C.sub.1-C.sub.6 alkyl, aryl and heteroaryl; wherein said
C.sub.1-C.sub.6 alkyl, aryl and heteroaryl are each optionally
substituted with one or more groups selected from: C.sub.1-C.sub.6
alkoxy, C.sub.1-C.sub.6 alkyl, aryl, cyano, C.sub.1-C.sub.6
haloalkyl, halogen and hydroxy; and R.sup.4 is selected from: H,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl; wherein said
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl are each optionally
substituted with one or more groups selected from: C.sub.1-C.sub.6
alkoxy, C.sub.1-C.sub.6 alkyl, carboxamide, cyano, halogen and
hydroxy.
19. The compound according to claim 1, selected from compounds of
Formula Ie and pharmaceutically acceptable salts, solvates and
hydrates thereof: ##STR00329## wherein: R.sup.1 is selected from: H
and methyl; R.sup.2 is selected from: H, 2-(methylsulfinyl)ethyl,
2-(methylsulfonyl)ethyl, 2-(methylthio)ethyl, 2,3-difluorophenyl,
2-aminoethylthio, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluorophenyl,
2-hydroxyethyl, 2-hydroxyethylsulfinyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl,
3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl,
3-hydroxypropylthio, 3-methoxyphenyl, 4-chloro-3-fluorophenyl,
4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, cyanomethoxy,
cyanomethylthio, cyclopropyl, ethoxy, ethyl, ethylthio, isopropyl,
methyl, methylsulfinyl, methylsulfonyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl; R.sup.3 is selected
from: 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl,
2-chlorophenyl, 2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl,
2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-methoxyphenyl, 2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl,
3,4-difluorophenyl, 3-chloro-2-fluorophenyl,
3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl,
3-isopropoxyphenyl, 3-methoxyphenyl, 4-chlorophenyl,
4-fluorophenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl,
5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl,
6-methoxypyridin-3-yl, benzhydryl, furan-2-yl, m-tolyl, phenyl,
p-tolyl, thiophen-2-yl and thiophen-3-yl; and R.sup.4 is selected
from: H, 2,3-difluorophenyl, 2,4-difluorophenyl,
2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio,
2-fluoro-4-methoxyphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-hydroxyethyl, 2-hydroxyethylthio, 2-methoxyethyl,
2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl,
3-chloro-2-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluorophenyl, 3-hydroxypropyl, 3-methoxyphenyl,
4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl,
4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio,
cyclopropyl, ethyl, isopropyl, methyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl.
20. The compound according to claim 1, selected from compounds of
Formula Ie and pharmaceutically acceptable salts, solvates and
hydrates thereof: ##STR00330## wherein: R.sup.1 is selected from: H
and methyl; R.sup.2 and R.sup.3 together with the pyrazole ring to
which they are both attached to form
4,5-dihydro-3H-benzo[e]indazol-3-yl or
indeno[2,1-c]pyrazol-1(8H)-yl; and R.sup.4 is selected from: H,
2,3-difluorophenyl, 2,4-difluorophenyl, 2-amino-2-oxoethoxy,
2-cyanoethyl, 2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl,
2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio,
3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl,
3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl,
4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl,
ethyl, isopropyl, methyl, methylthio, m-tolyl, n-propyl, phenyl,
p-tolyl and trifluoromethyl.
21. The compound according to claim 1, selected from compounds of
Formula Ig and pharmaceutically acceptable salts, solvates and
hydrates thereof: ##STR00331## wherein: R.sup.2 is selected from:
H, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl; wherein said
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl are each optionally
substituted with one or more groups selected from: C.sub.1-C.sub.6
alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, amino,
carboxamide, cyano, halogen and hydroxy; R.sup.3 is selected from:
C.sub.1-C.sub.6 alkyl, aryl and heteroaryl; wherein said
C.sub.1-C.sub.6 alkyl, aryl and heteroaryl are each optionally
substituted with one or more groups selected from: C.sub.1-C.sub.6
alkoxy, C.sub.1-C.sub.6 alkyl, aryl, cyano, C.sub.1-C.sub.6
haloalkyl, halogen and hydroxy; and R.sup.4 is selected from: H,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl; wherein said
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl are each optionally
substituted with one or more groups selected from: C.sub.1-C.sub.6
alkoxy, C.sub.1-C.sub.6 alkyl, carboxamide, cyano, halogen and
hydroxy.
22. The compound according to claim 1, selected from compounds of
Formula Ig and pharmaceutically acceptable salts, solvates and
hydrates thereof: ##STR00332## wherein: R.sup.2 is selected from:
H, 2-(methylsulfinyl)ethyl, 2-(methylsulfonyl)ethyl,
2-(methylthio)ethyl, 2,3-difluorophenyl, 2-aminoethylthio,
2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio,
2-fluoro-4-methoxyphenyl, 2-fluorophenyl, 2-hydroxyethyl,
2-hydroxyethylsulfinyl, 2-hydroxyethylthio, 2-methoxyethyl,
2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl,
3-chloro-2-fluorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl,
3-hydroxypropyl, 3-hydroxypropylthio, 3-methoxyphenyl,
4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-methoxyphenyl, cyanomethoxy, cyanomethylthio, cyclopropyl,
ethoxy, ethyl, ethylthio, isopropyl, methyl, methylsulfinyl,
methylsulfonyl, methylthio, m-tolyl, n-propyl, phenyl, p-tolyl and
trifluoromethyl; R.sup.3 is selected from: 2,3-difluorophenyl,
2,4-difluorophenyl, 2,5-difluorophenyl, 2-chlorophenyl,
2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl,
2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-methoxyphenyl, 2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl,
3,4-difluorophenyl, 3-chloro-2-fluorophenyl,
3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl,
3-isopropoxyphenyl, 3-methoxyphenyl, 4-chlorophenyl,
4-fluorophenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl,
5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl,
6-methoxypyridin-3-yl, benzhydryl, furan-2-yl, m-tolyl, phenyl,
p-tolyl, thiophen-2-yl and thiophen-3-yl; and R.sup.4 is selected
from: H, 2,3-difluorophenyl, 2,4-difluorophenyl,
2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio,
2-fluoro-4-methoxyphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-hydroxyethyl, 2-hydroxyethylthio, 2-methoxyethyl,
2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl,
3-chloro-2-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluorophenyl, 3-hydroxypropyl, 3-methoxyphenyl,
4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl,
4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio,
cyclopropyl, ethyl, isopropyl, methyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl.
23. The compound according to claim 1, selected from compounds of
Formula Ig and pharmaceutically acceptable salts, solvates and
hydrates thereof: ##STR00333## wherein: R.sup.2 and R.sup.3
together with the pyrazole ring to which they are both attached to
form a tricyclic heteroaryl; and R.sup.4 is selected from: H,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl; wherein said
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl are each optionally
substituted with one or more groups selected from: C.sub.1-C.sub.6
alkoxy, C.sub.1-C.sub.6 alkyl, carboxamide, cyano, halogen and
hydroxy.
24. The compound according to claim 1, selected from compounds of
Formula Ig and pharmaceutically acceptable salts, solvates and
hydrates thereof: ##STR00334## wherein: R.sup.2 and R.sup.3
together with the pyrazole ring to which they are both attached to
form 4,5-dihydro-3H-benzo[e]indazol-3-yl or
indeno[2,1-c]pyrazol-1(8H)-yl; and R.sup.4 is selected from: H,
2,3-difluorophenyl, 2,4-difluorophenyl, 2-amino-2-oxoethoxy,
2-cyanoethyl, 2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl,
2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio,
3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl,
3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl,
4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl,
ethyl, isopropyl, methyl, methylthio, m-tolyl, n-propyl, phenyl,
p-tolyl and trifluoromethyl.
25. The compound according to claim 1, selected from compounds of
Formula II and pharmaceutically acceptable salts, solvates and
hydrates thereof: ##STR00335## wherein: R.sup.2 is selected from:
H, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl; wherein said
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl are each optionally
substituted with one or more groups selected from: C.sub.1-C.sub.6
alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, amino,
carboxamide, cyano, halogen and hydroxy; R.sup.3 is selected from:
C.sub.1-C.sub.6 alkyl, aryl and heteroaryl; wherein said
C.sub.1-C.sub.6 alkyl, aryl and heteroaryl are each optionally
substituted with one or more groups selected from: C.sub.1-C.sub.6
alkoxy, C.sub.1-C.sub.6 alkyl, aryl, cyano, C.sub.1-C.sub.6
haloalkyl, halogen and hydroxy; and R.sup.4 is selected from: H,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl; wherein said
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl are each optionally
substituted with one or more groups selected from: C.sub.1-C.sub.6
alkoxy, C.sub.1-C.sub.6 alkyl, carboxamide, cyano, halogen and
hydroxy.
26. The compound according to claim 1, selected from compounds of
Formula II and pharmaceutically acceptable salts, solvates and
hydrates thereof: ##STR00336## wherein: R.sup.2 is selected from:
H, 2-(methylsulfinyl)ethyl, 2-(methylsulfonyl)ethyl,
2-(methylthio)ethyl, 2,3-difluorophenyl, 2-aminoethylthio,
2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio,
2-fluoro-4-methoxyphenyl, 2-fluorophenyl, 2-hydroxyethyl,
2-hydroxyethylsulfinyl, 2-hydroxyethylthio, 2-methoxyethyl,
2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl,
3-chloro-2-fluorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl,
3-hydroxypropyl, 3-hydroxypropylthio, 3-methoxyphenyl,
4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-methoxyphenyl, cyanomethoxy, cyanomethylthio, cyclopropyl,
ethoxy, ethyl, ethylthio, isopropyl, methyl, methylsulfinyl,
methylsulfonyl, methylthio, m-tolyl, n-propyl, phenyl, p-tolyl and
trifluoromethyl; R.sup.3 is selected from: 2,3-difluorophenyl,
2,4-difluorophenyl, 2,5-difluorophenyl, 2-chlorophenyl,
2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl,
2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-methoxyphenyl, 2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl,
3,4-difluorophenyl, 3-chloro-2-fluorophenyl,
3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl,
3-isopropoxyphenyl, 3-methoxyphenyl, 4-chlorophenyl,
4-fluorophenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl,
5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl,
6-methoxypyridin-3-yl, benzhydryl, furan-2-yl, m-tolyl, phenyl,
p-tolyl, thiophen-2-yl and thiophen-3-yl; and R.sup.4 is selected
from: H, 2,3-difluorophenyl, 2,4-difluorophenyl,
2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio,
2-fluoro-4-methoxyphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-hydroxyethyl, 2-hydroxyethylthio, 2-methoxyethyl,
2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl,
3-chloro-2-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluorophenyl, 3-hydroxypropyl, 3-methoxyphenyl,
4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl,
4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio,
cyclopropyl, ethyl, isopropyl, methyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl.
27. The compound according to claim 1, selected from compounds of
Formula II and pharmaceutically acceptable salts, solvates and
hydrates thereof: ##STR00337## wherein: R.sup.2 and R.sup.3
together with the pyrazole ring to which they are both attached to
form 4,5-dihydro-3H-benzo[e]indazol-3-yl or
indeno[2,1-c]pyrazol-1(8H)-yl; and R.sup.4 is selected from: H,
2,3-difluorophenyl, 2,4-difluorophenyl, 2-amino-2-oxoethoxy,
2-cyanoethyl, 2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl,
2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio,
3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl,
3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl,
4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl,
ethyl, isopropyl, methyl, methylthio, m-tolyl, n-propyl, phenyl,
p-tolyl and trifluoromethyl.
28. A compound according to claim 1 selected from the following
compounds and pharmaceutically acceptable salts, solvates and
hydrates thereof:
2-(((1r,4r)-4-((5-(4-fluorophenyl)-3-(methylthio)-4-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1r,4r)-4-((3-(4-fluorophenyl)-5-(methylthio)-4-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-(3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)ace-
tic acid;
2-(((1r,4r)-4-((1-phenyl-4,5-dihydro-3H-benzo[e]indazol-3-yl)met-
hyl)cyclohexyl)methoxy)acetic acid;
2-(((1r,4r)-4-((3-phenylindeno[2,1-c]pyrazol-1(8H)-yl)methyl)cyclohexyl)m-
ethoxy)acetic acid;
2-(((1r,4r)-4-((4-(3-methoxyphenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic acid;
2-(((1r,4r)-4-(4-(3-methoxyphenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1r,4r)-4-(3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)ace-
tic acid;
2-(((1r,4r)-4-(4,5-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)me-
thoxy)acetic acid;
2-(((1s,4s)-4-((3-(4-fluorophenyl)-5-(methylthio)-4-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1r,4r)-4-((5-methyl-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)m-
ethoxy)acetic acid;
2-(((1s,4s)-4-((5-(4-fluorophenyl)-3-(methylthio)-4-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-methoxyphenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-methoxyphenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-methyl-4,5-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)m-
ethoxy)acetic acid;
2-(((1s,4s)-4-((5-methyl-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)m-
ethoxy)acetic acid;
2-(((1s,4s)-4-((4-benzhydryl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)ac-
etic acid;
2-(((1r,4r)-4-((4-benzhydryl-1H-pyrazol-1-yl)methyl)cyclohexyl)-
methoxy)acetic acid;
2-(((1s,4s)-4-((3-methyl-5-phenyl-4-m-tolyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,5-difluorophenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(4-chlorophenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(4-fluorophenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chlorophenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-methyl-3-phenyl-4-m-tolyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(4-fluorophenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,3-difluorophenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,3-difluorophenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(4-chlorophenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,5-difluorophenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-methoxyphenyl)-3-(methylthio)-5-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-methoxyphenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(3-methoxyphenyl)-3-methyl-4-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(3-methoxyphenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(3-fluoro-5-methoxyphenyl)-3-methyl-4-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(3-fluoro-5-methoxyphenyl)-5-methyl-4-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(4-methoxyphenyl)-3-(methylthio)-4-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(4-methoxyphenyl)-5-(methylthio)-4-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(4-methoxyphenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-fluoro-5-methoxyphenyl)-5-methyl-3-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-fluorophenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chlorophenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(4-methoxyphenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-fluoro-5-methoxyphenyl)-3-methyl-5-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2-chlorophenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2-chlorophenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-fluorophenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4((5-methyl-3-phenyl-4-p-tolyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,4-difluorophenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(4-chlorophenyl)-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-fluorophenyl)-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(4-fluorophenyl)-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chloro-2-fluorophenyl)-5-methyl-3-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,4-difluorophenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chloro-2-fluorophenyl)-3-methyl-5-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-methyl-5-phenyl-4-p-tolyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chloro-4-fluorophenyl)-3-methyl-5-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chloro-4-fluorophenyl)-5-methyl-3-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(4-methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2-methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-phenyl-4-m-tolyl-1H-pyrazol-1-yl)methyl)cyclohexyl)meth-
oxy)acetic acid;
2-(((1s,4s)-4-((3-phenyl-4-p-tolyl-1H-pyrazol-1-yl)methyl)cyclohexyl)meth-
oxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chlorophenyl)-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2-fluorophenyl)-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-methyl-4-phenyl-5-m-tolyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-methyl-4-phenyl-3-m-tolyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(3-chlorophenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(3-fluorophenyl)-3-methyl-4-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(3-fluorophenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(3-chloro-2-fluorophenyl)-3-methyl-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(3-chloro-2-fluorophenyl)-5-methyl-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-fluorophenyl)-3-methyl-4-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(2-fluorophenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2,3-difluorophenyl)-3-methyl-4-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(2,3-difluorophenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(methylthio)-4,5-diphenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(methylthio)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,5-difluorophenyl)-3-(methylthio)-5-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,5-difluorophenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(5-cyano-2-fluorophenyl)-5-(methylthio)-3-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4((4-(3,4-difluorophenyl)-5-ethoxy-3-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-ethoxy-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)m-
ethoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,3-difluorophenyl)-3-(methylthio)-5-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,3-difluorophenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-isopropoxyphenyl)-3-(methylthio)-5-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-isopropoxyphenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,3-difluorophenyl)-5-(methylsulfonyl)-3-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,5-difluorophenyl)-5-(methylsulfonyl)-3-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(ethylthio)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(ethylthio)-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(ethylthio)-4-(2-fluoro-3-methoxyphenyl)-3-phenyl-1H-py-
razol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-fluorophenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2-fluoro-3-methoxyphenyl)-5-(methylthio)-3-phenyl-1H-p-
yrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-fluoro-5-methoxyphenyl)-5-(methylthio)-3-phenyl-1H-p-
yrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(4-fluorophenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chlorophenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(methylthio)-3-phenyl-4-(3-(trifluoromethyl)phenyl)-1H--
pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(4-chlorophenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-ethyl-4-(3-methoxyphenyl)-5-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-ethyl-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-ethyl-4,5-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)me-
thoxy)acetic acid;
2-(((1s,4s)-4-((5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)me-
thoxy)acetic acid;
2-(((1s,4s)-4-((3-ethyl-4-(3-fluorophenyl)-5-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-ethyl-4-(3-fluorophenyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-ethyl-4-(2-fluoro-3-methoxyphenyl)-5-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-ethyl-4-(2-fluoro-3-methoxyphenyl)-3-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,3-difluorophenyl)-3-ethyl-5-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,3-difluorophenyl)-5-ethyl-3-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(methylthio)-3-phenyl-4-(thiophen-2-yl)-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(furan-2-yl)-5-(methylthio)-3-phenyl-1H-pyrazol-1-yl)me-
thyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(methylthio)-3-phenyl-4-(thiophen-3-yl)-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(methylthio)-4-(5-methylthiophen-2-yl)-3-phenyl-1H-pyra-
zol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-isopropyl-4,5-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-fluorophenyl)-5-isopropyl-3-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-methoxyphenyl)-5-(methylsulfinyl)-3-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chlorophenyl)-3-ethyl-5-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chlorophenyl)-5-ethyl-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,3-difluorophenyl)-5-isopropyl-3-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(ethylthio)-4-(2-fluorophenyl)-3-phenyl-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(ethylthio)-4-(3-fluoro-5-methoxyphenyl)-3-phenyl-1H-py-
razol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-cyclopropyl-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-cyclopropyl-4,5-diphenyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-cyclopropyl-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-isopropyl-4-(3-methoxyphenyl)-5-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chlorophenyl)-3-isopropyl-5-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2-fluoro-3-methoxyphenyl)-3-isopropyl-5-phenyl-1H-pyra-
zol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4((5-cyclopropyl-4-(2-fluoro-3-methoxyphenyl)-3-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-cyclopropyl-4-(2,3-difluorophenyl)-3-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-isopropyl-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chlorophenyl)-5-isopropyl-3-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2-fluoro-3-methoxyphenyl)-5-isopropyl-3-phenyl-1H-pyra-
zol-1-yl)methyl)cyclohexyl)methoxy)acetic acid; methyl
2-(((1s,4s)-4-(5-(methylthio)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)methoxy)acetate;
2-(((1s,4s)-4-((4-(3-chlorophenyl)-3-cyclopropyl-5-phenyl-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chlorophenyl)-5-cyclopropyl-3-phenyl-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-fluoro-5-methylphenyl)-5-(methylthio)-3-phenyl-1H-py-
razol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(5-fluoropyridin-3-yl)-5-(methylthio)-3-phenyl-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetic acid; methyl
2-(((1s,4s)-4-((4-(3-methoxyphenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetate;
2-(((1s,4s)-4-((3-(4-fluorophenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(4-chlorophenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4((5-methyl-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(4-methoxyphenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(2,4-difluorophenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,3-difluorophenyl)-5-(ethylthio)-3-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(2-fluoro-4-methylphenyl)-5-methyl-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(4-chloro-2-fluorophenyl)-5-methyl-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(2-fluoro-4-methoxyphenyl)-5-methyl-4-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-hydroxyethylthio)-3,4-diphenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(5-fluoropyridin-3-yl)-5-methyl-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(ethylthio)-4-(5-fluoropyridin-3-yl)-3-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-ethyl-4-(5-fluoropyridin-3-yl)-3-phenyl-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((1-phenyl-4,5-dihydro-3H-benzo[e]indazol-3-yl)methyl)cyclo-
hexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3,4-diphenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-phenyl-4-p-tolyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)me-
thyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-hydroxyphenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-methoxyphenyl)-5-phenyl-3-(trifluoromethyl)-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-methoxyphenyl)-3-phenyl-5-(trifluoromethyl)-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
24(1R,4s)-4-((3-((S)-3,4-dihydroxybutyl)-4,5-diphenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic acid;
2-(((1R,4s)-4-((5-((S)-3,4-dihydroxybutyl)-3,4-diphenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetic acid;
2-(((1R,4s)-4-((5-((S)-3,4-dihydroxybutyl)-4-(3-fluorophenyl)-3-phenyl-1H-
-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1R,4s)-4-((4-(3,4-difluorophenyl)-3-((S)-3,4-dihydroxybutyl)-5-pheny-
l-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1R,4s)-4-((4-(3,4-difluorophenyl)-5-((S)-3,4-dihydroxybutyl)-3-pheny-
l-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1R,4s)-4-((5-((S)-3,4-dihydroxybutyl)-4-(3-hydroxyphenyl)-3-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1R,4s)-4-((4-(3-chlorophenyl)-5-((S)-3,4-dihydroxybutyl)-3-phenyl-1H-
-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(4-chlorophenyl)-5-ethyl-4-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-ethyl-3-(4-fluorophenyl)-4-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-ethyl-3-(2-fluoro-4-methoxyphenyl)-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-ethyl-3-(4-methoxyphenyl)-4-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-ethyl-3-(2-fluoro-4-methylphenyl)-4-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-ethyl-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)methoxy)acetic acid;
2-(((1S,4s)-4-((5-((R)-3,4-dihydroxybutyl)-4-(3-fluorophenyl)-3-phenyl-1H-
-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1S,4s)-4-((4-(3,4-difluorophenyl)-5-((R)-3,4-dihydroxybutyl)-3-pheny-
l-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1S,4s)-4-((4-(3-chlorophenyl)-5-((R)-3,4-dihydroxybutyl)-3-phenyl-1H-
-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-ethyl-4-(3-hydroxyphenyl)-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-hydroxyphenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(ethylthio)-4-(2-fluoro-3-hydroxyphenyl)-3-phenyl-1H-py-
razol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-ethyl-3-(4-hydroxyphenyl)-4-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(4-chloro-3-fluorophenyl)-5-ethyl-4-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(ethylthio)-4-(3-hydroxyphenyl)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-methoxyethyl)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cy-
clohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-methoxyethyl)-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-hydroxyphenyl)-5-(2-methoxyethyl)-3-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-methoxyethyl)-4-(6-methoxypyridin-3-yl)-3-phenyl-1H--
pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2-fluoro-3-hydroxyphenyl)-5-(2-methoxyethyl)-3-phenyl--
1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(cyanomethylthio)-4,5-diphenyl-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(cyanomethylthio)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(2-ethoxyethylthio)-4,5-diphenyl-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-ethoxyethylthio)-3,4-diphenyl-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(3-hydroxypropylthio)-3,4-diphenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(2-methoxyethylthio)-4,5-diphenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-methoxyethylthio)-3,4-diphenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,3-difluorophenyl)-5-(2-methoxyethyl)-3-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chloro-2-fluorophenyl)-5-(2-methoxyethyl)-3-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2-fluoro-3-methylphenyl)-5-(2-methoxyethyl)-3-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-methoxyethyl)-3-phenyl-4-m-tolyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-fluorophenyl)-5-(2-methoxyethyl)-3-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2-methoxypyridin-4-yl)-5-methyl-3-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-ethyl-4-(2-methoxypyridin-4-yl)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chlorophenyl)-5-(2-methoxyethyl)-3-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-hydroxyethylthio)-4-(3-methoxyphenyl)-3-phenyl-1H-py-
razol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chlorophenyl)-5-(2-hydroxyethylthio)-3-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-hydroxyethylthio)-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-ethyl-4-(5-methoxypyridin-3-yl)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-methoxyphenyl)-3-phenyl-5-propyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-fluorophenyl)-3-phenyl-5-propyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chlorophenyl)-3-phenyl-5-propyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-phenyl-5-propyl-4-m-tolyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2-fluoro-3-methoxyphenyl)-3-phenyl-5-propyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,3-difluorophenyl)-3-phenyl-5-propyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chloro-2-fluorophenyl)-3-phenyl-5-propyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2-fluoro-3-methylphenyl)-3-phenyl-5-propyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-hydroxyethylthio)-3-phenyl-4-m-tolyl-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2-fluoro-3-hydroxyphenyl)-3-phenyl-5-propyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-fluorophenyl)-5-(2-hydroxyethylthio)-3-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2-fluoro-3-hydroxyphenyl)-5-(2-(methylthio)ethyl)-3-ph-
enyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(5-methoxypyridin-3-yl)-5-methyl-3-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chloro-2-fluorophenyl)-5-(2-(methylthio)ethyl)-3-phe-
nyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-(methylthio)ethyl)-3-phenyl-4-m-tolyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chlorophenyl)-5-(2-hydroxyethylsulfinyl)-3-phenyl-1H-
-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2-fluoro-3-methylphenyl)-5-(2-(methylthio)ethyl)-3-phe-
nyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chloro-2-fluorophenyl)-5-(2-(methylsulfinyl)ethyl)-3-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-(methylsulfinyl)ethyl)-3-phenyl-4-m-tolyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-hydroxyphenyl)-5-(2-(methylthio)ethyl)-3-phenyl-1H-p-
yrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-fluorophenyl)-5-(2-(methylthio)ethyl)-3-phenyl-1H-py-
razol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(4-fluorophenyl)-4-phenyl-3-propyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(4-fluorophenyl)-4-phenyl-5-propyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(4-chloro-3-fluorophenyl)-4-phenyl-3-propyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(4-chloro-3-fluorophenyl)-4-phenyl-5-propyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(4-chlorophenyl)-4-phenyl-3-propyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(4-chlorophenyl)-4-phenyl-5-propyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(3,4-difluorophenyl)-4-phenyl-3-propyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(3,4-difluorophenyl)-4-phenyl-5-propyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-fluoro-4-methoxyphenyl)-4-phenyl-3-propyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(2-fluoro-4-methoxyphenyl)-4-phenyl-5-propyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(4-methoxyphenyl)-4-phenyl-3-propyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(4-methoxyphenyl)-4-phenyl-5-propyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-fluoro-4-methylphenyl)-4-phenyl-3-propyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(2-fluoro-4-methylphenyl)-4-phenyl-5-propyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chlorophenyl)-5-(2-(methylthio)ethyl)-3-phenyl-1H-py-
razol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-(methylthio)ethyl)-3,4-diphenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-fluoro-4-methylphenyl)-3-(2-methoxyethyl)-4-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(2-fluoro-4-methylphenyl)-5-(2-methoxyethyl)-4-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2-fluoro-4-methylphenyl)-5-(2-methoxyethyl)-3-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2-fluoro-4-methylphenyl)-5-(2-(methylthio)ethyl)-3-phe-
nyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-methoxyphenyl)-5-(2-(methylthio)ethyl)-3-phenyl-1H-p-
yrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,3-difluorophenyl)-5-(2-(methylthio)ethyl)-3-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1r,4r)-4-((3-(cyanomethylthio)-4-(3-methoxyphenyl)-5-phenyl-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(cyanomethylthio)-4-(3-methoxyphenyl)-3-phenyl-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(2-methoxyethyl)-5-(3-methoxyphenyl)-4-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-methoxyethyl)-3-(3-methoxyphenyl)-4-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chloro-2-fluorophenyl)-5-(2-(methylsulfonyl)ethyl)-3-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-aminoethylthio)-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-hydroxyethyl)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cy-
clohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-hydroxyethyl)-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,3-difluorophenyl)-5-(2-hydroxyethyl)-3-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-fluorophenyl)-5-(2-hydroxyethyl)-3-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(4-fluorophenyl)-5-(2-hydroxyethylthio)-4-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(4-fluorophenyl)-3-(2-hydroxyethylthio)-4-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4((5-(cyanomethylthio)-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(cyanomethylthio)-3-(4-fluorophenyl)-4-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(2-cyanoethyl)-4,5-diphenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-cyanoethyl)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(2-cyanoethyl)-4-(3-methoxyphenyl)-5-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-cyanoethyl)-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-cyanoethyl)-4-(3-hydroxyphenyl)-3-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chlorophenyl)-3-(2-cyanoethyl)-5-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chlorophenyl)-5-(2-cyanoethyl)-3-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(2-cyanoethyl)-4-(3-fluorophenyl)-5-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-cyanoethyl)-4-(3-fluorophenyl)-3-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(2-cyanoethyl)-4-(3-hydroxyphenyl)-5-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chloro-2-fluorophenyl)-3-(2-cyanoethyl)-5-phenyl-1H--
pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chloro-2-fluorophenyl)-5-(2-cyanoethyl)-3-phenyl-1H--
pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(3-hydroxypropyl)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(3-hydroxypropyl)-4-(3-methoxyphenyl)-3-phenyl-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(2,3-difluorophenyl)-5-(3-hydroxypropyl)-3-phenyl-1H-py-
razol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-fluorophenyl)-5-(3-hydroxypropyl)-3-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chlorophenyl)-5-(cyanomethylthio)-3-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chloro-2-fluorophenyl)-5-(2-hydroxyethyl)-3-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1r,4r)-4-((3-(2-amino-2-oxoethoxy)-4-(3-methoxyphenyl)-5-phenyl-1H-p-
yrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-amino-2-oxoethoxy)-4-(3-methoxyphenyl)-3-phenyl-1H-p-
yrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1r,4r)-4-((3-(2-amino-2-oxoethoxy)-4-(2-fluoro-3-methoxyphenyl)-5-ph-
enyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-amino-2-oxoethoxy)-4-(2-fluoro-3-methoxyphenyl)-3-ph-
enyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chloro-2-fluorophenyl)-5-(3-hydroxypropyl)-3-phenyl--
1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((4-(3-chlorophenyl)-5-(3-hydroxypropyl)-3-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic acid; and
2-(((1s,4s)-4-((5-(cyanomethoxy)-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid.
29. A compound according to claim 1 selected from the following
compounds and pharmaceutically acceptable salts, solvates and
hydrates thereof:
2-(((1s,4s)-4-((3-(3,4-difluorophenyl)-5-ethyl-4-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-fluoro-4-methylphenyl)-3-(2-hydroxyethyl)-4-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-fluoro-4-methylphenyl)-3-methyl-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(2-fluoro-4-methylphenyl)-5-(2-hydroxyethyl)-4-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(3-hydroxypropyl)-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)me-
thyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(3-hydroxypropyl)-4-phenyl-5-p-tolyl-1H-pyrazol-1-yl)me-
thyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-(methylsulfonyl)ethyl)-4-phenyl-3-p-tolyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((3-(2-fluoro-4-methylphenyl)-5-(2-(methylsulfonyl)ethyl)-4-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid;
2-(((1s,4s)-4-((5-(2-hydroxyethyl)-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic acid; and
2-(((1s,4s)-4-((1-p-tolyl-4,5-dihydro-3H-benzo[e]indazol-3-yl)methyl)cycl-
ohexyl)methoxy)acetic acid.
30. A pharmaceutical composition comprising a compound according to
claim 1 and a pharmaceutically acceptable carrier.
31. A method of modulating the activity of a PGI2 receptor by
contacting the receptor with a compound according to claim 1 or a
pharmaceutical composition according to claim 30.
32. A method of agonizing a PGI2 receptor by contacting the
receptor with a compound according to claim 1 or a pharmaceutical
composition according to claim 30.
33. A method for the treatment of a PGI2 receptor mediated disorder
in an individual, comprising administering to said individual in
need thereof, a therapeutically effective amount of a compound
according to claim 1 or a pharmaceutical composition according to
claim 30.
34. A method for the treatment of PAH in an individual, comprising
administering to said individual in need thereof, a therapeutically
effective amount of a compound according to claim 1 or a
pharmaceutical composition according to claim 30.
35. The method according to claim 34, wherein said PAH is selected
from: idiopathic PAH; familial PAH; PAH associated with a collagen
vascular disease selected from: scleroderma, CREST syndrome,
systemic lupus erythematosus (SLE), rheumatoid arthritis,
Takayasu's arteritis, polymyositis, and dermatomyositis; PAH
associated with a congenital heart disease selected from: atrial
septic defect (ASD), ventricular septic defect (VSD) and patent
ductus arteriosus in an individual; PAH associated with portal
hypertension; PAH associated with HIV infection; PAH associated
with ingestion of a drug or toxin; PAH associated with hereditary
hemorrhagic telangiectasia; PAH associated with splenectomy; PAH
associated with significant venous or capillary involvement; PAH
associated with pulmonary veno-occlusive disease (PVOD); and PAH
associated with pulmonary capillary hemangiomatosis (PCH) in an
individual.
36. A method for the treatment of a disorder selected from:
platelet aggregation, coronary artery disease, myocardial
infarction, transient ischemic attack, angina, stroke,
ischemia-reperfusion injury, restenosis, atrial fibrillation, blood
clot formation, atherosclerosis, atherothrombosis, asthma, a
symptom of asthma, a diabetic-related disorder, diabetic peripheral
neuropathy, diabetic nephropathy, diabetic retinopathy, glaucoma or
other disease of the eye with abnormal intraocular pressure,
hypertension, inflammation, psoriasis, psoriatic arthritis,
rheumatoid arthritis, Crohn's disease, transplant rejection,
multiple sclerosis, systemic lupus erythematosus (SLE), ulcerative
colitis, ischemia-reperfusion injury, restenosis, atherosclerosis,
acne, type 1 diabetes, type 2 diabetes, sepsis and chronic
obstructive pulmonary disorder (COPD) in an individual, comprising
administering to said individual in need thereof, a therapeutically
effective amount of a compound according to claim 1 or a
pharmaceutical composition according to claim 30.
37-49. (canceled)
50. A process for preparing a composition comprising admixing a
compound according to claim 1 and a pharmaceutically acceptable
carrier.
51. A compound according to claim 1 selected from the following
compound and pharmaceutically acceptable salts, solvates and
hydrates thereof:
2-(((1s,4s)-4-((4-(3-methoxyphenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic acid.
52. A compound according to claim 1 selected from the following
compound and pharmaceutically acceptable salts, solvates and
hydrates thereof:
2-(((1s,4s)-4-((4-(3-methoxyphenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic acid.
53. A compound according to claim 1 selected from the following
compound and pharmaceutically acceptable salts, solvates and
hydrates thereof:
2-(((1s,4s)-4-((5-(methylthio)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic acid.
54. A compound according to claim 1 selected from the following
compound and pharmaceutically acceptable salts, solvates and
hydrates thereof:
2-(((1s,4s)-4-((4-(3-chlorophenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic acid.
55. A compound according to claim 1 selected from the following
compound and pharmaceutically acceptable salts, solvates and
hydrates thereof:
2-(((1s,4s)-4-((5-ethyl-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic acid.
56. A compound according to claim 1 selected from the following
compound and pharmaceutically acceptable salts, solvates and
hydrates thereof:
2-(((1s,4s)-4-((5-(methylthio)-4-(5-methylthiophen-2-yl)-3-phenyl-1H-pyra-
zol-1-yl)methyl)cyclohexyl)methoxy)acetic acid.
57. A compound according to claim 1 selected from the following
compound and pharmaceutically acceptable salts, solvates and
hydrates thereof:
2-(((1s,4s)-4-(3-(2-fluoro-4-methylphenyl)-5-methyl-4-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic acid.
58. A compound according to claim 1 selected from the following
compound and pharmaceutically acceptable salts, solvates and
hydrates thereof:
2-(((1s,4s)-4-((3-(4-chloro-2-fluorophenyl)-5-methyl-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic acid.
59. A compound according to claim 1 selected from the following
compound and pharmaceutically acceptable salts, solvates and
hydrates thereof:
2-(((1s,4s)-4-((5-(2-hydroxyethylthio)-3,4-diphenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic acid.
60. A compound according to claim 1 selected from the following
compound and pharmaceutically acceptable salts, solvates and
hydrates thereof:
2-(((1s,4s)-4-(3-(4-fluorophenyl)-5-(2-hydroxyethylthio)-4-phenyl-1H-pyra-
zol-1-yl)methyl)cyclohexyl)methoxy)acetic acid.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to certain compounds of
Formula Ia and pharmaceutical compositions thereof that modulate
the activity of the PGI2 receptor. Compounds of the present
invention and pharmaceutical compositions thereof are directed to
methods useful in the treatment of: pulmonary arterial hypertension
(PAH); idiopathic PAH; familial PAH; PAH associated with: a
collagen vascular disease, a congenital heart disease, portal
hypertension, HIV infection, ingestion of a drug or toxin,
hereditary hemorrhagic telangiectasia, splenectomy, pulmonary
veno-occlusive disease (PVOD) or pulmonary capillary
hemangiomatosis (PCH); PAH with significant venous or capillary
involvement; platelet aggregation; coronary artery disease;
myocardial infarction; transient ischemic attack; angina; stroke;
ischemia-reperfusion injury; restenosis; atrial fibrillation; blood
clot formation in an angioplasty or coronary bypass surgery
individual or in an individual suffering from atrial fibrillation;
atherothrombosis; asthma or a symptom thereof; a diabetic-related
disorder such as diabetic peripheral neuropathy, diabetic
nephropathy or diabetic retinopathy; glaucoma or other disease of
the eye with abnormal intraocular pressure; hypertension;
inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis;
Crohn's disease; transplant rejection; multiple sclerosis; systemic
lupus erythematosus (SLE); ulcerative colitis; atherosclerosis;
acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic
obstructive pulmonary disorder (COPD).
BACKGROUND OF THE INVENTION
[0002] Prostacyclin (PGI2) is a lipid molecule derived from
arachidonic acid through the cyclooxygenase pathway. It is a potent
vasodilator, antiproliferative, anti-thrombotic and antiplatelet
agent that mediates its effects as an agonist of a G
protein-coupled receptor (PGI2 receptor; e.g., human PGI2 receptor,
GenBank.RTM. Accession No. NP.sub.--000951 and alleles thereof). It
is known that the binding of PGI2 (or other such agonist) to the
PGI2 receptor leads to coupling with the Gs protein and increases
intracellular cAMP levels. (See, e.g., Zhang et al., Arch. Biochem.
Biophys., 2006, 454:80-88.)
[0003] Pulmonary arterial hypertension (PAH) is a life-threatening
disease characterized by a progressive pulmonary vasculopathy
leading to right ventricular hypertrophy. Right heart failure
occurs if left untreated. Prostacyclin, which has vasodilatory and
antiproliferative effects on the pulmonary vasculature has been
found to be low in patients with PAH compared with normal controls.
Exogenous administration of prostacyclin or an analog of
prostacyclin (i.e., an agonist of the PGI2 receptor) has become an
important strategy in the treatment of PAH. (See, e.g., Tuder et
al., Am. J. Respir. Crit. Care. Med., 1999, 159:1925-1932; Humbert
et al., J. Am. Coll. Cardiol., 2004, 43:13 S-24S; Rosenzweig,
Expert Opin. Emerging Drugs, 2006, 11:609-619; McLaughlin et al.,
Circulation, 2006, 114:1417-1431; Rosenkranz, Clin. Res. Cardiol.,
2007, 96:527-541; Driscoll et al., Expert Opin. Pharmacother.,
2008, 9:65-81.)
[0004] Trepostinil and iloprost are FDA-approved analogs of
prostacyclin which, like prostacyclin, are not orally-active.
Beraprost is an orally-active analog of prostacyclin approved for
the treatment of PAH in Japan, but it has failed registration for
the treatment of PAH in Europe and in the US. Of the three
FDA-approved drugs, prostacyclin is the best studied in PAH
patients. The approximate annual cost of treating PAH with these
drugs is $25,000 to $200,000 depending on the dose. At present,
many experts consider intravenous prostacyclin to be the most
reliable agent for managing the sickest PAH patients. Due to the
short half-life of prostacyclin, intravenous treatment is
complicated by the need for a continuous infusion. Patients are at
risk for potentially fatal rebound pulmonary hypertension if the
infusion is abruptly disrupted, as well as significant risk of
catheter-related complications including sepsis. (See, e.g.,
Rosenzweig, Expert Opin. Emerging Drugs, 2006, 11:609-619; Naeije
et al., Expert Opin. Pharmacother., 2007, 8:2247-2265; Strauss et
al., Clin. Chest. Med., 2007, 28:127-142; Driscoll et al., Expert
Opin. Pharmacother., 2008, 9:65-81.)
[0005] There is considerable interest in developing prostacyclin
analogs (i.e., agonists of the PGI2 receptor) for use in the
treatment of other diseases, such as atherothrombosis. Developing
stable, orally-active analogs of prostacyclin (i.e., stable,
orally-active agonists of the PGI2 receptor) is a rate-limiting
step in achieving this goal (see, e.g., Arehart et al., Curr. Med.
Chem., 2007, 14:2161-2169; Arehart et al., Circ. Res., 2008,
102(8), 986-93, as well as in the improved management of PAH.
SUMMARY OF THE INVENTION
[0006] One aspect of the present invention encompasses certain
cyclohexane derivatives selected from compounds of Formula Ia and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00002##
[0007] wherein: [0008] R.sup.1 is selected from: H and
C.sub.1-C.sub.6 alkyl; and [0009] R.sup.2, R.sup.3, and R.sup.4 are
each independently selected from: H, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, aryl,
C.sub.3-C.sub.7 cycloalkyl and heteroaryl; wherein said
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl, C.sub.3-C.sub.7 cycloalkyl and heteroaryl are each
optionally substituted with one or more groups selected from:
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl, amino, carboxamide, cyano, C.sub.1-C.sub.6
haloalkyl, halogen and hydroxy; [0010] or [0011] R.sup.2 and
R.sup.3 together with the pyrazole ring to which they are both
attached to form a tricyclic heteroaryl; and R.sup.4 is selected
from: H, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl,
C.sub.1-C.sub.6 alkylthio, aryl, C.sub.3-C.sub.7 cycloalkyl and
heteroaryl; wherein said C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6
alkyl, C.sub.1-C.sub.6 alkylsulfinyl, C.sub.1-C.sub.6
alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, aryl, C.sub.3-C.sub.7
cycloalkyl and heteroaryl are each optionally substituted with one
or more groups selected from: C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, aryl,
cyano, C.sub.1-C.sub.6 haloalkyl, halogen and hydroxy.
[0012] One aspect of the present invention pertains to methods for
the treatment of a PGI2 receptor mediated disorder in an
individual, comprising administering to said individual in need
thereof, a therapeutically effective amount of a compound of the
present invention or a pharmaceutical composition thereof.
[0013] One aspect of the present invention pertains to methods for
the treatment of PAH in an individual, comprising administering to
said individual in need thereof, a therapeutically effective amount
of a compound of the present invention or a pharmaceutical
composition thereof.
[0014] One aspect of the present invention pertains to methods for
the treatment of idiopathic PAH in an individual, comprising
administering to said individual in need thereof, a therapeutically
effective amount of a compound of the present invention or a
pharmaceutical composition thereof.
[0015] One aspect of the present invention pertains to methods for
the treatment of familial PAH in an individual, comprising
administering to said individual in need thereof, a therapeutically
effective amount of a compound of the present invention or a
pharmaceutical composition thereof.
[0016] One aspect of the present invention pertains to methods for
the treatment of PAH associated with a collagen vascular disease in
an individual, comprising administering to said individual in need
thereof, a therapeutically effective amount of a compound of the
present invention or a pharmaceutical composition thereof.
[0017] One aspect of the present invention pertains to methods for
the treatment of PAH associated with a collagen vascular disease
selected from: scleroderma, CREST syndrome, systemic lupus
erythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis,
polymyositis, and dermatomyositis in an individual, comprising
administering to said individual in need thereof, a therapeutically
effective amount of a compound of the present invention or a
pharmaceutical composition thereof.
[0018] One aspect of the present invention pertains to methods for
the treatment of PAH associated with a congenital heart disease in
an individual, comprising administering to said individual in need
thereof, a therapeutically effective amount of a compound of the
present invention or a pharmaceutical composition thereof.
[0019] One aspect of the present invention pertains to methods for
the treatment of PAH associated with a congenital heart disease
selected from: atrial septic defect (ASD), ventricular septic
defect (VSD) and patent ductus arteriosus in an individual,
comprising administering to said individual in need thereof, a
therapeutically effective amount of a compound of the present
invention or a pharmaceutical composition thereof.
[0020] One aspect of the present invention pertains to methods for
the treatment of PAH associated with portal hypertension in an
individual, comprising administering to said individual in need
thereof, a therapeutically effective amount of a compound of the
present invention or a pharmaceutical composition thereof.
[0021] One aspect of the present invention pertains to methods for
the treatment of PAH associated with HIV infection in an
individual, comprising administering to said individual in need
thereof, a therapeutically effective amount of a compound of the
present invention or a pharmaceutical composition thereof.
[0022] One aspect of the present invention pertains to methods for
the treatment of PAH associated with ingestion of a drug or toxin
in an individual, comprising administering to said individual in
need thereof, a therapeutically effective amount of a compound of
the present invention or a pharmaceutical composition thereof.
[0023] One aspect of the present invention pertains to methods for
the treatment of PAH associated with hereditary hemorrhagic
telangiectasia in an individual, comprising administering to said
individual in need thereof, a therapeutically effective amount of a
compound of the present invention or a pharmaceutical composition
thereof.
[0024] One aspect of the present invention pertains to methods for
the treatment of PAH associated with splenectomy in an individual,
comprising administering to said individual in need thereof, a
therapeutically effective amount of a compound of the present
invention or a pharmaceutical composition thereof.
[0025] One aspect of the present invention pertains to methods for
the treatment of PAH associated with significant venous or
capillary involvement in an individual, comprising administering to
said individual in need thereof, a therapeutically effective amount
of a compound of the present invention or a pharmaceutical
composition thereof.
[0026] One aspect of the present invention pertains to methods for
the treatment of PAH associated with pulmonary veno-occlusive
disease (PVOD) in an individual, comprising administering to said
individual in need thereof, a therapeutically effective amount of a
compound of the present invention or a pharmaceutical composition
thereof.
[0027] One aspect of the present invention pertains to methods for
the treatment of PAH associated with pulmonary capillary
hemangiomatosis (PCH) in an individual, comprising administering to
said individual in need thereof, a therapeutically effective amount
of a compound of the present invention or a pharmaceutical
composition thereof.
[0028] One aspect of the present invention pertains to methods for
the treatment of platelet aggregation in an individual, comprising
administering to said individual in need thereof, a therapeutically
effective amount of a compound of the present invention or a
pharmaceutical composition thereof.
[0029] One aspect of the present invention pertains to methods for
the treatment of: coronary artery disease, myocardial infarction,
transient ischemic attack, angina, stroke, ischemia-reperfusion
injury, restenosis or atrial fibrillation in an individual,
comprising administering to said individual in need thereof, a
therapeutically effective amount of a compound of the present
invention or a pharmaceutical composition thereof.
[0030] One aspect of the present invention pertains to methods for
the treatment of blood clot formation in an angioplasty or coronary
bypass surgery individual comprising administering to said
individual in need thereof, a therapeutically effective amount of a
compound of the present invention or a pharmaceutical composition
thereof.
[0031] One aspect of the present invention pertains to methods for
the treatment of blood clot formation in an individual suffering
from atrial fibrillation comprising administering to said
individual in need thereof, a therapeutically effective amount of a
compound of the present invention or a pharmaceutical composition
thereof.
[0032] One aspect of the present invention pertains to methods for
the treatment of atherosclerosis in an individual, comprising
administering to said individual in need thereof, a therapeutically
effective amount of a compound of the present invention or a
pharmaceutical composition thereof.
[0033] One aspect of the present invention pertains to methods for
the treatment of atherothrombosis in an individual, comprising
administering to said individual in need thereof, a therapeutically
effective amount of a compound of the present invention or a
pharmaceutical composition thereof.
[0034] One aspect of the present invention pertains to methods for
the treatment of asthma in an individual, comprising administering
to said individual in need thereof, a therapeutically effective
amount of a compound of the present invention or a pharmaceutical
composition thereof.
[0035] One aspect of the present invention pertains to methods for
the treatment of a symptom of asthma in an individual, comprising
administering to said individual in need thereof, a therapeutically
effective amount of a compound of the present invention or a
pharmaceutical composition thereof.
[0036] One aspect of the present invention pertains to methods for
the treatment of a diabetic-related disorder in an individual,
comprising administering to said individual in need thereof, a
therapeutically effective amount of a compound of the present
invention or a pharmaceutical composition thereof.
[0037] One aspect of the present invention pertains to methods for
the treatment of diabetic peripheral neuropathy in an individual,
comprising administering to said individual in need thereof, a
therapeutically effective amount of a compound of the present
invention or a pharmaceutical composition thereof.
[0038] One aspect of the present invention pertains to methods for
the treatment of diabetic nephropathy in an individual, comprising
administering to said individual in need thereof, a therapeutically
effective amount of a compound of the present invention or a
pharmaceutical composition thereof.
[0039] One aspect of the present invention pertains to methods for
the treatment of diabetic retinopathy in an individual, comprising
administering to said individual in need thereof, a therapeutically
effective amount of a compound of the present invention or a
pharmaceutical composition thereof.
[0040] One aspect of the present invention pertains to methods for
the treatment of glaucoma or other disease of the eye with abnormal
intraocular pressure in an individual, comprising administering to
said individual in need thereof, a therapeutically effective amount
of a compound of the present invention or a pharmaceutical
composition thereof.
[0041] One aspect of the present invention pertains to methods for
the treatment of hypertension in an individual, comprising
administering to said individual in need thereof, a therapeutically
effective amount of a compound of the present invention or a
pharmaceutical composition thereof.
[0042] One aspect of the present invention pertains to methods for
the treatment of hypertension intended to confer protection against
cerebral ischemia in an individual, comprising administering to
said individual in need thereof, a therapeutically effective amount
of a compound of the present invention or a pharmaceutical
composition thereof.
[0043] One aspect of the present invention pertains to methods for
the treatment of inflammation in an individual, comprising
administering to said individual in need thereof, a therapeutically
effective amount of a compound of the present invention or a
pharmaceutical composition thereof.
[0044] One aspect of the present invention pertains to methods for
the treatment of an inflammatory disease in an individual,
comprising administering to said individual in need thereof, a
therapeutically effective amount of a compound of the present
invention or a pharmaceutical composition thereof.
[0045] One aspect of the present invention pertains to methods for
the treatment of an inflammatory disease selected from: psoriasis,
psoriatic arthritis, rheumatoid arthritis, Crohn's disease,
transplant rejection, multiple sclerosis, systemic lupus
erythematosus (SLE), ulcerative colitis, ischemia-reperfusion
injury, restenosis, atherosclerosis, acne, type 1 diabetes, type 2
diabetes, sepsis, chronic obstructive pulmonary disorder (COPD) and
asthma in an individual, comprising administering to said
individual in need thereof, a therapeutically effective amount of a
compound of the present invention or a pharmaceutical composition
thereof.
[0046] One aspect of the present invention pertains to methods of
modulating the activity of a PGI2 receptor by contacting the
receptor with a compound of the present invention.
[0047] One aspect of the present invention pertains to methods of
agonizing a PGI2 receptor by contacting the receptor with a
compound of the present invention.
[0048] One aspect of the present invention pertains to methods for
the treatment of PAH selected from: idiopathic PAH; familial PAH;
PAH associated with a collagen vascular disease selected from:
scleroderma, CREST syndrome, systemic lupus erythematosus (SLE),
rheumatoid arthritis, Takayasu's arteritis, polymyositis, and
dermatomyositis; PAH associated with a congenital heart disease
selected from: atrial septic defect (ASD), ventricular septic
defect (VSD) and patent ductus arteriosus in an individual; PAH
associated with portal hypertension; PAH associated with HIV
infection; PAH associated with ingestion of a drug or toxin; PAH
associated with hereditary hemorrhagic telangiectasia; PAH
associated with splenectomy; PAH associated with significant venous
or capillary involvement; PAH associated with pulmonary
veno-occlusive disease (PVOD); and PAH associated with pulmonary
capillary hemangiomatosis (PCH) in an individual comprising
administering to said individual in need thereof, a therapeutically
effective amount of a compound of the present invention or a
pharmaceutical composition thereof.
[0049] One aspect of the present invention pertains to methods for
the treatment of a disorder selected from: platelet aggregation,
coronary artery disease, myocardial infarction, transient ischemic
attack, angina, stroke, ischemia-reperfusion injury, restenosis,
atrial fibrillation, blood clot formation, atherosclerosis,
atherothrombosis, asthma, a symptom of asthma, a diabetic-related
disorder, diabetic peripheral neuropathy, diabetic nephropathy,
diabetic retinopathy, glaucoma or other disease of the eye with
abnormal intraocular pressure, hypertension, inflammation,
psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's
disease, transplant rejection, multiple sclerosis, systemic lupus
erythematosus (SLE), ulcerative colitis, ischemia-reperfusion
injury, restenosis, atherosclerosis, acne, type 1 diabetes, type 2
diabetes, sepsis and chronic obstructive pulmonary disorder (COPD)
in an individual comprising administering to said individual in
need thereof, a therapeutically effective amount of a compound of
the present invention or a pharmaceutical composition thereof.
[0050] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of a PGI2 receptor mediated
disorder.
[0051] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of PAH.
[0052] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of idiopathic PAH.
[0053] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of familial PAH.
[0054] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of PAH associated with collagen
vascular disease.
[0055] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of PAH associated with a collagen
vascular disease selected from: scleroderma, CREST syndrome,
systemic lupus erythematosus (SLE), rheumatoid arthritis,
Takayasu's arteritis, polymyositis, and dermatomyositis.
[0056] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of PAH associated with a congenital
heart disease.
[0057] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of PAH associated with a congenital
heart disease selected from: atrial septic defect (ASD),
ventricular septic defect (VSD) and patent ductus arteriosus.
[0058] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of PAH associated with portal
hypertension.
[0059] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of PAH associated with HIV
infection.
[0060] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of PAH associated with ingestion of a
drug or toxin.
[0061] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of PAH associated with hereditary
hemorrhagic telangiectasia.
[0062] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of PAH associated with
splenectomy.
[0063] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of PAH associated with significant
venous or capillary involvement.
[0064] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of PAH associated with pulmonary
veno-occlusive disease (PVOD).
[0065] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of PAH associated with pulmonary
capillary hemangiomatosis (PCH).
[0066] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of platelet aggregation.
[0067] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of a PGI2 receptor mediated disorder
selected from: coronary artery disease, myocardial infarction,
transient ischemic attack, angina, stroke, ischemia-reperfusion
injury, restenosis and atrial fibrillation.
[0068] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of blood clot formation in an
angioplasty or coronary bypass surgery individual.
[0069] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of blood clot formation in an
individual suffering from atrial fibrillation.
[0070] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of atherosclerosis.
[0071] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of atherothrombosis.
[0072] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of asthma.
[0073] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of a symptom of asthma.
[0074] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of a diabetic-related disorder.
[0075] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of diabetic peripheral neuropathy.
[0076] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of diabetic nephropathy.
[0077] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of diabetic retinopathy.
[0078] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of glaucoma or other disease of the
eye with abnormal intraocular pressure.
[0079] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of hypertension.
[0080] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of hypertension intended to confer
protection against cerebral ischemia.
[0081] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of inflammation.
[0082] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of an inflammatory disease.
[0083] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of an inflammatory disease selected
from: psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's
disease, transplant rejection, multiple sclerosis, systemic lupus
erythematosus (SLE), ulcerative colitis, ischemia-reperfusion
injury, restenosis, atherosclerosis, acne, type I diabetes, type 2
diabetes, sepsis, chronic obstructive pulmonary disorder (COPD) and
asthma.
[0084] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for modulating the activity of a PGI2 receptor.
[0085] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for agonizing a PGI2 receptor.
[0086] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of PAH selected from: idiopathic PAH;
familial PAH; PAH associated with a collagen vascular disease
selected from: scleroderma, CREST syndrome, systemic lupus
erythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis,
polymyositis, and dermatomyositis; PAH associated with a congenital
heart disease selected from: atrial septic defect (ASD),
ventricular septic defect (VSD) and patent ductus arteriosus in an
individual; PAH associated with portal hypertension; PAH associated
with HIV infection; PAH associated with ingestion of a drug or
toxin; PAH associated with hereditary hemorrhagic telangiectasia;
PAH associated with splenectomy; PAH associated with significant
venous or capillary involvement; PAH associated with pulmonary
veno-occlusive disease (PVOD); and PAH associated with pulmonary
capillary hemangiomatosis (PCH).
[0087] One aspect of the present invention pertains to the use of a
compound of the present invention in the manufacture of a
medicament for the treatment of a disorder selected from: platelet
aggregation, coronary artery disease, myocardial infarction,
transient ischemic attack, angina, stroke, ischemia-reperfusion
injury, restenosis, atrial fibrillation, blood clot formation,
atherosclerosis, atherothrombosis, asthma, a symptom of asthma, a
diabetic-related disorder, diabetic peripheral neuropathy, diabetic
nephropathy, diabetic retinopathy, glaucoma or other disease of the
eye with abnormal intraocular pressure, hypertension, inflammation,
psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's
disease, transplant rejection, multiple sclerosis, systemic lupus
erythematosus (SLE), ulcerative colitis, ischemia-reperfusion
injury, restenosis, atherosclerosis, acne, type 1 diabetes, type 2
diabetes, sepsis and chronic obstructive pulmonary disorder
(COPD).
[0088] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of the human
or animal body by therapy.
[0089] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of a PGI2
receptor mediated disorder.
[0090] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of PAH.
[0091] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of
idiopathic PAH.
[0092] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of familial
PAH
[0093] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of PAH
associated with a collagen vascular disease.
[0094] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of PAH
associated with a collagen vascular disease selected from:
scleroderma, CREST syndrome, systemic lupus erythematosus (SLE),
rheumatoid arthritis, Takayasu's arteritis, polymyositis, and
dermatomyositis.
[0095] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of PAH
associated with a congenital heart disease.
[0096] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of PAH
associated with a congenital heart disease selected from: atrial
septic defect (ASD), ventricular septic defect (VSD) and patent
ductus arteriosus.
[0097] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of PAH
associated with portal hypertension.
[0098] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of PAH
associated with HIV infection.
[0099] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of PAH
associated with ingestion of a drug or toxin.
[0100] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of PAH
associated with hereditary hemorrhagic telangiectasia.
[0101] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of PAH
associated with splenectomy.
[0102] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of PAH
associated with significant venous or capillary involvement.
[0103] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of PAH
associated with pulmonary veno-occlusive disease (PVOD).
[0104] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of PAH
associated with pulmonary capillary hemangiomatosis (PCH).
[0105] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of platelet
aggregation.
[0106] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of: coronary
artery disease, myocardial infarction, transient ischemic attack,
angina, stroke, ischemia-reperfusion injury, restenosis or atrial
fibrillation.
[0107] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of blood
clot formation in an angioplasty or coronary bypass surgery
individual.
[0108] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of blood
clot formation in an individual suffering from atrial
fibrillation.
[0109] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of
atherosclerosis.
[0110] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of
atherothrombosis.
[0111] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of
asthma.
[0112] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of a symptom
of asthma.
[0113] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of a
diabetic-related disorder.
[0114] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of diabetic
peripheral neuropathy.
[0115] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of diabetic
nephropathy.
[0116] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of diabetic
retinopathy.
[0117] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of glaucoma
or other disease of the eye with abnormal intraocular pressure.
[0118] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of
hypertension.
[0119] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of
hypertension intended to confer protection against cerebral
ischemia.
[0120] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of
inflammation.
[0121] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of an
inflammatory disease.
[0122] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of an
inflammatory disease selected from: psoriasis, psoriatic arthritis,
rheumatoid arthritis, Crohn's disease, transplant rejection,
multiple sclerosis, systemic lupus erythematosus (SLE), ulcerative
colitis, ischemia-reperfusion injury, restenosis, atherosclerosis,
acne, type 1 diabetes, type 2 diabetes, sepsis, chronic obstructive
pulmonary disorder (COPD) and asthma.
[0123] One aspect of the present invention pertains to compounds of
the present invention for use in a method of modulating the
activity of a PGI2 receptor.
[0124] One aspect of the present invention pertains to compounds of
the present invention for use in a method of agonizing a PGI2
receptor.
[0125] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of PAH
selected from: idiopathic PAH; familial PAH; PAH associated with a
collagen vascular disease selected from: scleroderma, CREST
syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis,
Takayasu's arteritis, polymyositis, and dermatomyositis; PAH
associated with a congenital heart disease selected from: atrial
septic defect (ASD), ventricular septic defect (VSD) and patent
ductus arteriosus in an individual; PAH associated with portal
hypertension; PAH associated with HIV infection; PAH associated
with ingestion of a drug or toxin; PAH associated with hereditary
hemorrhagic telangiectasia; PAH associated with splenectomy; PAH
associated with significant venous or capillary involvement; PAH
associated with pulmonary veno-occlusive disease (PVOD); and PAH
associated with pulmonary capillary hemangiomatosis (PCH).
[0126] One aspect of the present invention pertains to compounds of
the present invention for use in a method of treatment of a
disorder selected from: platelet aggregation, coronary artery
disease, myocardial infarction, transient ischemic attack, angina,
stroke, ischemia-reperfusion injury, restenosis, atrial
fibrillation, blood clot formation, atherosclerosis,
atherothrombosis, asthma, a symptom of asthma, a diabetic-related
disorder, diabetic peripheral neuropathy, diabetic nephropathy,
diabetic retinopathy, glaucoma or other disease of the eye with
abnormal intraocular pressure, hypertension, inflammation,
psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's
disease, transplant rejection, multiple sclerosis, systemic lupus
erythematosus (SLE), ulcerative colitis, ischemia-reperfusion
injury, restenosis, atherosclerosis, acne, type 1 diabetes, type 2
diabetes, sepsis and chronic obstructive pulmonary disorder (COPD).
One aspect of the present invention pertains to compounds for
preparing a composition comprising admixing a compound of the
present invention and a pharmaceutically acceptable carrier.
[0127] These and other aspects of the invention disclosed herein
will be set forth in greater detail as the patent disclosure
proceeds.
BRIEF DESCRIPTION OF THE DRAWINGS
[0128] FIG. 1 shows the results of an experiment which measured the
ability of Compound 14 to inhibit the right ventricle hypertrophic
response to MCT-induced pulmonary arterial hypertension in rat.
[0129] FIG. 2 shows the results of an experiment which measured the
ability of Compound 31 to inhibit the right ventricle hypertrophic
response to MCT-induced pulmonary arterial hypertension in rat.
[0130] FIG. 3 depicts a general method for the preparation of
compounds of the present invention. First,
cyclohexane-1,4-dicarboxylic acid is esterified and then reduced to
give the corresponding diol. The diol is mono-alkylated with
tert-butyl bromoacetate and the free hydroxyl is activated as a
sulfonate ester. Coupling of the sulfonate ester with a pyrazole
followed by acid hydrolysis affords compounds of Formula Ia.
[0131] FIG. 4 depicts an alternative general method for the
preparation of compounds of the present invention. In this method
the sulfonate ester shown in FIG. 3 is reacted in the presence of a
base with a pyrazole bearing a halogen at a position equivalent to
R.sup.3. The product then undergoes a Suzuki coupling with a
boronic acid derivative and then acid hydrolysis affords compounds
of Formula Ia.
[0132] FIG. 5 depicts a method of preparing an intermediate useful
in the synthesis of certain dihydroxy compounds of the present
invention. First, a 3-oxobutanoyl derivative is reacted with allyl
bromide in the presence of base to give a 3-oxohept-6-enoyl
derivative. Reaction with hydrazine hydrate gives a
5-(but-3-enyl)-1H-pyrazole which is converted to the diol with
AD-mix-.beta. and then protected with 2,2-dimethoxypropane.
[0133] FIG. 6 depicts a number of methods for synthesizing
intermediates useful in the preparation of compounds of the present
invention. In the first of these methods, a ketone derivative is
reacted with carbon disulfide in the presence of base, followed by
an alkyl halide, followed by hydrazine hydrate to give a
2-(alkylthio)-substituted pyrazole intermediate. In the second of
these methods, a methyl ketone is reacted with carbon disulfide in
the presence of base, followed by an alkyl halide, followed by
hydrazine hydrate to give a 2-(alkylthio)-substituted pyrazole
intermediate in which R.sup.3 is hydrogen. This may then be
converted to the corresponding iodide by treatment with sodium
iodide and base. In the third of these methods, a
3-oxo-3-propoxypropanoyl derivative is treated with hydrazine
hydrate to afford a 1H-pyrazol-5(4H)-one. Mitsunobu reaction
followed by bromination affords 2-alkoxy-3-bromo pyrazole
intermediates. In the fourth of these methods, a methyl ketone is
reacted with an acid chloride in the presence of base, then
hydrazine hydrate and finally bromine or sodium iodide in the
presence of base to give 3-halo-2-alkyl- or
3-halo-2-cycloalkyl-pyrazole intermediates.
[0134] FIG. 7 depicts three methods for the synthesis of certain
intermediates useful in the preparation of compounds of the present
invention. In the first of these methods a ketone derivative is
reacted first with carbon disulfide and methylene bromide in the
presence of base, then hydrazine hydrate and finally bromo
acetonitrile to give a 2-(cyanomethylthio)-pyrazole intermediate.
In the second of these methods, a ketone derivative is converted to
a 2-(tetrahydro-2H-pyran-2-yloxy)ethylthio-pyrazole. The
transformation may be accomplished by either reaction with carbon
disulfide, methylene bromide and base, followed by hydrazine
hydrate, followed by 2-(2-bromoethoxy)tetrahydro-2H-pyran, or
reaction with carbon disulfide and base, then
2-(2-bromoethoxy)tetrahydro-2H-pyran and finally hydrazine hydrate.
The third method describes the preparation of substituted
4,5-dihydro-3H-benzo[e]indazole and
1,8-dihydroindeno[2,1-c]pyrazole intermediates from
3,4-dihydronaphthalen-2(1H)-one or 1H-inden-2(3H)-one respectively
via reaction with an acid chloride in the presence of base followed
by reaction with hydrazine hydrate.
[0135] FIG. 8 depicts a method of preparing certain di-substituted
compounds of the present invention. .beta.-Keto aldehydes derived
from chalcone epoxides by Lewis acid-catalyzed rearrangement are
reacted with hydrazine hydrate to give di-substituted pyrazoles.
These are reacted with the sulfonate esters described in FIG. 3 to
give di-substituted compounds of Formula Ia as mixtures of
regioisomers.
[0136] FIG. 9 depicts a general method of preparing compounds of
the present invention. Starting from
4-(hydroxymethyl)cyclohexanecarboxylic acid the acid group is
esterified and the alcohol is protected with a benzyl group. Next,
the ester is reduced and reoxidized to the aldehyde. The aldehyde
undergoes reductive amination to give a Boc-protected hydrazine
which is subsequently deprotected and then coupled with an aldehyde
to give an imine. This is reacted with a nitroalkene is the
presence of base to form the pyrazole ring. Next, the benzyl
protecting group is removed reductively, the alcohol is reacted
with tert-butyl 2-diazoacetate in the presence of rhodium acetate
to give the 2-tert-butoxy-2-oxoethoxy derivative which is finally
converted to a compound of Formula Ia by treatment with acid.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0137] For clarity and consistency, the following definitions will
be used throughout this patent document.
[0138] The term "agonists" is intended to mean moieties that
interact and activate the receptor, such as, the PGI2 receptor and
initiate a physiological or pharmacological response characteristic
of that receptor. For example, when moieties activate the
intracellular response upon binding to the receptor, or enhance GTP
binding to membranes.
[0139] The term "contact or contacting" is intended to mean
bringing the indicated moieties together, whether in an in vitro
system or an in vivo system. Thus, "contacting" a PGI2 receptor
with a compound of the invention includes the administration of a
compound of the present invention to an individual, preferably a
human, having a PGI2 receptor, as well as, for example, introducing
a compound of the invention into a sample containing a cellular or
more purified preparation containing a PGI2 receptor.
[0140] The term "hydrate" as used herein means a compound of the
invention or a salt thereof, that further includes a stoichiometric
or non-stoichiometric amount of water bound by non-covalent
intermolecular forces.
[0141] The terms "including" and "such as" are illustrative and not
limitative.
[0142] The term "in need of treatment" and the term "in need
thereof," when referring to treatment are used interchangeably to
mean a judgment made by a caregiver (e.g. physician, nurse, nurse
practitioner, etc. in the case of humans; veterinarian in the case
of animals, including non-human mammals) that an individual or
animal requires or will benefit from treatment. This judgment is
made based on a variety of factors that are in the realm of a
caregiver's expertise, but that includes the knowledge that the
individual or animal is ill, or will become ill, as the result of a
disease, condition or disorder that is treatable by the compounds
of the invention. Accordingly, the compounds of the invention can
be used in a protective or preventive manner; or compounds of the
invention can be used to alleviate, inhibit or ameliorate the
disease, condition or disorder.
[0143] The term "individual" is intended to mean any animal,
including mammals, preferably mice, rats, other rodents, rabbits,
dogs, cats, swine, cattle, sheep, horses, or primates and most
preferably humans.
[0144] The term "modulate or modulating" is intended to mean an
increase or decrease in the amount, quality, response or effect of
a particular activity, function or molecule.
[0145] The term "pharmaceutical composition" is intended to mean a
composition comprising at least one active ingredient; including
but not limited to, salts, solvates and hydrates of compounds of
the present invention; whereby the composition is amenable to
investigation for a specified, efficacious outcome in a mammal (for
example, without limitation, a human). Those of ordinary skill in
the art will understand and appreciate the techniques appropriate
for determining whether an active ingredient has a desired
efficacious outcome based upon the needs of the artisan.
[0146] The term "solvate" as used herein means a compound of the
invention or a salt, thereof, that further includes a
stoichiometric or non-stoichiometric amount of a solvent bound by
non-covalent intermolecular forces. Preferred solvents are
volatile, non-toxic, and/or acceptable for administration to humans
in trace amounts.
[0147] The term "therapeutically effective amount" is intended to
mean the amount of active compound or pharmaceutical agent that
elicits the biological or medicinal response in a tissue, system,
animal, individual or human that is being sought by a researcher,
veterinarian, medical doctor or other clinician or caregiver; or in
an individual, which includes one or more of the following:
[0148] (1) Preventing the disease; for example, preventing a
disease, condition or disorder in an individual that may be
predisposed to the disease, condition or disorder but does not yet
experience or display the pathology or symptomatology of the
disease;
[0149] (2) Inhibiting the disease; for example, inhibiting a
disease, condition or disorder in an individual that is
experiencing or displaying the pathology or symptomatology of the
disease, condition or disorder (i.e., arresting further development
of the pathology and/or symptomatology); and
[0150] (3) Ameliorating the disease; for example, ameliorating a
disease, condition or disorder in an individual that is
experiencing or displaying the pathology or symptomatology of the
disease, condition or disorder (i.e., reversing the pathology
and/or symptomatology).
Chemical Group, Moiety or Radical
[0151] The term "AD-mix-.alpha." is intended to mean a mixture of
potassium osmate, potassium ferricyanide, potassium carbonate and
hydroquinine 1,4-phthalazinediyldiether.
[0152] The term "AD-mix-.beta." is intended to mean a mixture of
potassium osmate, potassium ferricyanide, potassium carbonate and
hydroquinidine 1,4-phthalazinediyl diether.
[0153] The term "C.sub.1-C.sub.6 alkoxy" is intended to mean a
C.sub.1-C.sub.6 alkyl radical, as defined herein, attached directly
to an oxygen atom. Some embodiments are 1 to 5 carbons; some
embodiments are 1 to 4 carbons; some embodiments are 1 to 3
carbons; and some embodiments are 1 or 2 carbons. Examples include
methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy,
isobutoxy, sec-butoxy and the like.
[0154] The term "C.sub.1-C.sub.6 alkyl" is intended to mean a
straight or branched carbon radical containing 1 to 6 carbons. Some
embodiments are 1 to 5 carbons. Some embodiments are 1 to 4
carbons. Some embodiments are 1 to 3 carbons. Some embodiments are
1 or 2 carbons. Some embodiments are 1 carbon. Examples of an alkyl
include, but are not limited to, methyl, ethyl, n-propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, pentyl,
isopentyl, t-pentyl, neo-pentyl, 1-methylbutyl [i.e.,
--CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.3], 2-methylbutyl [i.e.,
--CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.3], n-hexyl and the like.
[0155] The term "C.sub.1-C.sub.6 alkylsulfinyl" is intended to mean
a C.sub.1-C.sub.6 alkyl radical attached to the sulfur of a
sulfoxide radical having the formula: --S(O)-- wherein the alkyl
radical has the same definition as described herein. Examples
include, but are not limited to, methylsulfinyl, ethylsulfinyl,
n-propylsulfinyl, isopropylsulfonyl, n-butylsulfinyl,
sec-butylsulfinyl, isobutylsulfinyl, t-butylsulfinyl, and the
like.
[0156] The term "C.sub.1-C.sub.6 alkylsulfonyl" is intended to mean
a C.sub.1-C.sub.6 alkyl radical attached to the sulfur of a sulfone
radical having the formula: --S(O).sub.2-- wherein the alkyl
radical has the same definition as described herein. Examples
include, but are not limited to, methylsulfonyl, ethylsulfonyl,
n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl,
sec-butylsulfonyl, isobutylsulfonyl, t-butylsulfonyl, and the
like.
[0157] The term "C.sub.1-C.sub.6 alkylthio" is intended to mean a
C.sub.1-C.sub.6 alkyl radical attached to a sulfur atom (i.e.,
--S--) wherein the alkyl radical has the same definition as
described herein. Examples include, but are not limited to,
methylsulfanyl (i.e., CH.sub.3S--), ethylsulfanyl,
n-propylsulfanyl, iso-propylsulfanyl, n-butylsulfanyl,
sec-butylsulfanyl, iso-butylsulfanyl, t-butylsulfanyl, and the
like.
[0158] The term "amino" is intended to mean the group
--NH.sub.2.
[0159] The term "aryl" is intended to mean an aromatic ring radical
containing 6 to 10 ring carbons. Examples include phenyl and
naphthyl. In some embodiments aryl is intended to mean phenyl.
[0160] The term "carboxamide" is intended to mean the group
--CONH.sub.2.
[0161] The term "cyano" is intended to mean the group --CN.
[0162] The term "C.sub.3-C.sub.7 cycloalkyl" is intended to mean a
saturated ring radical containing 3 to 7 carbons. Some embodiments
contain 3 to 6 carbons. Some embodiments contain 3 to 5 carbons
Some embodiments contain 5 to 7 carbons. Some embodiments contain 3
to 4 carbons. Examples include cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl and the like.
[0163] The term "C.sub.1-C.sub.6 haloalkyl" is intended to mean a
C.sub.1-C.sub.6 alkyl group, defined herein, wherein the alkyl is
substituted with one halogen up to fully substituted and a fully
substituted C.sub.1-C.sub.6 haloalkyl can be represented by the
formula C.sub.nL.sub.2n+1 wherein L is a halogen and "n" is 1, 2,
3, 4, 5 or 6. When more than one halogen is present then they may
be the same or different and selected from the group consisting of
F, Cl, Br and I, preferably F. Some embodiments are 1 to 5 carbons,
some embodiments are 1 to 4 carbons, some embodiments are 1 to 3
carbons, and some embodiments are 1 or 2 carbons. Examples of
haloalkyl groups include, but are not limited to, fluoromethyl,
difluoromethyl, trifluoromethyl, chlorodifluoromethyl,
2,2,2-trifluoroethyl, pentafluoroethyl and the like.
[0164] The term "halogen" or "halo" is intended to mean to a
fluoro, chloro, bromo or iodo group.
[0165] The term "heteroaryl" is intended to mean an aromatic ring
system containing 5 to 14 aromatic ring atoms that may be a single
ring, two fused rings or three fused rings wherein at least one
aromatic ring atom is a heteroatom selected from, but not limited
to, the group consisting of O, S and N wherein the N can be
optionally substituted with H, C.sub.1-C.sub.4 acyl or
C.sub.1-C.sub.4 alkyl. Some embodiments contain 5 to 6 ring atoms
for example furanyl, thienyl, pyrrolyl, imidazolyl, oxazolyl,
thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, oxadiazolyl,
triazolyl, thiadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl,
pyridazinyl, triazinyl and the like. Some embodiments contain 8 to
14 ring atoms for example carbazolyl, quinolizinyl, quinolinyl,
isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl,
quinoxalinyl, triazinyl, indolyl, isoindolyl, indazolyl,
indolizinyl, purinyl, naphthyridinyl, pteridinyl, carbazolyl,
acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, benzoxazolyl,
benzothiazolyl, 1H-benzimidazolyl, imidazopyridinyl, benzothienyl,
benzofuranyl, isobenzofuran and the like.
[0166] The term "hydroxyl" or "hydroxy" is intended to mean the
group --OH.
[0167] The term "MP-carbonate" is intended to mean macroporous
triethylammonium methylpolystyrene carbonate.
Compounds of the Invention:
[0168] One aspect of the present invention pertains to certain
compounds as shown in Formula Ia:
##STR00003##
[0169] and pharmaceutically acceptable salts, solvates and hydrates
thereof; wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the
same definitions as described herein, supra and infra.
[0170] It is appreciated that certain features of the invention,
which are, for clarity, described in the context of separate
embodiments, may also be provided in combination in a single
embodiment. Conversely, various features of the invention, which
are, for brevity, described in the context of a single embodiment,
may also be provided separately or in any suitable subcombination.
All combinations of the embodiments pertaining to the chemical
groups represented by the variables (e.g., R.sup.1, R.sup.2,
R.sup.3 and R.sup.4) contained within the generic chemical formulae
described herein, for example, Ia, Ic, Ie, Ig, Ii, etc., are
specifically embraced by the present invention just as if each and
every combination was individually explicitly recited, to the
extent that such combinations embrace compounds that result in
stable compounds (i.e., compounds that can be isolated,
characterized and tested for biological activity). In addition, all
subcombinations of the chemical groups listed in the embodiments
describing such variables, as well as all subcombinations of uses
and medical indications described herein, are also specifically
embraced by the present invention just as if each and every
subcombination of chemical groups and subcombination of uses and
medical indications was individually and explicitly recited
herein.
[0171] As used herein, "substituted" indicates that at least one
hydrogen atom of the chemical group is replaced by a non-hydrogen
substituent or group, the non-hydrogen substituent or group can be
monovalent or divalent. When the substituent or group is divalent,
then it is understood that this group is further substituted with
another substituent or group. When a chemical group herein is
"substituted" it may have up to the full valance of substitution;
for example, a methyl group can be substituted by 1, 2, or 3
substituents, a methylene group can be substituted by 1 or 2
substituents, a phenyl group can be substituted by 1, 2, 3, 4, or 5
substituents, a naphthyl group can be substituted by 1, 2, 3, 4, 5,
6, or 7 substituents and the like. Likewise, "substituted with one
or more substituents" refers to the substitution of a group with
one substituent up to the total number of substituents physically
allowed by the group. Further, when a group is substituted with
more than one group they can be identical or they can be
different.
[0172] Compounds of the invention can also include tautomeric
forms, such as keto-enol tautomers and the like. Tautomeric forms
can be in equilibrium or sterically locked into one form by
appropriate substitution. It is understood that the various
tautomeric forms are within the scope of the compounds of the
present invention.
[0173] Compounds of the invention can also include all isotopes of
atoms occurring in the intermediates and/or final compounds.
Isotopes include those atoms having the same atomic number but
different mass numbers. For example, isotopes of hydrogen include
deuterium and tritium.
[0174] It is understood and appreciated that compounds of Formula
Ia and formulae related thereto may have one or more chiral centers
and therefore can exist as enantiomers and/or diastereoisomers. The
invention is understood to extend to and embrace all such
enantiomers, diastereoisomers and mixtures thereof, including but
not limited to racemates. It is understood that compounds of
Formula Ia and formulae used throughout this disclosure are
intended to represent all individual enantiomers and mixtures
thereof, unless stated or shown otherwise.
[0175] It is understood and appreciated that compounds of Formula
Ia exist as meso isomers. Such meso isomers may be referred to as
cis and trans. Certain cis meso isomers of compounds of Formula Ia
are named herein using the prefix (1s,4s) and certain trans meso
isomers of compounds of Formula Ia are named herein using the
prefix (1r,4r) as shown below.
##STR00004##
[0176] It is further understood and appreciated that certain
compounds of Formula Ia bear a 3,4-dihydroxybutyl substituent on
the pyrazole ring. When the absolute stereochemistry of the
dihydroxybutyl group is (S) then certain cis compounds of Formula
Ia are named herein using the prefix (1R,4s). When the absolute
stereochemistry of the dihydroxybutyl group is (R) then certain cis
compounds of Formula Ia are named herein using the prefix (1S,4s)
as shown below.
##STR00005##
[0177] It is well understood and appreciated in the art that
pyrazoles can exist in various tautomeric forms. Two possible
tautomeric forms of certain intermediates useful in the preparation
of compounds of the present invention are illustrated below:
##STR00006##
[0178] It is further understood that tautomeric forms can also have
corresponding nomenclature for each represented tautomer. The
present invention includes all tautomers and the various
nomenclature designations.
[0179] The Group R.sup.1:
[0180] In some embodiments, R.sup.1 is selected from: H and
C.sub.1-C.sub.6 alkyl.
[0181] In some embodiments, R.sup.1 is H.
[0182] In some embodiments, R.sup.1 is C.sub.1-C.sub.6 alkyl.
[0183] In some embodiments, R.sup.1 is methyl.
[0184] The Group R.sup.2:
[0185] In some embodiments, R.sup.2 is selected from: H,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl; wherein said
C.sub.r C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl are each optionally
substituted with one or more groups selected from: C.sub.1-C.sub.6
alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, amino,
carboxamide, cyano, halogen and hydroxy.
[0186] In some embodiments, R.sup.2 is selected from: H,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl; wherein said
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl are each optionally
substituted with one or more groups selected from: amino,
carboxamide, chloro, cyano, ethoxy, fluoro, hydroxy, methoxy,
methyl, methylsulfinyl, methylsulfonyl and methylthio.
[0187] In some embodiments, R.sup.2 is selected from: H, butyl,
cyclopropyl, ethoxy, ethyl, ethylsulfinyl, ethylthio, isopropyl,
methoxy, methyl, methylsulfinyl, methylsulfonyl, methylthio,
phenyl, propyl and propylthio; wherein said butyl, cyclopropyl,
ethoxy, ethyl, ethylsulfinyl, ethylthio, isopropyl, methoxy,
methyl, methylsulfinyl, methylsulfonyl, methylthio, phenyl, propyl
and propylthio are each optionally substituted with one or more
groups selected from: amino, carboxamide, chloro, cyano, ethoxy,
fluoro, hydroxy, methoxy, methyl, methylsulfinyl, methylsulfonyl
and methylthio.
[0188] In some embodiments, R.sup.2 is selected from: H,
2-(methylsulfinyl)ethyl, 2-(methylsulfonyl)ethyl,
2-(methylthio)ethyl, 2,3-difluorophenyl, 2-aminoethylthio,
2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio,
2-fluoro-4-methoxyphenyl, 2-fluorophenyl, 2-hydroxyethyl,
2-hydroxyethylsulfinyl, 2-hydroxyethylthio, 2-methoxyethyl,
2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl,
3-chloro-2-fluorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl,
3-hydroxypropyl, 3-hydroxypropylthio, 3-methoxyphenyl,
4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-methoxyphenyl, cyanomethoxy, cyanomethylthio, cyclopropyl,
ethoxy, ethyl, ethylthio, isopropyl, methyl, methylsulfinyl,
methylsulfonyl, methylthio, m-tolyl, n-propyl, phenyl and
trifluoromethyl.
[0189] In some embodiments, R.sup.2 is selected from: H,
2-(methylsulfinyl)ethyl, 2-(methylsulfonyl)ethyl,
2-(methylthio)ethyl, 2,3-difluorophenyl, 2-aminoethylthio,
2-amino-2-oxoethoxy, 2-cyanoethyl, 2-ethoxyethylthio,
2-fluoro-4-methoxyphenyl, 2-fluorophenyl, 2-hydroxyethyl,
2-hydroxyethylsulfinyl, 2-hydroxyethylthio, 2-methoxyethyl,
2-methoxyethylthio, 3,4-difluorophenyl, 3,4-dihydroxybutyl,
3-chloro-2-fluorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl,
3-hydroxypropyl, 3-hydroxypropylthio, 3-methoxyphenyl,
4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-methoxyphenyl, cyanomethoxy, cyanomethylthio, cyclopropyl,
ethoxy, ethyl, ethylthio, isopropyl, methyl, methylsulfinyl,
methylsulfonyl, methylthio, m-tolyl, n-propyl, phenyl, p-tolyl and
trifluoromethyl.
[0190] In some embodiments, R.sup.2 is H.
[0191] In some embodiments, R.sup.2 is 2-(methylsulfinyl)ethyl.
[0192] In some embodiments, R.sup.2 is 2-(methylsulfonyl)ethyl.
[0193] In some embodiments, R.sup.2 is 2-(methylthio)ethyl.
[0194] In some embodiments, R.sup.2 is 2,3-difluorophenyl.
[0195] In some embodiments, R.sup.2 is 2-aminoethylthio.
[0196] In some embodiments, R.sup.2 is 2-amino-2-oxoethoxy.
[0197] In some embodiments, R.sup.2 is 2-cyanoethyl.
[0198] In some embodiments, R.sup.2 is 2-ethoxyethylthio.
[0199] In some embodiments, R.sup.2 is
2-fluoro-4-methoxyphenyl.
[0200] In some embodiments, R.sup.2 is 2-fluorophenyl.
[0201] In some embodiments, R.sup.2 is 2-hydroxyethyl.
[0202] In some embodiments, R.sup.2 is 2-hydroxyethylsulfinyl.
[0203] In some embodiments, R.sup.2 is 2-hydroxyethylthio.
[0204] In some embodiments, R.sup.2 is 2-methoxyethyl.
[0205] In some embodiments, R.sup.2 is 2-methoxyethylthio.
[0206] In some embodiments, R.sup.2 is 3,4-difluorophenyl.
[0207] In some embodiments, R.sup.2 is 3,4-dihydroxybutyl.
[0208] In some embodiments, R.sup.2 is 3-chloro-2-fluorophenyl.
[0209] In some embodiments, R.sup.2 is
3-fluoro-5-methoxyphenyl.
[0210] In some embodiments, R.sup.2 is 3-fluorophenyl.
[0211] In some embodiments, R.sup.2 is 3-hydroxypropyl.
[0212] In some embodiments, R.sup.2 is 3-hydroxypropylthio.
[0213] In some embodiments, R.sup.2 is 3-methoxyphenyl.
[0214] In some embodiments, R.sup.2 is 4-chloro-3-fluorophenyl.
[0215] In some embodiments, R.sup.2 is 4-chlorophenyl.
[0216] In some embodiments, R.sup.2 is 4-fluorophenyl.
[0217] In some embodiments, R.sup.2 is 4-chlorophenyl.
[0218] In some embodiments, R.sup.2 is 4-chlorophenyl.
[0219] In some embodiments, R.sup.2 is 4-methoxyphenyl.
[0220] In some embodiments, R.sup.2 is cyanomethoxy.
[0221] In some embodiments, R.sup.2 is 4-chlorophenyl.
[0222] In some embodiments, R.sup.2 is cyanomethylthio.
[0223] In some embodiments, R.sup.2 is cyclopropyl.
[0224] In some embodiments, R.sup.2 is ethoxy.
[0225] In some embodiments, R.sup.2 is ethyl.
[0226] In some embodiments, R.sup.2 is ethylthio.
[0227] In some embodiments, R.sup.2 is isopropyl.
[0228] In some embodiments, R.sup.2 is methyl.
[0229] In some embodiments, R.sup.2 is methylsulfinyl.
[0230] In some embodiments, R.sup.2 is methyl.
[0231] In some embodiments, R.sup.2 is methylsulfonyl.
[0232] In some embodiments, R.sup.2 is methylthio.
[0233] In some embodiments, R.sup.2 is m-tolyl.
[0234] In some embodiments, R.sup.2 is n-propyl.
[0235] In some embodiments, R.sup.2 is phenyl.
[0236] In some embodiments, R.sup.2 is p-tolyl.
[0237] In some embodiments, R.sup.2 is trifluoromethyl.
[0238] The Group R.sup.3:
[0239] In some embodiments, R.sup.3 is selected from:
C.sub.1-C.sub.6 alkyl, aryl and heteroaryl; wherein said
C.sub.1-C.sub.6 alkyl, aryl and heteroaryl are each optionally
substituted with one or more groups selected from: C.sub.1-C.sub.6
alkoxy, C.sub.1-C.sub.6 alkyl, aryl, cyano, C.sub.1-C.sub.6
haloalkyl, halogen and hydroxy.
[0240] In some embodiments, R.sup.3 is selected from:
C.sub.1-C.sub.6 alkyl, aryl and heteroaryl; wherein said
C.sub.1-C.sub.6 alkyl, aryl and heteroaryl are each optionally
substituted with one or more groups selected from: chloro, cyano,
ethoxy, fluoro, hydroxy, isopropoxy, methoxy, methyl, phenyl and
trifluoromethyl.
[0241] In some embodiments, R.sup.3 is selected from: furan-2-yl,
methyl, phenyl, pyridin-3-yl, pyridin-4-yl, thiophen-2-yl and
thiophen-3-yl; wherein said furan-2-yl, methyl, phenyl,
pyridin-3-yl, pyridin-4-yl, thiophen-2-yl and thiophen-3-yl are
each optionally substituted with one or more groups selected from:
chloro, cyano, ethoxy, fluoro, hydroxy, isopropoxy, methoxy,
methyl, phenyl and trifluoromethyl.
[0242] In some embodiments, R.sup.3 is selected from:
2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl,
2-chlorophenyl, 2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl,
2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-methoxyphenyl, 2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl,
3,4-difluorophenyl, 3-chloro-2-fluorophenyl,
3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl,
3-isopropoxyphenyl, 3-methoxyphenyl, 4-chlorophenyl,
4-fluorophenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl,
5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl,
6-methoxypyridin-3-yl, benzhydryl, furan-2-yl, m-tolyl, phenyl,
p-tolyl, thiophen-2-yl and thiophen-3-yl.
[0243] In some embodiments, R.sup.3 is 2,3-difluorophenyl.
[0244] In some embodiments, R.sup.3 is 2,4-difluorophenyl.
[0245] In some embodiments, R.sup.3 is 2,5-difluorophenyl.
[0246] In some embodiments, R.sup.3 is 2-chlorophenyl.
[0247] In some embodiments, R.sup.3 is
2-fluoro-3-hydroxyphenyl.
[0248] In some embodiments, R.sup.3 is
2-fluoro-3-methoxyphenyl.
[0249] In some embodiments, R.sup.3 is 2-fluoro-3-methylphenyl.
[0250] In some embodiments, R.sup.3 is 2-fluoro-4-methylphenyl.
[0251] In some embodiments, R.sup.3 is 2-fluorophenyl.
[0252] In some embodiments, R.sup.3 is 2-methoxyphenyl.
[0253] In some embodiments, R.sup.3 is 2-methoxypyridin-4-yl.
[0254] In some embodiments, R.sup.3 is
3-(trifluoromethyl)phenyl.
[0255] In some embodiments, R.sup.3 is 3,4-difluorophenyl.
[0256] In some embodiments, R.sup.3 is 3-chloro-2-fluorophenyl.
[0257] In some embodiments, R.sup.3 is 3-chloro-4-fluorophenyl.
[0258] In some embodiments, R.sup.3 is 3-chlorophenyl.
[0259] In some embodiments, R.sup.3 is
3-fluoro-5-methoxyphenyl.
[0260] In some embodiments, R.sup.3 is 3-fluoro-5-methylphenyl.
[0261] In some embodiments, R.sup.3 is 3-fluorophenyl.
[0262] In some embodiments, R.sup.3 is 3-hydroxyphenyl.
[0263] In some embodiments, R.sup.3 is 3-isopropoxyphenyl.
[0264] In some embodiments, R.sup.3 is 3-methoxyphenyl.
[0265] In some embodiments, R.sup.3 is 4-chlorophenyl.
[0266] In some embodiments, R.sup.3 is 4-fluorophenyl.
[0267] In some embodiments, R.sup.3 is 4-methoxyphenyl.
[0268] In some embodiments, R.sup.3 is 5-cyano-2-fluorophenyl.
[0269] In some embodiments, R.sup.3 is 5-fluoropyridin-3-yl.
[0270] In some embodiments, R.sup.3 is 5-methoxypyridin-3-yl.
[0271] In some embodiments, R.sup.3 is 5-methylthiophen-2-yl.
[0272] In some embodiments, R.sup.3 is 6-methoxypyridin-3-yl.
[0273] In some embodiments, R.sup.3 is benzhydryl, furan-2-yl.
[0274] In some embodiments, R.sup.3 is m-tolyl.
[0275] In some embodiments, R.sup.3 is phenyl.
[0276] In some embodiments, R.sup.3 is p-tolyl.
[0277] In some embodiments, R.sup.3 is thiophen-2-yl.
[0278] In some embodiments, R.sup.3 is thiophen-3-yl.
[0279] The Group R.sup.4:
[0280] In some embodiments, R.sup.4 is H, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl; wherein said C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl are each optionally substituted with one
or more groups selected from: C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, carboxamide, cyano, halogen and hydroxy.
[0281] In some embodiments, R.sup.4 is selected from: H,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl; wherein said
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylthio, aryl and C.sub.3-C.sub.7 cycloalkyl are each optionally
substituted with one or more groups selected from: carboxamide,
chloro, cyano, ethoxy, fluoro, hydroxy, methoxy, methyl and
trifluoromethyl.
[0282] In some embodiments, R.sup.4 is selected from: H, butyl,
cyclopropyl, ethyl, ethylthio, isopropyl, methoxy, methyl,
methylthio, phenyl and propyl; wherein said butyl, cyclopropyl,
ethyl, ethylthio, isopropyl, methoxy, methyl, methylthio, phenyl
and propyl are each optionally substituted with one or more groups
selected from: carboxamide, chloro, cyano, ethoxy, fluoro, hydroxy,
methoxy, methyl and trifluoromethyl.
[0283] In some embodiments, R.sup.4 is selected from: H,
2,3-difluorophenyl, 2,4-difluorophenyl, 2-amino-2-oxoethoxy,
2-cyanoethyl, 2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl,
3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-chlorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-methoxyphenyl,
4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl,
4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio,
cyclopropyl, ethyl, isopropyl, methyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl.
[0284] In some embodiments, R.sup.4 is selected from: H,
2,3-difluorophenyl, 2,4-difluorophenyl, 2-amino-2-oxoethoxy,
2-cyanoethyl, 2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl,
2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio,
3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl,
3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl,
4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl,
ethyl, isopropyl, methyl, methylthio, m-tolyl, n-propyl, phenyl,
p-tolyl and trifluoromethyl.
[0285] In some embodiments, R.sup.4 is H.
[0286] In some embodiments, R.sup.4 is 2,3-difluorophenyl.
[0287] In some embodiments, R.sup.4 is 2,4-difluorophenyl.
[0288] In some embodiments, R.sup.4 is 2-amino-2-oxoethoxy.
[0289] In some embodiments, R.sup.4 is 2-cyanoethyl.
[0290] In some embodiments, R.sup.4 is 2-ethoxyethylthio.
[0291] In some embodiments, R.sup.4 is
2-fluoro-4-methoxyphenyl.
[0292] In some embodiments, R.sup.4 is 2-fluoro-4-methylphenyl.
[0293] In some embodiments, R.sup.4 is 2-fluorophenyl.
[0294] In some embodiments, R.sup.4 is 2-hydroxyethyl.
[0295] In some embodiments, R.sup.4 is 2-hydroxyethylthio.
[0296] In some embodiments, R.sup.4 is 2-methoxyethyl.
[0297] In some embodiments, R.sup.4 is 2-methoxyethylthio.
[0298] In some embodiments, R.sup.4 is 3,4-difluorophenyl.
[0299] In some embodiments, R.sup.4 is 3,4-dihydroxybutyl.
[0300] In some embodiments, R.sup.4 is 3-chloro-2-fluorophenyl.
[0301] In some embodiments, R.sup.4 is 3-chlorophenyl.
[0302] In some embodiments, R.sup.4 is
3-fluoro-5-methoxyphenyl.
[0303] In some embodiments, R.sup.4 is 3-fluorophenyl.
[0304] In some embodiments, R.sup.4 is 3-hydroxypropyl.
[0305] In some embodiments, R.sup.4 is 3-methoxyphenyl.
[0306] In some embodiments, R.sup.4 is 4-chloro-2-fluorophenyl.
[0307] In some embodiments, R.sup.4 is 4-chloro-3-fluorophenyl.
[0308] In some embodiments, R.sup.4 is 4-chlorophenyl.
[0309] In some embodiments, R.sup.4 is 4-fluorophenyl.
[0310] In some embodiments, R.sup.4 is 4-hydroxyphenyl.
[0311] In some embodiments, R.sup.4 is 4-methoxyphenyl.
[0312] In some embodiments, R.sup.4 is cyanomethylthio.
[0313] In some embodiments, R.sup.4 is cyclopropyl.
[0314] In some embodiments, R.sup.4 is ethyl.
[0315] In some embodiments, R.sup.4 is isopropyl.
[0316] In some embodiments, R.sup.4 is methyl.
[0317] In some embodiments, R.sup.4 is methylthio.
[0318] In some embodiments, R.sup.4 is m-tolyl.
[0319] In some embodiments, R.sup.4 is n-propyl.
[0320] In some embodiments, R.sup.4 is phenyl.
[0321] In some embodiments, R.sup.4 is p-tolyl.
[0322] In some embodiments, R.sup.4 is trifluoromethyl.
[0323] Certain Combinations of the Present Invention:
[0324] In some embodiments, R.sup.2, R.sup.3, and R.sup.4 are each
independently selected from: H, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, aryl,
C.sub.3-C.sub.7 cycloalkyl and heteroaryl; wherein said
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl, C.sub.3-C.sub.7 cycloalkyl and heteroaryl are each
optionally substituted with one or more groups selected from:
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl, amino, carboxamide, cyano, C.sub.1-C.sub.6
haloalkyl, halogen and hydroxy.
[0325] In some embodiments, R.sup.2, R.sup.3, and R.sup.4 are each
independently selected from: H, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, aryl,
C.sub.3-C.sub.7 cycloalkyl and heteroaryl; wherein said
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6
alkylthio, aryl, C.sub.3-C.sub.7 cycloalkyl and heteroaryl are each
optionally substituted with one or more groups selected from:
amino, carboxamide, chloro, cyano, ethoxy, fluoro, hydroxy,
isopropoxy, methoxy, methyl, methylsulfinyl, methylsulfonyl,
methylthio, phenyl and trifluoromethyl.
[0326] In some embodiments, R.sup.2, R.sup.3, and R.sup.4 are each
independently selected from: H, butyl, cyclopropyl, ethoxy, ethyl,
ethylsulfinyl, ethylthio, furan-2-yl, isopropyl, methoxy, methyl,
methylsulfinyl, methylsulfonyl, methylthio, phenyl, propyl,
propylthio, pyridin-3-yl, pyridin-4-yl, thiophen-2-yl and
thiophen-3-yl; wherein said butyl, cyclopropyl, ethoxy, ethyl,
ethylsulfinyl, ethylthio, furan-2-yl, isopropyl, methoxy, methyl,
methylsulfinyl, methylsulfonyl, methylthio, phenyl, propyl,
propylthio, pyridin-3-yl, pyridin-4-yl, thiophen-2-yl and
thiophen-3-yl are each optionally substituted with one or more
groups selected from: amino, carboxamide, chloro, cyano, ethoxy,
fluoro, hydroxy, isopropoxy, methoxy, methyl, methylsulfinyl,
methylsulfonyl, methylthio, phenyl and trifluoromethyl.
[0327] In some embodiments, R.sup.2, R.sup.3, and R.sup.4 are each
independently selected from: H, 2-(methylsulfinyl)ethyl,
2-(methylsulfonyl)ethyl, 2-(methylthio)ethyl, 2,3-difluorophenyl,
2,4-difluorophenyl, 2,5-difluorophenyl, 2-aminoethylthio,
2-amino-2-oxoethoxy, 2-chlorophenyl, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-3-hydroxyphenyl,
2-fluoro-3-methoxyphenyl, 2-fluoro-3-methylphenyl,
2-fluoro-4-methoxyphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-hydroxyethyl, 2-hydroxyethylsulfinyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 2-methoxyphenyl,
2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl,
3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl,
3-hydroxypropyl, 3-hydroxypropylthio, 3-isopropoxyphenyl,
3-methoxyphenyl, 4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl,
4-chlorophenyl, 4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl,
5-cyano-2-fluorophenyl, 5-fluoropyridin-3-yl,
5-methoxypyridin-3-yl, 5-methylthiophen-2-yl,
6-methoxypyridin-3-yl, benzhydryl, cyanomethoxy, cyanomethylthio,
cyclopropyl, ethoxy, ethyl, ethylthio, furan-2-yl, isopropyl,
methyl, methylsulfinyl, methylsulfonyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl, thiophen-2-yl, thiophen-3-yl and
trifluoromethyl.
[0328] In some embodiments, R.sup.2 and R.sup.3 together with the
pyrazole ring to which they are both attached to form a tricyclic
heteroaryl.
[0329] In some embodiments, wherein R.sup.2 and R.sup.3 together
with the pyrazole ring to which they are both attached to form
4,5-dihydro-3H-benzo[e]indazol-3-yl or
indeno[2,1-c]pyrazol-1(8H)-yl.
[0330] In some embodiments, wherein R.sup.2 and R.sup.3 together
with the pyrazole ring to which they are both attached to form
4,5-dihydro-3H-benzo[e]indazol-3-yl.
[0331] In some embodiments, wherein R.sup.2 and R.sup.3 together
with the pyrazole ring to which they are both attached to form
indeno[2,1-c]pyrazol-1(8H)-yl.
[0332] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula Ic and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00007##
[0333] wherein:
[0334] R.sup.1 is selected from: H and C.sub.1-C.sub.6 alkyl;
[0335] R.sup.2 is selected from: H, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl; wherein said C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl are each optionally substituted with one
or more groups selected from: C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, amino,
carboxamide, cyano, halogen and hydroxy;
[0336] R.sup.3 is selected from: C.sub.1-C.sub.6 alkyl, aryl and
heteroaryl; wherein said C.sub.1-C.sub.6 alkyl, aryl and heteroaryl
are each optionally substituted with one or more groups selected
from: C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, aryl, cyano,
C.sub.1-C.sub.6 haloalkyl, halogen and hydroxy; and
[0337] R.sup.4 is selected from: H, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl; wherein said C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl are each optionally substituted with one
or more groups selected from: C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, carboxamide, cyano, halogen and hydroxy.
[0338] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula Ic and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00008##
[0339] wherein:
[0340] R.sup.1 is selected from: H and methyl;
[0341] R.sup.2 is selected from: H, 2-(methylsulfinyl)ethyl,
2-(methylsulfonyl)ethyl, 2-(methylthio)ethyl, 2,3-difluorophenyl,
2-aminoethylthio, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluorophenyl,
2-hydroxyethyl, 2-hydroxyethylsulfinyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl,
3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl,
3-hydroxypropylthio, 3-methoxyphenyl, 4-chloro-3-fluorophenyl,
4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, cyanomethoxy,
cyanomethylthio, cyclopropyl, ethoxy, ethyl, ethylthio, isopropyl,
methyl, methylsulfinyl, methylsulfonyl, methylthio, m-tolyl,
n-propyl, phenyl and trifluoromethyl;
[0342] R.sup.3 is selected from: 2,3-difluorophenyl,
2,4-difluorophenyl, 2,5-difluorophenyl, 2-chlorophenyl,
2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl,
2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-methoxyphenyl, 2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl,
3,4-difluorophenyl, 3-chloro-2-fluorophenyl,
3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl,
3-isopropoxyphenyl, 3-methoxyphenyl, 4-chlorophenyl,
4-fluorophenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl,
5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl,
6-methoxypyridin-3-yl, benzhydryl, furan-2-yl, m-tolyl, phenyl,
p-tolyl, thiophen-2-yl and thiophen-3-yl; and
[0343] R.sup.4 is selected from: H, 2,3-difluorophenyl,
2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl,
3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-chlorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-methoxyphenyl,
4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl,
4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio,
cyclopropyl, ethyl, isopropyl, methyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl.
[0344] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula Ic and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00009##
[0345] wherein:
[0346] R.sup.1 is selected from: H and methyl;
[0347] R.sup.2 is selected from: H, 2-(methylsulfinyl)ethyl,
2-(methylsulfonyl)ethyl, 2-(methylthio)ethyl, 2,3-difluorophenyl,
2-aminoethylthio, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluorophenyl,
2-hydroxyethyl, 2-hydroxyethylsulfinyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl,
3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl,
3-hydroxypropylthio, 3-methoxyphenyl, 4-chloro-3-fluorophenyl,
4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, cyanomethoxy,
cyanomethylthio, cyclopropyl, ethoxy, ethyl, ethylthio, isopropyl,
methyl, methylsulfinyl, methylsulfonyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl;
[0348] R.sup.3 is selected from: 2,3-difluorophenyl,
2,4-difluorophenyl, 2,5-difluorophenyl, 2-chlorophenyl,
2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl,
2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-methoxyphenyl, 2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl,
3,4-difluorophenyl, 3-chloro-2-fluorophenyl,
3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl,
3-isopropoxyphenyl, 3-methoxyphenyl, 4-chlorophenyl,
4-fluorophenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl,
5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl,
6-methoxypyridin-3-yl, benzhydryl, furan-2-yl, m-tolyl, phenyl,
p-tolyl, thiophen-2-yl and thiophen-3-yl; and
[0349] R.sup.4 is selected from: H, 2,3-difluorophenyl,
2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl,
2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio,
3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl,
3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl,
4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl,
ethyl, isopropyl, methyl, methylthio, m-tolyl, n-propyl, phenyl,
p-tolyl and trifluoromethyl.
[0350] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula Ic and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00010##
[0351] wherein:
[0352] R.sup.1 is selected from: H and C.sub.1-C.sub.6 alkyl;
[0353] R.sup.2 and R.sup.3 together with the pyrazole ring to which
they are both attached to form a tricyclic heteroaryl; and
[0354] R.sup.4 is selected from: H, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl; wherein said C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl are each optionally substituted with one
or more groups selected from: C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, carboxamide, cyano, halogen and hydroxy.
[0355] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula Ic and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00011##
[0356] wherein:
[0357] R.sup.1 is selected from: H and methyl;
[0358] R.sup.2 and R.sup.3 together with the pyrazole ring to which
they are both attached to form 4,5-dihydro-3H-benzo[e]indazol-3-yl
or indeno[2,1-c]pyrazol-1(8H)-yl; and
[0359] R.sup.4 is selected from: H, 2,3-difluorophenyl,
2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl,
3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-chlorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-methoxyphenyl,
4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl,
4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio,
cyclopropyl, ethyl, isopropyl, methyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl.
[0360] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula Ic and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00012##
[0361] wherein:
[0362] R.sup.1 is selected from: H and methyl;
[0363] R.sup.2 and R.sup.3 together with the pyrazole ring to which
they are both attached to form 4,5-dihydro-3H-benzo[e]indazol-3-yl
or indeno[2,1-c]pyrazol-1(8H)-yl; and
[0364] R.sup.4 is selected from: H, 2,3-difluorophenyl,
2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl,
2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio,
3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl,
3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl,
4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl,
ethyl, isopropyl, methyl, methylthio, m-tolyl, n-propyl, phenyl,
p-tolyl and trifluoromethyl.
[0365] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula Ie and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00013##
[0366] wherein:
[0367] R.sup.1 is selected from: H and C.sub.1-C.sub.6 alkyl;
[0368] R.sup.2 is selected from: H, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl; wherein said C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl are each optionally substituted with one
or more groups selected from: C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, amino,
carboxamide, cyano, halogen and hydroxy;
[0369] R.sup.3 is selected from: C.sub.1-C.sub.6 alkyl, aryl and
heteroaryl; wherein said C.sub.1-C.sub.6 alkyl, aryl and heteroaryl
are each optionally substituted with one or more groups selected
from: C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, aryl, cyano,
C.sub.1-C.sub.6 haloalkyl, halogen and hydroxy; and
[0370] R.sup.4 is selected from: H, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl; wherein said C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl are each optionally substituted with one
or more groups selected from: C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, carboxamide, cyano, halogen and hydroxy.
[0371] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula Ie and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00014##
[0372] wherein:
[0373] R.sup.1 is selected from: H and methyl;
[0374] R.sup.2 is selected from: H, 2-(methylsulfinyl)ethyl,
2-(methylsulfonyl)ethyl, 2-(methylthio)ethyl, 2,3-difluorophenyl,
2-aminoethylthio, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluorophenyl,
2-hydroxyethyl, 2-hydroxyethylsulfinyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl,
3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl,
3-hydroxypropylthio, 3-methoxyphenyl, 4-chloro-3-fluorophenyl,
4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, cyanomethoxy,
cyanomethylthio, cyclopropyl, ethoxy, ethyl, ethylthio, isopropyl,
methyl, methylsulfinyl, methylsulfonyl, methylthio, m-tolyl,
n-propyl, phenyl and trifluoromethyl;
[0375] R.sup.3 is selected from: 2,3-difluorophenyl,
2,4-difluorophenyl, 2,5-difluorophenyl, 2-chlorophenyl,
2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl,
2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-methoxyphenyl, 2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl,
3,4-difluorophenyl, 3-chloro-2-fluorophenyl,
3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl,
3-isopropoxyphenyl, 3-methoxyphenyl, 4-chlorophenyl,
4-fluorophenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl,
5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl,
6-methoxypyridin-3-yl, benzhydryl, furan-2-yl, m-tolyl, phenyl,
p-tolyl, thiophen-2-yl and thiophen-3-yl; and
[0376] R.sup.4 is selected from: H, 2,3-difluorophenyl,
2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl,
3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-chlorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-methoxyphenyl,
4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl,
4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio,
cyclopropyl, ethyl, isopropyl, methyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl.
[0377] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula Ie and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00015##
[0378] wherein:
[0379] R.sup.1 is selected from: H and methyl;
[0380] R.sup.2 is selected from: H, 2-(methylsulfinyl)ethyl,
2-(methylsulfonyl)ethyl, 2-(methylthio)ethyl, 2,3-difluorophenyl,
2-aminoethylthio, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluorophenyl,
2-hydroxyethyl, 2-hydroxyethylsulfinyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl,
3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl,
3-hydroxypropylthio, 3-methoxyphenyl, 4-chloro-3-fluorophenyl,
4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, cyanomethoxy,
cyanomethylthio, cyclopropyl, ethoxy, ethyl, ethylthio, isopropyl,
methyl, methylsulfinyl, methylsulfonyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl;
[0381] R.sup.3 is selected from: 2,3-difluorophenyl,
2,4-difluorophenyl, 2,5-difluorophenyl, 2-chlorophenyl,
2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl,
2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-methoxyphenyl, 2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl,
3,4-difluorophenyl, 3-chloro-2-fluorophenyl,
3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl,
3-isopropoxyphenyl, 3-methoxyphenyl, 4-chlorophenyl,
4-fluorophenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl,
5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl,
6-methoxypyridin-3-yl, benzhydryl, furan-2-yl, m-tolyl, phenyl,
p-tolyl, thiophen-2-yl and thiophen-3-yl; and
[0382] R.sup.4 is selected from: H, 2,3-difluorophenyl,
2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl,
2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio,
3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl,
3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl,
4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl,
ethyl, isopropyl, methyl, methylthio, m-tolyl, n-propyl, phenyl,
p-tolyl and trifluoromethyl.
[0383] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula Ie and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00016##
[0384] wherein:
[0385] R.sup.1 is selected from: H and C.sub.1-C.sub.6 alkyl;
[0386] R.sup.2 and R.sup.3 together with the pyrazole ring to which
they are both attached to form a tricyclic heteroaryl; and
[0387] R.sup.4 is selected from: H, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl; wherein said C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl are each optionally substituted with one
or more groups selected from: C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, carboxamide, cyano, halogen and hydroxy.
[0388] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula Ie and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00017##
[0389] wherein:
[0390] R.sup.1 is selected from: H and methyl;
[0391] R.sup.2 and R.sup.3 together with the pyrazole ring to which
they are both attached to form 4,5-dihydro-3H-benzo[e]indazol-3-yl
or indeno[2,1-c]pyrazol-1(8H)-yl; and
[0392] R.sup.4 is selected from: H, 2,3-difluorophenyl,
2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl,
3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-chlorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-methoxyphenyl,
4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl,
4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio,
cyclopropyl, ethyl, isopropyl, methyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl.
[0393] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula Ie and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00018##
[0394] wherein:
[0395] R.sup.1 is selected from: H and methyl;
[0396] R.sup.2 and R.sup.3 together with the pyrazole ring to which
they are both attached to form 4,5-dihydro-3H-benzo[e]indazol-3-yl
or indeno[2,1-c]pyrazol-1(8H)-yl; and
[0397] R.sup.4 is selected from: H, 2,3-difluorophenyl,
2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl,
2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio,
3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl,
3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl,
4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl,
ethyl, isopropyl, methyl, methylthio, m-tolyl, n-propyl, phenyl,
p-tolyl and trifluoromethyl.
[0398] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula Ig and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00019##
[0399] wherein:
[0400] R.sup.2 is selected from: H, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl; wherein said C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl are each optionally substituted with one
or more groups selected from: C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, amino,
carboxamide, cyano, halogen and hydroxy;
[0401] R.sup.3 is selected from: C.sub.1-C.sub.6 alkyl, aryl and
heteroaryl; wherein said C.sub.1-C.sub.6 alkyl, aryl and heteroaryl
are each optionally substituted with one or more groups selected
from: C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, aryl, cyano,
C.sub.1-C.sub.6 haloalkyl, halogen and hydroxy; and
[0402] R.sup.4 is selected from: H, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl; wherein said C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl are each optionally substituted with one
or more groups selected from: C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, carboxamide, cyano, halogen and hydroxy.
[0403] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula Ig and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00020##
[0404] wherein:
[0405] R.sup.2 is selected from: H, 2-(methylsulfinyl)ethyl,
2-(methylsulfonyl)ethyl, 2-(methylthio)ethyl, 2,3-difluorophenyl,
2-aminoethylthio, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluorophenyl,
2-hydroxyethyl, 2-hydroxyethylsulfinyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl,
3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl,
3-hydroxypropylthio, 3-methoxyphenyl, 4-chloro-3-fluorophenyl,
4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, cyanomethoxy,
cyanomethylthio, cyclopropyl, ethoxy, ethyl, ethylthio, isopropyl,
methyl, methylsulfinyl, methylsulfonyl, methylthio, m-tolyl,
n-propyl, phenyl and trifluoromethyl;
[0406] R.sup.3 is selected from: 2,3-difluorophenyl,
2,4-difluorophenyl, 2,5-difluorophenyl, 2-chlorophenyl,
2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl,
2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-methoxyphenyl, 2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl,
3,4-difluorophenyl, 3-chloro-2-fluorophenyl,
3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl,
3-isopropoxyphenyl, 3-methoxyphenyl, 4-chlorophenyl,
4-fluorophenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl,
5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl,
6-methoxypyridin-3-yl, benzhydryl, furan-2-yl, m-tolyl, phenyl,
p-tolyl, thiophen-2-yl and thiophen-3-yl; and
[0407] R.sup.4 is selected from: H, 2,3-difluorophenyl,
2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl,
3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-chlorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-methoxyphenyl,
4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl,
4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio,
cyclopropyl, ethyl, isopropyl, methyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl.
[0408] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula Ig and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00021##
[0409] wherein:
[0410] R.sup.2 is selected from: H, 2-(methylsulfinyl)ethyl,
2-(methylsulfonyl)ethyl, 2-(methylthio)ethyl, 2,3-difluorophenyl,
2-aminoethylthio, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluorophenyl,
2-hydroxyethyl, 2-hydroxyethylsulfinyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl,
3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl,
3-hydroxypropylthio, 3-methoxyphenyl, 4-chloro-3-fluorophenyl,
4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, cyanomethoxy,
cyanomethylthio, cyclopropyl, ethoxy, ethyl, ethylthio, isopropyl,
methyl, methylsulfinyl, methylsulfonyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl;
[0411] R.sup.3 is selected from: 2,3-difluorophenyl,
2,4-difluorophenyl, 2,5-difluorophenyl, 2-chlorophenyl,
2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl,
2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-methoxyphenyl, 2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl,
3,4-difluorophenyl, 3-chloro-2-fluorophenyl,
3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl,
3-isopropoxyphenyl, 3-methoxyphenyl, 4-chlorophenyl,
4-fluorophenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl,
5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl,
6-methoxypyridin-3-yl, benzhydryl, furan-2-yl, m-tolyl, phenyl,
p-tolyl, thiophen-2-yl and thiophen-3-yl; and
[0412] R.sup.4 is selected from: H, 2,3-difluorophenyl,
2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl,
2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio,
3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl,
3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl,
4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl,
ethyl, isopropyl, methyl, methylthio, m-tolyl, n-propyl, phenyl,
p-tolyl and trifluoromethyl.
[0413] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula Ig and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00022##
[0414] wherein:
[0415] R.sup.2 and R.sup.3 together with the pyrazole ring to which
they are both attached to form a tricyclic heteroaryl; and
[0416] R.sup.4 is selected from: H, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl; wherein said C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl are each optionally substituted with one
or more groups selected from: C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, carboxamide, cyano, halogen and hydroxy.
[0417] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula Ig and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00023##
[0418] wherein:
[0419] R.sup.2 and R.sup.3 together with the pyrazole ring to which
they are both attached to form 4,5-dihydro-3H-benzo[e]indazol-3-yl
or indeno[2,1-c]pyrazol-1(8H)-yl; and
[0420] R.sup.4 is selected from: H, 2,3-difluorophenyl,
2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl,
3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-chlorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-methoxyphenyl,
4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl,
4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio,
cyclopropyl, ethyl, isopropyl, methyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl.
[0421] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula Ig and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00024##
[0422] wherein:
[0423] R.sup.2 and R.sup.3 together with the pyrazole ring to which
they are both attached to form 4,5-dihydro-3H-benzo[e] indazol-3-yl
or indeno[2,1-c]pyrazol-1(8H)-yl; and
[0424] R.sup.4 is selected from: H, 2,3-difluorophenyl,
2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl,
2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio,
3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl,
3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl,
4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl,
ethyl, isopropyl, methyl, methylthio, m-tolyl, n-propyl, phenyl,
p-tolyl and trifluoromethyl.
[0425] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula II and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00025##
[0426] wherein:
[0427] R.sup.2 is selected from: H, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl; wherein said C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl are each optionally substituted with one
or more groups selected from: C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfinyl,
C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylthio, amino,
carboxamide, cyano, halogen and hydroxy;
[0428] R.sup.3 is selected from: C.sub.1-C.sub.6 alkyl, aryl and
heteroaryl; wherein said C.sub.1-C.sub.6 alkyl, aryl and heteroaryl
are each optionally substituted with one or more groups selected
from: C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, aryl, cyano,
C.sub.1-C.sub.6 haloalkyl, halogen and hydroxy; and
[0429] R.sup.4 is selected from: H, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl; wherein said C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl are each optionally substituted with one
or more groups selected from: C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, carboxamide, cyano, halogen and hydroxy.
[0430] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula II and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00026##
[0431] wherein:
[0432] R.sup.2 is selected from: H, 2-(methylsulfinyl)ethyl,
2-(methylsulfonyl)ethyl, 2-(methylthio)ethyl, 2,3-difluorophenyl,
2-aminoethylthio, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluorophenyl,
2-hydroxyethyl, 2-hydroxyethylsulfinyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl,
3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl,
3-hydroxypropylthio, 3-methoxyphenyl, 4-chloro-3-fluorophenyl,
4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, cyanomethoxy,
cyanomethylthio, cyclopropyl, ethoxy, ethyl, ethylthio, isopropyl,
methyl, methylsulfinyl, methylsulfonyl, methylthio, m-tolyl,
n-propyl, phenyl and trifluoromethyl;
[0433] R.sup.3 is selected from: 2,3-difluorophenyl,
2,4-difluorophenyl, 2,5-difluorophenyl, 2-chlorophenyl,
2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl,
2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-methoxyphenyl, 2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl,
3,4-difluorophenyl, 3-chloro-2-fluorophenyl,
3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl,
3-isopropoxyphenyl, 3-methoxyphenyl, 4-chlorophenyl,
4-fluorophenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl,
5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl,
6-methoxypyridin-3-yl, benzhydryl, furan-2-yl, m-tolyl, phenyl,
p-tolyl, thiophen-2-yl and thiophen-3-yl; and
[0434] R.sup.4 is selected from: H, 2,3-difluorophenyl,
2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl,
3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-chlorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-methoxyphenyl,
4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl,
4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio,
cyclopropyl, ethyl, isopropyl, methyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl.
[0435] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula II and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00027##
[0436] wherein:
[0437] R.sup.2 is selected from: H, 2-(methylsulfinyl)ethyl,
2-(methylsulfonyl)ethyl, 2-(methylthio)ethyl, 2,3-difluorophenyl,
2-aminoethylthio, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl, 2-fluorophenyl,
2-hydroxyethyl, 2-hydroxyethylsulfinyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl,
3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-hydroxypropyl,
3-hydroxypropylthio, 3-methoxyphenyl, 4-chloro-3-fluorophenyl,
4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, cyanomethoxy,
cyanomethylthio, cyclopropyl, ethoxy, ethyl, ethylthio, isopropyl,
methyl, methylsulfinyl, methylsulfonyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl;
[0438] R.sup.3 is selected from: 2,3-difluorophenyl,
2,4-difluorophenyl, 2,5-difluorophenyl, 2-chlorophenyl,
2-fluoro-3-hydroxyphenyl, 2-fluoro-3-methoxyphenyl,
2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl,
2-methoxyphenyl, 2-methoxypyridin-4-yl, 3-(trifluoromethyl)phenyl,
3,4-difluorophenyl, 3-chloro-2-fluorophenyl,
3-chloro-4-fluorophenyl, 3-chlorophenyl, 3-fluoro-5-methoxyphenyl,
3-fluoro-5-methylphenyl, 3-fluorophenyl, 3-hydroxyphenyl,
3-isopropoxyphenyl, 3-methoxyphenyl, 4-chlorophenyl,
4-fluorophenyl, 4-methoxyphenyl, 5-cyano-2-fluorophenyl,
5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-methylthiophen-2-yl,
6-methoxypyridin-3-yl, benzhydryl, furan-2-yl, m-tolyl, phenyl,
p-tolyl, thiophen-2-yl and thiophen-3-yl; and
[0439] R.sup.4 is selected from: H, 2,3-difluorophenyl,
2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl,
2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio,
3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl,
3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl,
4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl,
ethyl, isopropyl, methyl, methylthio, m-tolyl, n-propyl, phenyl,
p-tolyl and trifluoromethyl.
[0440] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula II and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00028##
[0441] wherein:
[0442] R.sup.2 and R.sup.3 together with the pyrazole ring to which
they are both attached to form a tricyclic heteroaryl; and
[0443] R.sup.4 is selected from: H, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl; wherein said C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylthio, aryl and
C.sub.3-C.sub.7 cycloalkyl are each optionally substituted with one
or more groups selected from: C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkyl, carboxamide, cyano, halogen and hydroxy.
[0444] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula II and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00029##
[0445] wherein:
[0446] R.sup.2 and R.sup.3 together with the pyrazole ring to which
they are both attached to form 4,5-dihydro-3H-benzo[e]indazol-3-yl
or indeno[2,1-c]pyrazol-1(8H)-yl; and
[0447] R.sup.4 is selected from: H, 2,3-difluorophenyl,
2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethylthio,
2-methoxyethyl, 2-methoxyethylthio, 3,4-difluorophenyl,
3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl, 3-chlorophenyl,
3-fluoro-5-methoxyphenyl, 3-fluorophenyl, 3-methoxyphenyl,
4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chlorophenyl,
4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio,
cyclopropyl, ethyl, isopropyl, methyl, methylthio, m-tolyl,
n-propyl, phenyl, p-tolyl and trifluoromethyl.
[0448] One aspect of the present invention encompasses certain
pyrazole derivatives selected from compounds of Formula Ii and
pharmaceutically acceptable salts, solvates and hydrates
thereof:
##STR00030##
[0449] wherein:
[0450] R.sup.2 and R.sup.3 together with the pyrazole ring to which
they are both attached to form 4,5-dihydro-3H-benzo[e]indazol-3-yl
or indeno[2,1-c]pyrazol-1(8H)-yl; and
[0451] R.sup.4 is selected from: H, 2,3-difluorophenyl,
2,4-difluorophenyl, 2-amino-2-oxoethoxy, 2-cyanoethyl,
2-ethoxyethylthio, 2-fluoro-4-methoxyphenyl,
2-fluoro-4-methylphenyl, 2-fluorophenyl, 2-hydroxyethyl,
2-hydroxyethylthio, 2-methoxyethyl, 2-methoxyethylthio,
3,4-difluorophenyl, 3,4-dihydroxybutyl, 3-chloro-2-fluorophenyl,
3-chlorophenyl, 3-fluoro-5-methoxyphenyl, 3-fluorophenyl,
3-hydroxypropyl, 3-methoxyphenyl, 4-chloro-2-fluorophenyl,
4-chloro-3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-hydroxyphenyl, 4-methoxyphenyl, cyanomethylthio, cyclopropyl,
ethyl, isopropyl, methyl, methylthio, m-tolyl, n-propyl, phenyl,
p-tolyl and trifluoromethyl.
[0452] Some embodiments of the present invention include every
combination of one or more compounds selected from the following
group shown in TABLE A.
TABLE-US-00001 TABLE A Cpd No. Chemical Structure Chemical Name 1
##STR00031## 2-(((1r,4r)-4-((5-(4- fluorophenyl)-3-
(methylthio)-4-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 2 ##STR00032## 2-(((1r,4r)-4-((3-(4-
fluorophenyl)-5- (methylthio)-4-phenyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 3 ##STR00033##
2-(((1s,4s)-4-((3,4- diphenyl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 4 ##STR00034## 2-(((1r,4r)-4-((1-phenyl-
4,5-dihydro-3H- benzo[e]indazol-3- yl)methyl)cyclohexyl)
methoxy)acetic acid 5 ##STR00035## 2-(((1r,4r)-4-((3-
phenylindeno[2,1- c]pyrazol-1(8H)- yl)methyl)cyclohexyl)
methoxy)acetic acid 6 ##STR00036## 2-(((1r,4r)-4-((4-(3-
methoxyphenyl)-3-methyl- 5-phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 7 ##STR00037##
2-(((1r,4r)-4-((4-(3- methoxyphenyl)-5-methyl-
3-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 8
##STR00038## 2-(((1r,4r)-4-((3,4- diphenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 9 ##STR00039##
2-(((1r,4r)-4-((4,5- diphenyl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 10 ##STR00040## 2-(((1s,4s)-4-((3-(4-
fluorophenyl)-5- (methylthio)-4-phenyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 11 ##STR00041##
2-(((1r,4r)-4-((5-methyl- 3,4-diphenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 12 ##STR00042##
2-(((1s,45)-4-((5-(4- fluorophenyl)-3- (methylthio)-4-phenyl-1H-
pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 13
##STR00043## 2-(((1s,4s)-4-((4-(3- methoxyphenyl)-3-methyl-
5-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 14
##STR00044## 2-(((1s,4s)-4-((4-(3- methoxyphenyl)-5-methyl-
3-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 15
##STR00045## 2-(((1s,4s)-4-((3-methyl- 4,5-diphenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 16 ##STR00046##
2-(((1s,4s)-4-((5-methyl- 3,4-diphenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 17 ##STR00047##
2-(((1s,4s)-4-((4- benzhydryl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 18 ##STR00048## 2-(((1r,4r)-4-((4-
benzhydryl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
19 ##STR00049## 2-(((1s,4s)-4-((3-methyl-5- phenyl-4-m-tolyl-1H-
pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 20
##STR00050## 2-(((1s,4s)-4-((4-(2,5- difluorophenyl)-5-methyl-
3-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 21
##STR00051## 2-(((1s,4s)-4-((4-(4- chlorophenyl)-3-methyl-5-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 22
##STR00052## 2-(((1s,4s)-4-((4-(4- fluorophenyl)-5-methyl-3-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 23
##STR00053## 2-(((1s,4s)-4-((4-(3- chlorophenyl)-5-methyl-3-
phenyl-1H-pyrazol-1- yl)methyl)cyclohcxyl) methoxy)acetic acid 24
##STR00054## 2-(((1s,4s)-4-((5-methyl-3- phenyl-4-m-tolyl-1H-
pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 25
##STR00055## 2-(((1s,4s)-4-((4-(4- fluorophenyl)-3-methyl-5-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 26
##STR00056## 2-(((1s,4s)-4-((4-(2,3- difluorophenyl)-3-methyl-
5-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 27
##STR00057## 2-(((1s,4s)-4-((4-(2,3- difluorophenyl)-5-methyl-
3-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 28
##STR00058## 2-(((1s,4s)-4-((4-(4- chlorophenyl)-5-methyl-3-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 29
##STR00059## 2-(((1s,4s)-4-((4-(2,5- difluorophenyl)-3-methyl-
5-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 30
##STR00060## 2-(((1s,4s)-4-((4-(3- methoxyphenyl)-3-
(methylthio)-5-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 31 ##STR00061## 2-(((1s,4s)-4-((4-(3-
methoxyphenyl)-5- (methylthio)-3-phenyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 32 ##STR00062##
2-(((1s,4s)-4-((5-(3- methoxyphenyl)-3-methyl-
4-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 33
##STR00063## 2-(((1s,4s)-4-((3-(3- methoxyphenyl)-5-methyl-
4-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 34
##STR00064## 2-(((1s,4s)-4-((5-(3-fluoro- 5-methoxyphenyl)-3-
methyl-4-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic
acid 35 ##STR00065## 2-(((1s,4s)-4-((3-(3-fluoro-
5-methoxyphenyl)-5- methyl-4-phenyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 36 ##STR00066##
2-(((1s,4s)-4-((5-(4- methoxyphenyl)-3- (methylthio)-4-phenyl-1H-
pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 37
##STR00067## 2-(((1s,4s)-4-((3-(4- methoxyphenyl)-5-
(methylthio)-4-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 38 ##STR00068## 2-(((1s,4s)-4-((4-(4-
methoxyphenyl)-5-methyl- 3-phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 39 ##STR00069##
2-(((1s,4s)-4-((4-(3-fluoro- 5-methoxyphenyl)-5-
methyl-3-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic
acid 40 ##STR00070## 2-(((1s,4s)-4-((4-(3-
fluorophenyl)-5-methyl-3- phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 41 ##STR00071##
2-(((1s,4s)-4-((4-(3- chlorophenyl)-3-methyl-5-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 42
##STR00072## 2-(((1s,4s)-4-((4-(4- methoxyphenyl)-3-methyl-
5-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 43
##STR00073## 2-(((1s,4s)-4-((4-(3-fluoro- 5-methoxyphenyl)-3-
methyl-5-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic
acid 44 ##STR00074## 2-(((1s,4s)-4-((4-(2-
chlorophenyl)-5-methyl-3- phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 45 ##STR00075##
2-(((1s,4s)-4-((4-(2- chlorophenyl)-3-methyl-5-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 46
##STR00076## 2-(((1s,4s)-4-((4-(3- fluorophenyl)-3-methyl-5-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 47
##STR00077## 2-(((1s,4s)-4-((5-methyl-3- phenyl-4-p-tolyl-1H-
pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 48
##STR00078## 2-(((1s,45)-4-((4-(2,4- difluorophenyl)-5-methyl-
3-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 49
##STR00079## 2-(((1s,4s)-4-((4-(4- chlorophenyl)-3-phenyl-
1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 50
##STR00080## 2-(((1s,4s)-4-((4-(3- fluorophenyl)-3-phenyl-1H-
pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 51
##STR00081## 2-(((1s,4s)-4-((4-(4- fluorophenyl)-3-phenyl-1H-
pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 52
##STR00082## 2-(((1s,4s)-4-((4-(3-chloro- 2-fluorophenyl)-5-methyl-
3-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 53
##STR00083## 2-(((1s,4s)-4-((4-(2,4- difluorophenyl)-3-methyl-
5-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 54
##STR00084## 2-(((1s,4s)-4-((4-(3-chloro- 2-fluorophenyl)-3-methyl-
5-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 55
##STR00085## 2-(((1s,4s)-4-((3-methyl-5- phenyl-4-p-tolyl-1H-
pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 56
##STR00086## 2-(((1s,4s)-4-((4-(3-chloro- 4-fluorophenyl)-3-methyl-
5-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 57
##STR00087## 2-(((1s,4s)-4-((4-(3-chloro- 4-fluorophenyl)-5-methyl-
3-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 58
##STR00088## 2-(((1s,4s)-4-((4-(4- methoxyphenyl)-3-phenyl-
1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 59
##STR00089## 2-(((1s,4s)-4-((4-(2- methoxyphenyl)-3-phenyl-
1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 60
##STR00090## 2-(((1s,4s)-4-((3-phenyl-4- m-tolyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 61 ##STR00091##
2-(((1s,4s)-4-((3-phenyl-4- p-tolyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 62 ##STR00092##
2-(((1s,4s)-4-((4-(3- chlorophenyl)-3-phenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 63 ##STR00093##
2-(((1s,4s)-4-((4-(2- fiuorophenyl)-3-phenyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 64 ##STR00094##
2-(((1s,4s)-4-((3-methyl-4- phenyl-5-m-tolyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 65 ##STR00095##
2-(((1s,4s)-4-((5-methyl-4- phenyl-3-m-tolyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 66 ##STR00096##
2-(((1s,4s)-4-((3-(3- chlorophenyl)-5-methyl-4-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 67
##STR00097## 2-(((1s,4s)-4-((5-(3- fluorophenyl)-3-methyl-4-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 68
##STR00098## 2-(((1s,4s)-4-((3-(3- fluorophenyl)-5-methyl-4-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 69
##STR00099## 2-(((1s,4s)-4-((5-(3-chloro- 2-fluorophenyl)-3-methyl-
4-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 70
##STR00100## 2-(((1s,4s)-4-((3-(3-chloro- 2-fluorophenyl)-5-methyl-
4-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 71
##STR00101## 2-(((1s,4s)-4-((5-(2- fluorophenyl)-3-methyl-4-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 72
##STR00102## 2-(((1s,4s)-4-((3-(2- fluorophenyl)-5-methyl-4-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 73
##STR00103## 2-(((1s,4s)-4-((5-(2,3- difluorophenyl)-3-methyl-
4-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 74
##STR00104## 2-(((1s,4s)-4-((3-(2,3- difluorophenyl)-5-methyl-
4-phcnyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 75
##STR00105## 2-(((1s,4s)-4-((3- (methylthio)-4,5-diphenyl-
1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 76
##STR00106## 2-(((1s,4s)-4-((5- (methylthio)-3,4-diphenyl-
1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 77
##STR00107## 2-(((1s,4s)-4-((4-(2,5- difluorophenyl)-3-
(methylthio)-5-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 78 ##STR00108## 2-(((1s,4s)-4-((4-(2,5-
difluorophenyl)-5- (methylthio)-3-phenyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 79 ##STR00109##
2-(((1s,4s)-4-((4-(5-cyano- 2-fluorophenyl)-5-
(methylthio)-3-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 80 ##STR00110## 2-(((1s,4s)-4-((4-(3,4-
difluorophenyl)-5-ethoxy- 3-phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 81 ##STR00111##
2-(((1s,4s)-4-((5-ethoxy- 3,4-diphenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 82 ##STR00112##
2-(((1s,4s)-4-((4-(2,3- difluorophenyl)-3-
(methylthio)-5-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 83 ##STR00113## 2-(((1s,4s)-4-((4-(2,3-
difluorophenyl)-5- (methylthio)-3-phenyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 84 ##STR00114##
2-(((1s,4s)-4-((4-(3- isopropoxyphenyl)-3-
(methylthio)-5-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 85 ##STR00115## 2-(((1s,4s)-4-((4-(3-
isopropoxyphenyl)-5- (methylthio)-3-phenyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 86 ##STR00116##
2-(((1s,4s)-4-((4-(2,3- difluorophenyl)-5-
(methylsulfonyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 87 ##STR00117## 2-(((1s,4s)-4-((4-(2,5-
difluorophenyl)-5- (methylsulfonyl)-3-phenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 88 ##STR00118##
2-(((1s,4s)-4-((5- (ethylthio)-3,4-diphenyl- 1H-pyrazol-1H-
yl)methyl)cyclohexyl) methoxy)acetic acid 89 ##STR00119##
2-(((1s,4s)-4-((5- (ethylthio)-4-(3- methoxyphenyl)-3-phenyl-
1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 90
##STR00120## 2-(((1s,4s)-4-((5- (ethylthio)-4-(2-fluoro-3-
methoxyphenyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 91 ##STR00121## 2-(((1s,4s)-4-((4-(3-
fluorophenyl)-5- (methylthio)-3-phenyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 92 ##STR00122##
2-(((1s,4s)-4-((4-(2-fluoro- 3-methoxyphenyl)-5-
(methylthio)-3-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 93 ##STR00123## 2-(((1s,4s)-4-((4-(3-fluoro-
5-methoxyphenyl)-5- (methylthio)-3-phenyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 94 ##STR00124##
2-(((1s,4s)-4-((4-(4- fluorophenyl)-5- (methylthio)-3-phenyl-1H-
pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 95
##STR00125## 2-(((1s,4s)-4-((4-(3- chlorophenyl)-5-
(methylthio)-3-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 96 ##STR00126## 2-(((1s,4s)-4-((5-
(methylthio)-3-phenyl-4-(3- (trifluoromethyl)phenyl)- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 97 ##STR00127##
2-(((1s,4s)-4-((4-(4- chlorophenyl)-5- (methylthio)-3-phenyl-1H-
pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 98
##STR00128## 2-(((1s,4s)-4-((3-ethyl-4-(3- methoxyphenyl)-5-phenyl-
1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 99
##STR00129## 2-(((1s,4s)-4-((5-ethyl-4-(3- methoxyphenyl)-3-phenyl-
1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 100
##STR00130## 2-(((1s,4s)-4-((3-ethyl-4,5- diphenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 101 ##STR00131##
2-(((1s,4s)-4-((5-ethyl-3,4- diphenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 102 ##STR00132##
2-(((1s,4s)-4-((3-ethyl-4-(3- fluorophenyl)-5-phenyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 103 ##STR00133##
2-(((1s,4s)-4-((5-ethyl-4-(3- fluorophenyl)-3-phenyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 104 ##STR00134##
2-(((1s,4s)-4-((3-ethyl-4-(2- fluoro-3-methoxyphenyl)-
5-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
105 ##STR00135## 2-(((1s,4s)-4-((5-ethyl-4-(2-
fluoro-3-methoxyphenyl)- 3-phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 106 ##STR00136##
2-(((1s,4s)-4-((4-(2,3- difluorophenyl)-3-ethyl-5-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 107
##STR00137## 2-(((1s,4s)-4-((4-(2,3- difluorophenyl)-5-ethyl-3-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 108
##STR00138## 2-(((1s,4s)-4-((5- (methylthio)-3-phenyl-4-
(thiophen-2-yl)-1H- pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic
acid 109 ##STR00139## 2-(((1s,4s)-4-((4-(furan-2-
yl)-5-(methylthio)-3- phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 110 ##STR00140## 2-(((1s,4s)-4-((5-
(methylthio)-3-phenyl-4- (thiophen-3-yl)-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 111 ##STR00141##
2-(((1s,4s)-4-((5- (methylthio)-4-(5- methylthiophen-2-yl)-3-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 112
##STR00142## 2-(((1s,4s)-4-((3-isopropyl-
4,5-diphenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic
acid 113 ##STR00143## 2-(((1s,4s)-4-((4-(3-
fluorophenyl)-5-isopropyl- 3-phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 114 ##STR00144##
2-(((1s,4s)-4-((4-(3- methoxyphenyl)-5- (methylsulfinyl)-3-phenyl-
1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 115
##STR00145## 2-(((1s,4s)-4-((4-(3- chlorophenyl)-3-ethyl-5-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 116
##STR00146## 2-(((1s,4s)-4-((4-(3- chlorophenyl)-5-ethyl-3-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 117
##STR00147## 2-(((1s,4s)-4-((4-(2,3- difluorophenyl)-5-
isopropyl-3-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 118 ##STR00148## 2-(((1s,4s)-4-((5-
(ethylthio)-4-(2- fluorophenyl)-3-phenyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 119 ##STR00149##
2-(((1s,4s)-4-((5- (ethylthio)-4-(3-fluoro-5-
methoxyphenyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 120 ##STR00150## 2-(((1s,4s)-4-((5-
cyclopropyl-4-(3- methoxyphenyl)-3-phenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 121 ##STR00151##
2-(((1s,4s)-4-((3- cyclopropyl-4,5-diphenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 122 ##STR00152##
2-(((1s,4s)-4-((5- cyclopropyl-3,4-diphenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 123 ##STR00153##
2-(((1s,4s)-4-((3-isopropyl- 4-(3-methoxyphenyl)-5-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 124
##STR00154## 2-(((1s,4s)-4-((4-(3- chlorophenyl)-3-isopropyl-
5-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
125 ##STR00155## 2-(((1s,4S)-4-((4-(2-fluoro- 3-methoxyphenyl)-3-
isopropyl-5-phenyl-1H- pyrazol-1- yl)methyl)cyclohcxyl)
methoxy)acetic acid 126 ##STR00156## 2-(((1s,4s)-4-((5-
cyclopropyl-4-(2-fluoro-3- methoxyphenyl)-3-phenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 127 ##STR00157##
2-(((1s,4s)-4-((5- cyclopropyl-4-(2,3- difluorophenyl)-3-phenyl-
1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 128
##STR00158## 2-(((1s,4s)-4-((5-isopropyl- 4-(3-methoxyphenyl)-3-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 129
##STR00159## 2-(((1s,4s)-4-((4-(3- chlorophenyl)-5-isopropyl-
3-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
130 ##STR00160## 2-(((1s,4s)-4-((4-(2-fluoro- 3-methoxyphenyl)-5-
isopropyl-3-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 131 ##STR00161## methyl 2-(((1s,4s)-4-((5-
(methylthio)-3,4-diphenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetate 132 ##STR00162## 2-(((1s,4s)-4-((4-(3-
chlorophenyl)-3- cyclopropyl-5-phenyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 133 ##STR00163##
2-(((1s,4s)-4-((4-(3- chlorophenyl)-5- cyclopropyl-3-phenyl-1H-
pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 134
##STR00164## 2-(((1s,4s)-4-((4-(3-fluoro- 5-methylphenyl)-5-
(methylthio)-3-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 135 ##STR00165## 2-(((1s,4s)-4-((4-(5-
fluoropyridin-3-yl)-5- (methylthio)-3-phenyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 136 ##STR00166## methyl
2-(((1s,4s)-4-((4-(3- methoxyphenyl)-5-methyl- 3
-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetate 137
##STR00167## 2-(((1s,4s)-4-((3-(4- fluorophenyl)-5-methyl-4-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 138
##STR00168## 2-(((1s,4s)-4-((3-(4- chlorophenyl)-5-methyl-4-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 139
##STR00169## 2-(((1s,4s)-4-((5-methyl-4- phenyl-3-p-tolyl-1H-
pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 140
##STR00170## 2-(((1s,4s)-4-((3-(4- methoxyphenyl)-5-methyl-
4-phenyI-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
141 ##STR00171## 2-(((1s,4s)-4-((3-(2,4- difluorophenyl)-5-methyl-
4-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
142 ##STR00172## 2-(((1s,4s)-4-((4-(2,3- difluorophenyl)-5-
(ethylthio)-3-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 143 ##STR00173## 2-(((1s,4s)-4-((3-(2-fluoro-
4-methylphenyl)-5-methyl- 4-phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 144 ##STR00174##
2-(((1s,4s)-4-((3-(4-chloro- 2-fluorophenyl)-5-methyl-
4-phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
145 ##STR00175## 2-(((1s,4s)-4-((3-(2-fluoro- 4-methoxyphenyl)-5-
methyl-4-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic
acid 146 ##STR00176## 2-(((1s,4s)-4-((5-(2- hydroxyethylthio)-3,4-
diphenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
147 ##STR00177## 2-(((1s,4s)-4-((4-(5- fluoropyridin-3-yl)-5-
methyl-3-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic
acid 148 ##STR00178## 2-(((1s,4s)-4-((5- (ethylthio)-4-(5-
fluoropyridin-3-yl)-3- phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 149 ##STR00179## 2-(((1s,4s)-4-((5-ethyl-4-(5-
fluoropyridin-3-yl)-3- phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 150 ##STR00180## 2-(((1s,4s)-4-((1-phenyl-
4,5-dihydro-3H- benzo[e]indazol-3- yl)methyl)cyclohexyl)
methoxy)acetic acid 151 ##STR00181## 2-(((1s,4s)-4-((3,4-
diphenyl-5- (trifluoromethyl)-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid
152 ##STR00182## 2-(((1s,4s)-4-((3-phenyl-4-
p-tolyl-5-(trifluoromethyl)- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 153 ##STR00183## 2-(((1s,4s)-4-((4-(3-
hydroxyphenyl)-5-methyl- 3-phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 154 ##STR00184##
2-(((1s,4s)-4-((4-(3- methoxyphenyl)-5-phenyl-
3-(trifluoromethyl)-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 155 ##STR00185## 2-(((1s,4s)-4-((4-(3-
methoxyphenyl)-3-phenyl- 5-(trifluoromethyl)-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 156 ##STR00186##
2-(((1R,4s)-4-((3-((S)-3,4- dihydroxybutyl)-4,5-
diphenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
157 ##STR00187## 2-(((1R,4s)-4-((5-((S)-3,4- dihydroxybutyl)-3,4-
diphenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
158 ##STR00188## 2-(((1R,4s)-4-((5-((S)-3,4- dihydroxybutyl)-4-(3-
fluorophenyl)-3-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 159 ##STR00189## 2-(((1s,4s)-4-((4-(3,4-
difluorophenyl)-3-((S)-3,4- dihydroxybutyl)-5-phenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 160 ##STR00190##
2-(((1R,4s)-4-((4-(3,4- difluorophenyl)-5-((S)-3,4-
dihydroxybutyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 161 ##STR00191## 2-(((1R,4s)-((5-((S)-3,4-
dihydroxybutyl)-4-(3- hydroxyphenyl)-3-phenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 162 ##STR00192##
2-(((1R,4s)-4-((4-(3- chlorophenyl)-5-((S)-3,4-
dihydroxybutyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 163 ##STR00193## 2-(((1s,4s)-4-((3-(4-
chlorophenyl)-5-ethyl-4- phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 164 ##STR00194## 2-(((1s,4s)-4-((5-ethyl-3-(4-
fluorophenyl)-4-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 165 ##STR00195## 2-(((1s,4s)-4-((5-ethyl-3-(2-
fluoro-4-methoxyphenyl)- 4-phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 166 ##STR00196##
2-(((1s,4s)-4-((5-ethyl-3-(4- methoxyphenyl)-4-phenyl-
1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 167
##STR00197## 2-(((1s,4s)-4-((5-ethyl-3-(2-
fluoro-4-methylphenyl)-4- phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 168 ##STR00198##
2-(((1s,4s)-4-((5-ethyl-4- phenyl-3-p-tolyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 169 ##STR00199##
2-(((1S,4s)-4-((5-((R)-3,4- dihydroxybutyl)-4-(3-
fluorophenyl)-3-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 170 ##STR00200## 2-(((1S,4s)-4-((4-(3,4-
difluorophenyl)-5-((R)-3,4- dihydroxybutyl)-3-phenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 171 ##STR00201##
2-(((1S,4s)-4-((4-(3- chlorophenyl)-5-((R)-3,4-
dihydroxybutyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 172 ##STR00202## 2-(((1s,4s)-4-((5-ethyl-4-(3-
hydroxyphenyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 173 ##STR00203## 2-(((1s,4s)-4-((4-(3-
hydroxyphenyl)-5- (methylthio)-3-phenyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 174 ##STR00204##
2-(((1s,4s)-4-((5- (ethylthio)-4-(2-fluoro-3-
hydroxyphenyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 175 ##STR00205## 2-(((1s,4s)-4-((5-ethyl-3-(4-
hydroxyphenyl)-4-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 176 ##STR00206## 2-(((1s,4s)-4-((3-(4-chloro-
3-fluorophenyl)-5-ethyl-4- phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 177 ##STR00207##
2-(((1s,4s)-4-((5- (ethylthio)-4-(3- hydroxyphenyl)-3-phenyl-
1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 178
##STR00208## 2-(((1s,4s)-4-((5-(2- methoxyethyl)-3,4-
diphenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
179 ##STR00209## 2-(((1s,4s)-4-((5-(2- methoxyethyl)-4-(3-
methoxyphenyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 180 ##STR00210## 2-(((1s,4s)-4-((4-(3-
hydroxyphenyl)-5-(2- methoxyethyl)-3-phenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 181 ##STR00211##
2-(((1s,4s)-4-((5-(2- methoxyethyl)-4-(6- methoxypyridin-3-yl)-3-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 182
##STR00212## 2-(((1s,4s)-4-((4-(2-fluoro- 3-hydroxyphenyl)-5-(2-
methoxyethyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 183 ##STR00213## 2-(((1s,45)-4-((3-
(cyanomethylthio)-4,5- diphenyl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 184 ##STR00214## 2-(((1s,4s)-4-((5-
(cyanomethylthio)-3,4- diphenyl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 185 ##STR00215## 2-(((1s,4s)-4-((3-(2-
ethoxyethylthio)-4,5- diphenyl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 186 ##STR00216## 2-(((1s,4s)-4-((5-(2-
ethoxyethylthio)-3,4- diphenyl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 187 ##STR00217## 2-(((1s,4s)-4-((5-(3-
hydroxypropylthio)-3,4- diphenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 188 ##STR00218##
2-(((1s,4s)-4-((3-(2- methoxyethylthio)-4,5- diphenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 189 ##STR00219##
2-(((1s,4s)-4-((5-(2- methoxyethylthio)-3,4- diphenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 190 ##STR00220##
2-(((1s,4s)-4-((4-(2,3- difluorophenyl)-5-(2-
methoxyethyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 191 ##STR00221## 2-(((1s,4s)-4-((4-(3-chloro-
2-fluorophenyl)-5-(2- methoxyethyl)-3-phenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 192 ##STR00222##
2-(((1s,4s)-4-((4-(2-fluoro- 3-methylphenyl)-5-(2-
methoxyethyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 193 ##STR00223## 2-(((1s,4s)-4-((5-(2-
methoxyethyl)-3-phenyl-4- m-tolyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 194 ##STR00224##
2-(((1s,4s)-4-((4-(3- fluorophenyl)-5-(2- methoxyethyl)-3-phenyl-
1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 195
##STR00225## 2-(((1s,4s)-4-((4-(2- methoxypyridin-4-yl)-5-
methyl-3-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic
acid 196 ##STR00226## 2-(((1s,4s)-4-((5-ethyl-4-(2-
methoxypyridin-4-yl)-3- phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 197 ##STR00227## 2-(((1s,4s)-4-((4-(3-
chlorophenyl)-5-(2- methoxyethyl)-3-phenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) mcthoxy)acetic acid 198 ##STR00228##
2-(((1s,4s)-4-((5-(2- hydroxyethylthio)-4-(3-
methoxyphenyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 199 ##STR00229## 2-(((1s,4s)-4-((4-(3-
chlorophenyl)-5-(2- hydroxyethylthio)-3- phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 200 ##STR00230##
2-(((1s,4s)-4-((5-(2- hydroxyethylthio)-4- phenyl-3-p-tolyl-1H-
pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 201
##STR00231## 2-(((1s,4s)-4-((5-ethyl-4-(5- methoxypyridin-3-yl)-3-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 202
##STR00232## 2-(((1s,4s)-4-((4-(3- methoxyphenyl)-3-phenyl-
5-propyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
203 ##STR00233## 2-(((1s,4s)-4-((4-(3- fluorophenyl)-3-phenyl-5-
propyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 204
##STR00234## 2-(((1s,4s)-4-((4-(3- chlorophenyl)-3-phenyl-5-
propyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 205
##STR00235## 2-(((1s,4s)-4-((3-phenyl-5- propyl-4-m-tolyl-1H-
pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 206
##STR00236## 2-(((1s,4s)-4-((4-(2-fluoro- 3-methoxyphenyl)-3-
phenyl-5-propyl-1H- pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic
acid 207 ##STR00237## 2-(((1s,4s)-4-((4-(2,3-
difluorophenyl)-3-phenyl- 5-propyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 208 ##STR00238##
2-(((1s,4s)-4-((4-(3-chloro- 2-fluorophenyl)-3-phenyl-
5-propyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
209 ##STR00239## 2-(((1s,4s)-4-((4-(2-fluoro-
3-methylphenyl)-3-phenyl- 5-propyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 210 ##STR00240##
2-(((1s,4s)-4-((5-(2- hydroxyethylthio)-3- phenyl-4-m-tolyl-1H-
pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 211
##STR00241## 2-(((1s,4s)-4-((4-(2-fluoro- 3-hydroxyphenyl)-3-
phenyl-5-propyl-1H- pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic
acid 212 ##STR00242## 2-(((1s,4s)-4-((4-(3- fluorophenyl)-5-(2-
hydroxyethylthio)-3- phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 213 ##STR00243## 2-(((1s,4s)-4-((4-(2-fluoro-
3-hydroxyphenyl)-5-(2- (methylthio)ethyl)-3- phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 214 ##STR00244##
2-(((1s,4s)-4-((4-(5- methoxypyridin-3-yl)-5- methyl-3-phenyl-1H-
pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 215
##STR00245## 2-(((1s,4s)-4-((4-(3-chloro- 2-fluorophenyl)-5-(2-
(methylthio)ethyl)-3- phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 216 ##STR00246## 2-(((1s,4s)-4-((5-(2-
(methylthio)ethyl)-3- phenyl-4-m-tolyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 217 ##STR00247##
2-(((1s,4s)-4-((4-(3- chlorophenyl)-5-(2- hydroxyethylsulfinyl)-3-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 218
##STR00248## 2-(((1s,4s)-4-((4-(2-fluoro- 3-methylphenyl)-5-(2-
(methylthio)ethyl)-3- phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 219 ##STR00249## 2-(((1s,4s)-4-((4-(3-chloro-
2-fluorophenyl)-5-(2- (methylsulfinyl)ethyl)-3-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 220
##STR00250## 2-(((1s,4s)-4-((5-(2- (methylsulfinyl)ethyl)-3-
phenyl-4-m-tolyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
melhoxy)acetic acid 221 ##STR00251## 2-(((1s,4s)-4-((4-(3-
hydroxyphenyl)-5-(2- (methylthio)ethyl)-3- phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 222 ##STR00252##
2-(((1s,4s)-4-((4-(3- fluorophenyl)-5-(2- (methylthio)ethyl)-3-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
223 ##STR00253## 2-(((1s,4s)-4-((5-(4- fluorophenyl)-4-phenyl-3-
propyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 224
##STR00254## 2-(((1s,4s)-4-((3-(4- fluorophenyl)-4-phenyl-5-
propyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 225
##STR00255## 2-(((1s,4s)-4-((5-(4-chloro- 3-fluorophenyl)-4-phenyl-
3-propyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
226 ##STR00256## 2-(((1s,4s)-4-((3-(4-chloro-
3-fluorophenyl)-4-phenyl- 5-propyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 227 ##STR00257##
2-(((1s,4s)-4-((5-(4- chlorophenyl)-4-phenyl-3-
propyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 228
##STR00258## 2-(((1s,4s)-4-((3-(4- chlorophenyl)-4-phenyl-5-
propyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 229
##STR00259## 2-(((1s,4s)-4-((5-(3,4- difluorophenyl)-4-phenyl-
3-propyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
230 ##STR00260## 2-(((1s,4s)-4-((3-(3,4- difluorophenyl)-4-phenyl-
5-propyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
231 ##STR00261## 2-(((1s,4s)-4-((5-(2-fluoro- 4-methoxyphenyl)-4-
phenyl-3-propyl-1H- pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic
acid 232 ##STR00262## 2-(((1s,4s)-4-((3-(2-fluoro-
4-methoxyphenyl)-4- phenyl-5-propyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 233 ##STR00263##
2-((1s,4s)-4-((5-(4- methoxyphenyl)-4-phenyl-
3-propyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
234 ##STR00264## 2-(((1s,4s)-4-((3-(4- methoxyphenyl)-4-phenyl-
5-propyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
235 ##STR00265## 2-(((1s,4s)-4-((5-(2-fluoro-
4-methylphenyl)-4-phenyl- 3-propyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 236 ##STR00266##
2-(((1s,4s)-4-((3-(2-fluoro- 4-methylphenyl)-4-phenyl-
5-propyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
237 ##STR00267## 2-(((1s,4s)-4-((4-(3- chlorophenyl)-5-(2-
(methylthio)ethyl)-3- phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 238 ##STR00268## 2-(((1s,4s)-4-((5-(2-
(methylthio)ethyl)-3,4- diphenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 239 ##STR00269##
2-(((1s,4s)-4-((5-(2-fluoro- 4-methylphenyl)-3-(2-
methoxyethyl)-4-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 240 ##STR00270## 2-(((1s,4s)-4-((3-(2-fluoro-
4-methylphenyl)-5-(2- methoxyethyl)-4-phenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 241 ##STR00271##
2-(((1s,4s)-4-((4-(2-fluoro- 4-methylphenyl)-5-(2-
methoxyethyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 242 ##STR00272## 2-(((1s,4s)-4-((4-(2-fluoro-
4-methylphenyl)-5-(2- (methylthio)ethyl)-3- phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 243 ##STR00273##
2-(((1s,4s)-4-((4-(3- methoxyphenyl)-5-(2- (methylthio)ethyl)-3-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 244
##STR00274## 2-(((1s,4s)-((4-(2,3- difluorophenyl)-5-(2-
(methylthio)ethyl)-3- phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 245 ##STR00275## 2-(((1r,4r)-4-((3-
(cyanomethylthio)-4-(3- methoxyphenyl)-5-phenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 246 ##STR00276##
2-(((1s,4s)-4-((5- (cyanomethylthio)-4-(3- methoxyphenyl)-3-phenyl-
1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 247
##STR00277## 2-(((1s,4s)-4-((3-(2- methoxyethyl)-5-(3-
methoxyphenyl)-4-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 248 ##STR00278## 2-(((1s,41)-4-((5-(2-
methoxyethyl)-3-(3- methoxyphenyl)-4-phenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 249 ##STR00279##
2-(((1s,4s)-4-((4-(3-chloro- 2-fluorophenyl)-5-(2-
(methylsulfonyl)ethyl)-3- phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 250 ##STR00280##
2-(((1s,4s)-4-((5-(2- aminoethylthio)-4-phenyl-
3-p-tolyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
251 ##STR00281## 2-(((1s,4s)-4-((5-(2- hydroxyethyl)-3,4-
diphenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
252 ##STR00282## 2-(((1s,4s)-4-((5-(2- hydroxyethyl)-4-(3-
methoxyphenyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 253 ##STR00283## 2-(((1s,4s)-4-((4-(2,3-
difluorophenyl)-5-(2- hydroxyethyl)-3-phenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 254 ##STR00284##
2-(((1s,4s)-4-((4-(3- fluorophenyl)-5-(2- hydroxyethyl)-3-phenyl-
1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 255
##STR00285## 2-(((1s,4s)-4-((3-(4- fluorophenyl)-5-(2-
hydroxyethylthio)-4- phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 256 ##STR00286## 2-(((1s,4s)-4-((3-(4-
fluorophenyl)-3-(2- hydroxyethylthio)-4- phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 257 ##STR00287##
2-(((1s,4s)-4-((5- (cyanomethylthio)-4- phenyl-3-p-tolyl-1H-
pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 258
##STR00288## 2-(((1s,4s)-4-((5- (cyanomethylthio)-3-(4-
fluorophenyl)-4-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 259 ##STR00289## 2-(((1s,4s)-4-((3-(2-
cyanoethyl)-4,5-diphenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 260 ##STR00290## 2-(((1s,4s)-4-((5-(2-
cyanoethyl)-3,4-diphenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 261 ##STR00291## 2-(((1s,4s)-4-((3-(2-
cyanoethyl)-4-(3- methoxyphenyl)-5-phenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 262 ##STR00292##
2-(((1s,4s)-4-((5-(2- cyanoethyl)-4-(3- methoxyphenyl)-3-phenyl-
1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 263
##STR00293## 2-(((1s,4s)-4-((5-(2- cyanoethyl)-4-(3-
hydroxyphenyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 264 ##STR00294## 2-(((1s,4s)-4-((4-(3-
chlorophenyl)-3-(2- cyanoethyl)-5-phenyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 265 ##STR00295##
2-(((1s,4s)-4-((4-(3- chlorophenyl)-5-(2- cyanoethyl)-3-phenyl-1H-
pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 266
##STR00296## 2-(((1s,4s)-4-((3-(2- cyanoethyl)-4-(3-
fluorophenyl)-5-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 267 ##STR00297## 2-(((1s,4s)-4-((5-(2-
cyanoethyl)-4-(3- fluorophenyl)-3-phenyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 268 ##STR00298##
2-(((1s,4s)-4-((3-(2- cyanoethyl)-4-(3- hydroxyphenyl)-5-phenyl-
1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 269
##STR00299## 2-(((1s,4s)-4-((4-(3-chloro- 2-fluorophenyl)-3-(2-
cyanoethyl)-5-phenyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 270 ##STR00300## 2-(((1s,4s)-4-((4-(3-chloro-
2-fluorophenyl)-5-(2- cyanoethyl)-3-phenyl-1H- pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 271 ##STR00301##
2-(((1s,4s)-4-((5-(3- hydroxypropyl)-3,4- diphenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 272 ##STR00302##
2-(((1s,4s)-4-((5-(3- hydroxypropyl)-4-(3- methoxyphenyl)-3-phenyl-
1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 273
##STR00303## 2-(((1s,4s)-4-((4-(2,3- difluorophenyl)-5-(3-
hydroxypropyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 274 ##STR00304## 2-(((1s,4s)-4-((4-(3-
fluorophenyl)-5-(3- hydroxypropyl)-3-phenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 275 ##STR00305##
2-(((1s,4s)-4-((4-(3- chlorophenyl)-5- (cyanomethylthio)-3-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 276
##STR00306## 2-(((1s,4s)-4-((4-(3-chloro- 2-fluorophenyl)-5-(2-
hydroxyethyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 277 ##STR00307## 2-(((1r,4r)-4-((3-(2-amino-
2-oxoethoxy)-4-(3- methoxyphenyl)-5-phenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 278 ##STR00308##
2-(((1s,4s)-4-((5-(2-amino- 2-oxoethoxy)-4-(3-
methoxyphenyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 279 ##STR00309## 2-(((1r,4r)-4-((3-(2-amino-
2-oxoethoxy)-4-(2-fluoro- 3-methoxyphenyl)-5- phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 280 ##STR00310##
2-(((1s,4s)-4-((5-(2-amino- 2-oxoethoxy)-4-(2-fluoro-
3-methoxyphenyl)-3- phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 281 ##STR00311## 2-(((1s,4s)-4-((4-(3-chloro-
2-fluorophenyl)-5-(3- hydroxypropyl)-3-phenyl- 1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 282 ##STR00312##
2-(((1s,4s)-4-((4-(3- chlorophenyl)-5-(3- hydroxypropyl)-3-phenyl-
1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid 283
##STR00313## 2-(1s,4s)-4-((5- (cyanomethoxy)-4-(3-
methoxyphenyl)-3-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 284 ##STR00314## 2-(((1s,4s)-4-((3-(3,4-
difluorophenyl)-5-ethyl-4- phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 285 ##STR00315##
2-(((1s,4s)-4-((5-(2-fluoro- 4-methylphenyl)-3-(2-
hydroxyethyl)-4-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 286 ##STR00316## 2-(((1s,4s)-4-((5-(2-fluoro-
4-methylphenyl)-3-methyl- 4-phenyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 287 ##STR00317##
2-(((1s,4s)-4-((3-(2-fluoro- 4-methylphenyl)-5-(2-
hydroxyethyl)-4-phenyl- 1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 288 ##STR00318## 2-(((1s,4s)-4-((5-(3- hy
droxypropyl)-4-phenyl- 3-p-tolyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 289 ##STR00319##
2-(((1s,4s)-4-((3-(3- hydroxypropyl)-4-phenyl-
5-p-tolyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid
290 ##STR00320## 2-(((1s,4s)-4-((5-(2- (methylsulfonyl)ethyl)-4-
phenyl-3-p-tolyl-1H- pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 291 ##STR00321## 2-(((1s,4s)-4-((3-(2-fluoro-
4-methylphenyl)-5-(2- (methylsulfonyl)ethyl)-4-
phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl)
methoxy)acetic acid 292 ##STR00322## 2-(((1s,4s)-4-((5-(2-
hydroxyethyl)-4-phenyl-3- p-tolyl-1H-pyrazol-1-
yl)methyl)cyclohexyl) methoxy)acetic acid 293 ##STR00323##
2-(((1s,4s)-4-((1-p-tolyl- 4,5-dihydro-3H- benzo[e]indazol-3-
yl)methyl)cyclohexyl) methoxy)acetic acid
[0453] Additionally, individual compounds and chemical genera of
the present invention, for example those compounds found in TABLE A
including diastereoisomers and enantiomers thereof, encompass all
pharmaceutically acceptable salts, solvates and particularly
hydrates, thereof.
[0454] The compounds of the Formula Ia of the present invention may
be prepared according to relevant published literature procedures
that are used by one skilled in the art. Exemplary reagents and
procedures for these reactions appear hereinafter in the working
Examples. Protection and deprotection may be carried out by
procedures generally known in the art (see, for example, Greene, T.
W. and Wuts, P. G. M., Protecting Groups in Organic Synthesis,
3.sup.rd Edition, 1999 [Wiley]; incorporated herein by reference in
its entirety).
[0455] It is understood that the present invention embraces each
diastereoisomer, each enantiomer and mixtures thereof of each
compound and generic formulae disclosed herein just as if they were
each individually disclosed with the specific stereochemical
designation for each chiral carbon. Separation of the individual
isomers (such as, by chiral HPLC, recrystallization of
diastereoisomeric mixtures and the like) or selective synthesis
(such as, by enantiomeric selective syntheses and the like) of the
individual isomers is accomplished by application of various
methods which are well known to practitioners in the art.
Indications and Methods of Prophylaxis and/or Treatment
[0456] In addition to the foregoing beneficial uses for the
modulators of PGI2 receptor activity disclosed herein, the
compounds disclosed herein are useful in the treatment of several
additional diseases and disorders, and in the amelioration of
symptoms thereof. Without limitation, these include the
following:
[0457] 1. Pulmonary Arterial Hypertension (PAH)
[0458] Pulmonary arterial hypertension (PAH) has a multifactorial
pathobiology. Vasoconstriction, remodeling of the pulmonary vessel
wall, and thrombosis contribute to increased pulmonary vascular
resistance in PAH (Humbert et al., J. Am. Coll. Cardiol., 2004,
43:13 S-24S.)
[0459] The compounds of the present invention disclosed herein are
useful in the treatment of pulmonary arterial hypertension (PAH)
and symptoms thereof. PAH shall be understood to encompass the
following forms of pulmonary arterial hypertension described in the
2003 World Health Organization (WHO) clinical classification of
pulmonary arterial hypertension: idiopathic PAH (IPAH); familial
PAH (FPAH); PAH associated with other conditions (APAH), such as
PAH associated with collagen vascular disease, PAH associated with
congenital systemic-to-pulmonary shunts, PAH associated with portal
hypertension, PAH associated with HIV infection, PAH associated
with drugs or toxins, or PAH associated with Other; and PAH
associated with significant venous or capillary involvement.
[0460] Idiopathic PAH refers to PAH of undetermined cause.
[0461] Familial PAH refers to PAH for which hereditary transmission
is suspected or documented.
[0462] PAH associated with collagen vascular disease shall be
understood to encompass PAH associated with scleroderma, PAH
associated with CREST (calcinosis cutis, Raynaud's phenomenon,
esophageal dysfunction, sclerodactyl), and telangiectasias)
syndrome, PAH associated with systemic lupus erythematosus (SLE),
PAH associated with rheumatoid arthritis, PAH associated with
Takayasu's arteritis, PAH associated with polymyositis, and PAH
associated with dermatomyositis.
[0463] PAH associated with congenital systemic-to-pulmonary shunts
shall be understood to encompass PAH associated with atrial septic
defect (ASD), PAH associated with ventricular septic defect (VSD)
and PAH associated with patent ductus arteriosus.
[0464] PAH associated with drugs or toxins shall be understood to
encompass PAH associated with ingestion of a minorex, PAH
associated with ingestion of a fenfluramine compound (e.g., PAH
associated with ingestion of fenfluramine or PAH associated with
ingestion of dexfenfluramine), PAH associated with ingestion of
certain toxic oils (e.g., PAH associated with ingestion of rapeseed
oil), PAH associated with ingestion of pyrrolizidine alkaloids
(e.g., PAH associated with ingestion of bush tea) and PAH
associated with ingestion of monocrotaline.
[0465] PAH associated with Other shall be understood to encompass
PAH associated with a thyroid disorder, PAH associated with
glycogen storage disease, PAH associated with Gaucher disease, PAH
associated with hereditary hemorrhagic telangiectasia, PAH
associated with a hemoglobinopathy, PAH associated with a
myeloproliferative disorder, and PAH associated with
splenectomy.
[0466] PAH associated with significant venous or capillary
involvement shall be understood to encompass PAH associated with
pulmonary veno-occlusive disease (PVOD) and PAH associated with
pulmonary capillary hemangiomatosis (PCH).
[0467] (See, e.g., Simonneau et al., J. Am. Coll. Cardiol., 2004,
43:5 S-12S; McGoon et al., Chest, 2004, 126:14 S-34S; Rabinovitch,
Annu. Rev. Pathol. Mech. Dis., 2007, 2:369-399; McLaughlin et al.,
Circulation, 2006, 114:1417-1431; Strauss et al., Clin. Chest.
Med., 2007, 28:127-142; Taichman et al., Clin. Chest. Med., 2007,
28:1-22.)
[0468] Evidence for the association of PAH with scleroderma and the
beneficial effect of an agonist of the PGI2 receptor on PAH is
given by Badesch et al. (Badesch et al., Ann. Intern. Med., 2000,
132:425-434). Evidence for the association of PAH with the collagen
vascular diseases mixed connective tissue disease (MCTD), systemic
lupus erythematosus (SLE), Sjogren's syndrome and CREST syndrome
and the beneficial effect of an agonist of the PGI2 receptor on PAH
is given by Humbert et al. (Eur. Respir. J., 1999, 13:1351-1356).
Evidence for the association of PAH with CREST syndrome and the
beneficial effect of an agonist of the PGI2 receptor on PAH is
given by Miwa et at (Int. Heart J., 2007, 48:417-422). Evidence for
the association of PAH with SLE and the beneficial effect of an
agonist of the PGI2 receptor on PAH is given by Robbins et al.
(Chest, 2000, 117:14-18). Evidence for the association of PAH with
HIV infection and the beneficial of an agonist of the PGI2 receptor
on PAH is given by Aguilar et al. (Am. J. Respir. Crit. Care Med.,
2000, 162:1846-1850). Evidence for the association of PAH with
congenital heart defects (including ASD, VSD and patent ductus
arteriosus) and the beneficial effect of an agonist of the PGI2
receptor on PAH is given by Rosenzweig et al. (Circulation, 1999,
99:1858-1865). Evidence for the association of PAH with
fenfluramine and with dexfenfluramine, anorexigens, is given by
Archer et al. (Am. J. Respir. Crit. Care Med., 1998,
158:1061-1067). Evidence for the association of PAH with hereditary
hemorrhagic telangiectasia is given by McGoon et al. (Chest, 2004,
126:14-34). Evidence for the association of PAH with splenectomy is
given by Hoeper et al. (Ann. Intern. Med., 1999, 130:506-509).
Evidence for the association of PAH with portal hypertension and
the beneficial effect of an agonist of the PGI2 receptor on PAH is
given by Hoeper et al. (Eur. Respir. J., 2005, 25:502-508).
[0469] Symptoms of PAH include dyspnea, angina, syncope and edema
(McLaughlin et al., Circulation, 2006, 114:1417-1431). The
compounds of the present invention disclosed herein are useful in
the treatment of symptoms of PAH.
[0470] Tawara et al. have demonstrated that long-term inhibition of
Rho-kinase, an effector of the small GTPase Rho, ameliorates
monocrotaline-induced PAH in rats and hypoxia-induced PAH in mice.
The same group also reported that prostacyclin and its oral analog,
beraprost sodium (BPS), may lack direct inhibitory effect on
Rho-kinase in vitro, suggesting that combination therapy with a
Rho-kinase inhibitor and BPS is effective for the treatment of PAH.
Thus, male Sprague-Dawley rats were given a s.c. injection of
monocrotaline (60 mg/kg) and maintained with or without the
treatment with a Rho-kinase inhibitor, fasudil (30 mg/kg/day), BPS
(200 .mu.g/kg/day), or a combination of both drugs for three weeks.
The combination therapy, when compared with each monotherapy,
showed significantly more improvement in PAH, right ventricular
hypertrophy, and pulmonary medial thickness without any adverse
effects. (See, Tawara et al., Journal of Cardiovascular
Pharmacology (2007), 50(2), 195-200.)
[0471] The PGI2 receptor agonists disclosed herein, alone or in
combination with a Rho-kinase inhibitor, are useful in the
treatment of pulmonary arterial hypertension (PAH) and symptoms
thereof.
[0472] The enzyme tryptophan hydroxylase (TPH), has two known
isoforms: TPH1, which is expressed in the periphery, and TPH2,
which is expressed primarily in the brain. Mice genetically
deficient for the TPH1 gene ("knockout mice") have been reported.
In one case, the mice reportedly expressed normal amounts of
serotonin in classical serotonergic brain regions, but largely
lacked serotonin in the periphery. Walther, D. J., et al., Science
299:76 (2003). In another, the knockout mice exhibited abnormal
cardiac activity, which was attributed to a lack of peripheral
serotonin. Cote, F., et al., PNAS 100(23):13525-13530 (2003).
[0473] Recently, TPH knockout mice were studied in a
hypoxia-induced pulmonary arterial hypertension model. Morecroft,
I., et al., Hypertension 49:232-236 (2007). The results of those
studies suggest that TPH1 and peripheral serotonin play an
essential role in the development of hypoxia-induced elevations in
pulmonary pressures and hypoxia-induced pulmonary vascular
remodeling.
[0474] The PGI2 receptor agonists disclosed herein, alone or in
combination with a tryptophan hydroxylase inhibitor, are useful in
the treatment of pulmonary arterial hypertension (PAH) and symptoms
thereof.
[0475] 2. Antiplatelet Therapies (Conditions related to Platelet
Aggregation)
[0476] Antiplatelet agents (antiplatelets) are prescribed for a
variety of conditions. For example, in coronary artery disease they
are used to help prevent myocardial infarction or stroke in
patients who are at risk of developing obstructive blood clots
(e.g., coronary thrombosis).
[0477] In a myocardial infarction ("MI" or "heart attack"), the
heart muscle does not receive enough oxygen-rich blood as a result
of a blockage in the coronary blood vessels. If taken while an
attack is in progress or immediately afterward (preferably within
30 min), antiplatelets can reduce the damage to the heart.
[0478] A transient ischemic attack ("TIA" or "mini-stroke") is a
brief interruption of oxygen flow to the brain due to decreased
blood flow through arteries, usually due to an obstructing blood
clot. Antiplatelet drugs have been found to be effective in
preventing TIAs.
[0479] Angina is a temporary and often recurring chest pain,
pressure or discomfort caused by inadequate oxygen-rich blood flow
(ischemia) to some parts of the heart. In patients with angina,
antiplatelet therapy can reduce the effects of angina and the risk
of myocardial infarction.
[0480] Stroke is an event in which the brain does not receive
enough oxygen-rich blood, usually due to blockage of a cerebral
blood vessel by a blood clot. In high-risk patients, taking
antiplatelets regularly has been found to prevent the formation of
blood clots that cause first or second strokes.
[0481] Angioplasty is a catheter based technique used to open
arteries obstructed by a blood clot. Whether or not stenting is
performed immediately after this procedure to keep the artery open,
antiplatelets can reduce the risk of forming additional blood clots
following the procedure(s).
[0482] Coronary bypass surgery is a surgical procedure in which an
artery or vein is taken from elsewhere in the body and grafted to a
blocked coronary artery, rerouting blood around the blockage and
through the newly attached vessel. After the procedure,
antiplatelets can reduce the risk of secondary blood clots.
[0483] Atrial fibrillation is the most common type of sustained
irregular heart rhythm (arrhythmia). Atrial fibrillation affects
about two million Americans every year. In atrial fibrillation, the
atria (the heart's upper chambers) rapidly fire electrical signals
that cause them to quiver rather than contract normally. The result
is an abnormally fast and highly irregular heartbeat. When given
after an episode of atrial fibrillation, antiplatelets can reduce
the risk of blood clots forming in the heart and traveling to the
brain (embolism).
[0484] There is evidence that a PGI2 receptor agonist will inhibit
platelet aggregation and thus be a potential treatment as an
antiplatelet therapy (see, e.g., Moncada et al., Lancet, 1977,
1:18-20). It has been shown that genetic deficiency of the PGI2
receptor in mice leads to an increased propensity towards
thrombosis (Murata et al., Nature, 1997, 388:678-682).
[0485] PGI2 receptor agonists can be used to treat, for example,
claudication or peripheral artery disease as well as cardiovascular
complications, arterial thrombosis, atherosclerosis,
vasoconstriction caused by serotonin, ischemia-reperfusion injury,
and restenosis of arteries following angioplasty or stent
placement. (See, e.g., Fetalvero et al., Prostaglandins Other Lipid
Mediat., 2007, 82:109-118; Arehart et al., Curr. Med. Chem., 2007,
14:2161-2169; Davi et al., N. Engl. J. Med., 2007, 357:2482-2494;
Fetalvero et al., Am. J. Physiol. Heart. Circ. Physiol., 2006,
290:H1337-H1346; Murata et al., Nature, 1997, 388:678-682; Wang et
al., Proc. Natl. Acad. Sci. USA, 2006, 103:14507-14512; Xiao et
al., Circulation, 2001, 104:2210-2215; McCormick et al., Biochem.
Soc. Trans., 2007, 35:910-911; Arehart et al., Circ. Res., 2008,
102(8), 986-93.)
[0486] PGI2 receptor agonists can also be used alone or in
combination with thrombolytic therapy, for example, tissue-type
plasminogen activator (t-PA), to provide cardioprotection following
MI or postischemic myocardial dysfunction or protection from
ischemic injury during percutaneous coronary intervention, and the
like, including complications resulting therefrom. PGI2 receptor
agonists can also be used in antiplatelet therapies in combination
with, for example, alpha-tocopherol (vitamin E), echistatin (a
disintegrin) or, in states of hypercoagulability, heparin. (See,
e.g., Chan., J. Nutr., 1998, 128:1593-1596; Mardla et al.,
Platelets, 2004, 15:319-324; Bernabei et al., Ann. Thorac. Surg.,
1995, 59:149-153; Gainza et al., J. Nephrol., 2006,
19:648-655.)
[0487] The PGI2 receptor agonists disclosed herein provide
beneficial improvement in microcirculation to patients in need of
antiplatelet therapy by antagonizing the vasoconstrictive products
of the aggregating platelets in, for example and not limited to the
indications described above. Accordingly, in some embodiments, the
present invention provides methods for reducing platelet
aggregation in a patient in need thereof, comprising administering
to the patient a composition comprising a PGI2 receptor agonist
disclosed herein. In further embodiments, the present invention
provides methods for treating coronary artery disease, myocardial
infarction, transient ischemic attack, angina, stroke, atrial
fibrillation, or a symptom of any of the foregoing in a patient in
need of the treatment, comprising administering to the patient a
composition comprising a PGI2 receptor agonist disclosed
herein.
[0488] In further embodiments, the present invention provides
methods for reducing risk of blood clot formation in an angioplasty
or coronary bypass surgery patient, or a patient suffering from
atrial fibrillation, comprising administering to the patient a
composition comprising a PGI2 receptor agonist disclosed herein at
a time where such risk exists.
[0489] 3. Atherosclerosis
[0490] Atherosclerosis is a complex disease characterized by
inflammation, lipid accumulation, cell death and fibrosis. It is
the leading cause of mortality in many countries, including the
United States. Atherosclerosis, as the term is used herein, shall
be understood to encompass disorders of large and medium-sized
arteries that result in the progressive accumulation within the
intima of smooth muscle cells and lipids.
[0491] It has been shown that an agonist of the PGI2 receptor can
confer protection from atherosclerosis, such as from
atherothrombosis (Arehart et al., Curr. Med. Chem., 2007,
14:2161-2169; Stitham et al., Prostaglandins Other Lipid Mediat.,
2007, 82:95-108; Fries et al., Hematology Am. Soc. Hematol. Educ.
Program, 2005, :445-451; Egan et al., Science, 2004, 306:1954-1957;
Kobayashi et al., J. Clin. Invest., 2004, 114:784-794; Arehart et
al., Circ. Res., 2008, 102(8), 986-93).
[0492] It has been shown that defective PGI2 receptor signaling
appears to accelerate atherothrombosis in humans, i.e. that an
agonist of the PGI2 receptor can confer protection from
atherothrombosis in humans (Arehart et al., Circ. Res., 2008,
102(8), 986-93).
[0493] The compounds of the present invention disclosed herein are
useful in the treatment of atherosclerosis, and the treatment of
the symptoms thereof. Accordingly, in some embodiments, the present
invention provides methods for treating atherosclerosis in a
patient in need of the treatment, comprising administering to the
patient a composition comprising a PGI2 receptor agonist disclosed
herein. In further embodiments, methods are provided for treating a
symptom of atherosclerosis irra patient in need of the treatment,
comprising administering to the patient a composition comprising a
PGI2 receptor agonist disclosed herein.
[0494] 4. Asthma
[0495] Asthma is a lymphocyte-mediated inflammatory airway disorder
characterized by airway eosinophilia, increased mucus production by
goblet cells, and structural remodeling of the airway wall. The
prevalence of asthma has dramatically increased worldwide in recent
decades. It has been shown that genetic deficiency of the PGI2
receptor in mice augments allergic airway inflammation (Takahashi
et al., Br J Pharmacol, 2002, 137:315-322). It has been shown that
an agonist of the PGI2 receptor can suppress not only the
development of asthma when given during the sensitization phase,
but also the cardinal features of experimental asthma when given
during the challenge phase (Idzko et al., J. Clin. Invest., 2007,
117:464-472; Nagao et al., Am. J. Respir. Cell Mol. Biol., 2003,
29:314-320), at least in part through markedly interfering with the
function of antigen-presenting dendritic cells within the airways
(Idzko et al., J. Clin. Invest., 2007, 117:464-472; Zhou et al., J.
Immunol., 2007, 178:702-710; Jaffar et al., J. Immunol., 2007,
179:6193-6203; Jozefowski et al., Int. Immunopharmacol., 2003,
3:865-878). These cells are crucial for both the initiation and the
maintenance phases of allergic asthma, as depletion of airway
dendritic cells during secondary challenge in sensitized mice
abolished all characteristic features of asthma, an effect that
could be completely restored by adoptive transfer of wild-type
dendritic cells (van Rijt et al., J. Exp. Med., 2005, 201:981-991).
It has also been shown that an agonist of the PGI2 receptor can
inhibit proinflammatory cytokine secretion by human alveolar
macrophages (Raychaudhuri et al., J. Biol. Chem., 2002,
277:33344-33348). The compounds of the present invention disclosed
herein are useful in the treatment of asthma, and the treatment of
the symptoms thereof. Accordingly, in some embodiments, the present
invention provides methods for treating asthma in a patient in need
of the treatment, comprising administering to the patient a
composition comprising a PGI2 receptor agonist disclosed herein. In
further embodiments, methods are provided for treating a symptom of
asthma in a patient in need of the treatment, comprising
administering to the patient a composition comprising a PGI2
receptor agonist disclosed herein.
[0496] 5. Diabetic-Related Pathologies
[0497] Although hyperglycemia is the major cause for the
pathogenesis of diabetic complications such as diabetic peripheral
neuropathy (DPN), diabetic nephropathy (DN) and diabetic
retinopathy (DR), enhanced vasoconstriction and platelet
aggregation in diabetic patients has also been implicated to play a
role in disease progression (Cameron et al., Naunyn Schmiedebergs
Arch. Pharmacol., 2003, 367:607-614). Agonists of the PGI2 receptor
promote vasodilation and inhibit platelet aggregation. Improving
microvascular blood flow is able to benefit diabetic complications
(Cameron, Diabetologia, 2001, 44:1973-1988).
[0498] It has been shown that an agonist of the PGI2 receptor can
prevent and reverse motor and sensory peripheral nerve conduction
abnormalities in streptozotocin-diabetic rats (Cotter et al.,
Naunyn Schmiedebergs Arch. Pharmacol., 1993, 347:534-540). Further
evidence for the beneficial effect of an agonist of the PGI2
receptor in the treatment of diabetic peripheral neuropathy is
given by Hotta et al. (Diabetes, 1996, 45:361-366), Ueno et al.
(Jpn. J. Pharmacol., 1996, 70:177-182), Ueno et al. (Life Sci.,
1996, 59:PL105-PL110), Hotta et al. (Prostaglandins, 1995,
49:339-349), Shindo et al. (Prostaglandins, 1991, 41:85-96), Okuda
et al. (Prostaglandins, 1996, 52:375-384), and Koike et al. (FASEB
J., 2003, 17:779-781). Evidence for the beneficial effect of an
agonist of the PGI2 receptor in the treatment of diabetic
nephropathy is given by Owada et al. (Nephron, 2002, 92:788-796)
and Yamashita et al. (Diabetes Res. Clin. Pract., 2002,
57:149-161). Evidence for the beneficial effect of an agonist of
the PGI2 receptor in the treatment of diabetic retinopathy is given
by Yamagishi et al. (Mol. Med., 2002, 8:546-550), Burnette et al.
(Exp. Eye Res., 2006, 83:1359-1365), and Hotta et al. (Diabetes,
1996, 45:361-366). It has been shown that an agonist of the PGI2
receptor can reduce increased tumor necrosis factor-.alpha.
(TNF-.alpha.) levels in diabetic patients, implying that an agonist
of the PGI2 receptor may contribute to the prevention of
progression in diabetic complications (Fujiwara et al., Exp. Clin.
Endocrinol. Diabetes, 2004, 112:390-394).
[0499] 6. Glaucoma
[0500] Evidence that topical administration of an agonist of the
PGI2 receptor can result in a decrease in intraocular pressure
(IOP) in rabbits and dogs and thereby have beneficial effect in the
treatment of glaucoma is given by Hoyng et al. (Hoyng et al.,
Invest. Ophthalmol. Vis. Sci., 1987, 28:470-476).
[0501] 7. Hypertension
[0502] Agonists of the PGI2 receptor have been shown to have
activity for regulation of vascular tone, for vasodilation, and for
amelioration of pulmonary hypertension (see, e.g., Strauss et al.,
Clin Chest Med, 2007, 28:127-142; Driscoll et al., Expert Opin.
Pharmacother., 2008, 9:65-81). Evidence for a beneficial effect of
an agonist of the PGI2 receptor in the treatment of hypertension is
given by Yamada et al. (Peptides, 2008, 29:412-418). Evidence that
an agonist of the PGI2 receptor can protect against cerebral
ischemia is given by Dogan et al. (Gen. Pharmacol., 1996,
27:1163-1166) and Fang et al. (J. Cereb. Blood Flow Metab., 2006,
26:491-501).
[0503] 8. Anti-Inflammation Therapies
[0504] Anti-inflammation agents are prescribed for a variety of
conditions. For example, in an inflammatory disease they are used
to interfere with and thereby reduce an underlying deleterious
There is evidence that a PGI2 receptor agonist can inhibit
inflammation and thus be a potential treatment as an
anti-inflammation therapy. It has been shown that an agonist of the
PGI2 receptor can inhibit pro-inflammatory cytokine and chemokine
(interleukin-12 (IL-12), tumor necrosis factor-.alpha.
(INF-.alpha.), IL-1.alpha., IL-6, macrophage inflammatory protein-1
alpha (MIP-1.alpha.), monocyte chemoattractant protein-1 (MCP-1))
production and T cell stimulatory function of dendritic cells
(Jozefowski et al., Int. Immunopharmacol., 2003, 865-878; Zhou et
al., J. Immunol., 2007, 178:702-710; Nagao et al., Am. J. Respir.
Cell Mol. Biol., 2003, 29:314-320; Idzko et al., J. Clin. Invest.,
2007, 117:464-472). It has been shown that an agonist of the PGI2
receptor can inhibit pro-inflammatory cytokine (TNF-.alpha.,
IL-1.beta., IL-6, granulocyte macrophage stimulating factor
(GM-CSF)) production by macrophages (Raychaudhuri et al., J. Biol.
Chem., 2002, 277:33344-33348; Czeslick et al., Eur. J. Clin.
Invest., 2003, 33:1013-1017; Di Renzo et al., Prostaglandin Leukot.
Essent. Fatty Acids, 2005, 73:405-410; Shinomiya et al., Biochem.
Pharmacol., 2001, 61:1153-1160). It has been shown that an agonist
of the PGI2 receptor can stimulate anti-inflammatory cytokine
(IL-10) production by dendritic cells (Jozefowski et al., Int.
Immunopharmacol., 2003, 865-878; Zhou et al., J. Immunol., 2007,
178:702-710). It has been shown that an agonist of the PGI2
receptor can stimulate anti-inflammatory cytokine (IL-10)
production by macrophages (Shinomiya et al., Biochem. Pharmacol.,
2001, 61:1153-1160). It has been shown that an agonist of the PGI2
receptor can inhibit a chemokine (CCL17)-induced chemotaxis of
leukocytes (CD4.sup.+ Th2 T cells) (Jaffar et al., J. Immunol.,
2007, 179:6193-6203). It has been shown that an agonist of the PGI2
receptor can confer protection from atherosclerosis, such as from
atherothrombosis (Arehart et al., Curr. Med. Chem., 2007,
14:2161-2169; Stitham et al., Prostaglandins Other Lipid Mediat.,
2007, 82:95-108; Fries et al., Hematology Am. Soc. Hematol. Educ.
Program, 2005, :445-451; Egan et al., Science, 2004, 306:1954-1957;
Kobayashi et al., J. Clin. Invest., 2004, 114:784-794; Arehart et
al., Circ. Res., 2008, 102(8), 986-93). It has been shown that an
agonist of the PGI2 receptor can attenuate asthma (Idzko et al., J.
Clin. Invest., 2007, 117:464-472; Jaffar et al., J. Immunol., 2007,
179:6193-6203; Nagao et al., Am. J. Respir. Cell. Mol. Biol., 2003,
29:314-320). It has been shown that an agonist of the PGI2 receptor
can decrease TNF-.alpha. production in type 2 diabetes patients
(Fujiwara et al., Exp. Clin. Endocrinol. Diabetes, 2004,
112:390-394; Goya et al., Metabolism, 2003, 52:192-198). It has
been shown that an agonist of the PGI2 receptor can inhibit
ischemia-reperfusion injury (Xiao et al., Circulation, 2001,
104:2210-2215). It has been shown that an agonist of the PGI2
receptor can inhibit restenosis (Cheng et al., Science, 2002,
296:539-541). It has been shown that an agonist of the PGI2
receptor can attenuate pulmonary vascular injury and shock in a rat
model of septic shock (Harada et al., Shock, 2008, Feb. 21 Epub
ahead of print). It has been shown that an agonist of the PGI2
receptor can reduce the serum levels of TNF-.alpha. in vivo in
patients with rheumatoid arthritis, and this is associated with
improvement in the clinical course of the disease (Gao et al.,
Rheumatol. Int., 2002, 22:45-51; Boehme et al., Rheumatol. Int.,
2006, 26:340-347).
[0505] The compounds of the present invention disclosed herein
provide beneficial reduction of inflammation. The compounds of the
present invention disclosed herein provide beneficial reduction of
a deleterious inflammatory response associated with an inflammatory
disease. Accordingly, in some embodiments, the present invention
provides methods for reducing inflammation in a patient in need
thereof, comprising administering to the patient a composition
comprising a PGI2 receptor agonist disclosed herein. In some
embodiments, the present invention provides methods for decreasing
IL-12, TNF-.alpha., IL-1.alpha., IL-1.beta., IL-6, MIP-1.alpha. or
MCP-1 production in a patient in need thereof, comprising
administering to the patient a composition comprising a PGI2
receptor agonist disclosed herein. In some embodiments, the present
invention provides methods for decreasing TNF-.alpha. production in
a patient in need thereof, comprising administering to the patient
a composition comprising a PGI2 receptor agonist disclosed herein.
In some embodiments, the present invention provides methods for
increasing IL-10 production in a patient in need thereof,
comprising administering to the patient a composition comprising a
PGI2 receptor agonist disclosed herein. In some embodiments, the
present invention provides methods for reducing a deleterious
inflammatory response associated with an inflammatory disease in a
patient in need thereof, comprising administering to the patient a
composition comprising a PGI2 receptor agonist disclosed herein. In
some embodiments, the present invention provides methods for
treating an inflammatory disease or a symptom thereof in a patient
in need of the treatment comprising administering to the patient a
composition comprising a PGI2 receptor agonist disclosed herein. In
some embodiments, the present invention provides methods for
treating an inflammatory disease or a symptom thereof in a patient
in need of the treatment comprising administering to the patient a
composition comprising a PGI2 receptor agonist disclosed herein. In
some embodiments, the present invention provides methods for
treating an inflammatory disease or a symptom thereof in a patient
in need of the treatment comprising administering to the patient a
composition comprising a PGI2 receptor agonist disclosed herein,
wherein the inflammatory disease is selected from the group
consisting of psoriasis, psoriatic arthritis, rheumatoid arthritis,
Crohn's disease, transplant rejection, multiple sclerosis, systemic
lupus erythematosus (SLE), ulcerative colitis, ischemia-reperfusion
injury, restenosis, atherosclerosis, acne, diabetes (including type
1 diabetes and type 2 diabetes), sepsis, chronic obstructive
pulmonary disease (COPD), and asthma.
[0506] 9. Traumatic Brain Injury
[0507] Prostacyclin production is known to increase after brain
trauma, and in a recent study, the importance of prostacyclin for
posttraumatic hemodynamic alterations and neuron survival was
investigated. Prostacyclin receptor-deficient (IP.sup.-/-) mice
were compared to mice with functional prostacyclin receptors
(IP.sup.+/+) after a controlled cortical injury. Contusion volume
was increased in IP.sup.-/- mice compared with IP.sup.+/+ mice.
Three hours after trauma, cortical blood flow was decreased in the
injured cortex of both groups and the reduction in blood flow in
the cortex of the IP.sup.-/- mice persisted from 3 to 24 h, whereas
blood flow approached normal values in the IP.sup.+/+ mice after 24
h. (See, e.g., Lundblad et al. Journal of Cerebral Blood Flow &
Metabolism 28, 367-376).
[0508] The PGI2 receptor agonists disclosed herein provide
beneficial improvement in neuron survival after brain trauma.
Accordingly, in some embodiments, the present invention provides
methods for treating a traumatic brain injury in a patient in need
thereof, comprising administering to the patient a composition
comprising a PGI2 receptor agonist disclosed herein.
Pharmaceutical Compositions
[0509] A further aspect of the present invention pertains to
pharmaceutical compositions comprising one or more compounds as
described herein and one or more pharmaceutically acceptable
carriers. Some embodiments pertain to pharmaceutical compositions
comprising a compound of the present invention and a
pharmaceutically acceptable carrier.
[0510] Some embodiments of the present invention include a method
of producing a pharmaceutical composition comprising admixing at
least one compound according to any of the compound embodiments
disclosed herein and a pharmaceutically acceptable carrier.
[0511] Formulations may be prepared by any suitable method,
typically by uniformly mixing the active compound(s) with liquids
or finely divided solid carriers, or both, in the required
proportions and then, if necessary, forming the resulting mixture
into a desired shape.
[0512] Conventional excipients, such as binding agents, fillers,
acceptable wetting agents, tabletting lubricants and disintegrants
may be used in tablets and capsules for oral administration. Liquid
preparations for oral administration may be in the form of
solutions, emulsions, aqueous or oily suspensions and syrups.
Alternatively, the oral preparations may be in the form of dry
powder that can be reconstituted with water or another suitable
liquid vehicle before use. Additional additives such as suspending
or emulsifying agents, non-aqueous vehicles (including edible
oils), preservatives and flavorings and colorants may be added to
the liquid preparations. Parenteral dosage forms may be prepared by
dissolving the compound of the invention in a suitable liquid
vehicle and filter sterilizing the solution before filling and
sealing an appropriate vial or ampule. These are just a few
examples of the many appropriate methods well known in the art for
preparing dosage forms.
[0513] A compound of the present invention can be formulated into
pharmaceutical compositions using techniques well known to those in
the art. Suitable pharmaceutically-acceptable carriers, outside
those mentioned herein, are known in the art; for example, see
Remington, The Science and Practice of Pharmacy, 20.sup.th Edition,
2000, Lippincott Williams & Wilkins, (Editors: Gennaro et
al.)
[0514] While it is possible that, for use in the prophylaxis or
treatment, a compound of the invention may, in an alternative use,
be administered as a raw or pure chemical, it is preferable however
to present the compound or active ingredient as a pharmaceutical
formulation or composition further comprising a pharmaceutically
acceptable carrier.
[0515] Pharmaceutical formulations include those suitable for oral,
rectal, nasal, topical (including buccal and sub-lingual), vaginal
or parenteral (including intramuscular, sub-cutaneous and
intravenous) administration or in a form suitable for
administration by inhalation, insufflation or by a transdermal
patch. Transdermal patches dispense a drug at a controlled rate by
presenting the drug for absorption in an efficient manner with
minimal degradation of the drug. Typically, transdermal patches
comprise an impermeable backing layer, a single pressure sensitive
adhesive and a removable protective layer with a release liner. One
of ordinary skill in the art will understand and appreciate the
techniques appropriate for manufacturing a desired efficacious
transdermal patch based upon the needs of the artisan.
[0516] The compounds of the invention, together with a conventional
adjuvant, carrier, or diluent, may thus be placed into the form of
pharmaceutical formulations and unit dosages thereof and in such
form may be employed as solids, such as tablets or filled capsules,
or liquids such as solutions, suspensions, emulsions, elixirs, gels
or capsules filled with the same, all for oral use, in the form of
suppositories for rectal administration; or in the form of sterile
injectable solutions for parenteral (including subcutaneous) use.
Such pharmaceutical compositions and unit dosage forms thereof may
comprise conventional ingredients in conventional proportions, with
or without additional active compounds or principles and such unit
dosage forms may contain any suitable effective amount of the
active ingredient commensurate with the intended daily dosage range
to be employed.
[0517] For oral administration, the pharmaceutical composition may
be in the form of, for example, a tablet, capsule, suspension or
liquid. The pharmaceutical composition is preferably made in the
form of a dosage unit containing a particular amount of the active
ingredient. Examples of such dosage units are capsules, tablets,
powders, granules or a suspension, with conventional additives such
as lactose, mannitol, corn starch or potato starch; with binders
such as crystalline cellulose, cellulose derivatives, acacia, corn
starch or gelatins; with disintegrators such as corn starch, potato
starch or sodium carboxymethyl-cellulose; and with lubricants such
as talc or magnesium stearate. The active ingredient may also be
administered by injection as a composition wherein, for example,
saline, dextrose or water may be used as a suitable
pharmaceutically acceptable carrier.
[0518] Compounds of the present invention or a solvate, hydrate or
physiologically functional derivative thereof can be used as active
ingredients in pharmaceutical compositions, specifically as PGI2
receptor modulators. By the term "active ingredient" is defined in
the context of a "pharmaceutical composition" and is intended to
mean a component of a pharmaceutical composition that provides the
primary pharmacological effect, as opposed to an "inactive
ingredient" which would generally be recognized as providing no
pharmaceutical benefit.
[0519] The dose when using the compounds of the present invention
can vary within wide limits and as is customary and is known to the
physician, it is to be tailored to the individual conditions in
each individual case. It depends, for example, on the nature and
severity of the illness to be treated, on the condition of the
patient, on the compound employed or on whether an acute or chronic
disease state is treated or prophylaxis is conducted or on whether
further active compounds are administered in addition to the
compounds of the present invention. Representative doses of the
present invention include, but not limited to, about 0.001 mg to
about 5000 mg, about 0.001 mg to about 2500 mg, about 0.001 mg to
about 1000 mg, 0.001 mg to about 500 mg, 0.001 mg to about 250 mg,
about 0.001 mg to 100 mg, about 0.001 mg to about 50 mg and about
0.001 mg to about 25 mg. Multiple doses may be administered during
the day, especially when relatively large amounts are deemed to be
needed, for example 2, 3 or 4 doses. Depending on the individual
and as deemed appropriate from the patient's physician or caregiver
it may be necessary to deviate upward or downward from the doses
described herein.
[0520] The amount of active ingredient, or an active salt or
derivative thereof, required for use in treatment will vary not
only with the particular salt selected but also with the route of
administration, the nature of the condition being treated and the
age and condition of the patient and will ultimately be at the
discretion of the attendant physician or clinician. In general, one
skilled in the art understands how to extrapolate in vivo data
obtained in a model system, typically an animal model, to another,
such as a human. In some circumstances, these extrapolations may
merely be based on the weight of the animal model in comparison to
another, such as a mammal, preferably a human, however, more often,
these extrapolations are not simply based on weights, but rather
incorporate a variety of factors. Representative factors include
the type, age, weight, sex, diet and medical condition of the
patient, the severity of the disease, the route of administration,
pharmacological considerations such as the activity, efficacy,
pharmacokinetic and toxicology profiles of the particular compound
employed, whether a drug delivery system is utilized, on whether an
acute or chronic disease state is being treated or prophylaxis is
conducted or on whether further active compounds are administered
in addition to the compounds of the present invention and as part
of a drug combination. The dosage regimen for treating a disease
condition with the compounds and/or compositions of this invention
is selected in accordance with a variety factors as cited above.
Thus, the actual dosage regimen employed may vary widely and
therefore may deviate from a preferred dosage regimen and one
skilled in the art will recognize that dosage and dosage regimen
outside these typical ranges can be tested and, where appropriate,
may be used in the methods of this invention.
[0521] The desired dose may conveniently be presented in a single
dose or as divided doses administered at appropriate intervals, for
example, as two, three, four or more sub-doses per day. The
sub-dose itself may be further divided, e.g., into a number of
discrete loosely spaced administrations. The daily dose can be
divided, especially when relatively large amounts are administered
as deemed appropriate, into several, for example 2, 3 or 4 part
administrations. If appropriate, depending on individual behavior,
it may be necessary to deviate upward or downward from the daily
dose indicated.
[0522] The compounds of the present invention can be administrated
in a wide variety of oral and parenteral dosage forms. It will be
obvious to those skilled in the art that the following dosage forms
may comprise, as the active component, either a compound of the
invention or a pharmaceutically acceptable salt, solvate or hydrate
of a compound of the invention.
[0523] For preparing pharmaceutical compositions from the compounds
of the present invention, the selection of a suitable
pharmaceutically acceptable carrier can be either solid, liquid or
a mixture of both. Solid form preparations include powders,
tablets, pills, capsules, cachets, suppositories and dispersible
granules. A solid carrier can be one or more substances which may
also act as diluents, flavoring agents, solubilizers, lubricants,
suspending agents, binders, preservatives, tablet disintegrating
agents, or an encapsulating material.
[0524] In powders, the carrier is a finely divided solid which is
in a mixture with the finely divided active component.
[0525] In tablets, the active component is mixed with the carrier
having the necessary binding capacity in suitable proportions and
compacted to the desire shape and size. The powders and tablets may
contain varying percentage amounts of the active compound. A
representative amount in a powder or tablet may contain from 0.5 to
about 90 percent of the active compound; however, an artisan would
know when amounts outside of this range are necessary. Suitable
carriers for powders and tablets are magnesium carbonate, magnesium
stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin,
tragacanth, methylcellulose, sodium carboxymethylcellulose, a low
melting wax, cocoa butter and the like. The term "preparation" is
intended to include the formulation of the active compound with
encapsulating material as carrier providing a capsule in which the
active component, with or without carriers, is surrounded by a
carrier, which is thus in association with it. Similarly, cachets
and lozenges are included. Tablets, powders, capsules, pills,
cachets and lozenges can be used as solid forms suitable for oral
administration.
[0526] For preparing suppositories, a low melting wax, such as an
admixture of fatty acid glycerides or cocoa butter, is first melted
and the active component is dispersed homogeneously therein, as by
stirring. The molten homogenous mixture is then poured into
convenient sized molds, allowed to cool and thereby to
solidify.
[0527] Formulations suitable for vaginal administration may be
presented as pessaries, tampons, creams, gels, pastes, foams or
sprays containing in addition to the active ingredient such
carriers as are known in the art to be appropriate.
[0528] Liquid form preparations include solutions, suspensions and
emulsions, for example, water or water-propylene glycol solutions.
For example, parenteral injection liquid preparations can be
formulated as solutions in aqueous polyethylene glycol solution.
Injectable preparations, for example, sterile injectable aqueous or
oleaginous suspensions may be formulated according to the known art
using suitable dispersing or wetting agents and suspending agents.
The sterile injectable preparation may also be a sterile injectable
solution or suspension in a nontoxic parenterally acceptable
diluent or solvent, for example, as a solution in 1,3-butanediol.
Among the acceptable vehicles and solvents that may be employed are
water, Ringer's solution and isotonic sodium chloride solution. In
addition, sterile, fixed oils are conventionally employed as a
solvent or suspending medium. For this purpose any bland fixed oil
may be employed including synthetic mono- or diglycerides. In
addition, fatty acids such as oleic acid find use in the
preparation of injectables.
[0529] The compounds according to the present invention may thus be
formulated for parenteral administration (e.g. by injection, for
example bolus injection or continuous infusion) and may be
presented in unit dose form in ampoules, pre-filled syringes, small
volume infusion or in multi-dose containers with an added
preservative. The pharmaceutical compositions may take such forms
as suspensions, solutions, or emulsions in oily or aqueous vehicles
and may contain formulatory agents such as suspending, stabilizing
and/or dispersing agents. Alternatively, the active ingredient may
be in powder form, obtained by aseptic isolation of sterile solid
or by lyophilization from solution, for constitution with a
suitable vehicle, e.g. sterile, pyrogen-free water, before use.
[0530] Aqueous formulations suitable for oral use can be prepared
by dissolving or suspending the active component in water and
adding suitable colorants, flavors, stabilizing and thickening
agents, as desired.
[0531] Aqueous suspensions suitable for oral use can be made by
dispersing the finely divided active component in water with
viscous material, such as natural or synthetic gums, resins,
methylcellulose, sodium carboxymethylcellulose, or other well-known
suspending agents.
[0532] Also included are solid form preparations which are intended
to be converted, shortly before use, to liquid form preparations
for oral administration. Such liquid forms include solutions,
suspensions and emulsions. These preparations may contain, in
addition to the active component, colorants, flavors, stabilizers,
buffers, artificial and natural sweeteners, dispersants,
thickeners, solubilizing agents and the like.
[0533] For topical administration to the epidermis the compounds
according to the invention may be formulated as ointments, creams
or lotions, or as a transdermal patch.
[0534] Ointments and creams may, for example, be formulated with an
aqueous or oily base with the addition of suitable thickening
and/or gelling agents. Lotions may be formulated with an aqueous or
oily base and will in general also contain one or more emulsifying
agents, stabilizing agents, dispersing agents, suspending agents,
thickening agents, or coloring agents.
[0535] Formulations suitable for topical administration in the
mouth include lozenges comprising active agent in a flavored base,
usually sucrose and acacia or tragacanth; pastilles comprising the
active ingredient in an inert base such as gelatin and glycerin or
sucrose and acacia; and mouthwashes comprising the active
ingredient in a suitable liquid carrier.
[0536] Solutions or suspensions are applied directly to the nasal
cavity by conventional means, for example with a dropper, pipette
or spray. The formulations may be provided in single or multi-dose
form. In the latter case of a dropper or pipette, this may be
achieved by the patient administering an appropriate, predetermined
volume of the solution or suspension. In the case of a spray, this
may be achieved for example by means of a metering atomizing spray
pump.
[0537] Administration to the respiratory tract may also be achieved
by means of an aerosol formulation in which the active ingredient
is provided in a pressurized pack with a suitable propellant. If
the compounds of the present invention or pharmaceutical
compositions comprising them are administered as aerosols, for
example as nasal aerosols or by inhalation, this can be carried
out, for example, using a spray, a nebulizer, a pump nebulizer, an
inhalation apparatus, a metered inhaler or a dry powder inhaler.
Pharmaceutical forms for administration of the compounds of the
present invention as an aerosol can be prepared by processes well
known to the person skilled in the art. For their preparation, for
example, solutions or dispersions of the compounds of the present
invention in water, water/alcohol mixtures or suitable saline
solutions can be employed using customary additives, for example
benzyl alcohol or other suitable preservatives, absorption
enhancers for increasing the bioavailability, solubilizers,
dispersants and others and, if appropriate, customary propellants,
for example include carbon dioxide, CFCs, such as,
dichlorodifluoromethane, trichlorofluoromethane, or
dichlorotetrafluoroethane; and the like. The aerosol may
conveniently also contain a surfactant such as lecithin. The dose
of drug may be controlled by provision of a metered valve.
[0538] In formulations intended for administration to the
respiratory tract, including intranasal formulations, the compound
will generally have a small particle size for example of the order
of 10 microns or less. Such a particle size may be obtained by
means known in the art, for example by micronization. When desired,
formulations adapted to give sustained release of the active
ingredient may be employed.
[0539] Alternatively the active ingredients may be provided in the
form of a dry powder, for example, a powder mix of the compound in
a suitable powder base such as lactose, starch, starch derivatives
such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone
(PVP). Conveniently the powder carrier will form a gel in the nasal
cavity. The powder composition may be presented in unit dose form
for example in capsules or cartridges of, e.g., gelatin, or blister
packs from which the powder may be administered by means of an
inhaler.
[0540] The pharmaceutical preparations are preferably in unit
dosage forms. In such form, the preparation is subdivided into unit
doses containing appropriate quantities of the active component.
The unit dosage form can be a packaged preparation, the package
containing discrete quantities of preparation, such as packeted
tablets, capsules and powders in vials or ampoules. Also, the unit
dosage form can be a capsule, tablet, cachet, or lozenge itself, or
it can be the appropriate number of any of these in packaged
form.
[0541] Tablets or capsules for oral administration and liquids for
intravenous administration are preferred compositions.
[0542] The compounds according to the invention may optionally
exist as pharmaceutically acceptable salts including
pharmaceutically acceptable acid addition salts prepared from
pharmaceutically acceptable non-toxic acids including inorganic and
organic acids. Representative acids include, but are not limited
to, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric,
ethenesulfonic, dichloroacetic, formic, fumaric, gluconic,
glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic,
maleic, malic, mandelic, methanesulfonic, mucic, nitric, oxalic,
pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric,
oxalic, p-toluenesulfonic and the like. Certain compounds of the
present invention which contain a carboxylic acid functional group
may optionally exist as pharmaceutically acceptable salts
containing non-toxic, pharmaceutically acceptable metal cations and
cations derived from organic bases. Representative metals include,
but are not limited to, aluminium, calcium, lithium, magnesium,
potassium, sodium, zinc and the like. In some embodiments the
pharmaceutically acceptable metal is sodium. Representative organic
bases include, but are not limited to, benzathine
(N.sup.1,N.sup.2-dibenzylethane-1,2-diamine), chloroprocaine
(2-(diethylamino)ethyl 4-(chloroamino)benzoate), choline,
diethanolamine, ethylenediamine, meglumine
((2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentaol), procaine
(2-(diethylamino)ethyl 4-aminobenzoate), and the like. Certain
pharmaceutically acceptable salts are listed in Berge, et al.,
Journal of Pharmaceutical Sciences, 66:1-19 (1977), incorporated
herein by reference in its entirety.
[0543] The acid addition salts may be obtained as the direct
products of compound synthesis. In the alternative, the free base
may be dissolved in a suitable solvent containing the appropriate
acid and the salt isolated by evaporating the solvent or otherwise
separating the salt and solvent. The compounds of this invention
may form solvates with standard low molecular weight solvents using
methods known to the skilled artisan.
[0544] Compounds of the present invention can be converted to
"pro-drugs." The term "pro-drugs" refers to compounds that have
been modified with specific chemical groups known in the art and
when administered into an individual these groups undergo
biotransformation to give the parent compound. Pro-drugs can thus
be viewed as compounds of the invention containing one or more
specialized non-toxic protective groups used in a transient manner
to alter or to eliminate a property of the compound. In one general
aspect, the "pro-drug" approach is utilized to facilitate oral
absorption. A thorough discussion is provided in T. Higuchi and V.
Stella, Pro-drugs as Novel Delivery Systems Vol. 14 of the A.C.S.
Symposium Series; and in Bioreversible Carriers in Drug Design, ed.
Edward B. Roche, American Pharmaceutical Association and Pergamon
Press, 1987, both of which are hereby incorporated by reference in
their entirety.
[0545] Some embodiments of the present invention include a method
of producing a pharmaceutical composition for "combination-therapy"
comprising admixing at least one compound according to any of the
compound embodiments disclosed herein, together with at least one
known pharmaceutical agent as described herein and a
pharmaceutically acceptable carrier.
[0546] It is noted that when the PGI2 receptor modulators are
utilized as active ingredients in a pharmaceutical composition,
these are not intended for use only in humans, but in other
non-human mammals as well. Indeed, recent advances in the area of
animal health-care mandate that consideration be given for the use
of active agents, such as PGI2 receptor modulators, for the
treatment of an PGI2-associated disease or disorder in
companionship animals (e.g., cats, dogs, etc.) and in livestock
animals (e.g., cows, chickens, fish, etc.) Those of ordinary skill
in the art are readily credited with understanding the utility of
such compounds in such settings.
Hydrates and Solvates
[0547] It is understood that when the phrase pharmaceutically
acceptable salts, solvates and hydrates is used in referring to a
particular formula herein, it is intended to embrace solvates
and/or hydrates of compounds of the particular formula,
pharmaceutically acceptable salts of compounds of the particular
formula as well as solvates and/or hydrates of pharmaceutically
acceptable salts of compounds of the particular formula.
[0548] The compounds of the present invention can be administrated
in a wide variety of oral and parenteral dosage forms. It will be
apparent to those skilled in the art that the following dosage
forms may comprise, as the active component, either a compound of
the invention or a pharmaceutically acceptable salt or as a solvate
or hydrate thereof. Moreover, various hydrates and solvates of the
compounds of the invention and their salts will find use as
intermediates in the manufacture of pharmaceutical compositions.
Typical procedures for making and identifying suitable hydrates and
solvates, outside those mentioned herein, are well known to those
in the art; see for example, pages 202-209 of K. J. Guillory,
"Generation of Polymorphs, Hydrates, Solvates, and Amorphous
Solids," in: Polymorphism in Pharmaceutical Solids, ed. Harry G.
Brittan, Vol. 95, Marcel Dekker, Inc., New York, 1999, incorporated
herein by reference in its entirety. Accordingly, one aspect of the
present invention pertains to hydrates and solvates of compounds of
Formula Ia and/or their pharmaceutical acceptable salts, as
described herein, that can be isolated and characterized by methods
known in the art, such as, thermogravimetric analysis (TGA),
TGA-mass spectroscopy, TGA-Infrared spectroscopy, powder X-ray
diffraction (XRPD), Karl Fisher titration, high resolution X-ray
diffraction, and the like. There are several commercial entities
that provide quick and efficient services for identifying solvates
and hydrates on a routine basis. Example companies offering these
services include Wilmington PharmaTech (Wilmington, Del.), Avantium
Technologies (Amsterdam) and Aptuit (Greenwich, Conn.).
Other Utilities
[0549] Another object of the present invention relates to
radio-labeled compounds of the present invention that would be
useful not only in radio-imaging but also in assays, both in vitro
and in vivo, for localizing and quantitating the PGI2 receptor in
tissue samples, including human and for identifying PGI2 receptor
ligands by inhibition binding of a radio-labeled compound. It is a
further object of this invention to develop novel PGI2 receptor
assays of which comprise such radio-labeled compounds.
[0550] The present invention embraces isotopically-labeled
compounds of the present invention. Isotopically or radio-labeled
compounds are those which are identical to compounds disclosed
herein, but for the fact that one or more atoms are replaced or
substituted by an atom having an atomic mass or mass number
different from the atomic mass or mass number most commonly found
in nature. Suitable radionuclides that may be incorporated in
compounds of the present invention include but are not limited to
.sup.2H (also written as D for deuterium), .sup.3H (also written as
T for tritium), .sup.11C, .sup.13C, .sup.14C, .sup.15N, .sup.15N,
.sup.15O, .sup.17O, .sup.18O, .sup.18F, .sup.35S, .sup.36Cl,
.sup.75Br, .sup.76Br, .sup.77Br, .sup.82Br, .sup.123I, .sup.124I,
.sup.125I and .sup.131I. The radionuclide that is incorporated in
the instant radio-labeled compounds will depend on the specific
application of that radio-labeled compound. For example, for in
vitro PGI2 receptor labeling and competition assays, compounds that
incorporate .sup.3H, .sup.14C, .sup.82Br, .sup.125I, .sup.131I or
.sup.35S will generally be most useful. For radio-imaging
applications .sup.11C, .sup.18F, .sup.125I, .sup.123I, .sup.131I,
.sup.75Br, .sup.76Br or .sup.77Br will generally be most
useful.
[0551] It is understood that a "radio-labeled" or "labeled
compound" is a compound of Formula Ia, Ic, Ie, Ig, or Ii that has
incorporated at least one radionuclide; in some embodiments the
radionuclide is selected from the group consisting of .sup.3H,
.sup.14C, .sup.125I, .sup.35S and .sup.82Br.
[0552] Certain isotopically-labeled compounds of the present
invention are useful in compound and/or substrate tissue
distribution assays. In some embodiments the radionuclide .sup.3H
and/or .sup.14C isotopes are useful in these studies. Further,
substitution with heavier isotopes such as deuterium (i.e.,
.sup.2H) may afford certain therapeutic advantages resulting from
greater metabolic stability (e.g., increased in vivo half-life or
reduced dosage requirements) and hence may be preferred in some
circumstances. Isotopically labeled compounds of the present
invention can generally be prepared by following procedures
analogous to those disclosed in the Drawings and Examples infra, by
substituting an isotopically labeled reagent for a non-isotopically
labeled reagent. Other synthetic methods that are useful are
discussed infra. Moreover, it should be understood that all of the
atoms represented in the compounds of the invention can be either
the most commonly occurring isotope of such atoms or the scarcer
radio-isotope or nonradioactive isotope.
[0553] Synthetic methods for incorporating radio-isotopes into
organic compounds are applicable to compounds of the invention and
are well known in the art. These synthetic methods, for example,
incorporating activity levels of tritium into target molecules, are
as follows:
[0554] A. Catalytic Reduction with Tritium Gas: This procedure
normally yields high specific activity products and requires
halogenated or unsaturated precursors.
[0555] B. Reduction with Sodium Borohydride [.sup.3H]: This
procedure is rather inexpensive and requires precursors containing
reducible functional groups such as aldehydes, ketones, lactones,
esters and the like.
[0556] C. Reduction with Lithium Aluminum Hydride [.sup.3H]: This
procedure offers products at almost theoretical specific
activities. It also requires precursors containing reducible
functional groups such as aldehydes, ketones, lactones, esters and
the like.
[0557] D. Tritium Gas Exposure Labeling: This procedure involves
exposing precursors containing exchangeable protons to tritium gas
in the presence of a suitable catalyst.
[0558] E. N-Methylation using Methyl Iodide [.sup.3H]: This
procedure is usually employed to prepare O-methyl or
N-methyl(.sup.3H) products by treating appropriate precursors with
high specific activity methyl iodide (.sup.3H). This method in
general allows for higher specific activity, such as for example,
about 70-90 Ci/mmol.
[0559] Synthetic methods for incorporating activity levels of
.sup.125I into target molecules include:
[0560] A. Sandmeyer and like reactions: This procedure transforms
an aryl amine or a heteroaryl amine into a diazonium salt, such as
a diazonium tetrafluoroborate salt and subsequently to .sup.125I
labeled compound using Na.sup.125I. A represented procedure was
reported by Zhu, G-D. and co-workers in J. Org. Chem., 2002, 67,
943-948.
[0561] B. Ortho .sup.125Iodination of phenols: This procedure
allows for the incorporation of .sup.125I at the ortho position of
a phenol as reported by Collier, T. L. and co-workers in J.
Labelled Compd. Radiopharm., 1999, 42, S264-S266.
[0562] C. Aryl and heteroaryl bromide exchange with .sup.125I: This
method is generally a two step process. The first step is the
conversion of the aryl or heteroaryl bromide to the corresponding
tri-alkyltin intermediate using for example, a Pd catalyzed
reaction [i.e. Pd(Ph.sub.3P).sub.4] or through an aryl or
heteroaryl lithium, in the presence of a tri-alkyltinhalide or
hexaalkylditin [e.g., (CH.sub.3).sub.3SnSn(CH.sub.3).sub.3]. A
representative procedure was reported by Le Bas, M.-D. and
co-workers in J. Labelled Compd. Radiopharm. 2001, 44,
S280-5282.
[0563] A radiolabeled PGI2 receptor compound of Formula Ia can be
used in a screening assay to identify/evaluate compounds. In
general terms, a newly synthesized or identified compound (i.e.,
test compound) can be evaluated for its ability to reduce binding
of the "radio-labeled compound of Formula Ia" to the PGI2 receptor.
Accordingly, the ability of a test compound to compete with the
"radio-labeled compound of Formula Ia" for the binding to the PGI2
receptor directly correlates to its binding affinity.
[0564] The labeled compounds of the present invention bind to the
PGI2 receptor. In one embodiment the labeled compound has an
IC.sub.50 less than about 500 .mu.M, in another embodiment the
labeled compound has an IC.sub.50 less than about 100 .mu.M, in yet
another embodiment the labeled compound has an IC.sub.50 less than
about 10 .mu.M, in yet another embodiment the labeled compound has
an IC.sub.50 less than about 1 .mu.M and in still yet another
embodiment the labeled inhibitor has an IC.sub.50 less than about
0.1 .mu.M.
[0565] Other uses of the disclosed receptors and methods will
become apparent to those skilled in the art based upon, inter alia,
a review of this disclosure.
[0566] As will be recognized, the steps of the methods of the
present invention need not be performed any particular number of
times or in any particular sequence. Additional objects, advantages
and novel features of this invention will become apparent to those
skilled in the art upon examination of the following examples
thereof, which are intended to be illustrative and not intended to
be limiting.
EXAMPLES
Example 1
Syntheses of Compounds of the Present Invention
[0567] Illustrated syntheses for compounds of the present invention
are shown in FIGS. 3 through 9 where the symbols have the same
definitions as used throughout this disclosure.
[0568] The compounds of the invention and their syntheses are
further illustrated by the following examples. The following
examples are provided to further define the invention without,
however, limiting the invention to the particulars of these
examples. The compounds described herein, supra and infra, are
named according to the CS ChemDraw Ultra Version 7.0.1, AutoNom
version 2.2, or CS ChemDraw Ultra Version 9.0.7. In certain
instances common names are used and it is understood that these
common names would be recognized by those skilled in the art.
[0569] Chemistry: Proton nuclear magnetic resonance (.sup.1H NMR)
spectra were recorded on a Bruker Avance-400 equipped with a QNP
(Quad Nucleus Probe) or a BBI (Broad Band Inverse) and z-gradient.
Chemical shifts are given in parts per million (ppm) with the
residual solvent signal used as reference. NMR abbreviations are
used as follows: s=singlet, d=doublet, dd=doublet of doublets,
ddd=doublet of doublet of doublets, dt=doublet of triplets,
t=triplet, td=triplet of doublets, tt=triplet of triplets,
q=quartet, m=multiplet, bs=broad singlet, bt=broad triplet.
Microwave irradiations were carried out using a Smith
Synthesizer.TM. or an Emrys Optimizer.TM. (Biotage). Thin-layer
chromatography (TLC) was performed on silica gel 60 F.sub.254
(Merck), preparatory thin-layer chromatography (prep TLC) was
preformed on PK6F silica gel 60 A 1 mm plates (Whatman) and column
chromatography was carried out on a silica gel column using
Kieselgel 60, 0.063-0.200 mm (Merck). Evaporation was done under
reduced pressure on a Btichi rotary evaporator.
[0570] LCMS spec: HPLC-pumps: LC-LOAD VP, Shimadzu Inc.; HPLC
system controller: SCL-10A VP, Shimadzu Inc; UV-Detector: SPD-10A
VP, Shimadzu Inc; Autosampler: CTC HTS, PAL, Leap Scientific; Mass
spectrometer: API 150EX with Turbo Ion Spray source, AB/MDS Sciex;
Software: Analyst 1.2.
Example 1.1
Preparation of t-Butyl
2-(((1s,4s)-4-(Tosyloxymethyl)cyclohexyl)methoxy)acetate
Step A: Preparation of (1s,4s)-Diethyl
Cyclohexane-1,4-dicarboxylate.
[0571] To a solution of (1s,4s)-cyclohexane-1,4-dicarboxylic acid
(25 g, 145 mmol) in ethanol (150 mL) was added concentrated
H.sub.2SO.sub.4 (1 mL). The reaction was refluxed for 16 h, cooled
to room temperature and concentrated. The residue was extracted
with EtOAc and saturated NaHCO.sub.3, washed with brine, dried over
MgSO.sub.4, and filtered. The filtrate was concentrated to provide
the title compound as a colorless oil (30.5 g). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 1.25 (t, J=7.14 Hz, 6H), 1.64-1.70 (m,
4H), 1.87-1.92 (m, 4H), 2.44-2.46 (m, 2H), 4.11-1.46 (quartet,
J=7.12 Hz, 4H).
Step B: Preparation of (1s,4s)-Cyclohexane-1,4-diyldimethanol
[0572] To a solution of (1s,4s)-diethyl
cyclohexane-1,4-dicarboxylate (13.0 g, 56.9 mmol) in THF (500 mL)
was added lithium aluminum hydride (4.54 g, 120 mmol) in portions
at 0.degree. C. The mixture was stirred at that temperature for 2 h
and quenched with cold water, filtered and concentrated to give the
title compound as a colorless oil (8.2 g). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.27-1.42 (m, 8H), 1.46-1.54 (m, 2H),
3.26-3.31 (m, 4H), 4.27-4.30 (t, J=5.31 Hz, 2H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-(Hydroxymethyl)cyclohexyl)methoxy)acetate
[0573] To a solution of (1s,4s)-cyclohexane-1,4-diyldimethanol
(18.2 g, 126 mmol) in toluene (200 mL) was added NaOH (50% aqueous,
60 mL) and tetrabutylammonium iodide (2.331 g, 6.31 mmol), followed
by tert-butyl-2-bromoacetate (20.50 mL, 139 mmol) at room
temperature. The reaction mixture was stirred vigorously at room
temperature for 2 h and diluted with ethyl acetate and water. After
separation, the aqueous layer was extracted with EtOAc (3.times.30
mL). The combined organic layers were dried over MgSO.sub.4,
concentrated, and purified by silica gel column chromatography to
give the title compound as a colorless oil (13.5 g). .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. ppm 1.35-1.47 (m, 4H), 1.48 (s, 9H),
1.50-1.60 (m, 4H), 1.63-1.74 (m, 1H), 1.79-1.92 (m, 1H), 3.42 (d,
J=6.95 Hz, 2H), 3.55 (d, J=6.82 Hz, 2H), 3.93 (s, 1H), 3.94 (s,
2H).
Step D: Preparation of tert-Butyl
2-(((1s,4s)-4-(Tosyloxymethyl)cyclohexyl)methoxy)acetate
[0574] To a solution of tert-butyl
2-(((1s,4s)-4-(hydroxymethyl)cyclohexyl)methoxy)acetate (12.0 g,
46.4 mmol) in dichloromethane (150 mL) were added triethylamine
(4.70 g, 46.4 mmol) and 4-(dimethylamino)pyridine (0.567 g, 4.64
mmol), followed by 4-methylbenzene-1-sulfonyl chloride (8.86 g,
46.4 mmol). The reaction was stirred at room temperature for 16 h.
The solvent was removed and the residue was extracted with
EtOAc/H.sub.2O. The organic extracts were dried over MgSO.sub.4,
and concentrated. The residue was purified by silica gel column
chromatography to give the title compound as a pale liquid (9.5 g).
LCMS m/z=413.1 [M+H].sup.+; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 1.28-1.43 (m, 4H), 1.46-1.48 (m, 9H), 1.49-1.56 (m,
4H), 1.76-1.91 (m, 2H), 2.45 (s, 3H), 3.36 (d, J=6.95 Hz, 2H), 3.92
(d, J=7.05 Hz, 2H), 3.92 (s, 2H), 7.35 (d, J=8.46 Hz, 2H), 7.78 (d,
J=8.34 Hz, 2H).
Example 1.2
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic Acid (Compound 95)
Step A: Preparation of
4-(3-Chlorophenyl)-5-(methylthio)-3-phenyl-1H-pyrazole
[0575] To a solution of 2-(3-chlorophenyl)-1-phenylethanone (5 g,
21.67 mmol) in anhydrous THF (10 mL) was added a solution of 1.0 M
KO-t-Bu in THF. The reaction was stirred for 15 min at room
temperature, then CS.sub.2 (1.782 g, 23.41 mmol) was added. After
10 min, iodomethane (6.77 g, 47.7 mmol) was added and the reaction
was stirred for 4 h. The reaction was washed with saturated
NaHCO.sub.3 solution and dried over MgSO.sub.4. The filtrate was
concentrated under reduced pressure and the residue was triturated
with 10% ethyl acetate. The solid was suspended in ethanol and
hydrazine hydrate (5.43 g, 108 mmol) was added at room temperature.
The reaction was refluxed for 4 h. The reaction mixture was
concentrated under reduced pressure and the residue was triturated
with ethyl acetate/hexane to give the title compound as a white
solid (4.9 g). LCMS m/z=301.1 [M.sub.+H].sup.+.
Step B: Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic Acid
[0576] To a solution of
4-(3-chlorophenyl)-5-(methylthio)-3-phenyl-1H-pyrazole (4.98 g,
16.62 mmol) in DMF (2 mL) was added sodium hydride (0.399 g, 16.62
mmol) at 0.degree. C. After stirring for 10 min, tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (6.86 g,
16.62 mmol) was added and warmed to 40.degree. C. After stirring
for 12 h, the mixture was extracted with ethyl acetate. The organic
extract was concentrated under reduced pressure and the residue was
treated with 4.0 M HCl for 8 h. The mixture was concentrated under
reduced pressure and purified by HPLC to give the title compound
(3.89 g). LCMS m/z=486.1 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.31-1.50 (m, 8H), 1.74 (m, 1H), 2.14 (m,
1H), 2.31 (s, 3H), 3.52 (d, J=7.0 Hz, 2H), 3.58 (s, 2H), 4.25 (d,
J=7.5 Hz, 2H), 7.25-7.51 (m, 9H).
Example 1.3
Preparation of
2-(((1s,4s)-4-((4-(3,4-Difluorophenyl)-5-ethoxy-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic Acid (Compound 80)
Step A: Preparation of 3-Phenyl-1H-pyrazol-5(4H)-one
[0577] To a solution of propyl 3-oxo-3-phenylpropanoate (10 g, 48.5
mmol) in ethanol (100 mL) was added hydrazine hydrate (9.71 g, 194
mmol) at room temperature. The reaction was heated to 80.degree. C.
for 2 h, cooled to room temperature and concentrated. The residue
was crystallized from 20% ethyl acetate/hexane to give the title
compound (6.58 g). LCMS m/z=161.08 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm, 2.32 (br, 2H), 7.32-7.78 (m, 5H),
12.1 (s, 1H).
Step B: Preparation of 5-Ethoxy-3-phenyl-1H-pyrazole
[0578] To a solution of 3-phenyl-1H-pyrazol-5(4H)-one (1.0 g, 6.24
mmol), ethanol (0.288 g, 6.24 mmol) and triphenylphosphine (1.638
g, 6.24 mmol) in N-methylmorpholine (7 mL) was added diethylazo
dicarboxylate (0.988 mL, 6.24 mmol) dropwise at 0.degree. C. The
reaction was warmed to room temperature and stirred for 2 h. The
reaction was poured into H.sub.2O and extracted with ethyl acetate.
The extract was dried over MgSO.sub.4 and concentrated under
reduced pressure. The residue was purified by silica gel column
chromatography to give the title compound (0.89 g). LCMS m/z=189.19
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.32
(t, J=4.2 Hz, 3H), 4.32 (q, J=4.2 Hz, 2H), 6.45 (s, 1H), 7.41-7.94
(m, 5H), 11.3 (s, 1H).
Step C: Preparation of 4-Bromo-5-ethoxy-3-phenyl-1H-pyrazole
[0579] To a solution of 5-ethoxy-3-phenyl-1H-pyrazole (1.0 g, 5.31
mmol) in dichloromethane (20 mL), was added bromine (0.849 g, 5.31
mmol) dropwise at room temperature. The reaction was stirred for 2
h, washed with saturated NaHCO.sub.3 solution and concentrated
under reduced pressure. The residue was triturated with 10% ethyl
acetate/hexane to give the title compound as a yellowish solid
(1.20 g). LCMS m/z=268.07 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.38 (t, J=4.2 Hz, 3H), 4.39 (q, J=4.2
Hz, 2H), 7.45-7.85 (m, 5H), 12.4 (s, 1H).
Step D: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-Bromo-5-ethoxy-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate
[0580] To a solution of 4-bromo-5-ethoxy-3-phenyl-1H-pyrazole (1.5
g, 5.62 mmol) in DMF (5 mL) was added sodium hydride (0.135 g, 5.62
mmol) at room temperature. After stirring for 10 min, a solution of
tert-butyl 2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate
(2.317 g, 5.62 mmol) in DMF (1 mL) was added at room temperature.
The reaction was stirred at 45.degree. C. for 8 h. The mixture was
poured into H.sub.2O and extracted with ethyl acetate. The organic
extract was dried over MgSO.sub.4 and concentrated under reduced
pressure. The residue was purified by silica gel to give the title
compound (1.45 g). LCMS m/z=508.35 [M+H].sup.+.
Step E: Preparation of
2-(((1s,4s)-4-((4-(3,4-Difluorophenyl)-5-ethoxy-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic Acid
[0581] To a solution of tert-butyl
2-(((1s,4s)-4-((4-bromo-5-ethoxy-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate (110 mg, 0.217 mmol) in dioxane (2 mL) were
added 3,4-difluorophenylboronic acid (34.2 mg, 0.217 mmol),
Pd(PPh.sub.3).sub.4 (12.52 mg, 10.84 .mu.mol), and K.sub.2CO.sub.3
(59.9 mg, 0.434 mmol) at room temperature. The reaction was
irradiated under microwave for 1.5 h at 150.degree. C. The mixture
was filtered and the filtrate was concentrated under reduced
pressure. The residue was treated with 4.0 M HCl (5 mL). After
stirring for 10 h, the reaction was concentrated under reduced
pressure and purified by HPLC to give the title compound (85 mg).
LCMS m/z=485.3 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.21 (t, J=4.1 Hz, 3H), 1.30-1.41 (m, 8H), 1.63-1.74
(m, 1H), 2.18-2.23 (m, 1H), 3.49 (d, J=7.1 Hz, 2H), 3.71 (s, 2H),
3.85 (q, J=4.1 Hz, 2H), 4.12 (d, J=7.4 Hz, 2H), 7.76-7.32 (m,
8H).
Example 1.4
Preparation of
2-(((1s,4s)-4-((4-(5-Cyano-2-fluorophenyl)-5-(methylthio)-3-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 79)
Step A: Preparation of 5-(Methylthio)-3-phenyl-1H-pyrazole
[0582] To a solution of acetophenone (5.0 g, 41.6 mmol) and
CS.sub.2 (3.17 g, 41.6 mmol) in THF (150 mL) was added sodium
hydride (1.997 g, 83 mmol) at 0.degree. C. After 30 min at
0.degree. C., the reaction was warmed to room temperature and
stirred for 1 h, then refluxed for 4 h. The reaction was cooled to
room temperature, added iodomethane (16.23 g, 104 mmol), and
refluxed for another 12 h. The reaction was cooled and extracted
with ethyl acetate. The organic extracts were concentrated under
reduced pressure. The residue was diluted with ethanol (200 mL),
added hydrazine (1.334 g, 41.6 mmol), and refluxed for 4 h. After
cooling, the mixture was concentrated under reduced pressure and
extracted with ethyl acetate. The organic extracts were dried over
MgSO.sub.4 and concentrated under reduced pressure. The residue was
purified by silica gel column chromatography to give the title
compound (6.02 g). LCMS m/z=191.37 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 2.31 (s, 3H), 6.21 (s, 1H),
7.38-7.56 (m, 5H), 12.2 (s, 1H).
Step B: Preparation of
4-Iodo-5-(methylthio)-3-phenyl-1H-pyrazole
[0583] To a solution of 5-(methylthio)-3-phenyl-1H-pyrazole (1.5 g,
7.88 mmol) in THF (20 mL) and water (20 mL), were added sodium
iodide (1.182 g, 7.88 mmol), iodine (3.00 g, 11.83 mmol), and
K.sub.2CO.sub.3 (1.634 g, 11.83 mmol) at room temperature. The
reaction was warmed to 100.degree. C. and stirred for 2 h. The
reaction was quenched with 2.0 M aqueous sodium thiosulfite and
concentrated under reduced pressure. The mixture was extracted with
ethyl acetate and washed with NaHCO.sub.3 solution. The organic
extracts were dried over MgSO.sub.4 and concentrated under reduced
pressure. The residue was purified by silica gel column
chromatography to give the title compound (2.35 g). LCMS m/z=317.02
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 2.43
(s, 3H), 7.43-7.79 (m, 5H), 13.5 (s, 1H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-Iodo-5-(methylthio)-3-phenyl-1H-pyrazol-1-yl)methyl)cyc-
lohexyl)methoxy)acetate
[0584] To a solution of 5-(methylthio)-3,4-diphenyl-1H-pyrazole
(100 mg, 0.375 mmol) in DMF (3 mL), was added sodium hydride (9.01
mg, 0.375 mmol) at room temperature. After stirring for 10 min, a
solution of tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (154 mg,
0.375 mmol) in DMF (1 mL) was added at room temperature. The
reaction was heated to 45.degree. C. and stirred for 8 h. The
reaction was poured into H.sub.2O and extracted with ethyl acetate.
The organic extract was dried over MgSO.sub.4 and concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography to give the title compound (2.98 g). LCMS
m/z=557.48 [M+H].sup.+.
Step D: Preparation of
2-(((1s,4s)-4-((4-(5-Cyano-2-fluorophenyl)-5-(methylthio)-3-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid
[0585] To a solution of tert-butyl
2-(((1s,4s)-4-((4-iodo-5-(methylthio)-3-phenyl-1H-pyrazol-1-yl)methyl)cyc-
lohexyl)methoxy)acetate (110 mg, 0.198 mmol) in dioxane (2 mL),
were added 5-cyano-2-fluorophenylboronic acid (32.6 mg, 0.198
mmol), Pd(PPh.sub.3).sub.4 (11.42 mg, 9.88 mmol), and
K.sub.2CO.sub.3 (54.6 mg, 0.395 mmol) at room temperature. The
reaction was heated under microwave irradiation for 1.5 h at
150.degree. C. The mixture was filtered and concentrated under
reduced pressure. The residue was treated with 4.0 M HCl (5 mL) for
10 h. The mixture was concentrated under reduced pressure and
purified by HPLC to give the title compound (68 mg). LCMS m/z=494.5
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.31-1.40 (m, 8H), 1.60-1.78 (m, 1H), 2.18-2.20 (m, 1H), 2.38 (s,
3H), 3.51 (d, J=7.0 Hz, 2H), 3.79 (s, 2H), 4.19 (d, J=7.5 Hz, 2H),
7.21-7.34 (m, 5H), 7.80-7.41 (m, 3H).
Example 1.5
Preparation of
2-(((1s,4s)-4-((4-(Furan-2-yl)-5-(methylthio)-3-phenyl-1H-pyrazol-1-yl)me-
thyl)cyclohexyl)methoxy)acetic Acid (Compound 109)
[0586] To a solution of tert-butyl
2-(((1s,4s)-4-((4-iodo-5-(methylthio)-3-phenyl-1H-pyrazol-1-yl)methyl)cyc-
lohexyl)methoxy)acetate (150 mg, 0.270 mmol) in dioxane (1 mL), was
added furan-2-yl boronic acid (31.23 mg, 0.270 mmol) followed by
Pd(PPh.sub.3).sub.4 (15.57 mg, 0.013 mmol) and K.sub.2CO.sub.3
(74.5 mg, 0.539 mmol) at room temperature. The reaction was heated
under microwave at 120.degree. C. for 1.5 h. The mixture was
extracted with ethyl acetate and the organic extract was
concentrated under reduced pressure. The residue was treated with
4.0 M HCl (3.37 mL, 13.48 mmol) for 5 h. The reaction was
concentrated under reduced pressure and purified by HPLC to give
the title compound (88 mg). LCMS m/z=441.3 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 1.24-1.39 (m, 8H), 1.64-1.80
(m, 1H), 2.12-2.17 (m, 1H), 2.34 (s, 3H), 3.49 (d, J=7.0 Hz, 2H),
3.78 (s, 2H), 4.19 (d, J=7.5 Hz, 2H), 7.31-7.45 (m, 8H).
Example 1.6
Preparation of
2-(((1s,4s)-4-((4-(5-Fluoropyridin-3-yl)-5-(methylthio)-3-phenyl-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 135)
[0587] To a solution of tert-butyl
2-(((1s,4s)-4-((4-iodo-5-(methylthio)-3-phenyl-1H-pyrazol-1-yl)methyl)cyc-
lohexyl)methoxy)acetate (500 mg, 0.898 mmol) in dioxane (5 mL) was
added 5-fluoropyridin-3-ylboronic acid (127 mg, 0.898 mmol)
followed by Pd(PPh.sub.3).sub.4 (51.9 mg, 0.045 mmol) and
K.sub.2CO.sub.3 (248 mg, 1.797 mmol) at room temperature. The
reaction was heated under microwave irradiation at 120.degree. C.
for 1.5 h. The reaction mixture was extracted with ethyl acetate
and the organic extracts were concentrated under reduced pressure.
The residue was treated with 4.0 M HCl (11.23 mL, 44.9 mmol) in
dioxane for 5 h. The mixture was concentrated under reduced
pressure and the residue was purified by HPLC to give the title
compound as a solid. The solid was dissolved in acetonitrile (1 mL)
and water (2 mL) and added 1.0 eq. of NaOH in H.sub.2O (1 mL). The
mixture was concentrated under reduced pressure to give the sodium
salt of the title compound (210 mg). LCMS m/z=470.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.39-1.58 (m, 8H),
1.74-1.80 (m, 1H), 2.20 (s, 3H), 2.21-2.31 (m, 1H), 3.31 (d, J=7.0
Hz, 2H), 3.73 (s, 2H), 4.32 (d, J=7.5 Hz, 2H), 6.65-7.40 (m, 5H),
7.76-7.70 (m, 1H), 8.34 (s, 1H), 8.55 (s, 1H).
Example 1.7
Preparation of
2-(((1s,4s)-4-((5-(Methylthio)-4-(5-methylthiophen-2-yl)-3-phenyl-1H-pyra-
zol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 111)
[0588] To a solution of tert-butyl
2-(((1s,4s)-4-((4-iodo-5-(methylthio)-3-phenyl-1H-pyrazol-1-yl)methyl)cyc-
lohexyl)methoxy)acetate (500 mg, 0.981 mmol) in dioxane (5 mL) was
added 5-methylthiophen-2-ylboronic acid (139 mg, 0.981 mmol)
followed by Pd(PPh.sub.3).sub.4 (56.7 mg, 0.049 mmol) and
K.sub.2CO.sub.3 (271 mg, 1.963 mmol) at room temperature. The
reaction was heated under microwave at 120.degree. C. for 1.5 h.
The mixture was extracted with ethyl acetate and concentrated under
reduced pressure. The residue was treated with HCl (4.0 M in
dioxane) for 5 h. The mixture was concentrated under reduced
pressure and the residue was purified by HPLC to give the title
compound as a solid. The solid was dissolved in acetonitrile (1 mL)
and water (2 mL) and added 1.0 eq. of NaOH in H.sub.2O (1 mL). The
mixture was concentrated under reduced pressure to give the sodium
salt of the title compound (158 mg). LCMS m/z=470.1 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.21-1.49 (m, 8H),
1.63-1.79 (m, 1H), 2.08-2.13 (m, 1H), 2.15 (s, 3H), 2.35 (s, 3H),
3.54 (d, J=7.0 Hz, 2H), 3.88 (s, 2H), 4.20 (d, J=7.5 Hz, 2H),
7.23-7.48 (m, 7H).
Example 1.8
Preparation of
2-(((1s,4s)-4-((4-(3-Methoxyphenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid (Compound 14)
[0589] To a solution of tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate (1.5 g, 3.14 mmol) in dioxane (12 mL) was added
3-methoxyphenylboronic acid (0.477 g, 3.14 mmol) followed by
Pd(PPh.sub.3).sub.4 (0.182 g, 0.157 mmol) and K.sub.2CO.sub.3
(0.868 g, 6.28 mmol) at room temperature. The reaction was heated
under microwave irradiation at 150.degree. C. for 1 h. The reaction
was extracted with ethyl acetate and the organic extracts were
concentrated under reduced pressure. The residue was treated with
HCl (4.0 M in dioxane) for 5 h. The mixture was concentrated under
reduced pressure and the residue was purified by HPLC to give the
title compound as the free acid. The free acid was treated with
NaOH in 30% acetonitrile/H.sub.2O and the mixture was concentrated
under reduced pressure to give the sodium salt of the title
compound (0.687 g). LCMS m/z=449.2 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 1.30-1.52 (m, 8H), 1.71-1.83 (m,
1H), 2.01-2.11 (m, 1H), 2.20 (s, 3H), 3.41 (d, J=7.0 Hz, 2H), 3.78
(s, 2H), 3.85 (s, 3H), 4.13 (d, J=7.5 Hz, 2H), 6.65-7.40 (m,
9H).
Example 1.9
Preparation of
2-(((1R,4s)-4-((5-((S)-3,4-Dihydroxybutyl)-4-(3-hydroxyphenyl)-3-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
161)
Step A: Preparation of 1-Phenylhept-6-ene-1,3-dione
[0590] To a solution of 1-phenylbutane-1,3-dione (5 g, 30.8 mmol)
in THF (50 mL) was added sodium hydride (0.740 g, 30.8 mmol) at
0.degree. C. After warming and stirring at room temperature for 30
min, LDA, which was made by adding BuLi (1.975 g, 30.8 mmol) to a
solution of diisopropylamine (4.39 mL, 30.8 mmol) in THF (50 mL) at
-45.degree. C., was added at 0.degree. C. After stirring for 30 min
at the same temperature, 3-bromoprop-1-ene (3.73 g, 30.8 mmol) was
added at 0.degree. C. After stirring for 1 h, the reaction was
quenched with 1.0 M HCl and extracted with ethyl acetate. The
organic extract was dried over MgSO.sub.4 and concentrated under
reduced pressure to give the title compound without further
purification. LCMS m/z=203.19 [M+H].sup.+.
Step B: Preparation of 5-(But-3-enyl)-3-phenyl-1H-pyrazole
[0591] To a solution of 1-phenylhept-6-ene-1,3-dione (3 g, 14.83
mmol) in ethanol (50 mL) was added hydrazine hydrate (2.228 g, 44.5
mmol) at room temperature. The reaction was refluxed for 10 h,
cooled to room temperature and concentrated under reduced pressure.
The residue was extracted with ethyl acetate. The organic extract
was dried over MgSO.sub.4 and concentrated under reduced pressure
to give the title compound without further purification. LCMS
m/z=199.3 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 2.65-2.78 (m, 2H), 4.01-4.12 (m, 2H), 4.83-4.95 (m, 2H),
5.82-5.93 (m, 1H), 6.42 (s, 1H), 7.23-7.82 (m, 5H), 12.6 (s,
1H).
Step C: Preparation of
(S)-4-(3-Phenyl-1H-pyrazol-5-yl)butane-1,2-diol.
[0592] To a solution of 5-(but-3-enyl)-3-phenyl-1H-pyrazole (1 g,
5.04 mmol) in H.sub.2O (25 mL), and isopropanol (25 mL) was added
AD-mix-.beta. (5 g, 5.04 mmol) at room temperature. The reaction
was stirred for 48 h, quenched with Na.sub.2SO.sub.3 and extracted
with ethyl acetate. The organic extract was dried over MgSO.sub.4
and concentrated under reduced pressure to give the title compound
(1.02 g) without further purification. LCMS m/z=232.9
[M+H].sup.+.
Step D: Preparation of
(S)-5-(2-(2,2-Dimethyl-1,3-dioxolan-4-yl)ethyl)-3-phenyl-1H-pyrazole
[0593] To a solution of
(S)-4-(3-phenyl-1H-pyrazol-5-yl)butane-1,2-diol (2.5 g, 10.76 mmol)
in acetone (50 mL) were added 2,2-dimethoxypropane (11.21 g, 108
mmol) and p-toluenesulfonic acid (0.185 g, 1.076 mmol) at room
temperature. After stirring for 3 h, the reaction was concentrated
under reduced pressure. The residue was extracted with ethyl
acetate. The organic extract was dried over MgSO.sub.4 and
concentrated under reduced pressure to give the title compound
(2.70 g) without further purification. LCMS m/z=273.0
[M+H].sup.+.
Step E: Preparation of
(S)-4-Bromo-5-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-3-phenyl-1H-pyraz-
ole
[0594] To a solution of
(S)-5-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-3-phenyl-1H-pyrazole
(1.1 g, 4.04 mmol) and MP-carbonate in CH.sub.2Cl.sub.2 (50 mL) was
added bromine (0.645 g, 4.04 mmol) dropwise at 0.degree. C. After
stirring for 1 h, MP-carbonate (12.4 g, 40.4 mmol) was filtered off
and washed with CH.sub.2Cl.sub.2. The combined filtrate was poured
into water, extracted with CH.sub.2Cl.sub.2, dried over MgSO.sub.4,
and concentrated under reduced pressure. The residue was purified
by silica gel column chromatography to give the title compound as
an oil (1.129 g). LCMS m/z=351.1 [M+H].sup.+.
Step F: Preparation of tert-Butyl
2-(((1R,4s)-4-(4-Bromo-5-(2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-3--
phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
[0595] To a solution of
(S)-4-bromo-5-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-3-phenyl-1H-pyraz-
ole (1.23 g, 3.50 mmol) in DMF (10 mL) was added sodium hydride
(0.084 g, 3.50 mmol) at room temperature. After stirring for 30
min, tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (1.44 g,
3.50 mmol) was added and the reaction was heated to 45.degree. C.
After stirring for 12 h at the same temperature, the reaction was
poured into H.sub.2O and extracted with ethyl acetate. The organic
extract was dried over MgSO.sub.4 and concentrated under reduced
pressure to give the title compound without further purification.
LCMS m/z=592.1
Step G: Preparation of
2-(((1R,4s)-4-(5-((S)-3,4-Dihydroxybutyl)-4-(3-hydroxyphenyl)-3-phenyl-1H-
-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid.
[0596] To a solution of tert-butyl
2-(((1s,4s)-4-(4-bromo-5-(2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-3--
phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate (150 mg,
0.254 mmol) in dioxane (1 mL) was added 3-hydroxyphenylboronic acid
(35.0 mg, 0.254 mmol) followed by Pd(PPh.sub.3).sub.4 (14.65 mg,
0.013 mmol) and K.sub.2CO.sub.3 (70.1 mg, 0.507 mmol) at room
temperature. The reaction was heated under microwave at 120.degree.
C. for 1.5 h. The reaction was extracted with ethyl acetate and
concentrated under reduced pressure. The residue was treated with
HCl (4.0 M in dioxane) for 5 h. The mixture was concentrated under
reduced pressure and purified by HPLC to give the title compound
(59 mg). LCMS m/z=509.3 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) ppm 1.20-1.62 (m, 12H), 1.75-1.80 (m, 1H), 2.10-2.15
(m, 1H), 2.45-2.70 (m, 1H), 3.14-3.20 (m, 2H), 3.39 (d, J=7.0 Hz,
2H), 3.83 (s, 2H), 4.05 (d, J=7.5 Hz, 2H), 6.50-7.35 (m, 9H).
Example 1.10
Preparation of
2-(((1s,4s)-4-((5-(Cyanomethylthio)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetic Acid (Compound 184)
Step A: Preparation of 3,4-Diphenyl-1H-pyrazole-5(4H)-thione
[0597] To a solution of 1,2-diphenylethanone (10 g, 51.0 mmol) in
acetone (250 mL) were added K.sub.2CO.sub.3 (21.1 g, 153 mmol),
CS.sub.2 (11.62 g, 153 mmol), and dibromomethane (26.5 g, 153 mmol)
at room temperature. The reaction was stirred for 48 h at
40.degree. C. The reaction mixture was extracted with ethyl
acetate, dried over MgSO.sub.4, and concentrated under reduced
pressure. The resulting residue was diluted with ethanol (125 mL)
and hydrazine hydrate (2.55 g, 50.9 mmol) was added at room
temperature. The reaction was refluxed for 4 h, cooled, and
concentrated under reduced pressure. The residue was triturated
with isopropanol and dried under reduced pressure to give the title
compound as a white solid (8.25 g). LCMS m/z=253.1 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 3.14 (bs, 1H),
7.34-7.54 (m, 10H), 12.5 (s, 1H).
Step B: Preparation of
2-(3,4-Diphenyl-1H-pyrazol-5-ylthio)acetonitrile
[0598] To a solution of 3,4-diphenyl-1H-pyrazole-5(4H)-thione (0.5
g, 1.981 mmol) in DMF (5 mL), were added 2-bromoacetonitrile (0.238
g, 1.981 mmol) and K.sub.2CO.sub.3 (0.274 g, 1.981 mmol) at room
temperature. After stirring at the same temperature for 1 h, the
reaction was extracted with ethyl acetate; which was dried over
MgSO.sub.4 and concentrated under reduced pressure. The residue was
purified by silica gel column chromatography to give the title
compound (0.38 g). LCMS m/z=292.0 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 3.20 (s, 2H), 7.35-7.45 (m, 10H),
13.7 (s, 1H).
Step C: Preparation of
2-(((1s,4s)-4-((5-(Cyanomethylthio)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetic Acid
[0599] To a solution of
2-(3,4-diphenyl-1H-pyrazol-5-ylthio)acetonitrile (330 mg, 1.133
mmol) in DMF (2 mL) was added sodium hydride (27.2 mg, 1.133 mmol)
at 0.degree. C. After stirring for 10 min, tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (467 mg,
1.133 mmol) was added. The reaction was warmed to 40.degree. C. and
stirred for 12 h. The reaction mixture was extracted with ethyl
acetate. The organic extract was concentrated under reduced
pressure and the residue was treated with 4.0 M HCl for 8 h. The
mixture was concentrated under reduced pressure and the residue was
purified by HPLC to give the title compound (92 mg). LCMS m/z=476.3
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.31-1.53 (m, 8H), 1.63 (m, 1H), 2.15 (m, 1H), 3.32 (d, J=7.0 Hz,
2H), 3.63 (s, 2H), 3.73 (s, 2H), 4.25 (d, J=7.5 Hz, 2H), 7.21-7.35
(m, 10H).
Example 1.11
Preparation of
2-(((1s,4s)-4-((5-(Methylthio)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic Acid (Compound 76)
Step A: Preparation 5-(Methylthio)-3,4-diphenyl-1H-pyrazole
[0600] To a solution of 1,2-diphenylethanone (5 g, 25.5 mmol) in
anhydrous THF (10 mL) was added a solution of 1.0 M KO-t-Bu in THF
(108 mL). The reaction was stirred for 15 min at room temperature,
then CS.sub.2 (2.09 g, 27.5 mmol) was added. After 10 min,
iodomethane (7.96 g, 56.1 mmol) was added and the reaction was
stirred for 4 h. The reaction was washed with saturated NaHCO.sub.3
solution and dried over MgSO.sub.4. The filtrate was concentrated
under reduced pressure and the residue was triturated with 10%
ethyl acetate. The solid was suspended in ethanol and hydrazine
hydrate (5.10 g, 102 mmol) was added at room temperature. The
reaction was refluxed for 4 h. The reaction mixture was
concentrated under reduced pressure and the residue was triturated
with ethyl acetate/hexane to give the title compound as a white
solid (5.2 g). LCMS m/z=267.27 [M+H].sup.+.
Step B: Preparation of
2-(((1s,4s)-4-((5-(Methylthio)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic Acid
[0601] To a solution of 5-(methylthio)-3,4-diphenyl-1H-pyrazole
(100 mg, 0.375 mmol) in DMF (3 mL) was added sodium hydride (9.01
mg, 0.375 mmol) at room temperature. After stirring for 10 min, a
solution of tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (155 mg,
0.375 mmol) in DMF (1 mL) was added. The reaction was heated to
45.degree. C. and stirred for 8 h. The reaction mixture was poured
into H.sub.2O and extracted with ethyl acetate. The organic extract
was dried over MgSO.sub.4 and concentrated under reduced pressure.
The residue was treated with HCl (4.0 M in dioxane) overnight. The
mixture was concentrated under reduced pressure and the residue was
purified by HPLC to give the title compound (98 mg). LCMS
m/z=451.47 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.33-1.55 (m, 8H), 2.12 (s, 3H) 1.69-1.81 (m, 1H), 2.14-2.26
(m, 1H), 3.39 (d, J=7.0 Hz, 2H), 3.80 (s, 2H), 4.28 (d, J=7.5 Hz,
2H), 7.21-7.43 (m, 10H).
Example 1.12
Preparation of
2-(((1s,4s)-4-((4-(4-Chlorophenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 21)
Step A: Preparation of 5-Methyl-3-phenyl-1H-pyrazole
[0602] To a solution of acetophenone (10 g, 83 mmol) in anhydrous
toluene (10 mL) was added LiHMDS (1.0 M in THF, 83 mL, 83 mmol) via
syringe at 0.degree. C. under argon. After 5 min, acetyl chloride
(6.53 g, 83 mmol) was added in one portion via syringe. The ice
bath was removed and glacial AcOH (5 mL), EtOH (50 mL), and
hydrazine hydrate (12.50 g, 250 mmol) were added. The mixture was
refluxed for 2 h. After cooled to room temperature, the reaction
was neutralized to pH 7 by adding 1.0 M NaOH solution. The mixture
was extracted with EtOAc, washed with brine, dried over MgSO.sub.4,
and concentrated. The residue was purified by silica gel column
chromatography to give the title compound as a pale yellow oil
(12.05 g). LCMS m/z=159.0 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 2.25 (s, 3H), 6.42 (s, 1H), 7.20-7.44 (m,
3H), 7.67-7.82 (m, 2H), 12.53 (bs, 1H).
Step B: Preparation of 4-Bromo-5-methyl-3-phenyl-1H-pyrazole
[0603] To a solution of 5-methyl-3-phenyl-1H-pyrazole (8.0 g, 50.6
mmol) in dichloromethane (150 mL) was added bromine (8.08 g, 50.6
mmol) dropwise at 0.degree. C. The reaction was stirred at that
temperature for 30 min and continued at room temperature for 2 h.
After the reaction was quenched with an aqueous solution of
Na.sub.2SO.sub.3 (10% w/w, 10 mL), the organic solvent was removed
and the aqueous mixture was extracted with EtOAc, washed with
brine, dried over MgSO.sub.4, and concentrated. The residue was
purified by silica gel column chromatography to give the title
compound as a yellow oil (9.5 g). LCMS m/z=236.9 (M+H.sup.+).
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 2.26 (s, 3H),
7.30-7.57 (m, 5H), 13.12 (s, 1H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-(4-Bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate
[0604] To a solution of 4-bromo-5-methyl-3-phenyl-1H-pyrazole (2.0
g, 8.44 mmol) in DMF (5 mL) was added sodium hydride (0.202 g, 8.44
mmol) in portions at 0.degree. C. The reaction was stirred at
0.degree. C. for 1 h and tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (3.48 g,
8.44 mmol) was added. The reaction was heated to 42.degree. C.,
stirred for 16 h, and quenched with H.sub.2O (2 mL). The mixture
was extracted with ethyl acetate, dried over MgSO.sub.4 and
concentrated under reduced pressure. The residue was purified by
silica gel column chromatography to give the title compound as a
colorless liquid (3.05 g). LCMS m/z=477.3 (M+H.sup.+). .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 1.26-1.50 (m, 8H), 1.43 (s,
9H), 1.66-1.78 (m, 1H), 1.97-2.09 (m, 1H), 2.30 (s, 3H), 3.39 (d,
J=6.82 Hz, 2H), 3.94 (s, 2H), 4.06 (d, J=7.58 Hz, 2H), 7.30-7.50
(m, 3H), 7.74-7.85 (m, 2H).
Step D: Preparation of
2-(((1s,4s)-4-((4-(4-Chlorophenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid
[0605] To a solution of tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate (100 mg, 0.19 mmol) in dioxane (3 mL) were added
4-chlorophenylboronic acid (29.8 mg, 0.19 mmol),
tetrakis(triphenylphosphine)palladium (22 mg, 0.019 mmol), and
K.sub.2CO.sub.3 (2 M aqueous, 0.2 mL). The reaction was heated to
150.degree. C. under microwave irradiation for 4 h. The reaction
mixture was filtered and the filtrate was concentrated. The residue
was treated with HCl (4 M in dioxane, 5 mL) at room temperature for
10 h. The mixture was concentrated and the residue was purified by
HPLC to give the title compound (13.5 mg). LCMS m/z=453.4
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.01-1.19 (m, 4H), 1.21-1.36 (m, 4H), 1.54-1.66 (m, 1H), 1.86-1.98
(m, 1H), 2.22 (s, 3H), 3.19 (d, J=6.95 Hz, 2H), 3.89 (d, J=7.45 Hz,
2H), 3.91 (s, 2H), 7.04-7.11 (m, 2H), 7.21-7.31 (m, 5H), 7.39-7.47
(m, 2H).
Example 1.13
Preparation of
2-(((1s,4s)-4-((5-(Ethylthio)-4-(2-fluoro-3-methoxyphenyl)-3-phenyl-1H-py-
razol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 90)
[0606] From 5-(ethylthio)-3-phenyl-1H-pyrazole, using a similar
method to the one described in Example 1.4, the title compound was
obtained. LCMS m/z=513.1. .sup.1H NMR (400 MHz, DMSO-d.sub.6) ppm
0.96 (t, J=7.33 Hz, 3H), 1.30-1.52 (m, 8H), 1.68-1.80 (m, 1H),
2.14-2.26 (m, 1H), 2.53 (q, J=7.33 Hz, 2H), 3.37 (d, J=6.95 Hz,
2H), 3.68 (s, 2H), 3.84 (s, 3H), 4.28 (d, J=7.58 Hz, 2H), 6.76-6.94
(m, 2H), 7.13-7.40 (m, 6H).
Example 1.14
Preparation of
2-(((1s,4s)-4-((5-Ethyl-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 99)
Step A: Preparation of 5-Ethyl-3-phenyl-1H-pyrazole
[0607] To a solution of acetophenone (10 g, 83 mmol) in anhydrous
toluene (10 mL) added LiHMDS (85.0 mL, 1.0 M in THF, 85.0 mmol) via
syringe at 0.degree. C. under argon. After 5 min, propionyl
chloride (7.70 g, 83 mmol) was added in one portion via syringe.
The ice bath was removed after 10 min and AcOH (2 mL), EtOH (50
mL), and hydrazine hydrate (8.35 g, 116 mmol) were added. The
mixture was refluxed for 2 h. The resulting solution was added to
1.0 M NaOH solution, extracted with EtOAc, washed with brine, dried
over MgSO.sub.4, and concentrated. The residue was purified by
silica gel column chromatography to give the title compound as a
clear yellowish liquid (12.05 g). LCMS m/z=173.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.23 (t, J=7.58 Hz,
3H), 2.64 (q, J=7.07 Hz, 2H), 6.46 (s, 1H), 7.20-7.52 (m, 3H), 7.77
(d, J=6.32 Hz, 2H), 12.55 (s, 1H).
Step B: Preparation of 4-Bromo-5-ethyl-3-phenyl-1H-pyrazole
[0608] To a solution of 5-ethyl-3-phenyl-1H-pyrazole (10.0 g, 58.1
mmol) in DCM (150 mL) was added dropwise bromine (9.28 g, 58.1
mmol) at 0.degree. C. The reaction was stirred at that temperature
for 30 min and continued for 2 h at room temperature and then
quenched with aqueous Na.sub.2SO.sub.3 solution (10% w/w, 10 mL).
DCM was removed and the residue was extracted with EtOAc, washed
with brine, dried over MgSO.sub.4, and concentrated. The residue
was purified by silica gel column chromatography to give the title
compound as a yellow liquid (9.5 g). LCMS m/z=250.9 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.22 (t, J=7.58 Hz,
3H), 2.66 (q, J=7.58 Hz, 2H), 7.40-7.56 (m, 3H), 7.82 (d, J=7.58
Hz, 2H), 13.15 (s, 1H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-Bromo-5-ethyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate
[0609] To a solution of 4-bromo-5-ethyl-3-phenyl-1H-pyrazole (3.0
g, 11.95 mmol) in DMF (5 mL) was added sodium hydride (0.287 g,
11.95 mmol) followed by tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (4.93 g,
11.95 mmol). The reaction was heated at 45.degree. C. overnight,
quenched with water (2 mL), and the mixture was extracted with
EtOAc. The organic phase was washed with brine, dried over
MgSO.sub.4, and concentrated. The residue was purified by silica
gel column chromatography to give the title compound as a clear
liquid (4.5 g). LCMS m/z=491.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 1.25 (t, J=7.20 Hz, 3H), 1.31-1.43 (m, 4H),
1.49 (s, 9H), 1.51-1.60 (m, 4H), 1.76-1.90 (m, 1H), 2.12-2.24 (m,
1H), 2.72 (q, J=7.75 Hz, 2H), 3.46 (d, J=6.82 Hz, 2H), 3.92 (s,
2H), 4.01 (d, J=7.58 Hz, 2H), 7.31-7.43 (m, 3H), 7.86 (d, J=7.33
Hz, 2H).
Step D: Preparation of
2-(((1s,4s)-4-((5-Ethyl-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid
[0610] A mixture of 3-methoxyphenylboronic acid (0.141 g, 0.929
mmol), tert-butyl
2-(((1s,4s)-4-((5-ethyl-4-iodo-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl-
)methoxy)acetate (0.5 g, 0.929 mmol),
tetrakis(triphenylphosphine)palladium (0.107 g, 0.093 mmol),
K.sub.2CO.sub.3 (2 M aqueous, 0.5 mL) and dioxane (10 mL) was
heated to 150.degree. C. under microwave for 4 h. The reaction
mixture was filtered and the filtrate was concentrated. The residue
was treated with HCl (4 M in dioxane, 5 mL) at room temperature for
10 h. The mixture was concentrated and the residue was purified by
HPLC to give the title compound (0.135 g). LCMS m/z=463.2
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.04
(t, J=7.45 Hz, 3H), 1.35-1.55 (m, 8H), 1.71-1.83 (m, 1H), 2.06-2.18
(m, 1H), 2.60 (q, J=7.58 Hz, 2H), 3.40 (d, J=6.95 Hz, 2H), 3.70 (s,
3H), 3.72 (s, 2H), 4.02 (d, J=7.45 Hz, 2H), 6.69-6.78 (m, 2H),
6.85-6.91 (m, 1H), 7.15-7.36 (m, 6H).
Example 1.15
Preparation of
2-(((1s,4s)-4-((4-(3-Fluorophenyl)-5-isopropyl-3-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetic Acid (Compound 113)
Step A: Preparation of 5-Isopropyl-3-phenyl-1H-pyrazole
[0611] To a solution of acetophenone (1.21 g, 10.07 mmol) in dry
toluene (5 mL) was added LiHMDS (11.0 mL, 1.0 M in THF, 11.0 mmol)
via syringe at 0.degree. C. under argon. After 5 min, isobutyryl
chloride (1.073 g, 10.07 mmol) was added in one portion via
syringe. The ice bath was removed and AcOH (2 mL), EtOH (50 mL) and
THF (5 mL) were added to form a homogeneous mixture. Hydrazine
hydrate (2 mL, 10.07 mmol) was added and the reaction was refluxed
for 2 h. The reaction was cooled to room temperature and
concentrated. The residue was extracted with EtOAc, washed with
brine, dried over MgSO.sub.4, and concentrated. The residue was
purified by silica gel column chromatography to give the title
compound as a colorless oil (0.70 g). LCMS m/z=187.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.33 (d, J=6.82 Hz,
6H), 2.94-3.13 (m, 1H), 6.38 (s, 1H), 7.17-7.45 (m, 5H), 10.14 (bs,
1H).
Step B: Preparation of 4-Iodo-5-isopropyl-3-phenyl-1H-pyrazole
[0612] To a solution of 5-isopropyl-3-phenyl-1H-pyrazole (0.64 g,
3.44 mmol) in THF (20 mL) and water (20.00 mL) were added sodium
iodide (0.515 g, 3.44 mmol), iodine (1.308 g, 5.15 mmol), and
potassium carbonate (0.712 g, 5.15 mmol) at room temperature. The
reaction was refluxed for 2 h, cooled to room temperature and
quenched with 10% aqueous Na.sub.2SO.sub.3. The organic solvent was
removed under reduced pressure and the aqueous residue was
extracted with EtOAc. The organic extract was washed with
NaHCO.sub.3 solution, brine, dried over MgSO.sub.4, and
concentrated. The residue was purified by silica gel column
chromatography to give the title compound as a clear liquid (0.42
g). LCMS m/z=313.2 [M+H].sup.+; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 1.17 (d, J=7.07 Hz, 6H), 3.02 (septet, J=7.07 Hz, 1H),
7.23-7.32 (m, 3H), 7.60-7.67 (m, 2H), 11.81 (bs, 1H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-Iodo-5-isopropyl-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate
[0613] To a solution of 4-iodo-5-isopropyl-3-phenyl-1H-pyrazole
(0.35 g, 1.121 mmol) in DMF (5 mL) was added sodium hydride (0.027
g, 1.121 mmol) at room temperature. The reaction was stirred at
room temperature for 1 h and tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (0.463 g,
1.121 mmol) was added. The reaction was heated at 50.degree. C. for
16 h, cooled to room temperature, and quenched with water (2 mL).
The mixture was extracted with EtOAc. The organic extract was dried
over MgSO.sub.4 and concentrated. The residue was purified by
silica gel column chromatography to give the title compound as a
clear liquid (0.52 g). LCMS m/z=553.2 [M+H].sup.+; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 0.99-1.20 (m, 4H), 1.25-1.42 (m, 4H),
1.46 (d, J=7.20 Hz, 6H), 1.48 (s, 9H), 1.82-1.94 (m, 1H), 2.07-2.19
(m, 1H), 3.16-3.28 (m, 1H), 3.45 (d, J=7.07 Hz, 2H), 3.95 (s, 2H),
4.07 (d, J=7.71 Hz, 2H), 7.30-7.46 (m, 3H), 7.63-7.79 (m, 2H).
Step C: Preparation of
2-(((1s,4s)-4-((4-(3-Fluorophenyl)-5-isopropyl-3-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetic Acid
[0614] A mixture of 3-fluorophenylboronic acid (25.3 mg, 0.181
mmol), tert-butyl
2-(((1s,4s)-4-((4-iodo-5-isopropyl-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate (100 mg, 0.181 mmol),
tetrakis(triphenylphosphine)palladium (10.0 mg, 0.009 mmol),
K.sub.2CO.sub.3 (2 M aqueous, 0.2 mL) and dioxane (4 mL) was heated
to 150.degree. C. under microwave irradiation for 4 h. The mixture
was filtered and the filtrate was concentrated. The residue was
treated with HCl (4 M in dioxane, 5 mL) at room temperature for 10
h. The mixture was concentrated and the residue was purified by
HPLC to give the title compound (15.5 mg). LCMS m/z=465.3
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.10
(d, J=7.07 Hz, 6H), 1.34-1.59 (m, 8H), 1.72-1.85 (m, 1H), 2.06-2.19
(m, 1H), 3.09-3.22 (m, 1H), 3.44 (d, J=7.07 Hz, 2H), 4.00 (s, 2H),
4.08 (d, J=7.58 Hz, 2H), 7.00-7.10 (m, 2H), 7.14-7.28 (m, 5H),
7.37-7.46 (m, 2H).
Example 1.16
Preparation of
2-(((1s,4s)-4-((3-Cyclopropyl-4,5-diphenyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)methoxy)acetic Acid (Compound 121)
Step A: Preparation of 5-Cyclopropyl-3-phenyl-1H-pyrazole
[0615] To a solution of acetophenone (5.0 g, 41.6 mmol) in dry
toluene (5 mL) was added LiHMDS (42.0 mL, 1.0 M in THF, 42.0 mmol)
via syringe at 0.degree. C. under argon. After 5 min,
cyclopropanecarbonyl chloride (4.35 g, 41.6 mmol) was added in one
portion via syringe. The ice bath was removed and AcOH (2 mL), EtOH
(50 mL), and hydrazine hydrate (10 mL, 64% aqueous, 127.8 mmol) was
added. The mixture was refluxed for 30 min, cooled to room
temperature, and concentrated. The residue was extracted with
EtOAc, washed with brine, dried over MgSO.sub.4, and purified by
silica gel column chromatography to give the title compound as a
colorless oil (4.5 g). LCMS m/z=184.7 [M+H].sup.+; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 0.71-0.80 (m, 2H), 0.89-1.00 (m, 2H),
1.81-1.98 (m, 1H), 6.22 (s, 1H), 7.11-7.56 (m, 5H), 10.50 (bs,
1H).
Step B: Preparation of
5-Cyclopropyl-4-iodo-3-phenyl-1H-pyrazole
[0616] To a solution of 5-cyclopropyl-3-phenyl-1H-pyrazole (3.0 g,
16.28 mmol) in THF (20 mL) and water (20 mL) were added sodium
iodide (2.441 g, 16.28 mmol), iodine (6.20 g, 24.43 mmol), and
potassium carbonate (3.38 g, 24.43 mmol) at room temperature. The
reaction was refluxed for 2 h (100.degree. C.). The reaction was
cooled to room temperature and quenched with 10% aqueous
Na.sub.2SO.sub.3. The organic solvent was removed under reduced
pressure and the aqueous phase was extracted with EtOAc, washed
with NaHCO.sub.3 solution, brine, dried over MgSO.sub.4, and
concentrated. The residue was purified by silica gel column
chromatography (2.7 g). LCMS m/z=310.8 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 0.75-0.81 (m, 2H), 0.83-0.88
(m, 2H), 2.46-2.56 (m, 1H), 7.33-7.47 (m, 3H), 7.62-7.71 (m, 2H),
12.91 (s, 1H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-(3-Cyclopropyl-4-iodo-5-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate
[0617] A solution of 5-cyclopropyl-4-iodo-3-phenyl-1H-pyrazole (3.5
g, 11.29 mmol) in DMF (5 mL) was treated with sodium hydride (0.271
g, 11.29 mmol) at room temperature for 1 h, then tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (4.66 g,
11.29 mmol) was added. The reaction mixture was heated to
50.degree. C. for 16 h and quenched with water (2 mL). The mixture
was extracted by EtOAc, dried over MgSO.sub.4, and concentrated.
The residue was purified by silica gel column chromatography to
give the title compound as a colorless oil (4.5 g). LCMS m/z=551.1
[M+H].sup.+; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm
1.04-1.19 (m, 4H), 1.33-1.44 (m, 4H), 1.46 (s, 9H), 1.47 (d, J=8.08
Hz, 4H), 1.67-1.77 (m, 1H), 1.85-1.91 (m, 1H), 1.90-1.99 (m, 1H),
3.25 (d, J=7.07 Hz, 2H), 3.87 (s, 2H), 3.91 (d, J=7.58 Hz, 2H),
7.28-7.54 (m, 5H).
Step D: Preparation of
2-(((1s,4s)-4-((3-Cyclopropyl-4,5-diphenyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)methoxy)acetic Acid
[0618] A mixture of phenylboronic acid (25.3 mg, 0.181 mmol),
tert-butyl
2-(((1s,4s)-4-(3-cyclopropyl-4-iodo-5-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate (100 mg, 0.181 mmol),
tetrakis(triphenylphosphine)palladium (10.0 mg, 0.009 mmol),
K.sub.2CO.sub.3 (2 M aqueous, 0.2 mL) and dioxane (4 mL) was heated
to 150.degree. C. under microwave irradiation for 4 h. The mixture
was filtered and the filtrate was concentrated. The residue was
treated with HCl (4 M in dioxane, 5 mL) at room temperature for 10
h. The mixture was concentrated and the residue was purified by
HPLC to give the title compound (23.5 mg). LCMS m/z=445.1
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.32-1.55 (m, 8H), 1.71-1.82 (m, 1H), 2.04-2.17 (m, 1H), 2.28 (s,
3H), 2.93 (t, J=6.82 Hz, 2H), 3.16 (s, 3H), 3.40 (t, J=6.63 Hz,
2H), 3.41 (d, J=6.69 Hz, 2H), 3.87 (s, 2H), 4.07 (d, J=7.45 Hz,
2H), 6.87-6.98 (m, 2H), 7.07-7.13 (m, 2H), 7.16-7.31 (m, 5H).
Example 1.17
Preparation of
2-(((1s,4s)-4-((3-(2-Fluoro-4-methylphenyl)-5-methyl-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 143)
Step A: Preparation of 3-Iodo-5-methyl-4-phenyl-1H-pyrazole
[0619] To a solution of 5-methyl-4-phenyl-1H-pyrazole (5.0 g, 31.6
mmol) in THF (40 mL) and water (40 mL) were added sodium iodide
(4.74 g, 31.6 mmol), iodine (12.03 g, 47.4 mmol), and
K.sub.2CO.sub.3 (4.37 g, 31.6 mmol) at room temperature. The
reaction was refluxed for 2 h and then quenched with aqueous
Na.sub.2SO.sub.3 (10%). The mixture was extracted with ethyl
acetate, dried over MgSO.sub.4, and concentrated under reduced
pressure. The residue was purified by silica gel column
chromatography to give the title compound as a colorless oil (2.5
g). LCMS m/z=284.7 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 2.26 (s, 3H), 7.24-7.54 (m, 5H), 13.13 (s, 1H).
Step B: Preparation of tert-Butyl
2-(((1s,4s)-4-(3-Iodo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl-
)methoxy)acetate
[0620] A solution of 3-iodo-5-methyl-4-phenyl-1H-pyrazole (2.0 g,
7.04 mmol) in DMF (5 mL) was treated with sodium hydride (0.169 g,
7.04 mmol) at room temperature for 1 h, then tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (2.9 g,
7.04 mmol) was added. The reaction mixture was heated to 50.degree.
C. for 16 h before it was quenched by addition of water (2 mL). The
mixture was extracted with EtOAc, dried over MgSO.sub.4 and
concentrated. The residue was purified by silica gel column
chromatography to give the title compound as a colorless oil (1.5
g). LCMS m/z=525.0 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.27-1.52 (m, 8H), 1.44 (s, 9H), 1.68-1.80 (m, 1H),
1.95-2.07 (m, 1H), 1.99 (s, 3H), 3.40 (d, J=6.82 Hz, 2H), 3.96 (s,
2H), 4.03 (d, J=7.33 Hz, 2H), 7.28-7.46 (m, 5H).
Step C: Preparation of
2-(((1s,4s)-4-(3-(2-Fluoro-4-methylphenyl)-5-methyl-4-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic Acid
[0621] A solution of 2-fluoro-4-methylphenylboronic acid (29.4 mg,
0.191 mmol), tert-butyl 2-(((1s,4s)-4-((3-iodo-5-methyl-4-pheny
1-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate (100 mg, 0.191
mmol), tetrakis(triphenylphosphine)palladium (22.03 mg, 0.019
mmol), and K.sub.2CO.sub.3 (2 M aqueous, 0.5 mL) in dioxane (3 mL)
was heated to 150.degree. C. under microwave irradiation for 2 h.
The mixture was filtered and the filtrate was concentrated. The
residue was treated with HCl (4 M in dioxane, 3 mL) at room
temperature for 16 h. The mixture was concentrated and the residue
was purified by HPLC (Varian ProStar; Prep Column: Phenomenex.TM.
00G-4253-V0, Luna.TM. C18(2), 10 .mu.m, 100 .ANG., 250.times.50 mm
ID; Eluent: 40-65% ACN/H.sub.2O with 0.1% TFA over 15 min, and then
65% ACN/H.sub.2O with 0.1% FTA isocratic over 50 min) to give the
title compound (retention time: 41 min, 25.0 mg). LCMS m/z=451.1
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.32-1.52 (m, 8H), 1.69-1.79 (m, 1H), 2.02-2.13 (m, 1H), 2.28 (s,
3H), 2.30 (s, 3H), 3.39 (d, J=6.95 Hz, 2H), 3.99 (s, 2H), 4.06 (d,
J=7.45 Hz, 2H), 6.91 (d, J=11 Hz, 1H), 6.98 (d, J=7.8 Hz, 1H), 7.05
(m, 1H), 7.07 (m, 1H), 7.15-7.31 (m, 4H). A compound eluting at 37
min under the same HPLC conditions was collected and identified as
the regioisomer of the title compound,
2-(((1s,4s)-4-((5-(2-fluoro-4-methylphenyl)-3-methyl-4-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid (25.0 mg).
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.07-1.20 (m, 4H),
1.21-1.39 (m, 4H), 1.60-1.75 (m, 1H), 1.90-1.99 (m, 1H), 2.23 (s,
3H), 2.35 (s, 3H), 3.21 (d, J=6.95 Hz, 2H), 3.80 (bs, 2H), 4.92 (s,
2H), 7.05-7.27 (m, 8H).
Example 1.18
Preparation of
2-(((1s,4s)-4-(3-(4-Chloro-2-fluorophenyl)-5-methyl-4-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 144)
[0622] A solution of 4-chloro-2-fluorophenylboronic acid (33.2 mg,
0.191 mmol), tert-butyl
2-(((1s,4s)-4-((3-iodo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate (100 mg, 0.191 mmol),
tetrakis(triphenylphosphine)palladium (22.03 mg, 0.019 mmol), and
K.sub.2CO.sub.3 (2 M aqueous, 0.5 mL) in dioxane (3 mL) was heated
to 150.degree. C. under microwave irradiation for 2 h. The mixture
was filtered and the filtrate was concentrated. The residue was
treated with HCl (4 M in dioxane, 3 mL) at room temperature for 16
h. The mixture was concentrated and the residue was purified by
HPLC to give the title compound (23.0 mg). LCMS m/z=471.1
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.32-1.53 (m, 8H), 1.70-1.80 (m, 1H), 2.02-2.12 (m, 1H), 2.29 (s,
3H), 3.39 (d, J=6.95 Hz, 2H), 3.82 (s, 2H), 4.07 (d, J=7.45 Hz,
2H), 7.03-7.10 (m, 2H), 7.18-7.41 (m, 6H).
Example 1.19
Preparation of
2-(((1s,4s)-4-((5-(2-Hydroxyethylthio)-3,4-diphenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic Acid (Compound 146)
Step A: Preparation of
2-(1,3-Dithietan-2-ylidene)-1,2-diphenylethanone
[0623] To a solution of 1,2-diphenylethanone (10.0 g, 51.0 mmol) in
anhydrous THF (100 mL) was added KOtBu (1 M in THF, 51.0 mL, 51.0
mmol). The mixture was stirred for 30 min at room temperature, and
carbon disulfide (7.76 g, 102 mmol) was added. After 10 min,
dibromomethane (17.72 g, 102 mmol) was added and the reaction was
stirred for 4 h at room temperature. The reaction was quenched with
water (10 mL) and diluted with EtOAc. The organic layer was
separated, dried over MgSO.sub.4, and concentrated to give the
title compound as a yellow solid (13.0 g). LCMS m/z=285.0
[M+H].sup.+.
Step B: Preparation of 3,4-Diphenyl-1H-pyrazole-5-thiol
[0624] To a suspension of
2-(1,3-dithietan-2-ylidene)-1,2-diphenylethanone (1.88 g, 6.61
mmol) in ethanol (50 mL) was added hydrazine hydrate (0.496 g, 9.92
mmol). The reaction was refluxed for 16 h, cooled to room
temperature and concentrated. The residue was neutralized with HCl
(1.0 M) to pH 6-7 and extracted with EtOAc/H.sub.2O. The organic
extract was dried over MgSO.sub.4 and concentrated to give the
title compound (1.5 g). LCMS m/z=253.4 [M+H].sup.+; .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. ppm 4.01-4.19 (m, 1H), 6.92-7.58 (m,
10H).
Step C: Preparation of
3,4-Diphenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)-1H-pyrazole
[0625] To a solution of 3,4-diphenyl-1H-pyrazole-5-thiol (1.2 g,
4.76 mmol) and 2-(2-bromoethoxy)tetrahydro-2H-pyran (0.994 g, 4.76
mmol) in DMF (5 mL) was added K.sub.2CO.sub.3 (1.0 g, 7.23 mmol).
The reaction was stirred at 60.degree. C. for 2 h, cooled to room
temperature, and quenched with H.sub.2O (5 mL). The mixture was
extracted with EtOAc, dried over MgSO.sub.4, and concentrated. The
residue was purified by silica gel column chromatography to give
the title compound as a colorless oil (1.7 g). LCMS m/z=381.2
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.32-1.50 (m, 4H), 1.50-1.73 (m, 2H), 2.99-3.13 (m, 1H), 3.21-3.44
(m, 2H), 3.46-3.59 (m, 1H), 3.61-3.82 (m, 2H), 4.44-4.59 (m, 1H),
7.16-7.40 (m, 10H), 13.32 (bs, 1H).
Step D: Preparation of tert-Butyl
2-(((1s,4s)-4-(3,4-Diphenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)--
1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
[0626] To a solution of
3,4-diphenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)-1H-pyrazole
(2.0 g, 5.26 mmol) in DMF (5 mL) was added sodium hydride (0.126 g,
5.26 mmol) slowly at room temperature. The reaction was stirred at
room temperature for 30 min, and tert-butyl
2-(((1s,4s)-4-(tosyloxymethypcyclohexyl)methoxy)acetate (2.168 g,
5.26 mmol) was added. The reaction was gently heated to 60.degree.
C. for 16 h. After cooled to room temperature, the reaction was
quenched with H.sub.2O (5 mL). The mixture was extracted with
EtOAc, dried over MgSO.sub.4, and concentrated. The residue was
purified by silica gel column chromatography to give the title
compound as a colorless oil (2.5 g). LCMS m/z=621.4 [M+H].sup.+;
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.26-1.43 (m, 4H),
1.44-1.54 (m, 4H), 1.47 (s, 9H), 1.54-1.62 (m, 2H), 1.76-1.92 (m,
4H), 2.23-2.36 (m, 2H), 2.63 (t, J=6.69 Hz, 2H), 3.21-3.32 (m, 1H),
3.36 (d, J=6.95 Hz, 2H), 3.38-3.44 (m, 1H), 3.56-3.64 (m, 1H), 3.73
(t, J=11.18 Hz, 1H), 3.91 (s, 2H), 3.93 (d, J=7.07 Hz, 2H), 4.33
(t, J=7.71 Hz, 1H), 7.20-7.43 (m, 6H), 7.75-7.81 (m, 4H).
Step E: Preparation of
2-(((1s,4s)-4-((5-(2-Hydroxyethylthio)-3,4-diphenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic Acid
[0627] A mixture of tert-butyl
2-(((1s,4s)-4-(3,4-diphenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)--
1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate (100 mg, 0.21
mmol) and HCl (4.0 M in dioxane, 4 mL) was stirred at room
temperature for 16 h. The reaction mixture was concentrated and the
residue was purified by HPLC to give the title compound. LCMS
m/z=481.4 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.02-1.20 (m, 4H), 1.22-1.37 (m, 4H), 1.55-1.64 (m, 1H),
1.88-1.99 (m, 1H), 3.03 (t, J=6.82 Hz, 2H), 3.20 (d, J=6.82 Hz,
2H), 3.61 (t, J=6.82 Hz, 2H), 3.91 (s, 2H), 3.93 (d, J=7.20 Hz,
2H), 7.06-7.32 (m, 10H), 12.51 (br. s., 1H).
Example 1.20
Preparation of
2-(((1s,4s)-4-((4-(3-Hydroxyphenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid (Compound 153)
Step A: Preparation of 5-Methyl-3-phenyl-1H-pyrazole
[0628] To a solution of acetophenone (10 g, 83 mmol) in anhydrous
toluene (10 mL) was added LiHMDS (1.0 M in THF, 83 mL, 83 mmol) via
syringe at 0.degree. C. under argon. After 5 min, acetyl chloride
(6.53 g, 83 mmol) was added via syringe in one portion. The ice
bath was removed and AcOH (5 mL, glacial), EtOH (50 mL), and
hydrazine hydrate (12.50 g, 250 mmol) were added. The mixture was
refluxed for 2 h, cooled to room temperature, and neutralized to pH
7 by adding 1.0 M NaOH solution. The mixture was extracted with
EtOAc, washed with brine, dried over MgSO.sub.4, and concentrated.
The residue was purified by silica gel column chromatography to
give the title compound as a pale yellow oil (12.05 g). LCMS
m/z=159.0 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 2.25 (s, 3H), 6.42 (s, 1H), 7.20-7.44 (m, 3H), 7.67-7.82 (m,
2H), 12.53 (bs, 1H).
Step B: Preparation of 4-Bromo-5-methyl-3-phenyl-1H-pyrazole
[0629] To a solution of 5-methyl-3-phenyl-1H-pyrazole (8.0 g, 50.6
mmol) in dichloromethane (150 mL) was added bromine (8.08 g, 50.6
mmol) dropwise at 0.degree. C. The reaction was stirred at
0.degree. C. for 30 min and then at room temperature for 2 h before
quenching with aqueous Na.sub.2SO.sub.3 (10% w/w, 10 mL). The
organic solvent was removed and the aqueous phase was extracted
with EtOAc, washed with brine, dried over MgSO.sub.4, and
concentrated. The residue was purified by silica gel column
chromatography to give the title compound as a yellow oil (9.5 g).
LCMS m/z=236.9 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 2.26 (s, 3H), 7.30-7.57 (m, 5H), 13.12 (s, 1H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-(4-Bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate
[0630] To a solution of 4-bromo-5-methyl-3-phenyl-1H-pyrazole (2.0
g, 8.44 mmol) in DMF (5 mL) were added sodium hydride (0.202 g,
8.44 mmol) in portions at 0.degree. C. The reaction was stirred at
that temperature for 1 h and tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (3.48 g,
8.44 mmol) was added. The reaction was gently heated to 42.degree.
C. for 16 h, cooled to room temperature, and quenched with H.sub.2O
(2 mL). The mixture was extracted with ethyl acetate, dried over
MgSO.sub.4 and concentrated under reduced pressure. The residue was
purified by silica gel column chromatography to give the title
compound as a colorless liquid (3.05 g). LCMS m/z=477.3
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.26-1.50 (m, 8H), 1.43 (s, 9H), 1.66-1.78 (m, 1H), 1.97-2.09 (m,
1H), 2.30 (s, 3H), 3.39 (d, J=6.82 Hz, 2H), 3.94 (s, 2H), 4.06 (d,
J=7.58 Hz, 2H), 7.30-7.50 (m, 3H), 7.74-7.85 (m, 2H).
Step D: Preparation of
2-(((1s,4s)-4-((4-(3-Hydroxyphenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid
[0631] To a solution of tert-butyl
2-(((1s,4s)-4-((4-iodo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate (100 mg, 0.191 mmol) in dioxane (3 mL) was added
3-hydroxyphenylboronic acid (26.3 mg, 0.191 mmol),
tetrakis(triphenylphosphine)palladium (22.03 mg, 0.019 mmol), and
K.sub.2CO.sub.3 (2 M aqueous, 0.2 mL, 0.4 mmol). The mixture was
heated to 150.degree. C. under microwave irradiation for 4 h,
filtered through a plug of silica gel, and concentrated. The
residue was treated with HCl (4 M in dioxane, 3 mL) for 10 h. The
mixture was concentrated and the residue was purified by HPLC to
give the title compound (25.6 mg). LCMS m/z=435.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.31-1.54 (m, 8H),
1.70-1.81 (m, 1H), 2.03-2.13 (m, 1H), 2.19 (s, 3H), 3.42 (d, J=7.07
Hz, 2H), 3.99 (s, 2H), 4.03 (d, J=7.45 Hz, 2H), 6.52-6.73 (m, 4H),
7.11-7.39 (m, 5H), 9.44 (bs, 1H).
Example 1.21
Preparation of
2-(((1s,4s)-4-((5-(2-Methoxyethyl)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cy-
clohexyl)methoxy)acetic Acid (Compound 178)
Step A: Preparation of 5-(2-Methoxyethyl)-3-phenyl-1H-pyrazole
[0632] To a solution of acetophenone (3.5 g, 29.1 mmol) in dry
toluene (10 mL) was added LiHMDS (1.0 M in toluene) via syringe at
0.degree. C. under argon. After 5 min, 3-methoxypropanoyl chloride
(3.57 g, 29.1 mmol) was added in one portion via syringe. The ice
bath was removed and AcOH (2 mL), EtOH (100 mL), and hydrazine
hydrate (4.37 g, 87 mmol) were added. The reaction was refluxed for
2 h, cooled to room temperature, and concentrated. The residue was
extracted with EtOAc/H.sub.2O, washed with brine, dried over
MgSO.sub.4, and concentrated. The resulting residue was purified by
silica gel column chromatography to give the title compound as a
pale yellow oil (2.0 g). LCMS m/z=203.1 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 2.85 (bs, 2H), 3.27 (s, 3H),
3.59 (t, J=6.82 Hz, 2H), 6.49 (s, 1H), 7.21-7.46 (m, 3H), 7.74 (m,
2H), 12.56 (s, 1H).
Step B: Preparation of
4-Bromo-5-(2-methoxyethyl)-3-phenyl-1H-pyrazole
[0633] To a solution of 5-(2-methoxyethyl)-3-phenyl-1H-pyrazole
(2.0 g, 9.89 mmol) in DCM (100 mL) was added bromine (4.74 g, 29.7
mmol) dropwise at 0.degree. C. The reaction was stirred at
0.degree. C. for 1 h and then at room temperature for 2 h before
quenching with Na.sub.2SO.sub.3 (10% aqueous). The organic phase
was removed and the aqueous layer was extracted with DCM
(2.times.50 mL). The organic layers were combined, washed with
brine, dried over MgSO.sub.4, and concentrated to give the title
compound (2.5 g). LCMS m/z=281.1 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 2.87 (t, J=6.82 Hz, 2H), 3.27 (s, 3H),
3.62 (t, J=6.82 Hz, 2H), 5.75 (s, 1H), 7.35-7.51 (m, 3H), 7.75-7.82
(m, 2H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-Bromo-5-(2-methoxyethyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate
[0634] To a solution of
4-bromo-5-(2-methoxyethyl)-3-phenyl-1H-pyrazole (3.0 g, 10.67 mmol)
in DMF (5 mL) was added sodium hydride (0.256 g, 10.67 mmol),
followed by tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (4.40 g,
10.67 mmol). The reaction was gently heated to 45.degree. C.
overnight. After quenching with water (5 mL), the mixture was
extracted with EtOAc, washed with brine, dried over MgSO.sub.4, and
concentrated. The residue was purified by silica gel column
chromatography to give the title compound (4.5 g). LCMS m/z=523.4
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.69-1.80 (m, 4H), 1.81-1.89 (m, 4H), 1.91 (s, 9H), 2.19-2.30 (m,
2H), 2.90 (s, 3H), 3.46 (t, J=6.63 Hz, 2H), 3.89 (d, J=6.95 Hz,
2H), 4.02 (t, J=6.32 Hz, 2H), 4.43 (s, 2H), 4.56 (d, J=7.45 Hz,
2H), 7.81-7.99 (m, 3H), 8.24-8.32 (m, 2H).
Step D: Preparation of
2-(((1s,4s)-4-((5-(2-Methoxyethyl)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cy-
clohexyl)methoxy)acetic Acid
[0635] To a solution of tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-methoxyethyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate (100 mg, 0.192 mmol) in dioxane (3 mL)
was added phenylboronic acid (23.4 mg, 0.192 mmol),
tetrakis(triphenylphosphine)palladium (22.03 mg, 0.019 mmol), and
K.sub.2CO.sub.3 (2 M aqueous, 0.5 mL). The reaction was heated
under microwave irradiation at 150.degree. C. for 4 h, filtered
through a plug of silica gel and concentrated. The residue was
treated with HCl (4M in dioxane, 3 mL) for 10 h, and the mixture
was purified by HPLC to give the title compound (23.5 mg). LCMS
m/z=463.3 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.33-1.56 (m, 8H), 1.71-1.84 (m, 1H), 2.05-2.20 (m, 1H), 2.84
(t, J=6.82 Hz, 2H), 3.13 (s, 3H), 3.35 (t, J=6.82 Hz, 2H), 3.39 (d,
J=7.07 Hz, 2H), 3.67 (s, 2H), 4.06 (d, J=7.33 Hz, 2H), 7.15-7.42
(m, 10H).
Example 1.22
Preparation of
2-(((1s,4s)-4-((5-(2-Methoxyethyl)-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 179)
[0636] To a solution of tert-butyl
2-(als,4s)-4-((4-bromo-5-(2-methoxyethyl)-3-phenyl-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetate (100 mg, 0.192 mmol) in dioxane (3 mL)
was added 3-methoxyphenylboronic acid (23.4 mg, 0.192 mmol),
tetrakis(triphenylphosphine)palladium (22.03 mg, 0.019 mmol), and
K.sub.2CO.sub.3 (2 M aqueous, 0.5 mL). The reaction was heated
under microwave irradiation at 150.degree. C. for 4 h, filtered
through a plug of silica gel and concentrated. The residue was
treated with HCl (4M in dioxane, 3 mL) for 10 h. The mixture was
purified by HPLC to give the title compound (23.5 mg). LCMS
m/z=493.4 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.32-1.56 (m, 8H), 1.72-1.85 (m, 1H), 2.06-2.18 (m, 1H), 2.85
(t, J=6.69 Hz, 2H), 3.16 (s, 3H), 3.36-3.38 (m, 2H), 3.40 (d,
J=3.03 Hz, 2H), 3.66 (s, 2H), 3.70 (s, 3H), 4.05 (d, J=7.33 Hz,
2H), 6.71-6.80 (m, 2H), 6.85-6.91 (m, 1H), 7.16-7.35 (m, 6H).
Example 1.23
Preparation of
2-(((1s,4s)-4-((4-(3-Chloro-2-fluorophenyl)-5-(2-(methylthio)ethyl)-3-phe-
nyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
215)
Step A: Preparation of
5-(2-(Methylthio)ethyl)-3-phenyl-1H-pyrazole
[0637] To a solution of acetophenone (5.0 g, 41.6 mmol) in dry
toluene (10 mL) was added LiHMDS (1.0 M in toluene, 42 mL, 42 mmol)
via syringe at 0.degree. C. under argon. After 5 min,
3-(methylthio)propanoyl chloride (5.77 g, 41.6 mmol) was added in
one portion via syringe. The ice bath was removed and AcOH (5 mL),
EtOH (100 mL), and hydrazine hydrate (6.25 g, 125 mmol) were added.
The mixture was refluxed for 2 h, cooled to room temperature, and
concentrated. The residue was partitioned between EtOAc and water,
and the organic phase was washed with brine, dried over MgSO.sub.4,
and concentrated. The resulting residue was purified by silica gel
column chromatography to give the title compound as a pale yellow
oil (6.5 g). LCMS m/z=219.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 2.09 (s, 3H), 2.77 (t, J=7.71 Hz, 2H),
2.84-2.95 (m, 2H), 6.53 (s, 1H), 7.18-7.50 (m, 3H), 7.63-7.84 (m,
2H), 12.60 (bs, 1H).
Step B: Preparation of
4-Bromo-5-(2-(methylthio)ethyl)-3-phenyl-1H-pyrazole
[0638] To a solution of
5-(2-(methylthio)ethyl)-3-phenyl-1H-pyrazole (4.0 g, 18.32 mmol) in
methanol (20 mL) was added N-bromosuccinimide (3.26 g, 18.32 mmol)
slowly at 0.degree. C. The reaction was stirred at 0.degree. C. for
2 h. The mixture was concentrated and purified by silica gel column
chromatography to give the title compound (3.4 g). LCMS m/z=297.0
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 2.11
(s, 3H), 2.79 (t, J=7.83 Hz, 2H), 2.83-2.97 (m, 2H), 7.32-7.56 (m,
3H), 7.67-7.88 (m, 2H), 13.20 (bs, 1H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-(4-Bromo-5-(2-(methylthio)ethyl)-3-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetate
[0639] To a solution of
4-bromo-5-(2-(methylthio)ethyl)-3-phenyl-1H-pyrazole (3.4 g, 11.44
mmol) in DMF (5 mL) was added sodium hydride (0.275 g, 11.44 mmol)
at room temperature, followed by tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (4.72 g,
11.44 mmol). The reaction was heated to 45.degree. C. overnight,
cooled to room temperature, and quenched with water (5 mL). The
mixture was extracted with EtOAc, washed with brine, dried over
MgSO.sub.4, and concentrated. The residue was purified by silica
gel column chromatography to give the title compound (3.5 g). LCMS
m/z=539.1 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.30-1.40 (m, 4H), 1.43 (s, 9H), 1.44-1.52 (m, 4H), 1.70-1.80
(m, 1H), 2.03-2.11 (m, 1H), 2.14 (s, 3H), 2.72 (t, J=7.07 Hz, 2H),
3.00 (t, J=7.20 Hz, 2H), 3.40 (d, J=6.95 Hz, 2H), 3.94 (s, 2H),
4.09 (d, J=7.45 Hz, 2H), 7.32-7.51 (m, 3H), 7.75-7.84 (m, 2H).
Step D: Preparation of
2-(((1s,4s)-4-((4-(3-Chloro-2-fluorophenyl)-5-(2-(methylthio)ethyl)-3-phe-
nyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid
[0640] To a solution of tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-(methylthio)ethyl)-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetate (100 mg, 0.19 mmol) in dioxane (3
mL) were added 2-fluoro-3-chlorophenylboronic acid (32.4 mg, 0.19
mmol), tetrakis(triphenylphosphine)palladium (22 mg, 0.019 mmol),
and K.sub.2CO.sub.3 (2 M aqueous, 0.2 mL). The reaction mixture was
heated to 150.degree. C. under microwave irradiation for 4 h. The
mixture was then filtered through a plug of silica gel and
concentrated, and the residue was treated with HCl (4 M in dioxane,
5 mL) at room temperature for 10 h. The mixture was concentrated
and the residue was purified by HPLC to give the title compound
(24.5 mg). LCMS m/z=531.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.32-1.55 (m, 8H), 1.71-1.83 (m, 1H),
1.86 (s, 3H), 2.06-2.19 (m, 1H), 2.50 (t, J=7.83 Hz, 2H), 2.85 (t,
J=7.39 Hz, 2H), 3.40 (d, J=6.95 Hz, 2H), 3.71 (s, 2H), 4.09 (d,
J=7.33 Hz, 2H), 7.15-7.38 (m, 6H), 7.54-7.65 (m, 2H).
Example 1.24
Preparation of
2-(((1s,4s)-4-((4-(3-Methoxyphenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 31)
Step A: Preparation of
2-(3-Methoxyphenyl)-3,3-bis(methylthio)-1-phenylprop-2-en-1-one
[0641] To a solution of 2-(3-methoxyphenyl)-1-phenylethanone (5.0
g, 22.10 mmol) in anhydrous THF (44.0 mL) was added a solution of
potassium tert-butoxide (1 M in THF, 46.0 mL, 46.0 mmol). The
reaction mixture was stirred for 15 min at room temperature, and
then CS.sub.2 (1.45 mL, 24.05 mmol) was added. After several
minutes, MeI (3.40 mL, 54.4 mmol) was added and the reaction was
stirred for 5 h. Upon completion, the reaction mixture was diluted
with saturated NaHCO.sub.3 and extracted with EtOAc. The combined
organic layers were washed with H.sub.2O, brine, dried over
MgSO.sub.4 and concentrated to give the title compound as an orange
oil.
Step B: Preparation of
4-(3-Methoxyphenyl)-5-(methylthio)-3-phenyl-1H-pyrazole
[0642] To a solution of
2-(3-methoxyphenyl)-3,3-bis(methylthio)-1-phenylprop-2-en-1-one in
EtOH (100 mL) was added hydrazine hydrate (5.36 mL, 110 mmol). The
reaction mixture was refluxed overnight, additional hydrazine
hydrate (1.00 mL, 20.6 mmol) was added, and the mixture was
refluxed until the reaction was complete. The mixture was
concentrated under reduced pressure, washed with H.sub.2O and
extracted with CH.sub.2Cl.sub.2. The combined organic layers were
washed with H.sub.2O, brine, dried over MgSO.sub.4 and concentrated
to give the title compound (6.67 g). LCMS m/z=397 [M+H].sup.+.
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-(3-Methoxyphenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetate
[0643] In a reaction vial was placed
4-(3-methoxyphenyl)-5-(methylthio)-3-phenyl-1H-pyrazole (2.241 g,
7.56 mmol) and NaH (357.4 mg, 8.94 mmol) in DMF (36.0 mL). The
mixture was stirred at room temperature for 15 min then a solution
of tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (3.0415 g,
7.37 mmol) in DMF (10.0 mL) was added. The reaction was heated at
45.degree. C. for 15 h. Upon completion, the reaction mixture was
quenched with H.sub.2O and extracted with EtOAc. The combined
organic layers were washed with brine, dried over MgSO.sub.4, and
concentrated. The residue was purified by silica gel column
chromatography to give the title compound.
Step D: Preparation of
2-(((1s,4s)-4-((4-(3-Methoxyphenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic Acid
[0644] To tert-butyl
2-(((1s,4s)-4-((4-(3-methoxyphenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetate obtained above was added 4 M
HCl in dioxane. The reaction was stirred at room temperature
overnight. Upon completion, the reaction was basified with 10% NaOH
and organic impurities were extracted out with MTBE. The aqueous
layer was then acidified with 1 M HCl and extracted with MTBE. The
combined organic layers were dried over MgSO.sub.4 and
concentrated. The residue obtained was dissolved in ACN and 1 N
NaOH solution (2.45 mL, 2.45 mmol) was added. The mixture was
lyophilized to give a solid which was recrystallized from isopropyl
alcohol to give the sodium salt of the title compound as an
off-white solid (897.6 mg). LCMS m/z=481 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 1.17-1.80 (m, 10H), 2.14 (s, 3H),
3.34 (d, J=7.0 Hz, 2H), 3.50 (s, 2H), 3.71 (s, 3H), 4.27 (d, J=7.5
Hz, 2H), 6.80-6.85 (m, 2H), 6.89-6.94 (m, 1H), 7.21-7.37 (m,
6H).
Example 1.25
Preparation of
2-(((1s,4s)-4-((5-(2-Hydroxyethylthio)-4-(3-methoxyphenyl)-3-phenyl-1H-py-
razol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 198)
Step A: Preparation of
4-(3-Methoxyphenyl)-3-phenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)-
-1H-pyrazole
[0645] To a stirred solution of
2-(3-methoxyphenyl)-1-phenylethanone (1.25 g, 5.52 mmol) in THF
(11.05 mL) was added potassium tert-butoxide (11.49 mL, 11.49
mmol). After 30 min, CS.sub.2 (0.363 mL, 6.02 mmol) was added and
the mixture was stirred for 10 min before
2-(2-bromoethoxy)tetrahydro-2H-pyran (2.086 mL, 13.81 mmol) was
added and the reaction was stirred overnight. The mixture was
diluted with ethanol (11.05 mL). Acetic acid (1.898 mL, 33.1 mmol)
was added followed by hydrazine hydrate (2.71 mL, 55.2 mmol). The
reaction was stirred at 85.degree. C. overnight and concentrated
under reduced pressure. The residue was extracted with
EtOAc/H.sub.2O (twice). The organic phases were combined and washed
with brine, dried over MgSO.sub.4 and concentrated. The residue was
purified by silica gel column chromatography to give the title
compound as a white solid (1.681 g). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 1.52-1.64 (m, 3H), 1.65-1.93 (m, 3H), 3.06
(t, J=5.94 Hz, 2H), 3.49-3.57 (m, 1H), 3.65-3.71 (m, 1H), 3.72 (s,
3H), 3.88-3.95 (m, 1H), 3.97-4.05 (m, 1H), 4.66-4.69 (m, 1H),
6.79-6.90 (m, 3H), 7.19-7.26 (m, 1H), 7.26-7.33 (m, 3H), 7.37-7.45
(m, 2H), 10.91 (bs, 1H).
Step B: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-(3-Methoxyphenyl)-3-phenyl-5-(2-(tetrahydro-2H-pyran-2--
yloxy)ethylthio)-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
and tert-Butyl
2-(((1s,4s)-4-((4-(3-Methoxyphenyl)-5-phenyl-3-(2-(tetrahydro-2H-pyran-2--
yloxy)ethylthio)-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
[0646] To a stirred solution of
4-(3-methoxyphenyl)-3-phenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)-
-1H-pyrazole (0.123 g, 0.3 mmol) was added 60% NaH (0.012 g, 0.300
mmol). After 20 min, tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (0.124 g,
0.300 mmol) was added. The reaction was heated to 70.degree. C. for
18 h, cooled to room temperature, and diluted with water. The
mixture was extracted three times with EtOAc. The combined extracts
were washed with brine, dried over MgSO.sub.4 and concentrated. The
residue was purified by silica gel column chromatography to give
the title compound as a mixture of regioisomers (46 mg). LCMS
m/z=651.7 [M+H].sup.+.
Step C: Preparation of
2-(((1s,4s)-4-((5-(2-Hydroxyethylthio)-4-(3-methoxyphenyl)-3-phenyl-1H-py-
razol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid
[0647] To a stirred solution of tert-butyl
2-(((1s,4s)-4-((4-(3-methoxyphenyl)-3-phenyl-5-(2-(tetrahydro-2H-pyran-2--
yloxy)ethylthio)-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
(46 mg, 0.071 mmol) and tert-butyl
2-(((1s,4s)-4-((4-(3-methoxyphenyl)-5-phenyl-3-(2-(tetrahydro-2H-pyran-2--
yloxy)ethylthio)-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
(a mixture of regioisomers) in DCM (214 .mu.L) was added water
(21.42 .mu.L), triethylsilane (113 .mu.l, 0.707 mmol), and TFA (109
.mu.L, 1.413 mmol). The reaction was stirred overnight, further TFA
(0.5 mL) was added and the reaction was stirred for an additional 1
h. The solvent was evaporated. The residue was taken up in 70%
acetonitrile/water and purified by HPLC (50% acetonitrile/water;
isocratic) to give the title compound as a solid. LCMS m/z=511.5
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.31-1.45 (m, 4H), 1.45-1.54 (m, 4H), 1.69-1.80 (m, J=4.55 Hz, 1H),
2.18 (bs, 1H), 2.51-2.56 (m, 2H), 2.60 (t, J=6.69 Hz, 2H), 2.60 (t,
J=6.69 Hz, 1H), 3.41 (d, J=7.07 Hz, 2H), 3.71 (s, 3H), 3.96-4.01
(m, 2H), 4.29 (d, J=7.58 Hz, 2H), 6.79-6.84 (m, 2H), 6.88-6.95 (m,
1H), 7.23-7.30 (m, 4H), 7.30-7.37 (m, 2H).
Example 1.26
Preparation of
2-(((1s,4s)-4-((5-(2-Hydroxyethylthio)-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methoxy)acetic Acid (Compound 200)
Step A: Preparation of
4-Phenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)-3-p-tolyl-1H-pyrazo-
le
[0648] From 2-phenyl-1-p-tolylethanone, using a similar method to
the one described in Example 1.25, step A, the title compound was
obtained as a white solid. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 1.54-1.64 (m, 3H), 1.66-1.90 (m, 3H), 2.33 (s, 3H),
3.05 (t, J=5.43 Hz, 2H), 3.47-3.56 (m, 1H), 3.64-3.72 (m, 1H),
3.86-3.94 (m, 1H), 3.95-4.01 (m, 1H), 4.63-4.67 (m, 1H), 7.10 (d,
J=8.08 Hz, 2H), 7.25-7.30 (m, 5H), 7.30-7.39 (m, 2H).
Step B: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-Phenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)-3-p-
-tolyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
[0649] From
4-phenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)-3-p-tolyl-1H-pyrazo-
le, using a similar method to the one described in Example 1.25,
step B, the title compound was obtained as a clear solid. LCMS
m/z=635.6 [M+H].sup.+.
Step C: Preparation of
2-4(1s,4s)-4-((5-(2-Hydroxyethylthio)-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic Acid
[0650] From tert-butyl
2-(((1s,4s)-4-(4-phenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)-3-p--
tolyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate, using a
method similar to the one described in Example 1.25, Step C, the
title compound was obtained as a white solid. LCMS m/z=495.3
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.32-1.45 (m, 4H), 1.45-1.52 (m, 4H), 1.68-1.80 (m, 1H), 2.13-2.22
(m, 1H), 2.25 (s, 3H), 2.56 (t, J=6.69 Hz, 2H), 3.23-3.29 (m, 2H),
3.41 (d, J=6.82 Hz, 2H), 3.98-4.01 (m, 2H), 4.28 (d, J=7.58 Hz,
2H), 4.75 (bs, 1H), 7.06 (d, J=7.83 Hz, 2H), 7.20 (d, J=8.08 Hz,
2H), 7.23-7.28 (m, 2H), 7.30-7.43 (m, 3H), 12.52 (bs, 1H).
Example 1.27
Preparation of
2-(((1r,4r)-4-((3,4-Diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)ac-
etic Acid (Compound 8) and
2-0(1r,4r)-4-((4,5-Diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)ace-
tic Acid (Compound 9)
Step A: Preparation of 3,4-Diphenyl-1H-pyrazole
[0651] Phenyl(3-phenyloxiran-2-yOmethanone (5.0 g, 22.3 mmol) was
suspended in dry Et.sub.2O (40 mL) under an argon balloon. Boron
trifluoride diethyl etherate (3.00 mL, 23.7 mmol) was added slowly
via syringe. The reaction was refluxed at 50.degree. C. for an
hour, then cooled and extracted with 60 mL each of H.sub.2O and
Et.sub.2O/EtOAc. The aqueous layer was extracted again with EtOAc
(60 mL). The combined organic layer was dried and concentrated to
give 3-oxo-2,3-diphenylpropanal.
[0652] 3-Oxo-2,3-diphenylpropanal (5.00 g, 22.3 mmol) was dissolved
in EtOH (40 mL). Hydrazine monohydrate (2.0 mL, 38.7 mmol) was
added slowly via syringe. The reaction was stirred at room
temperature for an hour. The solvent was evaporated and the residue
was purified by silica gel column chromatography to yield the title
compound as a light purple solid (2.75 g). LCMS m/z=221.1
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
6.99-7.57 (m, 10H), 7.66-8.09 (bs, 1H), 13.15 (bs, 1H).
Step B: Preparation of
2-(((1r,4r)-4-((3,4-Diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)ac-
etic Acid and
2-(((1r,4r)-4-((4,5-Diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)ac-
etic Acid
[0653] 3,4-Diphenyl-1H-pyrazole (16.02 mg, 0.073 mmol) was
dissolved in DMF (0.4 mL). NaH (1.745 mg, 0.073 mmol) was added and
the reaction was stirred at room temperature for 15 min.
tert-Butyl-2-(((1r,4r)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate
(prepared in a similar manner to Example 1.1) (30.0 mg, 0.073 mmol)
was added and the reaction was stirred at room temperature for an
hour. After this time, the reaction was partitioned between with
H.sub.2O (2 mL) and EtOAc (2 mL). The aqueous layer was extracted
with EtOAc (2 mL). The organic layers were combined, dried and
concentrated. The resulting oil was redissolved in HCl (4 M in
dioxane) (400 .mu.L, 1.600 mmol) and stirred overnight. The solvent
was evaporated and the residue was purified by preparative LC/MS
(50% acetonitrile/water; isocratic) to yield Compound 8 as a white
solid (6.5 mg); LCMS m/z=405.5 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 0.86-1.12 (m, 4H), 1.44-1.58 (m, 1H),
1.61-1.71 (m, 2H), 1.73-1.80 (m, 2H), 1.80-1.91 (m, 1H), 3.26 (d,
J=6.32 Hz, 2H), 3.95 (s, 2H), 4.00 (d, J=7.07 Hz, 2H), 7.20-7.27
(m, 3H), 7.27-7.36 (m, 5H), 7.36-7.44 (m, 2H), 7.92 (s, 1H); and
Compound 9 as a white solid (1.0 mg); LCMS m/z=405.6 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 0.68-0.88 (m, 4H),
1.33-1.50 (m, J=9.98 Hz, 3H), 1.57-1.78 (m, 3H), 3.20 (d, J=6.32
Hz, 2H), 3.78 (d, J=7.20 Hz, 2H), 3.92 (s, 2H), 7.07-7.16 (m, 3H),
7.16-7.22 (m, 2H), 7.30-7.36 (m, 2H), 7.47-7.56 (m, 3H), 7.83 (s,
1H).
Example 1.28
Preparation of
2-(((1s,4s)-4-(1-Phenyl-4,5-dihydro-3H-benzo[e]indazol-3-yl)methyl)cycloh-
exyl)methoxy)acetic Acid (Compound 150)
Step A: Preparation of 1-Phenyl-4,5-dihydro-3H-benzo[e]indazole
[0654] 3,4-Dihydronaphthalen-2(1H)-one (2.080 g, 14.23 mmol) was
dissolved in toluene (15 mL) and the solution was cooled on an ice
bath. LiHMDS (7.470 mL, 7.470 mmol) was added with vigorous
stirring. One minute later benzoyl chloride (0.8258 mL, 7.114 mmol)
was added. The reaction was removed from the ice bath and stirred
for another minute. AcOH (4 mL) was added with stirring, followed
by EtOH (10 mL), THF (5 mL), and hydrazine monohydrate (5 mL, 96.8
mmol). After 10 min, the solution was poured into a seperatory
funnel loaded with 1 M NaOH (30 mL) and extracted with additional
H.sub.2O (70 mL) and EtOAc (100 mL). The aqueous layer was
extracted again with EtOAc (100 mL). The combined organic layer was
dried and concentrated. The residue was purified by silica gel
column chromatography to yield the title compound as a light-purple
colored solid. LCMS m/z=247.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 2.72-2.86 (m, 2H), 2.90-3.00 (m, 2H),
6.99-7.09 (m, 2H), 7.11-7.21 (m, 1H), 7.23-7.29 (m, 1H), 7.37-7.61
(m, 5H), 12.75 (s, 0.7H), 12.97 (s, 0.3H).
Step B: Preparation of
2-(((1s,4s)-4-(1-Phenyl-4,5-dihydro-3H-benzo[e]indazol-3-yl)methyl)cycloh-
exyl)methoxy)acetic Acid
[0655] 1-Phenyl-4,5-dihydro-3H-benzo[e]indazole (100 mg, 0.406
mmol) was dissolved in DMF (0.4 mL). Sodium hydride (9.74 mg, 0.406
mmol) was added. The reaction was stirred at room temperature for
10 min and then tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (167 mg,
0.406 mmol), pre-dissolved in DMF (0.2 mL) was added. The reaction
was stirred for 1 h at 50.degree. C. After this time, more NaH (10
mg) was added. The reaction was again stirred for 1 h at 50.degree.
C. The mixture was extracted with 15 mL each of H.sub.2O and EtOAc.
The aqueous layer was extracted again with EtOAc (15 mL). The
combined organic layer was dried and concentrated. The residue was
redissolved in HCl (4 M in dioxane) (507 .mu.L, 2.030 mmol) and
stirred overnight at room temperature. The solvent was evaporated
and the residue was purified by preparative LC/MS to give the title
compound as a light-tan solid (35 mg). LCMS m/z=431.4 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.28-1.54 (m, 8H),
1.69-1.80 (m, 1H), 2.00-2.10 (m, 1H), 2.85 (d, J=7.83 Hz, 2H), 2.97
(t, J=7.33 Hz, 2H), 3.41 (d, J=6.95 Hz, 2H), 3.99 (s, 2H), 4.04 (d,
J=7.58 Hz, 2H), 6.98-7.08 (m, 2H), 7.10-7.18 (m, 1H), 7.22-7.30 (m,
1H), 7.35-7.50 (m, 3H), 7.54-7.60 (m, 2H).
Example 1.29
Preparation of
2-(((1s,4s)-4-((3-(2-Fluoro-4-methylphenyl)-5-methyl-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 143)
Step A: Preparation of (1s,4s)-Ethyl
4-(Hydroxymethyl)cyclohexanecarboxylate
[0656] To a solution of
(1s,4s)-4-(hydroxymethyl)cyclohexanecarboxylic acid (10 g, 63.2
mmol) in ethanol (100 mL), was added sulfuric acid (0.31 g, 3.16
mmol) at room temperature. After heating for 10 h at 85.degree. C.,
the reaction was cooled to room temperature and concentrated under
reduced pressure. The residue was extracted with ethyl acetate,
dried over MgSO.sub.4, and then concentrated under reduced pressure
to give the title compound (4.98 g). NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.15 (t, J=7.1 Hz, 3H), 1.40-1.54 (m, 7H), 2.55 (m,
1H), 1.82 (m, 2H), 3.21 (d, J=6.4 Hz, 2H), 4.01 (q, J=7.1 Hz,
2H).
Step B: Preparation of
((1s,4s)-4-(Benzyloxymethyl)cyclohexyl)methanol
[0657] To a solution of (1s,4s)-ethyl
4-(hydroxymethyl)cyclohexanecarboxylate (5 g, 26.8 mmol) in DMF (50
mL) was added (bromomethyl)benzene (4.59 g, 26.8 mmol) followed by
NaH (0.644 g, 26.8 mmol) at 0.degree. C. After stirring for 4 h at
room temperature, the mixture was poured into water and extracted
with ethyl acetate. The extract was dried over MgSO.sub.4 and
concentrated under reduced pressure. The residue was purified by
silica gel column chromatography to give (1s,4s)-ethyl
4-(benzyloxymethyl)cyclohexanecarboxylate (3.2 g, 13.66 mmol). The
above material was dissolved in THF (50 mL) and lithium aluminum
hydride (1.02 g, 26.8 mmol) was added at 0.degree. C. After
stirring for 1 h at room temperature, the reaction was quenched
with H.sub.2O (5 mL) at 0.degree. C. After stirring at room
temperature for 1 h, the resulting precipitate was filtered off.
The filtrate was dried over MgSO.sub.4 and concentrated under
reduced pressure to give the title compound (3.2 g). .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 0.84-0.99 (m, 7H), 1.35 (m,
1H), 1.46 (m, 1H), 1.52 (m, 1H), 3.23 (d, J=7.0 Hz, 2H), 3.25 (d,
J=5.7 Hz, 2H), 4.45 (s, 2H), 7.21-7.40 (m, 5H).
Step C: Preparation of
(1s,4s)-4-(Benzyloxymethyl)cyclohexanecarbaldehyde
[0658] To a solution of DMSO (1.32 mL, 18.78 mmol) in
CH.sub.2Cl.sub.2 (50 mL) was added oxalyl dichloride (1.19 g, 9.39
mmol) dropwise at -50.degree. C. After stirring for 10 min,
((1s,4s)-4-(benzyloxymethyl)cyclohexyl)methanol (2.0 g, 8.53 mmol)
and triethylamine (4.32 g, 42.7 mmol) were added at the same
temperature. After stirring for 1 h at room temperature, the
reaction was extracted with CH.sub.2Cl.sub.2 and dried over
MgSO.sub.4. The organic layer was concentrated under reduced
pressure to give the title compound (1.9 g). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 0.91-1.21 (m, 6H), 1.45 (m, 1H),
1.75-1.95 (m, 2H), 2.25 (m, 1H), 3.25 (d, J=7.1 Hz, 2H), 4.42 (s,
2H), 7.25-7.42 (m, 5H), 9.52 (s, 1H).
Step D: Preparation of tert-Butyl
2-(((1s,4s)-4-(Benzyloxymethyl)cyclohexyl)methyl)hydrazinecarboxylate
[0659] To a solution of
(1s,4s)-4-(benzyloxymethyl)cyclohexanecarbaldehyde (1.2 g, 5.17
mmol) in MeOH (50 mL) was added tert-butyl hydrazinecarboxylate
(0.68 g, 5.17 mmol) at room temperature. After stirring for 1 h,
the reaction was concentrated under reduced pressure. The residue
was dissolved in MeOH (25 mL) and acetic acid (25 mL). NaCNBH.sub.3
(0.33 g, 5.17 mmol) was added at 0.degree. C. After stirring for 30
min, the reaction was concentrated under reduced pressure. The
residue was dissolved in ethyl acetate and washed with 0.1 M NaOH.
The extract was dried over MgSO.sub.4 and concentrated under
reduced pressure. The residue was purified by silica gel column
chromatography to give the title compound (0.85 g). LCMS m/z=349.4
[M+H].sup.+.
Step E: Preparation of
1-(((1s,4s)-4-(Benzyloxymethyl)cyclohexyl)methyl)-2-(2-fluoro-4-methylben-
zylidene)hydrazine
[0660] To a solution of tert-butyl
1-(((1s,4s)-4-(benzyloxymethyl)cyclohexyl)methyl)hydrazinecarboxylate
(1.0 g, 2.87 mmol) in CH.sub.2Cl.sub.2 (5 mL), was added TFA (5.0
mL) at room temperature. After stirring for 3 h at the same
temperature, the reaction was concentrated under reduced pressure.
The residue was dissolved in THF (10 mL) and
2-fluoro-4-methylbenzaldehyde (0.40 g, 2.87 mmol) was added. After
stirring for 30 min, the reaction was washed with saturated
NaHCO.sub.3. The organics were dried over MgSO.sub.4 and
concentrated under reduced pressure to give the title compound
(0.96 g). LCMS m/z=369.3 [M+H].sup.+.
Step F: Preparation of
1-(((1s,4s)-4-(Benzyloxymethyl)cyclohexyl)methyl)-3-(2-fluoro-4-methylphe-
nyl)-5-methyl-4-phenyl-1H-pyrazole
[0661] To a solution of
1-(((1s,4s)-4-(benzyloxymethyl)cyclohexyl)methyl)-2-(2-fluoro-4-methylben-
zylidene)hydrazine (0.5 g, 1.357 mmol) and
(2-nitroprop-1-enyl)benzene (0.22 g, 1.36 mmol) in THF (5 mL) at
-78.degree. C., was added potassium butan-1-olate (0.152 g, 1.357
mmol) dropwise. After 10 min, TFA (0.21 mL, 2.71 mmol) was added at
the same temperature and maintained for 2 h. After warming to room
temperature, the reaction was extracted with ethyl acetate, dried
over MgSO.sub.4, and then concentrated under reduced pressure. The
residue was purified by silica gel column chromatography to give
the title compound (0.49 g). LCMS m/z=483.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.34-1.52 (m, 8H), 1.85 (m,
1H), 2.15 (m, 1H), 2.25 (s, 3H), 2.31 (s, 3H), 3.34 (d, J=7.0 Hz,
2H), 4.25 (d, J=7.4 Hz, 2H), 4.51 (s, 2H), 6.92-7.38 (m, 4H),
7.39-7.45 (m, 9H).
Step G: Preparation of
((1s,4s)-4-(3-(2-Fluoro-4-methylphenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methanol
[0662] To a solution of
1-(((1s,4s)-4-(benzyloxymethyl)cyclohexyl)methyl)-3-(2-fluoro-4-methylphe-
nyl)-5-methyl-4-phenyl-1H-pyrazole (100 mg, 0.21 mmol) in MeOH (5
mL), was added ammonium formate (261 mg, 4.14 mmol) followed by 10%
Pd/C (5 mg). The reaction was heated to 80.degree. C. for 10 h.
After filtration of insoluble material, the reaction was
concentrated under reduced pressure to give the title compound as a
colorless oil (78 mg). LCMS m/z=393.3 [M+H].sup.+.
Step H: Preparation of tert-Butyl
2-(((1s,4s)-4-(3-(2-Fluoro-4-methylphenyl)-5-methyl-4-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetate
[0663] To a solution of
((1s,4s)-4-(3-(2-fluoro-4-methylphenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methanol (20 mg, 0.051 mmol) and
(Rh(OAc).sub.2).sub.2 (2.25 mg, 5.10 .mu.mol) in CH.sub.2Cl.sub.2
(2 mL), was added a solution of tert-butyl 2-diazoacetate (7.24 mg,
0.051 mmol) in CH.sub.2Cl.sub.2 (0.5 mL) dropwise for 10 min at
-10.degree. C. The reaction was stirred for 1 h at the same
temperature. The solid material was filtered off and the filtrate
was concentrated under reduced pressure. The residue was purified
by silica gel column chromatography to give the title compound (20
mg). LCMS m/z=507.5 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.30-1.45 (m, 17H), 1.75 (m, 1H), 2.11
(m, 1H), 2.28 (s, 3H), 2.30 (s, 3H), 3.52 (d, J=7.0 Hz, 2H), 3.95
(s, 2H), 4.05 (d, J=7.3 Hz, 2H), 6.90 (d, J=11.5 Hz, 1H), 6.95 (d,
J=7.7 Hz, 1H), 7.05-7.33 (m, 6H).
Step I: Preparation of
2-(((1s,4s)-4-((3-(2-Fluoro-4-methylphenyl)-5-methyl-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid
[0664] tert-Butyl
2-(((1s,4s)-4-((3-(2-fluoro-4-methylphenyl)-5-methyl-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetate (250 mg, 0.49 mmol) was
treated with HCl (4.0 M in dioxane, 10 mL) at room temperature.
After stirring for 12 h, the reaction was concentrated in vacuo and
purified by HPLC. The free acid was dissolved in acetonitrile (5
mL) and H.sub.2O (2 mL), added into a solution of sodium hydroxide
(19.74 mg, 0.49 mmol) in H.sub.2O (10 mL), and dried under reduced
pressure to give the sodium salt of the title compound (149 mg).
LCMS m/z=451.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.32-1.52 (m, 8H), 1.71-1.81 (m, 1H), 2.02-2.13 (m,
1H), 2.28 (s, 3H), 2.30 (s, 3H), 3.37 (d, J=6.7 Hz, 2H), 3.61 (s,
2H), 4.05 (d, J=7.3 Hz, 2H), 6.91 (d, J=11.2 Hz, 1H), 6.98 (d,
J=7.9 Hz, 1H), 7.05 (s, 1H), 7.07 (s, 1H), 7.16-7.32 (m, 4H).
Example 1.30
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-5-(2-hydroxyethylthio)-3-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 199)
Step A: Preparation of
4-(3-Chlorophenyl)-3-phenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)--
1H-pyrazole
[0665] From 2-(3-chlorophenyl)-1-phenethanone, using a similar
method to the one described in Example 1.25, Step A, the title
compound was obtained as a yellow solid. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 1.51-1.65 (m, 3H), 1.66-1.92 (m, 3H), 3.07
(t, J=5.81 Hz, 2H), 3.49-3.59 (m, 1H), 3.66-3.75 (m, 1H), 3.87-3.96
(m, 1H), 3.97-4.04 (m, 1H), 4.68 (dd, J=4.29, 3.03 Hz, 1H),
7.09-7.15 (m, 1H), 7.23-7.27 (m, 2H), 7.28-7.33 (m, 4H), 7.34-7.42
(m, 2H), 10.95 (bs, 1H).
Step B: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-3-phenyl-5-(2-(tetrahydro-2H-pyran-2-y-
loxy)ethylthio)-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
and tert-Butyl
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-5-phenyl-3-(2-(tetrahydro-2H-pyran-2-y-
loxy)ethylthio)-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
as a Mixture of Regioisomers
[0666] From
4-(3-chlorophenyl)-3-phenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)--
1H-pyrazole, using a similar method to the one described in Example
1.25, Step B, the title compound was obtained as a clear oil (a
mixture of regioisomers). LCMS m/z=655.4 [M+H].sup.+.
Step C: Preparation of
2-4(1s,4s)-4-((4-(3-Chlorophenyl)-5-(2-hydroxyethylthio)-3-phenyl-1H-pyra-
zol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid
[0667] From tert-butyl
2-(((1s,4s)-4-((4-(3-chlorophenyl)-3-phenyl-5-(2-(tetrahydro-2H-pyran-2-y-
loxy)ethylthio)-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
and tert-butyl
2-(((1s,4s)-4-((4-(3-chlorophenyl)-5-phenyl-3-(2-(tetrahydro-2H-pyran-2-y-
loxy)ethylthio)-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
as a mixture of regioisomers, using a similar method to the one
described in Example 1.25, Step C, the title compound was obtained
as a clear solid. LCMS m/z=515.5 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.32-1.54 (m, 8H), 1.71-1.79 (m, 1H),
2.11-2.23 (m, 1H), 2.51-2.55 (m, 2H), 2.61 (t, J=6.57 Hz, 2H), 3.30
(t, J=6.57 Hz, 1H), 3.41 (d, J=6.82 Hz, 2H), 3.98 (s, 2H), 4.30 (d,
J=7.58 Hz, 2H), 7.18-7.23 (m, 1H), 7.25-7.34 (m, 6H), 7.38-7.44 (m,
2H).
Example 1.31
Preparation of
2-(((1s,4s)-4-((5-(2-Hydroxyethylthio)-3-phenyl-4-m-tolyl-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methoxy)acetic Acid (Compound 210)
Step A: Preparation of
3-Phenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)-4-m-tolyl-1H-pyrazo-
le
[0668] From 1-phenyl-2-m-tolylethanone, using a similar method to
the one described in Example 1.25, Step A, the title compound was
obtained as a white solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.30-1.51 (m, 4H), 1.52-1.73 (m, 2H), 2.26 (s, 3H),
3.10 (t, J=6.82 Hz, 2H), 3.32-3.45 (m, 1H), 3.53-3.67 (m, 1H),
3.68-3.76 (m, 1H), 3.76-3.84 (m, 1H), 4.55 (t, J=3.16 Hz, 1H), 6.97
(d, J=7.33 Hz, 1H), 7.04 (s, 1H), 7.08-7.14 (m, 1H), 7.20-7.27 (m,
2H), 7.29-7.37 (m, 4H), 13.30 (s, 1H).
Step B: Preparation of tert-Butyl
2-(((1s,4s)-4-((3-Phenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)-4-m-
-tolyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate and
tert-Butyl
2-4(1s,4s)-4-((5-Phenyl-3-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)-4-m--
tolyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate as a
Mixture of Regioisomers
[0669] From
3-phenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)-4-m-tolyl-1H-pyrazo-
le, using a similar method to the one described in Example 1.25,
Step B, the title compound was obtained as a clear oil (a mixture
of regioisomers). LCMS m/z=635.7 [M+H].sup.+.
Step C: Preparation of
2-(((1s,4s)-4-((5-(2-Hydroxyethylthio)-3-phenyl-4-m-tolyl-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methoxy)acetic Acid
[0670] From tert-butyl
2-(((1s,4s)-4-(3-phenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)-4-m--
tolyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate and
tert-butyl
2-(((1s,4s)-4-((5-phenyl-3-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)-4-m-
-tolyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate as a
mixture of regioisomers, using a similar method to the one
described in Example 1.25, Step C, the title compound was obtained
as a yellow oily solid. LCMS m/z=495.4 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 1.33-1.44 (m, 4H), 1.44-1.53
(m, 4H), 1.68-1.80 (m, 1H), 2.13-2.23 (m, 1H), 2.30 (s, 3H), 2.58
(t, J=6.69 Hz, 2H), 3.17 (d, J=5.05 Hz, 1H), 3.26-3.35 (m, 2H),
3.41 (d, J=7.07 Hz, 2H), 3.99 (s, 2H), 4.29 (d, J=7.58 Hz, 2H),
7.02 (d, J=7.58 Hz, 1H), 7.10 (s, 1H), 7.16 (d, J=7.83 Hz, 1H),
7.22-7.29 (m, 4H), 7.30-7.35 (m, 2H).
Example 1.32
Preparation of
2-(((1s,4s)-4-((4-(3-Fluorophenyl)-5-(2-hydroxyethylthio)-3-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 212)
Step A: Preparation of
4-(3-Fluoorophenyl)-3-phenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)-
-1H-pyrazole
[0671] From 2-(3-fluorophenyl)-1-phenethanone, using a similar
method to the one described in Example 1.25, Step A, the title
compound was obtained as a white solid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.31-1.51 (m, 4H), 1.50-1.75 (m, 2H),
3.12 (t, J=6.69 Hz, 2H), 3.33-3.43 (m, 1H), 3.52-3.66 (m, 1H),
3.67-3.76 (m, 1H), 3.76-3.84 (m, 1H), 4.55 (t, J=3.28 Hz, 1H),
6.96-7.05 (m, 2H), 7.08-7.15 (m, 1H), 7.23-7.44 (m, 6H), 13.41 (s,
1H).
Step B: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-(3-Fluoorophenyl)-3-phenyl-5-(2-(tetrahydro-2H-pyran-2--
yloxy)ethylthio)-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
and tert-Butyl
2-(((1s,4s)-4-((4-(3-Fluoorophenyl)-5-phenyl-3-(2-(tetrahydro-2H-pyran-2--
yloxy)ethylthio)-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
as a Mixture of Regioisomers.
[0672] From
4-(3-fluorophenyl)-3-phenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)--
1H-pyrazole, using a similar method to the one described in Example
1.25, Step B, the title compound was obtained as a clear oil (a
mixture of regioisomers). LCMS m/z=639.5 [M+H].sup.+.
Step C: Preparation of
2-(((1s,4s)-4-((4-(3-Fluorophenyl)-5-(2-hydroxyethylthio)-3-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid
[0673] From tert-butyl
2-(((1s,4s)-4-((4-(3-fluoorophenyl)-3-phenyl-5-(2-(tetrahydro-2H-pyran-2--
yloxy)ethylthio)-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
and tert-butyl
2-(((1s,4s)-4-((4-(3-fluoorophenyl)-5-phenyl-3-(2-(tetrahydro-2H-pyran-2--
yloxy)ethylthio)-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
as a mixture of regioisomers, using a similar method to the one
described in Example 1.25, Step C, the title compound was obtained
as a clear oily solid. LCMS m/z=499.6 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 1.34-1.45 (m, 4H), 1.45-1.53 (m,
4H), 1.69-1.81 (m, 1H), 2.11-2.22 (m, 1H), 2.43-2.56 (m, 2H), 2.60
(t, J=6.69 Hz, 1H), 3.21-3.33 (m, 2H), 3.41 (d, J=7.07 Hz, 2H),
3.99-4.00 (m, 2H), 4.30 (d, J=7.58 Hz, 2H), 7.05-7.12 (m, 2H),
7.13-7.22 (m, 1H), 7.23-7.34 (m, 5H), 7.38-7.46 (m, 1H), 12.52 (s,
1H).
Example 1.33
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-5-(2-hydroxyethylsulfinyl)-3-phenyl-1H-
-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
217)
[0674] To a solution of
2-(((1s,4s)-4-((4-(3-chlorophenyl)-5-(2-hydroxyethylthio)-3-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic acid (18.3 mg, 0.036
mmol) in DCM (178 .mu.L) was added mCPBA (5.82 mg, 0.034 mmol). The
reaction was stirred for 20 min and concentrated under reduced
pressure. The residue was taken up in ACN/H.sub.2O and purified via
preparative HPLC to give the title compound (9.7 mg) as a white
solid. LCMS m/z=531.3 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.33-1.55 (m, J=4.29 Hz, 8H), 1.72-1.80
(m, 1H), 2.26 (bs, 1H), 2.98-3.10 (m, 1H), 3.25-3.28 (m, 2H), 3.40
(d, J=7.20 Hz, 1H), 3.57-3.66 (m, 1H), 3.68-3.77 (m, 1H), 3.99 (s,
2H), 4.28-4.50 (m, 2H), 5.08 (bs, 1H), 7.21-7.27 (m, 1H), 7.27-7.33
(m, 5H), 7.38-7.46 (m, 3H), 12.51 (s, 1H).
Example 1.34
Preparation of
2-(((1s,4s)-4-((5-(2-Aminoethylthio)-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetic Acid (Compound 250)
Step A: Preparation of tert-Butyl
2-(4-Phenyl-3-p-tolyl-1H-pyrazol-5-ylthio)ethylcarbamate
[0675] From 2-phenyl-1-p-tolylethanone and tert-butyl
2-bromoethylcarbamate, using a similar method to the one described
in Example 1.25, Step A, the title compound was obtained as a light
yellow solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.36
(s, 9H), 2.28 (s, 3H), 2.71-2.78 (m, 1H), 2.94 (t, J=7.07 Hz, 2H),
3.13-3.21 (m, 2H), 6.88 (t, J=5.68 Hz, 1H), 7.13-7.23 (m, 6H),
7.32-7.37 (m, 2H), 13.26 (s, 1H).
Step B: Preparation of tert-Butyl
2-(((1s,4s)-4-((5-(2-(tert-Butoxycarbonylamino)ethylthio)-4-phenyl-3-p-to-
lyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate and
tert-Butyl
2-(((1s,4s)-4-((3-(2-(tert-Butoxycarbonylamino)ethylthio)-4-phenyl-5-p-to-
lyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate as a Mixture
of Regioisomers.
[0676] From tert-butyl
2-(4-phenyl-3-p-tolyl-1H-pyrazol-5-ylthio)ethylcarbamate, using a
similar method to the one described in Example 1.25, Step B, the
title compound was obtained as a clear oil (a mixture of
regioisomers). LCMS m/z=650.7 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.34 (s, 9H), 1.36-1.46 (m, 3H), 1.43 (s,
9H), 1.45-1.52 (m, 3H), 1.68-1.80 (m, 1H), 2.12-2.21 (m, 1H), 2.25
(s, 3H), 2.51-2.55 (m, 2H), 2.83 (q, J=6.61 Hz, 2H), 3.14-3.19 (m,
2H), 3.40 (d, J=6.82 Hz, 2H), 3.95 (s, 2H), 4.26 (d, J=7.58 Hz,
2H), 6.64-6.75 (m, 1H), 7.05 (d, J=7.96 Hz, 2H), 7.20 (d, J=8.08
Hz, 2H), 7.23-7.27 (m, 2H), 7.30-7.42 (m, 3H).
Step C: Preparation of
2-(((1s,4s)-4-((5-(2-Aminoethylthio)-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetic Acid
[0677] From tert-butyl
2-(((1s,4s)-4-((5-(2-(tert-butoxycarbonylamino)ethylthio)-4-phenyl-3-p-to-
lyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate and
tert-butyl
2-(((1s,4s)-4-(3-(2-(tert-butoxycarbonylamino)ethylthio)-4-phenyl-5-p-tol-
yl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate as a mixture
of regioisomers, using a similar method to the one described in
Example 1.25, Step C, the title compound was obtained as a white
solid. LCMS m/z=494.5 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.30-1.46 (m, J=23.31, 5.62 Hz, 4H),
1.46-1.54 (m, 4H), 1.70-1.85 (m, 1H), 2.14-2.23 (m, 1H), 2.26 (s,
3H), 2.57-2.74 (m, 4H), 3.42 (d, J=7.07 Hz, 2H), 4.00 (s, 2H), 4.28
(d, J=7.45 Hz, 2H), 7.07 (d, J=7.96 Hz, 2H), 7.20 (d, J=8.08 Hz,
2H), 7.24-7.29 (m, 2H), 7.31-7.45 (m, 3H), 7.64 (bs, 2H), 12.54 (s,
1H).
Example 1.35
Preparation of
2-(((1s,4s)-4-(3-(4-Fluorophenyl)-5-(2-hydroxyethylthio)-4-phenyl-1H-pyra-
zol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 255)
Step A: Preparation of
3-(4-Fluorophenyl)-4-phenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)--
1H-pyrazole
[0678] From 1-(4-fluorophenyl)-2-phenethanone, using a similar
method to the one described in Example 1.25, Step A, the title
compound was obtained as a white solid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.32-1.51 (m, 3H), 1.52-1.75 (m, 3H),
3.10 (t, J=6.63 Hz, 2H), 3.33-3.44 (m, 1H), 3.53-3.66 (m, 1H),
3.68-3.83 (m, 2H), 4.52-4.57 (m, 1H), 7.11 (t, J=8.27 Hz, 1H), 7.21
(t, J=8.97 Hz, 3H), 7.24-7.43 (m, 5H), 13.34 (s, 1H).
Step B: Preparation of tert-butyl
2-(((1s,4s)-4-((3-(4-Fluorophenyl)-4-phenyl-5-(2-(tetrahydro-2H-pyran-2-y-
loxy)ethylthio)-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
and tert-Butyl
2-(((1s,4s)-4-((5-(4-Fluorophenyl)-4-phenyl-3-(2-(tetrahydro-2H-pyran-2-y-
loxy)ethylthio)-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
as a Mixture of Regioisomers.
[0679] From
4-(3-fluorophenyl)-3-phenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)--
1H-pyrazole, using a similar method to the one described in Example
1.25, Step B, the title compound was obtained as a clear oil (a
mixture of regioisomers). LCMS m/z=639.6 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 1.30-1.42 (m, 4H), 1.43 (s,
9H), 1.45-1.54 (m, 7H), 1.56-1.79 (m, 3H), 2.14-2.24 (m, 1H),
2.65-2.72 (m, 2H), 3.20-3.28 (m, 2H), 3.31-3.37 (m, 1H), 3.39 (d,
J=6.82 Hz, 2H), 3.47-3.56 (m, 1H), 3.58-3.66 (m, 1H), 3.95 (s, 2H),
4.30 (dd, J=7.39, 3.09 Hz, 2H), 4.34-4.36 (m, 1H), 7.06-7.13 (m,
2H), 7.24-7.28 (m, 2H), 7.29-7.44 (m, 5H).
Step C: Preparation of
2-(((1s,4s)-4-((3-(4-Fluorophenyl)-5-(2-hydroxyethylthio)-4-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid
[0680] From tert-butyl
2-(((1s,4s)-4-((3-(4-fluorophenyl)-4-phenyl-5-(2-(tetrahydro-2H-pyran-2-y-
loxy)ethylthio)-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
and Cert-butyl
2-(((1s,4s)-4-((5-(4-fluorophenyl)-4-phenyl-3-(2-(tetrahydro-2H-pyran-2-y-
loxy)ethylthio)-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate,
using a similar method to the one described in Example 1.25, Step
C, the title compounds were obtained as clear oily solids. LCMS
m/z=499.7 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.29-1.45 (m, 4H), 1.45-1.53 (m, 4H), 1.69-1.80 (m, 1H),
2.14-2.22 (m, 1H), 2.57 (t, J=6.69 Hz, 2H), 3.25-3.29 (m, 2H),
3.28-3.32 (m, 1H), 3.40 (d, J=6.95 Hz, 2H), 3.97 (s, 2H), 4.29 (d,
J=7.45 Hz, 2H), 7.06-7.14 (m, 2H), 7.23-7.28 (m, 2H), 7.30-7.43 (m,
5H).
Example 1.36
Preparation of
2-(((1s,4s)-4-((5-(4-Fluorophenyl)-3-(2-hydroxyethylthio)-4-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 256)
[0681] From tert-butyl
2-(((1s,4s)-4-((3-(4-fluorophenyl)-4-phenyl-5-(2-(tetrahydro-2H-pyran-2-y-
loxy)ethylthio)-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
and tert-butyl
2-(((1s,4s)-4-((5-(4-fluorophenyl)-4-phenyl-3-(2-(tetrahydro-2H-pyran-2-y-
loxy)ethylthio)-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate,
using a similar method to the one described in Example 1.25, Step
C, the title compound was obtained as clear oil solid. LCMS
m/z=499.7 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 0.81-0.99 (m, 2H), 1.01-1.14 (m, 2H), 1.46-1.59 (m, 1H), 1.65
(dd, J=13.20, 2.08 Hz, 2H), 1.76 (dd, J=12.44, 2.08 Hz, 2H),
1.86-1.97 (m, 1H), 2.56 (t, J=6.63 Hz, 2H), 3.27 (dd, J=13.52, 6.69
Hz, 4H), 3.91 (s, 2H), 4.20 (d, J=7.20 Hz, 2H), 4.76 (bs, 1H),
7.07-7.14 (m, 2H), 7.25-7.28 (m, 2H), 7.31-7.43 (m, 5H).
Example 1.37
Preparation of
2-(((1s,4s)-4-((5-(2-Hydroxyethyl)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cy-
clohexyl)methoxy)acetic Acid (Compound 251)
Step A: Preparation of 2-(3-Phenyl-1H-pyrazol-5-yl)ethanol
[0682] 5-(2-(Benzyloxy)ethyl-3-phenyl-1H-pyrazole (2.1 g, 7.54
mmol) was dissolved in acetic acid (10 mL) and THF (10 mL).
Palladium on carbon (0.080 g, 0.754 mmol) was added and the
reaction was stirred for 4 days under hydrogen atmosphere on the
Parr shaker at 55 psi. After this time, the reaction was filtered
through celite and washed with EtOAc. The solvents were evaporated.
The reaction progress was checked by TLC and shown to be
.about.50-60% complete. The reaction was set up on the Parr shaker
again. After three more days on the Parr shaker, the reaction was
stopped. The reaction was filtered through celite and the solvents
removed. The reaction was extracted (70 mL each of H.sub.2O and
EtOAc). The aqueous layer was extracted again with EtOAc (70 mL).
The combined organic layer was dried and concentrated, and the
residue was purified by column chromatography to give the title
compound (665 mg) as a white solid. LCMS m/z=189.4 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 2.68-2.82 (m, 2H),
3.60-3.71 (m, 2H), 4.73-4.81 (m, 1H), 6.48 (s, 1H), 7.20-7.49 (m,
3H), 7.55-7.96 (m, 2H), 12.53 (s, 1H).
Step B: Preparation of
2-(4-Bromo-3-phenyl-1H-pyrazol-5-yl)ethanol
[0683] 2-(3-Phenyl-1H-pyrazol-5-yl)ethanol (664 mg, 3.53 mmol) was
dissolved in dry DCM (40 mL) and THF (10 mL). The reaction was
cooled in an ice bath and Br.sub.2 (363 .mu.L, 7.06 mmol),
pre-dissolved in DCM (3 mL), was added slowly dropwise via addition
funnel. The reaction was stirred for 2 h in an ice bath, then the
reaction was quenched by the addition of Na.sub.2SO.sub.3 (20 mL of
10% solution; the reaction went from reddish-brown to clear and
some bubbling was observed). The reaction was extracted (100 mL
each of H.sub.2O and DCM). The aqueous layer was extracted again
with DCM (100 mL). The combined organic layer was back extracted
again with H.sub.2O (200 mL). The organic layer was dried and
concentrated to yield the title compound (880 mg) as a light yellow
solid. LCMS m/z=267.1 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 2.78 (t, J=7.14 Hz, 2H), 3.66 (t, J=7.14
Hz, 2H), 7.35-7.42 (m, 1H), 7.43-7.51 (m, 2H), 7.72-7.84 (m,
2H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-(4-Bromo-5-(2-hydroxyethyl)-3-phenyl-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetate
[0684] 2-(4-Bromo-3-phenyl-1H-pyrazol-5-yl)ethanol (880 mg, 3.29
mmol), tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (1359 mg,
3.29 mmol), and cesium carbonate (2147 mg, 6.59 mmol) were added to
DMF (15 mL). The reaction was heated to 80.degree. C. and stirred
at this temperature for 1 h. The reaction was cooled and extracted
(50 mL each of H.sub.2O and EtOAc). The aqueous layer was extracted
again with EtOAc (50 mL). The combined organic layer was back
extracted with H.sub.2O (100 mL). The organic layer was dried,
concentrated, and the residue was purified by chromatography to
yield the title compound (640 mg) as a light yellow oil. LCMS
m/z=507.4 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.28-1.53 (m, 17H), 1.69-1.81 (m, J=5.31 Hz, 1H), 2.02-2.14 (m,
1H), 2.87 (t, J=6.76 Hz, 2H), 3.39 (d, J=6.95 Hz, 2H), 3.56-3.66
(m, 2H), 3.94 (s, 2H), 4.10 (d, J=7.45 Hz, 2H), 4.92 (t, J=5.43 Hz,
1H), 7.33-7.40 (m, 1H), 7.40-7.49 (m, 2H), 7.75-7.85 (m, 2H).
Step D: Preparation of
2-(41s,4s)-4-((5-(2-Hydroxyethyl)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyc-
lohexyl)methoxy)acetic Acid
[0685] tert-Butyl
2-(((1s,4s)-4-((4-bromo-5-(2-hydroxyethyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate (30 mg, 0.059 mmol), phenyl boronic
acid (1.1 eq), tetrakistriphenylphospinepalladium (3.42 mg, 2.96
.mu.mol, and K.sub.2CO.sub.3 (16.34 mg, 0.118 mmol) were added to a
vial with dioxane (300 .mu.L). The reaction was heated in a
microwave at 150.degree. C. for 1 h. After this time, the reaction
was filtered through a plug of MgSO.sub.4. The solvent was removed
and the resulting oil (t-butyl ester intermediate) was re-dissolved
in HCl (500 .mu.L, 2.000 mmol). The reaction was stirred overnight
at room temperature. The next day, the solvent was removed and the
product was purified by preparative LC/MS to give the title
compound (4.2 mg) as a white solid. LCMS m/z=449.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.33-1.59 (m, 8H),
1.73-1.82 (m, 1H), 2.09-2.21 (m, 1H), 2.75 (t, J=7.14 Hz, 2H),
3.40-3.46 (m, 4H), 3.98-4.00 (m, 2H), 4.06-4.09 (m, 2H), 7.15-7.25
(m, 5H), 7.26-7.34 (m, 3H), 7.34-7.42 (m, 2H).
Example 1.38
Preparation of
2-(((1s,4s)-4-((5-(2-Hydroxyethyl)-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 252)
[0686] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-hydroxyethyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate and 3-methoxyphenylboronic acid, using
a similar method to the one described in Example 1.37, the title
compound was obtained as a white solid. LCMS m/z=479.6 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.32-1.59 (m, 8H),
1.71-1.86 (m, 1H), 2.06-2.22 (m, 1H), 2.76 (t, J=6.19 Hz, 2H),
3.41-3.50 (m, 4H), 3.70 (s, 3H), 4.00 (s, 2H), 4.07 (d, J=6.32 Hz,
2H), 6.73-6.80 (m, 2H), 6.85-6.92 (m, 1H), 7.14-7.36 (m, 6H).
Example 1.39
Preparation of Sodium
2-(((1s,4s)-4-((5-(2-Hydroxyethyl)-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetate
[0687]
2-(((1s,4s)-4-((5-(2-Hydroxyethyl)-4-(3-methoxyphenyl)-3-phenyl-1H--
pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid (8.2 mg, 0.017
mmol) was dissolved in ACN (0.2 mL). NaOH (5.71 .mu.L, 0.017 mmol)
was added, followed by H.sub.2O (0.2 mL), and the reaction was
stirred for an hour. After this time, the reaction was frozen and
lyophilized to give the title compound (8.5 mg) as a white solid.
LCMS m/z=479.4 [M-Na+H].sup.+.
Example 1.40
Preparation of
2-(((1s,4s)-4-((4-(2,3-Difluorophenyl)-5-(2-hydroxyethyl)-3-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 253)
[0688] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-hydroxyethyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate and 2,3-difluorophenylboronic acid,
using a similar method to the one described in Example 1.37, the
title compound was obtained as a white solid. LCMS m/z=485.4
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.31-1.55 (m, 8H), 1.73-1.83 (m, 1H), 2.09-2.19 (m, 1H), 2.73 (t,
J=7.01 Hz, 2H), 3.37-3.45 (m, 4H), 4.00 (s, 2H), 4.10 (d, J=7.45
Hz, 2H), 7.10-7.17 (m, 1H), 7.19-7.32 (m, 6H), 7.38-7.49 (m,
1H).
Example 1.41
Preparation of
2-4(1s,4s)-4-((4-(3-Fluorophenyl)-5-(2-hydroxyethyl)-3-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 254)
[0689] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-hydroxyethyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate and 3-fluorophenylboronic acid, using
a similar method to the one described in Example 1.37, the title
compound was obtained as a white solid. LCMS m/z=467.6 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.32-1.59 (m, 8H),
1.77 (dd, J=9.92, 4.48 Hz, 1H), 2.09-2.19 (m, 1H), 2.77 (t, J=7.01
Hz, 2H), 3.41-3.48 (m, 4H), 4.00 (s, 2H), 4.08 (d, J=7.45 Hz, 2H),
6.99-7.08 (m, 2H), 7.10-7.18 (m, 1H), 7.18-7.32 (m, 5H), 7.35-7.45
(m, 1H).
Example 1.42
Preparation of
2-(((1s,4s)-4-((4-(3-Chloro-2-fluorophenyl)-5-(2-hydroxyethyl)-3-phenyl-1-
H-pyrazol-1-ypmethypcyclohexyl)methoxy)acetic Acid (Compound
276)
[0690] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-hydroxyethyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate and 3-chloro-2-fluorophenylboronic
acid, using a similar method to the one described in Example 1.37,
the title compound was obtained as a white solid. LCMS m/z=501.5
[M+H].sup.+.
Example 1.43
Preparation of
2-(((1s,4s)-4-((5-(3-Hydroxypropyl)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetic Acid (Compound 271)
Step A: Preparation of 5-(But-3-enyl)-3-phenyl-1H-pyrazole
[0691] Acetophenone (4.92 mL, 42.2 mmol) was dissolved in toluene
(50 mL). The reaction was cooled on an ice bath. LiHMDS (42.2 mL,
42.2 mmol) was added via syringe and the reaction was stirred for 2
min. Pent-4-enoyl chloride (4.66 mL, 42.2 mmol) was added and then
the reaction was stirred for 2 more min. Hydrazine hydrate (8.18
mL, 169 mmol) was then added, along with AcOH (2 mL) and EtOH (2
mL). The reaction was warmed to room temperature and then heated in
an oil bath to 80.degree. C. for 1 h. After this time, the reaction
was cooled and an extraction was performed (200 mL each of H.sub.2O
and EtOAc). The aqueous layer was extracted again with EtOAc (200
mL). The combined organic layer was dried, concentrated, and the
residue was purified by column chromatography to give the title
compound (5.4 g) as a yellow oil. LCMS m/z=199.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 2.39 (q, J=7.28 Hz,
2H), 2.61-2.76 (m, 2H), 5.00 (d, J=9.98 Hz, 1H), 5.04-5.13 (m, 1H),
5.78-5.95 (m, 1H), 6.47 (s, 1H), 7.21-7.33 (m, 1H), 7.33-7.48 (m,
2H), 7.65-7.81 (m, 2H), 12.56 (s, 1H).
Step B: Preparation of 3-(3-Phenyl-1H-pyrazol-5-yl)propan-1-ol
[0692] 5-(But-3-enyl)-3-phenyl-1H-pyrazole (5.4 g, 27.2 mmol) was
dissolved in MeOH (40 mL) and DCM (10 mL). The reaction was cooled
on a dry-ice/acetone bath and ozone was bubbled through the
solution for .about.2 h. The reaction was transferred into an ice
bath and NaBH.sub.4 (1.546 g, 40.9 mmol) was added slowly
portion-wise (bubbling was observed). Upon complete addition, the
reaction was removed from the ice bath and stirred at room
temperature for 1 h. Excess solvent was evaporated and the reaction
was extracted (100 mL each of H.sub.2O and EtOAc). The aqueous
layer was extracted again with EtOAc (100 mL). The combined organic
layer was dried, concentrated, and the residue was purified by
column chromatography to yield the title compound (3.0 g) as a
white solid. LCMS m/z=203.3 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.72-1.82 (m, 2H), 2.54-2.69 (m, 2H),
3.46 (q, J=6.11 Hz, 2H), 4.40-4.54 (m, 1H), 6.45 (s, 1H), 7.21-7.45
(m, 3H), 7.66-7.79 (m, J=7.45 Hz, 2H), 12.53 (s, 1H).
Step C: Preparation of
3-(4-Bromo-3-phenyl-1H-pyrazol-5-yl)propan-1-ol
[0693] 3-(3-Phenyl-1H-pyrazol-5-yl)propan-1-ol (3.0 g, 14.83 mmol)
was dissolved in dry DCM (40 mL) and THF (15 mL). The reaction was
cooled in an ice bath and Br.sub.2 (1.146 mL, 22.25 mmol)
pre-dissolved in DCM (10 mL) was added slowly dropwise via addition
funnel. The reaction was stirred for 2 h in an ice bath. The
reaction was quenched by the addition of Na.sub.2SO.sub.3 (20 mL of
10% solution; the reaction went from reddish-brown to clear and
some bubbling was observed). The reaction was extracted (100 mL
each of H.sub.2O and DCM). The aqueous layer was extracted again
with DCM (100 mL). The combined organic layer was back extracted
again with H.sub.2O (200 mL). The organic layer was dried and
concentrated to give the title compound (4.08 g) as a yellow solid.
LCMS m/z=281.3 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.72-1.83 (m, 2H), 2.61-2.68 (m, 2H), 3.47 (t, J=6.44
Hz, 2H), 7.39 (t, J=7.33 Hz, 1H), 7.47 (t, J=7.45 Hz, 2H), 7.78 (d,
J=7.07 Hz, 2H).
Step D: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-Bromo-5-(3-hydroxypropyl)-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetate
[0694] 3-(4-Bromo-3-phenyl-1H-pyrazol-5-yl)propan-1-ol, tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (2.93 g,
7.11 mmol), and cesium carbonate (4.64 g, 14.23 mmol) were
dissolved in DMF (35 mL). The reaction was heated to 80.degree. C.
in an oil bath and stirred at this temperature for an hour. The
reaction was cooled and extracted (100 mL each of H.sub.2O and
EtOAc). The aqueous layer was extracted again with EtOAc (100 mL).
The combined organic layer was back extracted once with H.sub.2O
(200 mL). The organic layer was dried, concentrated, and the
residue was purified by column chromatography to give the title
compound (1.54 g) as a light yellow oil. LCMS m/z=521.7
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
0.97-1.05 (m, 4H), 1.26-1.55 (m, 13H), 1.65-1.79 (m, 3H), 2.01-2.12
(m, 1H), 2.71-2.77 (m, 2H), 3.39 (d, J=6.95 Hz, 2H), 3.46 (t,
J=6.19 Hz, 2H), 3.94 (s, 2H), 4.06 (d, J=7.45 Hz, 2H), 7.32-7.39
(m, 1H), 7.40-7.48 (m, 2H), 7.77-7.82 (m, J=8.34, 1.14 Hz, 2H).
Step E: Preparation of
2-(((1s,4s)-4-((5-(3-Hydroxypropyl)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetic Acid
[0695] tert-Butyl
2-(((1s,4s)-4-(4-bromo-5-(3-hydroxypropyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate (50 mg, 0.096 mmol), phenylboronic
acid (1.1 eq), tetrakis(triphenylphosphine)palladium(0) (11.08 mg,
9.59 .mu.mol, and K.sub.2CO.sub.3 (26.5 mg, 0.192 mmol) were added
to a vial with dioxane (0.4 mL). The reaction was heated in a
microwave at 150.degree. C. for 2 h. After this time, the reaction
was filtered through a plug of MgSO.sub.4. The solvent was removed
and the ester intermediate obtained was re-dissolved in HCl (4M in
dioxane) (503 .mu.L, 2.013 mmol). The reaction was stirred
overnight at room temperature. The next day, the solvent was
removed and the residue was purified by preparative LC/MS. After
lyophilizing the reaction, there was observed the side-product
formation of the TFA-ester off of the side chain alcohol.
Therefore, the product was dissolved in THF (0.3 mL). Then 3M LiOH
(50 .mu.L) was added. The reactions were stirred at room
temperature overnight. The next day, 1 M HCl (200 mL) was added to
make the reaction acidic. The reactions were extracted (2 mL each
of HCUH.sub.2O and EtOAc). The aqueous layer was extracted again
with EtOAc (2 mL). The combined organic layer was dried and
concentrated. The resulting oil was re-dissolved in ACN (0.3 mL)
and H.sub.2O (0.2 mL). The mixture was frozen and lyophilized to
give the title compound (8.9 mg) as a white solid. LCMS m/z=463.5
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.32-1.60 (m, 10H), 1.71-1.84 (m, 1H), 2.08-2.19 (m, 1H), 2.59-2.65
(m, 2H), 3.31 (t, J=6.19 Hz, 2H), 3.43-3.44 (m, 2H), 3.99 (s, 2H),
4.05 (d, J=7.33 Hz, 2H), 7.14-7.25 (m, 5H), 7.26-7.40 (m, 5H).
Example 1.44
Preparation of
2-(((1s,4s)-4-((5-(3-Hydroxypropyl)-4-(3-methoxyphenyl)-3-phenyl-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 272)
[0696] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(3-hydroxypropyl)-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetate and 3-methoxyphenylboronic acid,
using a similar method to the one described in Example 1.43, the
title compound was obtained as a white solid. LCMS m/z=493.6
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.32-1.61 (m, 10H), 1.72-1.83 (m, 1H), 2.08-2.18 (m, 1H), 2.60-2.66
(m, 2H), 3.33 (t, J=6.19 Hz, 2H), 3.42 (d, J=6.82 Hz, 2H), 3.70 (s,
3H), 3.99 (s, 2H), 4.04 (d, J=7.33 Hz, 2H), 6.70-6.75 (m, 2H), 6.87
(dd, J=7.96, 2.15 Hz, 1H), 7.16-7.37 (m, 6H).
Example 1.45
Preparation of
2-4(1s,4s)-4-((4-(2,3-Difluorophenyl)-5-(3-hydroxypropyl)-3-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 273)
[0697] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(3-hydroxypropyl)-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetate and 2,3-difluorophenylboronic acid,
using a similar method to the one described in Example 1.43, the
title compound was obtained as a white solid. LCMS m/z=499.7
[M+H].sup.+.
Example 1.46
Preparation of
2-(((1s,4s)-4-((4-(3-Fluorophenyl)-5-(3-hydroxypropyl)-3-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 274)
[0698] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(3-hydroxypropyl)-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetate and 3-fluorophenylboronic acid, using
a similar method to the one described in Example 1.43, the title
compound was obtained as a white solid. LCMS m/z=481.3
[M+H].sup.+.
Example 1.47
Preparation of
2-(((1s,4s)-4-((4-(3-Chloro-2-fluorophenyl)-5-(3-hydroxypropyl)-3-phenyl--
1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
281)
[0699] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(3-hydroxypropyl)-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetate and 3-chloro-2-fluorophenylboronic
acid, using a similar method to the one described in Example 1.43,
the title compound was obtained as a white solid. LCMS m/z=515.5
[M+H].sup.+.
Example 1.48
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-5-(3-hydroxypropyl)-3-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 282)
[0700] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(3-hydroxypropyl)-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetate and 3-chlorophenylboronic acid, using
a similar method to the one described in Example 1.43, the title
compound was obtained as a white solid. LCMS m/z=497.5
[M+H].sup.+.
Example 1.49
Preparation of
2-4(1s,4s)-4-((5-(3-hydroxypropyl)-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid (Compound 288)
Step A: Preparation of
5-(But-3-enyl)-4-phenyl-3-p-tolyl-1H-pyrazole
[0701] 2-Phenyl-1-p-tolylethanone (1.0 g, 4.76 mmol) was dissolved
in Toluene (20 mL). The reaction was cooled in an ice bath and then
LiHMDS (4.76 mL, 4.76 mmol) was added slowly via syringe. The
reaction was stirred at this temperature for 5 min and then
pent-4-enoyl chloride (0.564 g, 4.76 mmol) was added. The reaction
was warmed to room temperature and stirred at this temperature for
20 min. After this time EtOH (10 mL), AcOH (2 mL), and hydrazine
hydrate (0.231 mL, 4.76 mmol) were added to the reaction. The
reaction was heated to 80.degree. C. and stirred at this
temperature for an hour. After this time, the reaction was cooled
and extracted (50 mL each of EtOAc and 1 M NaOH). The aqueous layer
was extracted again with EtOAc (50 mL). The combined organic layer
was dried, concentrated, and the residue was purified by silica gel
column chromatography to give the title compound (355 mg) as a
colorless oil. LCMS m/z=289.0 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 2.22-2.32 (m, 5H), 2.55-2.69 (m, 2H),
4.86-5.02 (m, 2H), 5.75 (s, 1H), 6.99-7.24 (m, 6H), 7.25-7.31 (m,
1H), 7.33-7.39 (m, 2H), 12.74 (s, 1H).
Step B: Preparation of
3-(4-Phenyl-3-p-tolyl-1H-pyrazol-5-yl)propan-1-ol.
[0702] 5-(But-3-enyl)-4-phenyl-3-p-tolyl-1H-pyrazole (360 mg, 1.248
mmol) was dissolved in MeOH (20 mL) and DCM (5 mL). The reaction
was cooled to -78.degree. C. and ozone was bubbled through the
solution. After the starting material was consumed, the reaction
was cooled in an ice bath. Sodium borohydride (70.8 mg, 1.872 mmol)
was added to the reaction. The reaction was warmed to room
temperature and stirred for an hour. The solvent was removed under
reduced pressure and the reaction was extracted (50 mL each of
H.sub.2O and EtOAc). The aqueous layer was extracted again with
EtOAc (50 mL). The combined organic layer was dried, concentrated,
and the residue was purified by silica gel column chromatography to
give the title compound (130 mg) as a white solid. LCMS m/z=293.1
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.60-1.74 (m, 2H), 2.25 (s, 3H), 2.54-2.62 (m, 2H), 3.33-3.44 (m,
2H), 4.44 (br. s., 1H), 7.16 (t, J=6.44 Hz, 6H), 7.24-7.30 (m, 1H),
7.32-7.38 (m, 2H), 12.71 (s, 1H).
Step C: Preparation of
2-(((1s,4s)-4-((5-(3-Hydroxypropyl)-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)me-
thyl)cyclohexyl)methoxy)acetic Acid
[0703] 3-(4-Phenyl-3-p-tolyl-1H-pyrazol-5-yl)propan-1-ol (50 mg,
0.171 mmol), tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (70.5 mg,
0.171 mmol), and Cs.sub.2CO.sub.3 (111 mg, 0.342 mmol) were
suspended in DMF (0.5 mL). The reaction was heated at 80.degree. C.
for an hour. The mixture was cooled and extracted (2 mL each of
H.sub.2O and EtOAc). The aqueous layer was extracted again with
EtOAc (2 mL). The combined organic layer was filtered through a
plug of MgSO.sub.4. The solvents were removed, then the resulting
oil was re-dissolved in HCl (4M in dioxane) (0.5 mL, 2.000 mmol).
The reaction was stirred at room temperature overnight. The mixture
was purified by preparative LC/MS. After lyophilization, the
product was re-dissolved in THF (0.3 mL) and stirred with 1 M NaOH
(100 .mu.L) overnight. The reaction was then made acidic by
addition of 1 M HCl (200 .mu.L). The reaction was extracted (2 mL
each of H.sub.2O and EtOAc). The aqueous layer was extracted again
with EtOAc (2 mL). The combined organic layer was filtered through
a plug of MgSO.sub.4 and concentrated to give the title compound
(3.5 mg), one of the two regioisomers, as a colorless oil. LCMS
m/z=477.4 [M+H].sup.+.
Example 1.50
Preparation of
2-(((1s,4s)-4-((3-(3-Hydroxypropyl)-4-phenyl-5-p-tolyl-1H-pyrazol-1-yl)me-
thyl)cyclohexyl)methoxy)acetic Acid (Compound 289)
[0704] The title compound was isolated as one of the two
regioisomers from Example 1.49, Step C, to give an oil. LCMS
m/z=477.5 [M+H].sup.+.
Example 1.51
Preparation of
2-(((1s,4s)-4-((5-(2-fluoro-4-methylphenyl)-3-methyl-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 286)
Step A: Preparation of tert-Butyl
2-(((1s,4s)-4-((5-(2-Fluoro-4-methylphenyl)-3-methyl-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetate
[0705] 3-(2-Fluoro-4-methylphenyl)-5-methyl-4-phenyl-1H-pyrazole
(2.82 g, 10.59 mmol) was dissolved in dry DMF (40 mL).
Cs.sub.2CO.sub.3 (6.90 g, 21.18 mmol) and tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (4.37 g,
10.59 mmol) were added. The reaction was heated to 80.degree. C.
and stirred at this temperature for 1 h. The reaction was cooled
and extracted (100 mL each of H.sub.2O and EtOAc). The aqueous
layer was extracted again with EtOAc (100 mL). The combined organic
layer was back extracted once with H.sub.2O/Brine (200 mL). The
organic layer was dried, concentrated, and the residue was purified
by chromatography to give the title compound (3.2 g), a mixture of
regioisomers, as a colorless oil. LCMS m/z=507.2 [M+H].sup.+.
Step B: Preparation of
2-(((1s,4s)-4-((5-(2-Fluoro-4-methylphenyl)-3-methyl-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid
[0706] tert-Butyl
2-(((1s,4s)-4-((3-(2-fluoro-4-methylphenyl)-5-methyl-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetate (3.2 g, 6.32 mmol) was
dissolved in HCl (4M in dioxane) (50.0 mL, 200 mmol). The reaction
was stirred overnight at room temperature. The solvent was removed
and the residue was purified by HPLC to give the title compound as
a colorless oil (746 mg). LCMS m/z=451.3 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d6) .delta. ppm 1.08-1.20 (m, 4H), 1.22-1.37 (m,
4H), 1.57-1.69 (m, 1H), 1.90-1.97 (m, 1H), 2.23 (s, 3H), 2.35 (s,
3H), 3.22 (d, J=6.82 Hz, 2H), 3.71-3.87 (m, 2H), 3.92 (s, 2H),
7.04-7.11 (m, 4H), 7.11-7.20 (m, 2H), 7.24 (t, J=7.33 Hz, 2H).
Example 1.52
Preparation of
2-(((1s,4s)-4-(3-(4-Chlorophenyl)-5-ethyl-4-phenyl-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetic Acid (Compound 163)
Step A: Preparation of
1-(Dimethylamino)-2-phenylpent-1-en-3-one
[0707] To a solution of 1-phenylbutan-2-one (5.00 g, 33.7 mmol) in
DMF (80.0 mL) was added 1,1-dimethoxy-N,N-dimethylmethanamine (6.03
g, 50.6 mmol). The resulting mixture was stirred at 90.degree. C.
for 16 h. Upon completion, the reaction mixture was quenched with
water (40.0 mL), extracted with EtOAc (4.times.50.0 mL), and washed
with brine. The combined organics were dried over MgSO.sub.4,
filtered, and concentrated to give a brown oil. This brown oil was
purified by flash chromatography to give the title compound as a
yellow oil (3.32 g). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm
0.97 (t, J=7.32 Hz, 3H), 2.19 (q, J=7.49 Hz, 2H), 2.67 (s, 6H),
7.14-7.41 (m, 5H), 7.61 (s, 1H).
Step B: Preparation of 5-Ethyl-4-phenyl-1H-pyrazole
[0708] To a mixture of 1-(dimethylamino)-2-phenylpent-1-en-3-one
(3.32 g, 16.33 mmol) in EtOH (80.0 mL) was added hydrazine hydrate
(1.58 mL, 32.66 mmol). The resulting mixture was stirred at
80.degree. C. for 3 h. The reaction mixture was cooled to room
temperature and concentrated to give a solid. The solid was
re-crystallized, using 20% ethanol in water to give the title
compound as a white solid (2.81 g). LCMS m/z=173 [M+H].sup.+;
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.31 (t, J=7.58 Hz,
3H), 2.88 (q, J=7.58 Hz, 2H), 7.22-7.30 (m, 1H), 7.35-7.42 (m,
4H).
Step C: Preparation of 3-Bromo-5-ethyl-4-phenyl-1H-pyrazole
[0709] To a solution of 5-ethyl-4-phenyl-1H-pyrazole (3.34 g, 19.39
mmol) in dichloromethane (111.0 mL), was added bromine (1.49 mL,
29.09 mmol) at 25.degree. C. The reaction was stirred at room
temperature for 72 h and quenched with NaOH (aq.) to pH 12. The
organics were separated. The aqueous layer was extracted again with
DCM (3.times.). The combined organics were washed with brine, dried
(MgSO.sub.4), filtered and concentrated to give a red oil. This oil
was purified by flash chromatography to give the title compound as
a yellow oil (2.84 g). LCMS m/z=251.2 [M+H].sup.+.
Step D: Preparation of tert-Butyl
2-(((1s,4s)-4-((3-Bromo-5-ethyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate
[0710] To a solution of 3-bromo-5-ethyl-4-phenyl-1H-pyrazole (0.364
g, 1.451 mmol) in DMF (5.0 mL), was slowly added 60% sodium hydride
(0.070 g, 1.740 mmol). The solution was allowed to stir for a total
of 20 min, before a mixture of tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (0.598 g,
1.450 mmol) in DMF (1.0 mL) was added. The reaction mixture was
then stirred at 45.degree. C. for 12 h. Upon completion, the
reaction mixture was quenched with water and extracted with EtOAc
(4.times.). The combined organics were dried over MgSO.sub.4,
filtered, and concentrated to give a brown oil. This brown oil was
purified by flash chromatography to give the title compound as a
yellow oil (0.213 g). LCMS m/z=491.4, 493.5 [M+H].sup.+; .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.13-1.29 (m, 4H), 1.27-1.41
(m, 2H), 1.43-1.62 (m, 13H), 1.79-1.93 (m, 2H), 2.09-2.25 (m, 1H),
2.76 (q, J=7.58 Hz, 2H), 3.39-3.50 (m, 2H), 3.84-4.05 (m, 4H),
7.20-7.28 (m, 2H), 7.33-7.39 (m, 1H), 7.45-7.54 (m, 2H)
Step E: Preparation of tert-Butyl
2-(((1s,4s)-4-((3-(4-Chlorophenyl)-5-ethyl-4-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate
[0711] To a solution of 4-chlorophenylboronic acid (0.019 g, 0.122
mmol), tert-butyl
2-(((1s,4s)-4-((3-bromo-5-ethyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate (0.060 g, 0.122 mmol),
tetrakis(triphenylphosphine)palladium (0) (0.004 g, 0.004 mmol) in
benzene (3.0 mL) and EtOH (1.0 mL) was added sodium carbonate
(0.122 mL, 0.244 mmol). The reaction mixture was then heated in a
microwave at 130.degree. C. for 1 h. Upon completion, the reaction
mixture was diluted with water and extracted with EtOAc (3.times.).
The combined organics were dried over MgSO.sub.4, filtered, and
concentrated to give a yellow oil. This yellow oil was re-suspended
in ACN/H.sub.2O and purified by HPLC to give the title compound as
a white solid (0.032 g). LCMS m/z=523.4, 525.8 [M+H].sup.+.
Step F: Preparation of
2-(((1s,4s)-4-((3-(4-Chlorophenyl)-5-ethyl-4-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic Acid
[0712] To a solution of tert-butyl
2-(((1s,4s)-4-((3-(4-chlorophenyl)-5-ethyl-4-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate (0.032 g, 0.060 mmol) in DCM (2.0 mL)
was added 4M HCl in dioxane (0.151 mL, 0.602 mmol). The resulting
reaction mixture was stirred at 25.degree. C. for 16 h. The
reaction was concentrated to give a yellow oil. This yellow oil was
then re-suspended in ACN/H.sub.2O and purified by HPLC to give the
title compound as a white solid (0.004 g). LCMS m/z=467.5
[M+H].sup.+.
Example 1.53
Preparation of
2-(((1s,4s)-4-(3-(3,4-difluorophenyl)-5-ethyl-4-phenyl-1H-pyrazol-1-yl)me-
thyl)cyclohexyl)methoxy)acetic Acid (Compound 284)
Step A: Preparation of tert-Butyl
2-(((1s,4s)-4-((3-(3,4-Difluorophenyl)-5-ethyl-4-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetate
[0713] From 3,4-difluorophenylboronic acid and tert-butyl
2-(((1s,4s)-4-((3-bromo-5-ethyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate, using a similar method to the one described in
Example 1.52, Step E, the title compound was obtained as a white
solid. LCMS m/z=525.5 [M+H].sup.+.
Step B:
2-(((1s,4s)-4-(3-(3,4-Difluorophenyl)-5-ethyl-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid
[0714] From tert-butyl
2-(((1s,4s)-4-(3-(3,4-difluorophenyl)-5-ethyl-4-phenyl-1H-pyrazol-1-yl)me-
thyl)cyclohexyl)methoxy)acetate, using a similar method to the one
described in Example 1.52, Step F, the title compound was obtained
as a white solid. LCMS m/z=469.5 [M+H].sup.+.
Example 1.54
Preparation of
2-(((1s,4s)-4-((5-Ethyl-3-(4-fluorophenyl)-4-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic Acid (Compound 164)
Step A: Preparation of tert-Butyl
2-(((1s,4s)-4-(5-Ethyl-3-(4-fluorophenyl)-4-phenyl-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetate
[0715] From 4-difluorophenylboronic acid and tert-butyl
2-(((1s,4s)-4-(3-bromo-5-ethyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl-
)methoxy)acetate, using a similar method to the one described in
Example 1.52, Step E, the title compound was obtained as a white
solid. LCMS m/z=507.4 [M+H].sup.+.
Step B: Preparation of
2-(((1s,4s)-4-(5-Ethyl-3-(4-fluorophenyl)-4-phenyl-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetic Acid
[0716] From tert-butyl
2-(((1s,4s)-4-((5-ethyl-3-(4-fluorophenyl)-4-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate, using a similar method to the one
described in Example 1.52, Step F, the title compound was obtained
as a white solid. LCMS m/z=451.3 [M+H].sup.+.
Example 1.55
Preparation of
2-(((1s,4s)-4-((5-Ethyl-3-(2-fluoro-4-methoxyphenyl)-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 165)
Step A: Preparation of tert-Butyl
2-(((1s,4s)-4-((5-Ethyl-3-(2-fluoro-4-methoxyphenyl)-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetate
[0717] To a solution of 2-fluoro-4-methoxyphenylboronic acid (0.021
g, 0.122 mmol), tert-butyl
2-(((1s,4s)-4-((3-bromo-5-ethyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate (0.060 g, 0.122 mmol), aq. Na.sub.2CO.sub.3 (2 M
solution, 0.122 mL, 0.244 mmol), and Pd(PPh.sub.3).sub.4 (0.004 g,
0.004 mmol) in EtOH (1.0 mL) and benzene (3.0 mL). The reaction
mixture was then heated in a microwave at 130.degree. C. for 1 h.
Upon completion, the reaction mixture was quenched with H.sub.2O
and extracted with EtOAc (2.times.). The combined organics layers
were dried over MgSO.sub.4, filtered and concentrated to give the
title compound as a yellow oil without further purification. LCMS
m/z=537.5 [M+H].sup.+.
Step B: Preparation of
2-(((1s,4s)-4-((5-Ethyl-3-(2-fluoro-4-methoxyphenyl)-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid
[0718] To tert-butyl
2-(((1s,4s)-4-((5-ethyl-3-(2-fluoro-4-methoxyphenyl)-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetate obtained was added 4 M HCl
(0.610 mL, 2.44 mmol) in 1,4-dioxane. The reaction mixture was
stirred at 40.degree. C. for 6 h. The reaction mixture was
concentrated and the residue was purified by HPLC to give the title
compound (0.005 g) as a white solid. LCMS m/z=481.2
[M+H].sup.+.
Example 1.56
Preparation of
2-(((1s,4s)-4-((5-Ethyl-3-(4-methoxyphenyl)-4-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 166)
[0719] From 4-methoxyphenylboronic acid and tert-butyl
2-(((1s,4s)-4-(3-bromo-5-ethyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl-
)methoxy)acetate, using a similar method to the one described in
Example 1.55, the title compound was obtained as a white solid.
LCMS m/z=463.4 [M+H].sup.+.
Example 1.57
Preparation of
2-(((1s,4s)-4-((5-Ethyl-3-(2-fluoro-4-methylphenyl)-4-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 167)
[0720] From 2-fluoro-4-methylphenylboronic acid and tert-butyl
2-(((1s,4s)-4-((3-bromo-5-ethyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate, using a similar method to the one described in
Example 1.55, the title compound was obtained as a white solid.
LCMS m/z=465.2 [M+H].sup.+.
Example 1.58
Preparation of
2-(((1s,4s)-4-((5-Ethyl-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)methoxy)acetic Acid (Compound 168)
[0721] From p-tolylboronic acid and tert-butyl
2-(((1s,4s)-4-((3-bromo-5-ethyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate, using a similar method to the one described in
Example 1.55, the title compound was obtained as a white solid.
LCMS m/z=447.5 [M+H].sup.+.
Example 1.59
Preparation of
2-(((1s,4s)-4-((5-Ethyl-3-(4-hydroxyphenyl)-4-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 175)
[0722] From 4-hydroxyphenylboronic acid and tert-butyl
2-(((1s,4s)-4-(3-bromo-5-ethyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl-
)methoxy)acetate, using a similar method to the one described in
Example 1.55. The title compound was obtained as a white solid.
LCMS m/z=449.3 [M+H].sup.+.
Example 1.60
Preparation of
2-(((1s,4s)-4-((3-(4-Chloro-3-fluorophenyl)-5-ethyl-4-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 176)
[0723] From 4-chloro-3-fluorophenylboronic acid and tert-butyl
2-(((1s,4s)-4-(3-bromo-5-ethyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl-
)methoxy)acetate, using a similar method to the one described in
Example 1.55. The title compound was obtained as a white solid.
LCMS m/z=485.4 [M+H].sup.+.
Example 1.61
Preparation of
2-(((1s,4s)-4-((4-(3-Methoxyphenyl)-3-phenyl-5-propyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid (Compound 202)
Step A: Preparation of 3-Phenyl-5-propyl-1H-pyrazole
[0724] To a solution of acetophenone (4.87 mL, 41.6 mmol) in dry
toluene (5.0 mL) cooled to 0.degree. C. was added LiHMDS (41.6 mL,
41.6 mmol). The resulting mixture was stirred at 0.degree. C. for 5
min before butyryl chloride (4.36 mL, 41.6 mmol) was added in
portions. After the addition of the butyryl chloride, the ice bath
was then removed before AcOH (2.0 mL) and EtOH (10.0 mL) were added
to form a homogenous mixture, then hydrazine hydrate (3.03 mL, 62.4
mmol) was added. The resulting mixture was heated to reflux. After
30 min, the reaction mixture was quenched with 1.0 M NaOH solution,
extracted with EtOAc and washed with brine. The combined organics
were dried over MgSO.sub.4, filtered, and concentrated to give an
orange oil. This orange oil was purified by silica gel flash
chromatography to give the title compound as a yellow oil (3.83 g).
LCMS m/z=187.2 [M+H].sup.+; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 0.92 (t, J=7.33 Hz, 3H), 1.58-1.71 (m, 2H), 2.57 (t,
J=7.58 Hz, 2H), 6.34 (s, 1H), 7.22-7.39 (m, 3H), 7.72 (d, J=7.83
Hz, 2H).
Step B: Preparation of 4-Bromo-3-phenyl-5-propyl-1H-pyrazole
[0725] To a solution of 3-phenyl-5-propyl-1H-pyrazole (3.83 g,
20.56 mmol) in dichloromethane (118.0 mL) was added bromine (1.05
mL, 20.56 mmol) at 25.degree. C. The reaction mixture was stirred
at room temperature for 16 h. The reaction mixture was then
quenched with 2 M Na.sub.2CO.sub.3 (aq.) to pH 12 and the organics
were separated. The aqueous layer was extracted with DCM (thrice).
The combined organics were washed with brine, dried over
MgSO.sub.4, filtered and concentrated to give a red oil. This oil
was purified by silica gel flash chromatography to give the title
compound as a yellow oil (3.44 g). LCMS m/z=265.1, 267.1
[M+H].sup.+; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 0.97 (t,
J=7.33 Hz, 3H), 1.63-1.74 (m, 2H), 2.57 (t, J=7.58 Hz, 2H),
7.37-7.48 (m, 3H), 7.77-7.82 (m, 2H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-Bromo-3-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate
[0726] To a solution of 4-bromo-3-phenyl-5-propyl-1H-pyrazole (1.00
g, 3.77 mmol) in DMF (13.0 mL) was slowly added 60% sodium hydride
(0.181 g, 4.53 mmol). The solution was allowed to stir for a total
of 20 min, before a mixture of tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (1.556 g,
3.77 mmol) in DMF (2.0 mL) was added. The reaction mixture was then
stirred at 45.degree. C. for 12 h, quenched with water and
extracted with EtOAc (4 times). The combined organics were dried
over MgSO.sub.4, filtered, and concentrated to give a brown oil.
This brown oil was purified by silica gel flash chromatography to
give the title compound as a yellow oil (1.501 g). LCMS m/z=505.4,
507.4 [M+H].sup.+; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm
1.02 (t, J=7.45 Hz, 3H), 1.29-1.41 (m, 2H), 1.43-1.59 (m, 15H),
1.65 (d, J=7.83 Hz, 2H), 1.82-1.94 (m, 1H), 2.13-2.24 (m, 1H), 2.66
(t, J=7.83 Hz, 2H), 3.46 (d, J=7.07 Hz, 2H), 3.95 (s, 2H), 4.00 (d,
J=7.58 Hz, 2H), 7.33 (d, J=7.58 Hz, 1H), 7.40 (t, J=7.45 Hz, 2H),
7.84-7.89 (m, 2H).
Step D: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-(3-Methoxyphenyl)-3-phenyl-5-propyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetate
[0727] To a solution of 3-methoxyphenylboronic acid (0.029 g, 0.194
mmol), tert-butyl
2-(((1s,4s)-4-((4-bromo-3-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate (0.098 g, 0.194 mmol), aq. Na.sub.2CO.sub.3 (2 M
solution, 0.194 mL, 0.388 mmol), and Pd(PPh.sub.3).sub.4 (0.004 g,
0.007 mmol) in EtOH (1.0 mL) and benzene (3.0 mL). The reaction
mixture was then heated in a microwave at 130.degree. C. for 1 h,
quenched with H.sub.2O and extracted with EtOAc (2.times.). The
combined organics layers were dried over MgSO.sub.4, filtered and
concentrated to give the title compound as a yellow oil without
purification. LCMS m/z=533.4 [M+H].sup.+.
Step E: Preparation of
2-(((1s,4s)-4-((4-(3-Methoxyphenyl)-3-phenyl-5-propyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid
[0728] To tert-butyl
2-(((1s,4s)-4-((4-(3-methoxyphenyl)-3-phenyl-5-propyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetate obtained was added 4 M HCl (0.969
mL, 3.88 mmol) in 1,4-dioxane. The resulting reaction mixture was
stirred at 25.degree. C. for 4 h. The reaction was concentrated to
give a yellow oil. This yellow oil was purified by HPLC to give the
title compound (0.026 g) as a white solid. LCMS m/z=477.4
[M+H].sup.+; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 0.87 (t,
J=7.33 Hz, 3H), 1.33-1.62 (m, 9H), 1.86-1.97 (m, 1H), 2.17-2.29 (m,
1H), 2.54-2.62 (m, 2H), 3.50-3.55 (m, 2H), 3.72 (s, 3H), 3.86 (s,
1H), 4.02-4.13 (m, 4H), 6.70-6.86 (m, 3H), 7.15-7.27 (m, 4H),
7.34-7.43 (m, 2H).
Example 1.62
Preparation of
2-(((1s,4s)-4-((4-(3-Fluorophenyl)-3-phenyl-5-propyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 203)
[0729] From 3-fluorophenylboronic acid tert-butyl
2-(((1s,4s)-4-(4-bromo-3-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate, using a similar method to the one described in
Example 1.61, Step D & E, the title compound was obtained as a
white solid. LCMS m/z=465.2 [M+H].sup.+.
Example 1.63
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-3-phenyl-5-propyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 204)
[0730] From 3-chlorophenylboronic acid and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate, using a similar method to the one described in
Example 1.62, the title compound was obtained as a white solid.
LCMS m/z=481.3 [M+H].sup.+.
Example 1.64
Preparation of
2-(((1s,4s)-4-(3-Phenyl-5-propyl-4-m-tolyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)methoxy)acetic Acid (Compound 205)
[0731] From m-tolylboronic acid and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate, using a similar method to the one described in
Example 1.62, the title compound was obtained as a white solid.
LCMS m/z=461.5 [M+H].sup.+.
Example 1.65
Preparation of
2-(((1s,4s)-4-((4-(2-Fluoro-3-methoxyphenyl)-3-phenyl-5-propyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 206)
[0732] From 2-fluoro-3-methoxyphenylboronic acid and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate, using a similar method to the one described in
Example 1.62, the title compound was obtained as a white solid.
LCMS m/z=495.5 [M+H].sup.+.
Example 1.66
Preparation of
2-(((1s,4s)-4-((4-(2,3-Difluorophenyl)-3-phenyl-5-propyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic Acid (Compound 207).
[0733] From 2,3-difluorophenylboronic acid and Cert-butyl
2-(((1s,4s)-4-(4-bromo-3-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate, using a similar method to the one described in
Example 1.62, the title compound was obtained as a white solid.
LCMS m/z=483.4 [M+H].sup.+.
Example 1.67
Preparation of
2-(((1s,4s)-4-((4-(3-Chloro-2-fluorophenyl)-3-phenyl-5-propyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 208)
[0734] From 3-chloro-2-fluorophenylboronic acid and tert-butyl
2-(((1s,4s)-4-(4-bromo-3-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate, using a similar method to the one described in
Example 1.62, the title compound was obtained as a white solid.
LCMS m/z=499.7 [M+H].sup.+.
Example 1.68
Preparation of
2-(((1s,4s)-4-((4-(2-Fluoro-3-methylphenyl)-3-phenyl-5-propyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 209)
[0735] From 2-fluoro-3-methylphenylboronic acid and tert-butyl
2-(((1s,4s)-4-(4-bromo-3-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate, using a similar method to the one described in
Example 1.62, the title compound was obtained as a white solid.
LCMS m/z=479.6 [M+H].sup.+.
Example 1.69
Preparation of
2-(((1s,4s)-4-((4-(2-Fluoro-3-hydroxyphenyl)-3-phenyl-5-propyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 211)
[0736] From 2-fluoro-3-hydroxyphenylboronic acid and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate, using a similar method to the one described in
Example 1.62, the title compound was obtained as a white solid.
LCMS m/z=481.3 [M+H].sup.+.
Example 1.70
Preparation of
2-(((1s,4s)-4-((5-(4-Fluorophenyl)-4-phenyl-3-propyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 223)
Step A: Preparation of 1-(Dimethylamino)-2-phenylhex-1-en-3-one
[0737] To a solution of 1-phenylpentan-2-one (5.00 g, 30.8 mmol) in
dry DMF (80.0 mL) was added 1,1-dimethoxy-N,N-dimethylmethanamine
(6.16 mL, 46.2 mmol). The resulting mixture was heated at
90.degree. C. After 16 h, the reaction mixture was quenched with
water, extracted with EtOAc (3.times.) and washed with brine. The
combined organics were dried over MgSO.sub.4, filtered, and
concentrated to give a yellow oil. This yellow oil was purified by
silica gel flash chromatography to give the title compound as a
yellow oil (3.51 g). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm
0.76-0.83 (m, 3H), 0.83-0.89 (m, 2H), 2.11-2.19 (m, 2H), 2.62-2.71
(m, 6H), 7.15-7.42 (m, 5H), 7.61 (s, 1H).
Step B: Preparation of 4-Phenyl-5-propyl-1H-pyrazole
[0738] To a solution of 1-(dimethylamino)-2-phenylhex-1-en-3-one
(3.51 g, 16.2 mmol) in ethanol (80.0 mL), was added hydrazine
hydrate (1.57 mL, 32.4 mmol). The reaction mixture was stirred at
80.degree. C. After 3 h, the reaction mixture was cooled to room
temperature, concentrated under reduced pressure and crystallized
in 20% ethanol/H.sub.2O to give the title compound as a white solid
(3.01 g). LCMS m/z=187.1 [M+H].sup.+; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 0.92-1.00 (m, 3H), 1.64-1.76 (m, 2H),
2.75-2.84 (m, 2H), 7.36-7.41 (m, 5H), 7.65 (s, 1H).
Step C: Preparation of 3-Bromo-4-phenyl-5-propyl-1H-pyrazole
[0739] To a solution of 4-phenyl-5-propyl-1H-pyrazole (1.43 g, 7.68
mmol) in acetonitrile (38.0 mL), was added N-bromosuccinimide (1.50
g, 8.45 mmol). The reaction mixture was stirred at 82.degree. C.
After 16 h, the reaction mixture was quenched with 2 M
Na.sub.2CO.sub.3 (aq.) to pH 12 and the organics were separated.
The aqueous layer was extracted with EtOAc (3.times.). The combined
organics were dried over MgSO.sub.4, filtered and concentrated to
give a dark oil. This oil was purified by silica gel flash
chromatography to give the title compound as a yellow oil (0.310
g). LCMS m/z=265.1, 267.1 [M+H].sup.+.
Step D: Preparation of tert-Butyl
2-(((1s,4s)-4-((3-Bromo-4-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-Butyl
2-(((1s,4s)-4-((5-Bromo-4-phenyl-3-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate
[0740] To a solution of 3-bromo-4-phenyl-5-propyl-1H-pyrazole
(0.940 g, 3.55 mmol) in DMF (12.0 mL), was slowly added 60% sodium
hydride (0.170 g, 4.25 mmol). The solution was stirred for a total
of 20 min, before a mixture of tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (1.463 g,
3.55 mmol) in DMF (2.0 mL) was added. The reaction mixture was then
stirred at 45.degree. C. for 12 h, quenched with water and
extracted with EtOAc (4.times.). The combined organics were dried
over MgSO.sub.4, filtered, and concentrated to give a brown oil.
This brown oil was purified by silica gel flash chromatography to
give a mixture of regioisomers, the title compounds as a yellow oil
(1.219 g). LCMS m/z=505.4 [M+H].sup.+; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 0.85 (t, J=7.33 Hz, 3H), 1.32-1.63 (m,
18H), 1.76-1.93 (m, 2H), 2.17-2.29 (m, 1H), 2.56-2.64 (m, 2H), 3.45
(d, J=6.82 Hz, 2H), 3.95 (s, 2H), 4.05-4.14 (m, 2H), 7.28-7.35 (m,
3H), 7.36-7.43 (m, 2H).
Step E: Preparation of tert-Butyl
2-(((1s,4s)-4-((5-(4-Fluorophenyl)-4-phenyl-3-propyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetate and tert-Butyl
2-(((1s,4s)-4-(3-(4-Fluorophenyl)-4-phenyl-5-propyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate
[0741] To a solution of 4-fluorophenylboronic acid (0.032 g, 0.231
mmol), a mixture of regioisomers, tert-butyl
2-(((1s,4s)-4-((3-bromo-4-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-bromo-4-phenyl-3-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate (0.117 g, 0.231 mmol), aq. Na.sub.2CO.sub.3 (2 M
solution, 0.231 mL, 0.463 mmol), and Pd(PPh.sub.3).sub.4 (0.008 g,
0.007 mmol) in EtOH (1.0 mL) and benzene (3.0 mL). The reaction
mixture was then heated under microwave at 130.degree. C. for 1 h,
quenched with H.sub.2O and extracted with EtOAc (2.times.). The
combined organics layers were dried over MgSO.sub.4, filtered and
concentrated to give a mixture of regioisomers, the title compounds
as a yellow oil without further purification. LCMS m/z=521.7
[M+H].sup.+.
Step F: Preparation of
2-(((1s,4s)-4-((5-(4-Fluorophenyl)-4-phenyl-3-propyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid
[0742] To a mixture of regioisomers, tert-Butyl
2-(((1s,4s)-4-((5-(4-Fluorophenyl)-4-phenyl-3-propyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetate and tert-Butyl
2-(((1s,4s)-4-(3-(4-Fluorophenyl)-4-phenyl-5-propyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate obtained was added 4 M HCl (1.16 mL,
4.63 mmol) in 1,4-dioxane. The resulting reaction mixture was
stirred at 25.degree.. After 4 h, the reaction mixture concentrated
to give a yellow oil. This yellow oil was purified by HPLC to give
the title compound (0.019 g) as a white solid. LCMS m/z=465.3
[M+H].sup.+.
Example 1.71
Preparation of
2-(((1s,4s)-4-(3-(4-Fluorophenyl)-4-phenyl-5-propyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic Acid (Compound 224)
[0743] From a mixture of regioisomers, tert-butyl
2-(((1s,4s)-4-((5-(4-fluorophenyl)-4-phenyl-3-propyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(3-(4-fluorophenyl)-4-phenyl-5-propyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate, using a similar method to the one
described in Example 1.70, Step F, the title compound was obtained
as a second isomer. LCMS m/z=465.3 [M+H].sup.+; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 0.87 (t, J=7.26 Hz, 3H), 1.16-1.30 (m,
1H), 1.33-1.68 (m, 8H), 1.94 (s, 2H), 2.21 (s, 1H), 2.52-2.64 (m,
2H), 3.53 (d, J=6.95 Hz, 2H), 3.97-4.19 (m, 4H), 6.91 (t, J=8.72
Hz, 2H), 7.13-7.19 (m, 2H), 7.28-7.39 (m, 5H).
Example 1.72
Preparation of
2-(((1s,4s)-4-((5-(4-Chloro-3-fluorophenyl)-4-phenyl-3-propyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 225)
[0744] From 4-chloro-3-fluorophenylboronic acid and a mixture of
regioisomers, tert-butyl
2-(((1s,4s)-4-((3-bromo-4-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-bromo-4-phenyl-3-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate, using a similar method to the one described in
Example 1.70, Step E & F, the title compound was obtained as a
white solid. LCMS m/z=499.6 [M+H].sup.+.
Example 1.73
Preparation of
2-(((1s,4s)-4-((3-(4-Chloro-3-fluorophenyl)-4-phenyl-5-propyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 226)
[0745] From 4-chloro-3-fluorophenylboronic acid and a mixture of
regioisomers, tert-butyl
2-(((1s,4s)-4-((3-bromo-4-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-bromo-4-phenyl-3-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate, using a similar method to the one described in
Example 1.72, the title compound was obtained as an isomer. LCMS
m/z=499.7 [M+H].sup.+.
Example 1.74
Preparation of
2-(((1s,4s)-4-((5-(4-Chlorophenyl)-4-phenyl-3-propyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 227)
[0746] From 4-chlorophenylboronic acid and a mixture of
regioisomers, tert-butyl
2-(((1s,4s)-4-((3-bromo-4-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-bromo-4-phenyl-3-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate, using a similar method to the one described in
Example 1.72, the title compound was obtained as a white solid.
LCMS m/z=481.2 [M+H].sup.+.
Example 1.75
Preparation of
2-(((1s,4s)-4-((3-(4-Chlorophenyl)-4-phenyl-5-propyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 228)
[0747] From 4-chlorophenylboronic acid and a mixture of
regioisomers, tert-butyl
2-(((1s,4s)-4-((3-bromo-4-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-bromo-4-phenyl-3-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate, using a similar method to the one described in
Example 1.72, the title compound was obtained as a white solid.
LCMS m/z=481.4 [M+H].sup.+.
Example 1.76
Preparation of
2-(((1s,4s)-4-((5-(3,4-Difluorophenyl)-4-phenyl-3-propyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic Acid (Compound 229)
[0748] From 3,4-difluorophenylboronic acid and a mixture of
regioisomers, tert-butyl
2-(((1s,4s)-4-((3-bromo-4-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-bromo-4-phenyl-3-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate, using a similar method to the one described in
Example 1.72, the title compound was obtained as a white solid.
LCMS m/z=483.4 [M+H].sup.+.
Example 1.77
Preparation of
2-(((1s,4s)-4-((3-(3,4-Difluorophenyl)-4-phenyl-5-propyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic Acid (Compound 230)
[0749] From 3,4-difluorophenylboronic acid and a mixture of
regioisomers, tert-butyl
2-(((1s,4s)-4-(3-bromo-4-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-bromo-4-phenyl-3-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate, using a similar method to the one described in
Example 1.72, the title compound was obtained as a white solid.
LCMS m/z=483.4 [M+H].sup.+.
Example 1.78
Preparation of
2-(((1s,4s)-4-((5-(2-Fluoro-4-methoxyphenyl)-4-phenyl-3-propyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 231)
[0750] From 2-fluoro-4-methoxyphenylboronic acid and a mixture of
regioisomers, tert-butyl
2-(((1s,4s)-4-((3-bromo-4-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-bromo-4-phenyl-3-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate, using a similar method to the one described in
Example 1.72, the title compound was obtained as a white solid.
LCMS m/z=495.6 [M+H].sup.+.
Example 1.79
Preparation of
2-(((1s,4s)-4-(3-(2-Fluoro-4-methoxyphenyl)-4-phenyl-5-propyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 232)
[0751] From 2-fluoro-4-methoxyphenylboronic acid and a mixture of
regioisomers, tert-butyl
2-(((1s,4s)-4-(3-bromo-4-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-bromo-4-phenyl-3-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate, using a similar method to the one described in
Example 1.72, the title compound was obtained as a white solid.
LCMS m/z=495.5 [M+H].sup.+.
Example 1.80
Preparation of
2-(((1s,4s)-4-((5-(4-Methoxyphenyl)-4-phenyl-3-propyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid (Compound 233)
[0752] From 4-methoxyphenylboronic acid and a mixture of
regioisomers, tert-butyl
2-(((1s,4s)-4-((3-bromo-4-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-bromo-4-phenyl-3-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate, using a similar method to the one described in
Example 1.72, the title compound was obtained as a white solid.
LCMS m/z=477.4 [M+H].sup.+.
Example 1.81
Preparation of
2-4(1s,4s)-4-((3-(4-Methoxyphenyl)-4-phenyl-5-propyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 234)
[0753] From 4-methoxyphenylboronic acid and a mixture of
regioisomers, tert-butyl
2-(((1s,4s)-4-((3-bromo-4-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-bromo-4-phenyl-3-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate, using a similar method to the one described in
Example 1.72, the title compound was obtained as a white solid.
LCMS m/z=477.5 [M+H].sup.+.
Example 1.82
Preparation of
2-(((1s,4s)-4-((5-(2-Fluoro-4-methylphenyl)-4-phenyl-3-propyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 235)
[0754] From 2-fluoro-4-methylphenylboronic acid and a mixture of
regioisomers, tert-butyl
2-(((1s,4s)-4-((3-bromo-4-phenyl-5-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-bromo-4-phenyl-3-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate, using a similar method to the one described in
Example 1.72, the title compound was obtained as a white solid.
LCMS m/z=479.5 [M+H].sup.+.
Example 1.83
Preparation of
2-4(1s,4s)-4-((3-(2-Fluoro-4-methylphenyl)-4-phenyl-5-propyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 236)
[0755] From 2-fluoro-4-methylphenylboronic acid and a mixture of
regioisomers, tert-butyl 2-(((1s,4s)-4((3-bromo-4-phenyl-5-propy
1-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-bromo-4-phenyl-3-propyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate, using a similar method to the one described in
Example 1.72, the title compound was obtained as a white solid.
LCMS m/z=479.4 [M+H].sup.+.
Example 1.84
Preparation of
2-(((1s,4s)-4-((5-(Cyanomethylthio)-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)me-
thyl)cyclohexyl)methoxy)acetic Acid (Compound 257)
Step A: Preparation of
2-(1,3-Dithietan-2-ylidene)-2-phenyl-1-p-tolylethanone
[0756] To a solution of 2-phenyl-1-p-tolylethanone (3.00 g, 14.27
mmol) in THF (50.0 mL) was added KOtBu (30.0 mL, 30.0 mmol),
CS.sub.2 (0.862 mL, 14.27 mmol) and dibromomethane (0.994 mL, 14.27
mmol). The reaction was stirred at 25.degree. C. for 12 h, quenched
with water (40.0 mL) and extracted with EtOAc (3.times.50.0 mL).
The combined organics were dried over MgSO.sub.4, filtered, and
concentrated to give the title compound as a brown oil without
further purification. LCMS m/z=299.2 [M+H].sup.+.
Step B: Preparation of A Mixture of
4-Phenyl-3-p-tolyl-1H-pyrazole-5(4H)-thione and
1,2-Bis(4-phenyl-3-p-tolyl-1H-pyrazol-5-yl)disulfane
[0757] To a solution of
2-(1,3-dithietan-2-ylidene)-2-phenyl-1-p-tolylethanone dissolved in
iso-propanol (25.0 mL) was added hydrazine (7.00 mL, 143.0 mmol).
The reaction was stirred at 100.degree. C. for 16 h. After cooling
to room temperature, a precipitate was formed. The precipitate was
filtered and washed with isopropanol and dried under reduced
pressure to give the title compounds as a mixture of
4-phenyl-3-p-tolyl-1H-pyrazole-5(4H)-thione and
1,2-bis(4-phenyl-3-p-tolyl-1H-pyrazol-5-yl)disulfane as a white
solid (2.24 g). LCMS m/z=267.2 [M+H].sup.+; 531.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 2.31 (s, 3H), 7.04
(d, J=7.58 Hz, 2H), 7.10-7.16 (m, 1H), 7.17-7.27 (m, 5H), 7.39 (d,
J=7.33 Hz, 2H).
Step C: Preparation of
2-(4-Phenyl-3-p-tolyl-1H-pyrazol-5-ylthio)acetonitrile
[0758] To a mixture of 4-phenyl-3-p-tolyl-1H-pyrazole-5(4H)-thione
and 1,2-bis(4-phenyl-3-p-tolyl-1H-pyrazol-5-yl)disulfane (0.500 g,
1.88 mmol) in DMF (12.5 mL) was added 2-bromoacetonitrile (0.125
mL, 1.88 mmol) and K.sub.2CO.sub.3 (0.259 g, 1.88 mmol). The
reaction was stirred at 25.degree. C. for 72 h, quenched with water
(40.0 mL) and extracted with EtOAc (4.times.50.0 mL) and washed
with brine. The combined organics were dried over MgSO.sub.4,
filtered, and concentrated to give the title compound as a yellow
oil (0.547 g). LCMS m/z=306.2 [M+H].sup.+.
Step C: Preparation of tert-Butyl
2-4(1s,4s)-4-((5-(Cyanomethylthio)-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetate
[0759] To a solution of
2-(4-phenyl-3-p-tolyl-1H-pyrazol-5-ylthio)acetonitrile (0.250 g,
0.819 mmol) in anhydrous DMF (4.0 mL) was added cesium carbonate
(0.533 g, 1.64 mmol) and tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (0.338 g,
0.819 mmol) in DMF (1.0 mL). The reaction was heated at 80.degree.
C. for 1 h, quenched with water and extracted with EtOAc
(2.times.). The combined organics were dried over MgSO.sub.4,
filtered, and concentrated to give the title compound as a yellow
oil without further purification. LCMS m/z=546.4 [M+H].sup.+.
Step D: Preparation of
2-(((1s,4s)-4-((5-(Cyanomethylthio)-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)me-
thyl)cyclohexyl)methoxy)acetic Acid
[0760] To Cert-butyl
2-(((1s,4s)-4-((5-(cyanomethylthio)-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)me-
thyl)cyclohexyl)methoxy)acetate obtained above was added 4 M HCl
(4.09 mL, 16.37 mmol) in 1,4-dioxane. The reaction was stirred at
25.degree. C. for 16 h and concentrated to give a yellow oil. This
yellow oil was purified by HPLC to give the title compound as a
white solid (0.013 g). LCMS m/z=490.5 [M+H].sup.+.
Example 1.85
Preparation of
2-(((1r,4r)-4-(3-(Cyanomethylthio)-4-(3-methoxyphenyl)-5-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 245)
Step A: Preparation of
2-(4-(3-Methoxyphenyl)-3-phenyl-1H-pyrazol-5-ylthio)acetonitrile
[0761] To a solution of
4-(3-methoxyphenyl)-3-phenyl-1H-pyrazole-5(4H)-thione (0.200 g,
0.708 mmol) in DMF (5.0 mL) was added 2-bromoacetonitrile (0.047
mL, 0.708 mmol) and K.sub.2CO.sub.3 (0.098 g, 0.708 mmol). The
mixture was stirred at 25.degree. C. for 72 h, quenched with water
(40.0 mL), extracted with EtOAc (4.times.50.0 mL) and washed with
brine. The combined organics were dried over MgSO.sub.4, filtered,
and concentrated to give a brown oil. This brown oil was purified
by silica gel flash chromatography to give the title compound as a
white solid (0.158 g). LCMS m/z=332.3 [M+H].sup.+; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 3.67 (s, 2H), 3.74 (s, 3H), 6.82-6.89
(m, 3H), 7.23-7.29 (m, 1H), 7.34 (s, 5H).
Step B: Preparation of tert-Butyl
2-(((1r,4r)-4-((3-(Cyanomethylthio)-4-(3-methoxyphenyl)-5-phenyl-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetate and tert-Butyl
2-(((1s,4s)-4-((5-(Cyanomethylthio)-4-(3-methoxyphenyl)-3-phenyl-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetate
[0762] To a solution of
2-(4-(3-methoxyphenyl)-3-phenyl-1H-pyrazol-5-ylthio)acetonitrile
(0.158 g, 0.492 mmol) in DMF (2.0 mL) at 0.degree. C. was slowly
added 60% sodium hydride (0.022 g, 0.541 mmol). The solution was
allowed to stir for a total of 20 min, before a mixture of
tert-butyl 2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate
(0.203 g, 0.492 mmol) in DMF (1.0 mL) was added. The reaction
mixture was then stirred at 40.degree. C. for 16 h, quenched with
water and extracted with EtOAc (2.times.). The combined organics
were dried over MgSO.sub.4, filtered, and concentrated to give a
mixture of tert-butyl
2-(((1r,4r)-4-((3-(cyanomethylthio)-4-(3-methoxyphenyl)-5-phenyl-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-(cyanomethylthio)-4-(3-methoxyphenyl)-3-phenyl-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetate without further
purification. LCMS m/z=562.4 [M+H].sup.+.
Step C: Preparation of
2-(((1r,4r)-4-((3-(Cyanomethylthio)-4-(3-methoxyphenyl)-5-phenyl-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid
[0763] To the mixture of tert-butyl
2-(((1r,4r)-4-((3-(cyanomethylthio)-4-(3-methoxyphenyl)-5-phenyl-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-(cyanomethylthio)-4-(3-methoxyphenyl)-3-phenyl-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetate obtained above was added
4 M HCl (2.46 mL, 9.83 mmol) in 1,4-dioxane. The reaction was
stirred at 25.degree. C. for 16 h and concentrated to give a yellow
oil. This yellow oil was purified by HPLC to give the title
compound (0.042 g) as a white solid. LCMS m/z=506.5
[M+H].sup.+.
Example 1.86
Preparation of
2-(((1s,4s)-4-((5-(Cyanomethylthio)-4-(3-methoxyphenyl)-3-phenyl-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 246)
[0764] From a mixture of regioisomers tert-butyl
2-(((1r,4r)-4-((3-(cyanomethylthio)-4-(3-methoxyphenyl)-5-phenyl-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-(cyanomethylthio)-4-(3-methoxyphenyl)-3-phenyl-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetate, using a similar method
to the one described in Example 1.85, Step C, the title compound
was also isolated as a white solid. LCMS m/z=506.4 [M+H].sup.+.
Example 1.87
Preparation of
2-(((1s,4s)-4-((5-(Cyanomethylthio)-3-(4-fluorophenyl)-4-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 258)
[0765] From 1-(4-fluorophenyl)-2-phenylethanone, using a similar
method to the one described in Example 1.85, the title compound was
obtained as a white solid. LCMS m/z=494.5 [M+H].sup.+.
Example 1.88
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-5-(cyanomethylthio)-3-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 275)
[0766] From 2-(3-chlorophenyl)-1-phenylethanone, using a similar
method to the one described in Example 1.85, the title compound was
obtained as a white solid. LCMS m/z=510.3 [M+H].sup.+.
Example 1.89
Preparation of
2-(((1r,4r)-4-((3-(2-Amino-2-oxoethoxy)-4-(3-methoxyphenyl)-5-phenyl-1H-p-
yrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
277)
Step A: Preparation of
2-(3-Phenyl-1H-pyrazol-5-yloxy)acetonitrile
[0767] To a solution of 3-phenyl-1H-pyrazol-5(4H)-one (1.00 g, 6.24
mmol) in DMF (5.0 mL) was added 2-bromoacetonitrile (0.520 mL, 7.80
mmol) and K.sub.2CO.sub.3 (0.863 g, 6.24 mmol). The reaction was
stirred at 25.degree. C. for 12 h, quenched with water (40.0 mL),
extracted with EtOAc (3.times.50.0 mL) and washed with brine. The
combined organics were dried over MgSO.sub.4, filtered, and
concentrated to give the title compound as a yellow oil. This
yellow oil was purified by silica gel flash chromatography to give
the title compound as a clear oil (0.990 g). LCMS m/z=200.3
[M+H].sup.+.
Step B: Preparation of
2-(4-Bromo-3-phenyl-1H-pyrazol-5-yloxy)acetonitrile
[0768] To a solution of 2-(3-phenyl-1H-pyrazol-5-yloxy)acetonitrile
(0.500 g, 2.51 mmol) in dichloromethane (15.0 mL), was added
bromine (0.129 mL, 2.51 mmol) at 25.degree. C. The reaction was
stirred at room temperature for 1 h and quenched with 2 M
Na.sub.2CO.sub.3 (aq.) to pH 12. The organics were separated. The
aqueous layer was extracted with DCM (3.times.). The combined
organics were washed with brine, dried (MgSO.sub.4), filtered and
concentrated to give a red oil. This oil was purified by silica gel
flash chromatography to give the title compound as a yellow solid
(0.360 g). LCMS m/z=278.1, 280.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 5.21 (s, 2H), 7.39-7.61 (m, 3H),
7.70-7.77 (m, 2H), 13.04 (s, 1H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-Bromo-5-(cyanomethoxy)-3-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate and tert-Butyl
2-(((1s,4s)-4-((4-Bromo-3-(cyanomethoxy)-5-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate
[0769] To a solution of
2-(4-bromo-3-phenyl-1H-pyrazol-5-yloxy)acetonitrile (0.570 g, 2.50
mmol) in anhydrous DMF (18.0 mL) was added cesium carbonate (1.34
g, 4.10 mmol) and a mixture of tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (0.846 g,
2.50 mmol) in DMF (2.0 mL). The reaction was heated at 80.degree.
C. for 1 h, quenched with water and extracted with EtOAc
(3.times.). The combined organics were dried over MgSO.sub.4,
filtered, and concentrated to give a yellow oil. This oil was
purified by silica gel flash chromatography to give the title
compound as a clear oil (0.386 g). LCMS m/z=518.4, 520.5
[M+H].sup.+; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm
1.09-1.22 (m, 1H), 1.28-1.57 (m, 13H), 1.61 (s, 1H), 1.69-1.91 (m,
2H), 1.95-2.08 (m, 1H), 2.45 (s, 2H), 3.26 (d, J=6.82 Hz, 1H), 3.36
(d, J=6.82 Hz, 1H), 3.83-3.97 (m, 3H), 4.97 (d, 2H), 7.31-7.38 (m,
2H), 7.45-7.51 (m, 1H), 7.78 (d, J=8.34 Hz, 2H).
Step D: Preparation of tert-Butyl
2-(((1s,4s)-4-((3-(Cyanomethoxy)-4-(3-methoxyphenyl)-5-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetate and tert-Butyl
2-(((1s,4s)-4-((5-(Cyanomethoxy)-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetate.
[0770] To a solution of 3-methoxyphenylboronic acid (0.019 g, 0.123
mmol), tert-butyl
2-(((1s,4s)-44(4-bromo-5-(cyanomethoxy)-3-phenyl-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetate (0.064 g, 0.123 mmol), aq.
Na.sub.2CO.sub.3 (2 M solution, 0.123 mL, 0.247 mmol), and
Pd(PPh.sub.3).sub.4 (0.004 g, 0.004 mmol) in EtOH (1.0 mL) and
benzene (3.0 mL). The reaction mixture was then heated in a
microwave at 130.degree. C. for 1 h, quenched with H.sub.2O and
extracted with EtOAc (2.times.). The combined organics layers were
dried over MgSO.sub.4, filtered and concentrated to give the title
compounds as a dark solid mixture without further purification.
LCMS m/z=546.5 [M+H].sup.+.
Step E: Preparation of
2-(((1s,4s)-4-((3-(2-Amino-2-oxoethoxy)-4-(3-methoxyphenyl)-5-phenyl-1H-p-
yrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid
[0771] To tert-butyl
2-(((1r,4r)-4-((3-(2-Amino-2-oxoethoxy)-4-(3-methoxyphenyl)-5-phenyl-1H-p-
yrazol-1-yl)methyl)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-(2-Amino-2-oxoethoxy)-4-(3-methoxyphenyl)-3-phenyl-1H-p-
yrazol-1-yl)methyl)cyclohexyl)methoxy)acetate obtained was added 4
M HCl (0.309 mL, 1.23 mmol) in 1,4-dioxane. The reaction was
stirred at 25.degree. C. for 16 h, and concentrated to give a
yellow oil. This yellow oil was purified by HPLC to give the title
compound (0.004 g) as a white solid. LCMS m/z=508.3
[M+H].sup.+.
Example 1.90
Preparation of
2-(((1s,4s)-4-((5-(2-Amino-2-oxoethoxy)-4-(3-methoxyphenyl)-3-phenyl-1H-p-
yrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
278)
[0772] From the same mixture of tert-butyl
2-(((1s,4s)-4-((3-(cyanomethoxy)-4-(3-methoxyphenyl)-5-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(5-(cyanomethoxy)-4-((3-methoxyphenyl)-3-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetate obtained, using a similar
method to the one described in Example 1.89, Step E, the title
compound was also isolated as a white solid. LCMS m/z=509.4
[M+H].sup.+.
Example 1.91
Preparation of
2-(((1r,4r)-4-((3-(2-Amino-2-oxoethoxy)-4-(2-fluoro-3-methoxyphenyl)-5-ph-
enyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid
(Compound 279)
[0773] From 2-fluoro-3-methoxyphenylboronic acid and a mixture of
tert-Butyl
2-(((1s,4s)-4-((4-Bromo-5-(cyanomethoxy)-3-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate and tert-Butyl
2-(((1s,4s)-4-((4-Bromo-3-(cyanomethoxy)-5-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate, using a similar method to the one
described in Example 1.89, Step D&E, the title compound was
obtained as a white solid. LCMS m/z=526.8 [M+H].sup.+.
Example 1.92
Preparation of
2-(((1s,4s)-4-((5-(2-Amino-2-oxoethoxy)-4-(2-fluoro-3-methoxyphenyl)-3-ph-
enyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid
(Compound 280)
[0774] From 2-fluoro-3-methoxyphenylboronic acid and a mixture of
tert-butyl
2-(((1s,4s)-4-((4-Bromo-5-(cyanomethoxy)-3-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-Bromo-3-(cyanomethoxy)-5-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate, using a similar method to the one
described in Example 1.89, Step D&E, the title compound was
obtained as a white solid. LCMS m/z=527.6 [M+H].sup.+.
Example 1.93
Preparation of
2-4(1s,4s)-4-((5-(Cyanomethoxy)-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 283)
[0775] From 3-methoxyphenylboronic acid, using a similar method to
the one described in Example 1.89, Step D&E, the title compound
was obtained as a white solid. LCMS m/z=490.5 [M+H].sup.+.
Example 1.94
Preparation of
2-(((1s,4s)-4-((4-Benzhydryl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)ac-
etic Acid (Compound 17)
[0776] A mixture of 4-benzhydryl-1H-pyrazole (30 mg, 0.128 mmol),
tert-butyl
2-(((1s,4s)-4-((methylsulfonyloxy)methyl)cyclohexyl)methoxy)acetate
(43.1 mg, 0.128 mmol), potassium tert-butoxide (28.7 mg, 0.256
mmol) and 18-Crown-6 (6.77 mg, 0.026 mmol) was stirred at room
temperature overnight. The mixture was purified by preparative LCMS
to give the title compound (one of the two regioisomers separated).
LCMS m/z=419.3 [M+H].sup.+; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 7.36-7.27 (m, 5H), 7.23 (m, 2H), 7.17 (m, 4H), 7.03 (s,
1H), 5.34 (s, 1H), 4.07 (m, 4H), 3.46 (d, 2H, J=5.6 Hz), 2.06 (m,
1H), 1.85 (m, 1H), 1.58-1.44 (m, 6H), 1.28 (m, 2H).
Example 1.95
Preparation of
2-(((1r,4r)-4-((4-Benzhydryl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)ac-
etic Acid (Compound 18)
[0777] A mixture of 4-benzhydryl-1H-pyrazole (30 mg, 0.128 mmol),
tert-butyl
2-(((1s,4s)-4-((methylsulfonyloxy)methyl)cyclohexyl)methoxy)acetate
(43.1 mg, 0.128 mmol), potassium tert-butoxide (28.7 mg, 0.256
mmol) and 18-Crown-6 (6.77 mg, 0.026 mmol) was stirred at room
temperature overnight. The mixture was purified by preparative LCMS
to give the title compound (one of the two regioisomers separated).
LCMS m/z=419.3 [M+H].sup.+; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 7.31-7.27 (m, 5H), 7.23 (d, 2H, J=7 Hz), 7.17 (m, 4H),
6.97 (s, 1H), 5.34 (s, 1H), 4.08 (s, 2H), 3.93 (d, 2H, J=6.8 Hz),
3.36 (d, 2H, J=6.3 Hz), 1.83 (m, 3H), 1.63 (m, 3H), 0.99 (m,
4H).
Example 1.96
Preparation of
2-(((1s,4s)-4-((3,4-Diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)ac-
etic Acid (Compound 3)
[0778] A mixture of 3,4-diphenyl-1H-pyrazole (50 mg, 0.227 mmol),
tert-butyl
2-(((1s,4s)-4-((methylsulfonyloxy)methyl)cyclohexyl)methoxy)acetate
(76 mg, 0.227 mmol), potassium tert-butoxide (76 mg, 0.681 mmol)
and 18-Crown-6 (12.00 mg, 0.045 mmol) in DMF (2 mL) was stirred at
25.degree. C. for 18 h. The mixture was purified by HPLC to give
the title compound. LCMS m/z=405.3 [M+H].sup.+; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 7.47 (m, 3H), 7.30 (m, 4H), 7.26 (m,
4H), 4.16 (d, 2H, J=7.6 Hz), 4.11 (s, 2H), 3.50 (d, 2H, J=6.8 Hz),
2.22 (m, 1H), 1.90 (m, 1H), 1.58 (m, 6H), 1.40 (m, 2H).
Example 1.97
Preparation of
2-(((1s,4s)-4-((3-Methyl-5-phenyl-4-m-tolyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic Acid (Compound 19)
Step A: Preparation of (1s,4s)-Diethyl
Cyclohexane-1,4-dicarboxylate
[0779] To a solution of (1s,4s)-cyclohexane-1,4-dicarboxylic acid
(25 g, 145 mmol) in ethanol (150 mL) was added concentrated
H.sub.2SO.sub.4 (1 mL). The reaction was refluxed for 16 h, cooled
to room temperature and concentrated. The residue was extracted
with EtOAc and saturated NaHCO.sub.3, washed with brine, dried over
MgSO.sub.4, and filtered. The filtrate was concentrated to provide
the title compound as a colorless oil (30.5 g). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 1.25 (t, J=7.14 Hz, 6H), 1.64-1.70 (m,
4H), 1.87-1.92 (m, 4H), 2.44-2.46 (m, 2H), 4.11-1.46 (quartet,
J=7.12 Hz, 4H).
Step B: Preparation of (1s,4s)-Cyclohexane-1,4-diyldimethanol
[0780] To a solution of (((1s,4s)-diethyl
cyclohexane-1,4-dicarboxylate (13.0 g, 56.9 mmol) in THF (500 mL)
was added lithium aluminum hydride (4.54 g, 120 mmol) in portions
at 0.degree. C. The mixture was stirred at that temperature for 2 h
and quenched with cold water, filtered and concentrated to give the
title compound as colorless oil (8.2 g). .sup.1H NMR (400 MHz,
DMSO-d6) .delta. ppm 1.27-1.42 (m, 8H), 1.46-1.54 (m, 2H),
3.26-3.31 (m, 4H), 4.27-4.30 (t, J=5.31 Hz, 2H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-(Hydroxymethyl)cyclohexyl)methoxy)acetate
[0781] To a solution of (1s,4s)-cyclohexane-1,4-diyldimethanol
(18.2 g, 126 mmol) in toluene (200 mL) was added NaOH (50% aq., 60
mL) and tetrabutylammonium iodide (2.331 g, 6.31 mmol), followed by
tert-butyl-2-bromoacetate (20.50 mL, 139 mmol) at room temperature.
The reaction mixture was stirred violently at room temperature for
2 h and diluted with ethyl acetate and water. After separation, the
aqueous layer was extracted with EtOAc (3.times.30 mL). The
combined organic layers were dried over MgSO.sub.4, concentrated,
and purified by silica gel column chromatography to give the title
compound as colorless oil (13.5 g). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 1.35-1.47 (m, 4H), 1.48 (s, 9H), 1.50-1.60
(m, 4H), 1.63-1.74 (m, 1H), 1.79-1.92 (m, 1H), 3.42 (d, J=6.95 Hz,
2H), 3.55 (d, J=6.82 Hz, 2H), 3.93 (s, 1H), 3.94 (s, 2H).
Step D: Preparation of tert-Butyl
2-(((1s,4s)-4-(Tosyloxymethyl)cyclohexyl)methoxy)acetate
[0782] To a solution of tert-butyl
2-(((1s,4s)-4-(hydroxymethyl)cyclohexyl)methoxy)acetate (12.0 g,
46.4 mmol) in dichloromethane (150 mL) were added triethylamine
(4.70 g, 46.4 mmol) and 4-(dimethylamino)pyridine (0.567 g, 4.64
mmol), followed by 4-methylbenzene-1-sulfonyl chloride (8.86 g,
46.4 mmol). The reaction was stirred at room temperature for 16 h.
The solvent was removed and the residue was extracted with
EtOAc/H.sub.2O. The organic extracts were dried over MgSO.sub.4,
and concentrated. The residue was purified by silica gel column
chromatography to give the title compound as pale liquid (9.5 g).
LCMS m/z=413.1 [M+H].sup.+; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 1.28-1.43 (m, 4H), 1.46-1.48 (m, 9H), 1.49-1.56 (m,
4H), 1.76-1.91 (m, 2H), 2.45 (s, 3H), 3.36 (d, J=6.95 Hz, 2H), 3.92
(d, J=7.05 Hz, 2H), 3.92 (s, 2H), 7.35 (d, J=8.46 Hz, 2H), 7.78 (d,
J=8.34 Hz, 2H).
Step E: Preparation of 5-Methyl-3-phenyl-1H-pyrazole
[0783] To a solution of acetophenone (10 g, 83 mmol) in anhydrous
toluene (10 mL) was added LiHMDS (1.0 M in THF, 83 mL, 83 mmol) via
syringe at 0.degree. C. under argon. After 5 min, acetyl chloride
(6.53 g, 83 mmol) was added in one portion via syringe. The ice
bath was removed and glacial AcOH (5 mL), EtOH (50 mL), and
hydrazine hydrate (12.50 g, 250 mmol) were added. The mixture was
refluxed for 2 h. After cooled to room temperature, the reaction
was neutralized to pH 7 by adding 1.0 M NaOH solution. The mixture
was extracted with EtOAc, washed with brine, dried over MgSO.sub.4,
and concentrated. The residue was purified by silica gel column
chromatography to give the title compound as pale yellow oil (12.05
g). LCMS m/z=159.0 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 2.25 (s, 3H), 6.42 (s, 1H), 7.20-7.44 (m, 3H),
7.67-7.82 (m, 2H), 12.53 (bs, 1H).
Step F: Preparation of 4-Bromo-5-methyl-3-phenyl-1H-pyrazole
[0784] To a solution of 5-methyl-3-phenyl-1H-pyrazole (8.0 g, 50.6
mmol) in dichloromethane (150 mL) was added bromine (8.08 g, 50.6
mmol) dropwise at 0.degree. C. The reaction was stirred at that
temperature for 30 min and continued at room temperature for 2 h.
After quenched with aqueous solution of Na.sub.2SO.sub.3 (10% wt
aq., 10 mL), the organic solvent was removed and the aqueous
mixture was extracted with EtOAc, washed with brine, dried over
MgSO.sub.4, and concentrated. The residue was purified by silica
gel column chromatography to give the title compound as yellow oil
(9.5 g). LCMS m/z=236.9 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 2.26 (s, 3H), 7.30-7.57 (m, 5H), 13.12
(s, 1H).
Step G: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-Bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-Butyl
2-(((1s,4s)-4-((4-Bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a Mixture of Regioisomers
[0785] To a solution of 4-bromo-5-methyl-3-phenyl-1H-pyrazole (2.0
g, 8.44 mmol) in DMF (5 mL) were added sodium hydride (0.202 g,
8.44 mmol) in portions at 0.degree. C. The reaction was stirred at
that temperature for 1 h and tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (3.48 g,
8.44 mmol) was added. The reaction was heated to 42.degree. C.,
stirred for 16 h, and quenched with H.sub.2O (2 mL). The mixture
was extracted with ethyl acetate, dried over MgSO.sub.4 and
concentrated under reduced pressure. The residue was purified by
silica gel column chromatography to give the title compound as a
colorless liquid (3.05 g) (mixture of two isomers). LCMS m/z=477.3
[M+H].sup.+.
Step H: Preparation of
2-(((1s,4s)-4-((3-Methyl-5-phenyl-4-m-tolyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic Acid
[0786] To a solution of tert-butyl
2-(((1s,4s)-4-(4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers (100 mg, 0.19 mmol)
in dioxane (3 mL) were added m-tolylboronic acid (25.8 mg, 0.19
mmol), tetrakis(triphenylphosphine)palladium (22 mg, 0.019 mmol),
and K.sub.2CO.sub.3 (2 M aq., 0.2 mL). The reaction was heated to
150.degree. C. under microwave irradiation for 4 h. The reaction
mixture was filtered and concentrated. The residue was treated with
HCl (4 M in dioxane, 5 mL) at room temperature for 10 h. The
mixture was concentrated and purified by HPLC to give the title
compound (13.5 mg) as a white solid. LCMS m/z=433.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.01-1.19 (m, 4H),
1.21-1.36 (m, 4H), 1.54-1.66 (m, 1H), 1.86-1.98 (m, 1H), 2.22 (s,
3H), 3.19 (d, J=6.95 Hz, 2H), 3.89 (d, J=7.45 Hz, 2H), 3.91 (s,
2H), 7.04-7.11 (m, 2H), 7.21-7.31 (m, 5H), 7.39-7.47 (m, 2H).
Example 1.98
Preparation of
2-(((1s,4s)-4-((4-(2,5-Difluorophenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic Acid (Compound 20)
[0787] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers, and
2,5-difluorophenylboronic acid, the title compound was obtained
using a similar method to the one described in Example 1.97. LCMS
m/z=455.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 0.99-1.21 (m, 4H), 1.21-1.38 (m, 4H), 1.54-1.66 (m, 1H),
1.88-2.02 (m, 1H), 2.13 (s, 3H), 3.20 (d, J=7.07 Hz, 2H), 3.91 (s,
2H), 3.93 (d, J=7.07 Hz, 2H), 6.93-7.00 (m, 1H), 7.05-7.27 (m, 5H),
7.38-7.43 (m, 2H).
Example 1.99
Preparation of
2-(((1s,4s)-4-((4-(4-Fluorophenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 22)
[0788] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
4-fluorophenylboronic, the title compound was obtained using a
similar method to the one described in Example 1.97. LCMS m/z=437.2
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.33-1.54 (m, 8H), 1.71-1.82 (m, 1H), 2.05-2.15 (m, 1H), 2.20 (s,
3H), 3.43 (d, J=7.07 Hz, 2H), 4.00 (s, 2H), 4.05 (d, J=7.58 Hz,
2H), 7.17-7.21 (m, 3H), 7.21-7.28 (m, 3H), 7.29-7.34 (m, 3H).
Example 1.100
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 23)
[0789] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
3-chlorophenylboronic acid, the title compound was obtained using a
similar method to the one described in Example 1.97. LCMS m/z=453.3
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.34-1.55 (m, 8H), 1.73-1.82 (m, 1H), 2.04-2.16 (m, 1H), 2.23 (s,
3H), 3.43 (d, J=7.07 Hz, 2H), 4.01 (s, 2H), 4.06 (d, J=7.58 Hz,
2H), 7.09-7.14 (m, 1H), 7.18-7.41 (m, 8H).
Example 1.101
Preparation of
2-(((1s,4s)-4-((5-Methyl-3-phenyl-4-m-tolyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic Acid (Compound 24)
[0790] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and m-tolylboronic
acid, the title compound was obtained using a similar method to the
one described in Example 1.97. LCMS m/z=433.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.33-1.55 (m, 8H),
1.72-1.82 (m, 1H), 2.07-2.15 (m, 1H), 2.19 (s, 3H), 2.28 (s, 3H),
3.43 (d, J=6.82 Hz, 2H), 4.00 (s, 2H), 4.05 (d, J=7.58 Hz, 2H),
6.88-7.14 (m, 3H), 7.15-7.29 (m, 3H), 7.29-7.39 (m, 3H).
Example 1.102
Preparation of
2-(((1s,4s)-4-((4-(4-Fluorophenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 25)
[0791] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
4-fluorophenylboronic acid, the title compound was obtained using a
similar method to the one described in Example 1.97. LCMS m/z=437.2
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.01-1.20 (m, 4H), 1.21-1.36 (m, 4H), 1.52-1.67 (m, 1H), 1.86-2.00
(m, 1H), 2.20 (s, 3H), 3.19 (d, J=6.82 Hz, 2H), 3.88 (d, J=7.58 Hz,
2H), 3.91 (s, 2H), 6.96-7.17 (m, 4H), 7.18-7.31 (m, 2H), 7.34-7.48
(m, 3H).
Example 1.103
Preparation of
2-(((1s,4s)-4-((4-(2,3-Difluorophenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic Acid (Compound 26)
[0792] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
2,3-difluorophenylboronic acid, the title compound was obtained
using a similar method to the one described in Example 1.97. LCMS
m/z=455.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 0.98-1.20 (m, 4H), 1.21-1.38 (m, 4H); 1.53-1.69 (m, 1H),
1.88-2.02 (m, 1H), 2.13 (s, 3H), 3.19 (d, J=7.07 Hz, 2H), 3.91 (s,
2H), 3.94 (d, J=7.33 Hz, 2H), 6.91-6.97 (m, 1H), 7.05-7.12 (m, 1H),
7.20-7.25 (m, 3H), 7.37-7.42 (m, 3H).
Example 1.104
Preparation of
2-(((1s,4s)-4-((4-(2,3-Difluorophenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic Acid (Compound 27)
[0793] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
2,3-difluorophenylboronic acid, the title compound was obtained
using a similar method to the one described in Example 1.97. LCMS
m/z=455.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.31-1.54 (m, 8H), 1.71-1.81 (m, 1H), 2.05-2.15 (m, 1H), 2.17
(s, 3H), 3.42 (d, J=7.07 Hz, 2H), 3.99 (s, 2H), 4.07 (d, J=7.58 Hz,
2H), 7.02-7.09 (m, 2H), 7.19-7.32 (m, 4H), 7.34-7.46 (m, 2H).
Example 1.105
Preparation of
2-(((1s,4s)-4-((4-(4-Chlorophenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 28)
[0794] From tert-butyl
2-(((1s,4s)-4-(4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
4-chlorophenylboronic acid, the title compound was obtained using a
similar method to the one described in Example 1.97. LCMS m/z=453.2
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.31-1.57 (m, 8H), 1.70-1.83 (m, 1H), 2.03-2.14 (m, 1H), 2.21 (s,
3H), 3.42 (d, J=6.95 Hz, 2H), 4.00 (s, 2H), 4.05 (d, J=7.58 Hz,
2H), 7.14-7.20 (m, 2H), 7.22-7.34 (m, 5H), 7.38-7.44 (m, 2H).
Example 1.106
Preparation of
2-(((1s,4s)-4-((4-(2,5-Difluorophenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic Acid (Compound 29)
[0795] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
2,5-difluorophenylboronic acid, the title compound was obtained
using a similar method to the one described in Example 1.97. LCMS
m/z=455.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 0.99-1.21 (m, 4H), 1.21-1.38 (m, 4H), 1.54-1.66 (m, 1H),
1.88-2.02 (m, 1H), 2.13 (s, 3H), 3.20 (d, J=7.07 Hz, 2H), 3.91 (s,
2H), 3.93 (d, J=7.07 Hz, 2H), 6.93-7.00 (m, 1H), 7.05-7.27 (m, 5H),
7.38-7.43 (m, 2H).
Example 1.107
Preparation of
2-(((1s,4s)-4-((5-(3-Methoxyphenyl)-3-methyl-4-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid (Compound 32)
Step A: Preparation of 3-Bromo-5-methyl-4-phenyl-1H-pyrazole
[0796] To a solution of 5-methyl-4-phenyl-1H-pyrazole (3.0 g, 18.96
mmol) in acetic acid (glacial, 100 mL) was added bromine (1.457 mL,
28.4 mmol) at room temperature. The reaction was stirred at room
temperature for 2 h. After quenched with aqueous solution of
Na.sub.2SO.sub.3 (10% wt aq., 10 mL), the reaction was concentrated
and extracted with EtOAc, washed with brine, dried over MgSO.sub.4,
and purified by silica gel column chromatography to give the title
compound as yellow oil (2.8 g). LCMS m/z=236.9 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 2.26 (s, 3H), 7.24-7.54 (m,
5H), 13.13 (s, 1H).
Step B: Preparation of tert-Butyl
2-(((1s,4s)-4-(5-Bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-Butyl
2-(((1s,4s)-4-((3-Bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a Mixture of Regioisomers.
[0797] A solution of 3-bromo-5-methyl-4-phenyl-1H-pyrazole (2.0 g,
7.04 mmol) in DMF (10 mL) was treated with sodium hydride (0.169 g,
7.04 mmol) at 0.degree. C. for 1 h, then a solution of tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (2.90 g,
7.04 mmol) in DMF (5 mL) was added. The reaction mixture was gently
warmed to 60.degree. C. for 16 h and quenched by water (2 mL). The
mixture was extracted by EtOAc, dried over MgSO.sub.4, and purified
by silica gel column chromatography to give the title compound
(2.25 g) (mixture of two regioisomers). LCMS m/z=477.3
[M+H].sup.+.
Step C: Preparation of
2-(((1s,4s)-4-((5-(3-Methoxyphenyl)-3-methyl-4-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid
[0798] To a solution of tert-butyl
2-(((1s,4s)-4-((5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers (100 mg, 0.19 mmol)
in dioxane (3 mL) were added 3-methoxyphenylboronic acid (28.9 mg,
0.19 mmol), tetrakis(triphenylphosphine)palladium (22 mg, 0.019
mmol), and K.sub.2CO.sub.3 (2 M aq., 0.2 mL). The reaction was
heated to 150.degree. C. under microwave irradiation for 4 h. The
reaction mixture was filtered and concentrated. The residue was
treated with HCl (4.0 M in dioxane, 5 mL) at room temperature for
10 h. The mixture was concentrated and purified by HPLC to give the
title compound (one of the two regioisomers separated) as a white
solid. LCMS m/z=449.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.09-1.20 (m, 4H), 1.22-1.38 (m, 4H),
1.57-1.69 (m, 1H), 1.89-1.99 (m, 1H), 2.21 (s, 3H), 3.23 (d, J=6.82
Hz, 2H), 3.77 (s, 3H), 3.86 (d, J=7.33 Hz, 2H), 3.92 (s, 2H),
6.94-6.99 (m, 2H), 7.04-7.10 (m, 2H), 7.11-7.19 (m, 3H), 7.20-7.26
(m, 2H).
Example 1.108
Preparation of
2-(((1s,4s)-4-((3-(3-Methoxyphenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid (Compound 33)
[0799] From tert-butyl
2-(((1s,4s)-4-((5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
3-methoxyphenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.107. LCMS m/z=449.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.32-1.54 (m, 8H),
1.71-1.80 (m, 1H), 2.04-2.14 (m, 1H), 2.19 (s, 3H), 3.42 (d, J=6.82
Hz, 2H), 3.71 (s, 3H), 3.99 (s, 2H), 4.03 (d, J=7.58 Hz, 2H),
6.77-6.84 (m, 2H), 7.12-7.19 (m, 2H), 7.20-7.31 (m, 3H), 7.32-7.39
(m, 2H).
Example 1.109
Preparation of
2-(((1s,4s)-4-((5-(3-Fluoro-5-methoxyphenyl)-3-methyl-4-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 34)
[0800] From tert-butyl
2-(((1s,4s)-4-((5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
3-fluoro-5-methoxyphenylboronic acid, the title compound (one of
the two regioisomers separated) was obtained using a similar method
to the one described in Example 1.107. LCMS m/z=467.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.09-1.22 (m, 4H),
1.23-1.39 (m, 4H), 1.56-1.69 (m, 1H), 1.88-2.00 (m, 1H), 2.20 (s,
3H), 3.24 (d, J=6.32 Hz, 2H), 3.72 (s, 3H), 3.79 (d, J=7.57 Hz,
2H), 3.93 (s, 2H), 6.60-6.92 (m, 3H), 7.05-7.35 (m, 5H).
Example 1.110
Preparation of
2-(((1s,4s)-4-((3-(3-Fluoro-5-methoxyphenyl)-5-methyl-4-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 35)
[0801] From tert-butyl
2-(((1s,4s)-4-((5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
3-fluoro-5-methoxyphenylboronic acid, the title compound (one of
the two regioisomers separated) was obtained using a similar method
to the one described in Example 1.107. LCMS m/z=467.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.33-1.54 (m, 8H),
1.71-1.81 (m, 1H), 2.05-2.14 (m, 1H), 2.18 (s, 3H), 3.42 (d, J=6.82
Hz, 2H), 3.59 (s, 3H), 3.99 (s, 2H), 4.05 (d, J=7.58 Hz, 2H),
6.62-6.71 (m, 4H), 7.17-7.23 (m, 1H), 7.29-7.44 (m, 3H).
Example 1.111
Preparation of
2-(((1s,4s)-4-((4-(4-Methoxyphenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid (Compound 38).
[0802] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
4-methoxyphenylboronic acid (26.6 mg, 0.19 mmol), the title
compound (one of the two regioisomers separated) was obtained using
a similar method to the one described in Example 1.97. LCMS
m/z=449.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.31-1.54 (m, 8H), 1.71-1.81 (m, 1H), 2.04-2.14 (m, 1H), 2.17
(s, 3H), 3.42 (d, J=6.82 Hz, 2H), 3.77 (s, 3H), 4.00 (s, 2H), 4.04
(d, J=7.58 Hz, 2H), 6.90-6.96 (m, 2H), 7.04-7.11 (m, 2H), 7.16-7.27
(m, 3H), 7.30-7.37 (m, 2H).
Example 1.112
Preparation of
2-(((1s,4s)-4-((4-(3-Fluoro-5-methoxyphenyl)-5-methyl-3-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 39)
[0803] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
3-fluoro-5-methoxyphenylboronic acid, the title compound (one of
the two regioisomers separated) was obtained using a similar method
to the one described in Example 1.97. LCMS m/z=467.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.31-1.55 (m, 8H),
1.70-1.82 (m, 1H), 2.03-2.14 (m, 1H), 2.23 (s, 3H), 3.42 (d, J=7.07
Hz, 2H), 3.70 (s, 3H), 3.99 (s, 2H), 4.04 (d, J=7.58 Hz, 2H),
6.39-6.81 (m, 3H), 7.19-7.36 (m, 5H).
Example 1.113
Preparation of
2-(((1s,4s)-4-((4-(3-Fluorophenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 40)
[0804] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
3-fluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.97. LCMS m/z=437.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.34-1.53 (m, 8H),
1.72-1.81 (m, 1H), 2.04-2.15 (m, 1H), 2.23 (s, 3H), 3.43 (d, J=7.07
Hz, 2H), 4.00 (s, 2H), 4.06 (d, J=7.58 Hz, 2H), 6.93-7.01 (m, 2H),
7.08-7.15 (m, 1H), 7.20-7.35 (m, 5H), 7.35-7.44 (m, 1H).
Example 1.114
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 41)
[0805] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
3-chlorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.97. LCMS m/z=453.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.02-1.20 (m, 4H),
1.21-1.35 (m, 4H), 1.54-1.65 (m, 1H), 1.88-1.98 (m, 1H), 2.24 (s,
3H), 3.20 (d, J=6.82 Hz, 2H), 3.89 (d, J=7.58 Hz, 2H), 3.91 (s,
2H), 7.00-7.08 (m, 2H), 7.17-7.30 (m, 5H), 7.40-7.48 (m, 2H).
Example 1.115
Preparation of
2-(((1s,4s)-4-((4-(4-Methoxyphenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid (Compound 42)
[0806] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
4-methoxyphenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.97. LCMS m/z=449.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.01-1.19 (m, 4H),
1.20-1.35 (m, 4H), 1.54-1.64 (m, 1H), 1.86-1.97 (m, 1H), 2.19 (s,
3H), 3.19 (d, J=6.82 Hz, 2H), 3.69 (s, 3H), 3.87 (d, J=7.33 Hz,
2H), 3.91 (s, 2H), 6.76-6.82 (m, 2H), 6.95-7.02 (m, 2H), 7.19-7.26
(m, 2H), 7.35-7.45 (m, 3H).
Example 1.116
Preparation of
2-(((1s,4s)-4-((4-(3-Fluoro-5-methoxyphenyl)-3-methyl-5-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 43)
[0807] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
3-fluoro-5-methoxyphenylboronic acid, the title compound (one of
the two regioisomers separated) was obtained using a similar method
to the one described in Example 1.97. LCMS m/z=467.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.01-1.20 (m, 4H),
1.21-1.36 (m, 4H), 1.56-1.64 (m, 1H), 1.88-1.97 (m, 1H), 2.25 (s,
3H), 3.20 (d, J=7.07 Hz, 2H), 3.60 (s, 3H), 3.87 (d, J=7.33 Hz,
2H), 3.91 (s, 2H), 6.36-6.65 (m, 4H), 7.20-7.52 (m, 4H).
Example 1.117
Preparation of
2-(((1s,4s)-4-((4-(2-Chlorophenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 44)
[0808] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
2-chlorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.97. LCMS m/z=453.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.32-1.53 (m, 8H),
1.71-1.82 (m, 1H), 2.08 (s, 3H), 2.08-2.17 (m, 1H), 3.42 (d, J=6.82
Hz, 2H), 3.99 (s, 2H), 4.06 (d, J=7.58 Hz, 2H), 7.16-7.30 (m, 4H),
7.33-7.44 (m, 3H), 7.52-7.59 (m, 2H).
Example 1.118
Preparation of
2-(((1s,4s)-4-((4-(2-Chlorophenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 45)
[0809] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
2-chlorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.97. LCMS m/z=453.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.00-1.20 (m, 4H),
1.20-1.37 (m, 4H), 1.55-1.64 (m, 1H), 1.91-2.00 (m, 1H), 2.03 (s,
3H), 3.18 (d, J=6.82 Hz, 2H), 3.90 (s, 2H), 3.95 (d, J=7.58 Hz,
2H), 7.14-7.29 (m, 4H), 7.31-7.39 (m, 3H), 7.41-7.45 (m, 2H).
Example 1.119
Preparation of
2-(((1s,4s)-4-((4-(3-Fluorophenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 46)
[0810] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
3-fluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.97. LCMS m/z=437.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.02-1.19 (m, 4H),
1.21-1.36 (m, 4H), 1.55-1.66 (m, 1H), 1.87-1.98 (m, 1H), 2.24 (s,
3H), 3.20 (d, J=7.07 Hz, 2H), 3.88 (d, J=7.33 Hz, 2H), 3.91 (s,
2H), 6.79-7.01 (m, 3H), 7.22-7.30 (m, 3H), 7.40-7.47 (m, 3H).
Example 1.120
Preparation of
2-(((1s,4s)-4-((5-Methyl-3-phenyl-4-p-tolyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic Acid (Compound 47)
[0811] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and p-tolylboronic
acid, the title compound (one of the two regioisomers separated)
was obtained using a similar method to the one described in Example
1.97. LCMS m/z=433.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.34-1.53 (m, 8H), 1.71-1.80 (m, 1H),
2.04-2.14 (m, 1H), 2.18 (s, 3H), 2.32 (s, 3H), 3.42 (d, J=7.07 Hz,
2H), 3.99 (s, 2H), 4.04 (d, J=7.58 Hz, 2H), 7.02-7.07 (m, 2H),
7.14-7.27 (m, 5H), 7.30-7.35 (m, 2H).
Example 1.121
Preparation of
2-(((1s,4s)-4-((4-(2,4-Difluorophenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic Acid (Compound 48)
[0812] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
2,4-difluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.97. LCMS m/z=455.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.33-1.53 (m, 8H),
1.72-1.81 (m, 1H), 2.06-2.13 (m, 1H), 2.14 (s, 3H), 3.43 (d, J=7.07
Hz, 2H), 4.00 (s, 2H), 4.07 (d, J=7.58 Hz, 2H), 7.07-7.15 (m, 2H),
7.19-7.34 (m, 6H).
Example 1.122
Preparation of
2-(((1s,4s)-4-((4-(4-Chlorophenyl)-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic Acid (Compound 49)
Step A: Preparation of 4-Bromo-3-phenyl-1H-pyrazole
[0813] To a solution of 3-phenyl-1H-pyrazole-4-carbaldehyde (10.0
g, 58.1 mmol) in acetic acid (100 mL, 58.1 mmol) was added bromine
(10 mL, 195 mmol) dropwise at room temperature. The reaction was
stirred at room temperature for 2 h. After quenched with aqueous
solution of Na.sub.2SO.sub.3 (10% wt aq., 10 mL), the reaction was
concentrated and extracted with EtOAc, washed with brine, dried
over MgSO.sub.4, and purified by silica gel column chromatography
to give the title compound as yellow oil (10.2 g). LCMS m/z=223.0
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
7.37-7.53 (m, 3H), 7.76-7.84 (m, 2H), 7.91 (s, 1H).
Step B: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-Bromo-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methox-
y)acetate and tert-Butyl
2-(((1s,4s)-4-((4-Bromo-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methox-
y)acetate as a Mixture of Regioisomers
[0814] A solution of 3-bromo-5-methyl-4-phenyl-1H-pyrazole (2.0 g,
7.04 mmol) in DMF (10 mL) was treated with sodium hydride (0.169 g,
7.04 mmol) at 0.degree. C. for 1 h, then a solution of tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (2.90 g,
7.04 mmol) in DMF (5 mL) was added. The reaction mixture was gently
warmed to 60.degree. C. for 16 h and quenched by water (2 mL). The
mixture was extracted by EtOAc, dried over MgSO.sub.4, and
concentrated. The residue was purified by column chromatography to
give the title compound as a mixture of regioisomers (2.25 g). LCMS
m/z=462.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.22-1.33 (m, 4H), 1.35-1.48 (m, 4H), 1.43 (s, 9H), 1.65-1.79
(m, 1H), 2.02-2.15 (m, 1H), 3.37 (d, J=6.82 Hz, 2H), 3.95 (s, 2H),
4.09 (d, J=7.58 Hz, 2H), 7.34-7.51 (m, 3H), 7.76-7.84 (m, 2H), 8.08
(s, 1H).
Step C: Preparation of
2-(((1s,4s)-4-((4-(4-Chlorophenyl)-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic Acid
[0815] To a solution of tert-butyl
2-(((1s,4s)-4-((4-bromo-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methox-
y)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy-
)acetate as a mixture of regioisomers (100 mg, 0.22 mmol) in
dioxane (3 mL) were added 4-chlorophenylboronic acid (34.4 mg, 0.22
mmol), tetrakis(triphenylphosphine)palladium (25 mg, 0.022 mmol),
and K.sub.2CO.sub.3 (2 M aq., 0.2 mL). The reaction was heated to
150.degree. C. under microwave irradiation for 4 h. The reaction
mixture was filtered and concentrated. The residue was treated with
HCl (4.0 M in dioxane, 5 mL) at room temperature for 10 h. The
mixture was concentrated and purified by HPLC to give the title
compound (one of the two regioisomers separated) as a white solid.
LCMS m/z=438.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.29-1.52 (m, 8H), 1.71-1.79 (m, 1H), 2.07-2.19 (m,
1H), 3.40 (d, J=6.82 Hz, 2H), 3.99 (s, 2H), 4.09 (d, J=7.83 Hz,
2H), 7.21-7.27 (m, 2H), 7.29-7.42 (m, 7H), 7.98 (s, 1H).
Example 1.123
Preparation of
2-(((1s,4s)-4-((4-(3-Fluorophenyl)-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic Acid (Compound 50)
[0816] From tert-butyl 2-(((1s,4s)-4-((4-bromo-3-pheny
1-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methox-
y)acetate as a mixture of regioisomers and 3-fluorophenylboronic
acid, the title compound (one of the two regioisomers separated)
was obtained using a similar method to the one described in Example
1.122. LCMS m/z=423.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.27-1.55 (m, 8H), 1.67-1.84 (m, 1H),
2.07-2.22 (m, 1H), 3.41 (d, J=6.82 Hz, 2H), 4.00 (s, 2H), 4.10 (d,
J=7.58 Hz, 2H), 6.99-7.10 (m, 3H), 7.29-7.43 (m, 6H), 8.04 (s,
1H).
Example 1.124
Preparation of
2-(((1s,4s)-4-((4-(4-Fluorophenyl)-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic Acid (Compound 51)
[0817] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methox-
y)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methox-
y)acetate as a mixture of regioisomers and 4-fluorophenylboronic
acid, the title compound (one of the two regioisomers separated)
was obtained using a similar method to the one described in Example
1.122. LCMS m/z=423.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.28-1.53 (m, 8H), 1.70-1.80 (m, 1H),
2.08-2.18 (m, 1H), 3.40 (d, J=6.82 Hz, 2H), 3.99 (s, 2H), 4.09 (d,
J=7.58 Hz, 2H), 7.10-7.17 (m, 2H), 7.22-7.36 (m, 5H), 7.36-7.41 (m,
2H), 7.93 (s, 1H).
Example 1.125
Preparation of
2-(((1s,4s)-4-((4-(3-Chloro-2-fluorophenyl)-5-methyl-3-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 52)
[0818] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
3-chloro-2-fluorophenylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.97. LCMS m/z=470.1 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.30-1.54 (m, 8H),
1.71-1.82 (m, 1H), 2.05-2.14 (m, 1H), 2.16 (s, 3H), 3.43 (d, J=7.07
Hz, 2H), 4.00 (s, 2H), 4.07 (d, J=7.58 Hz, 2H), 7.16-7.36 (m, 6H),
7.50-7.63 (m, 2H).
Example 1.126
Preparation of
2-(((1s,4s)-4-((4-(2,4-Difluorophenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic Acid (Compound 53)
[0819] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
2,4-difluorophenylboronic acid, the title compound was obtained
using a similar method to the one described in Example 1.97. LCMS
m/z=455.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.02-1.18 (m, 4H), 1.21-1.35 (m, 4H), 1.55-1.64 (m, 1H),
1.89-1.99 (m, 1H), 2.10 (s, 3H), 3.19 (d, J=7.07 Hz, 2H), 3.91 (s,
2H), 3.93 (d, J=7.33 Hz, 2H), 6.94-7.02 (m, 2H), 7.11-7.24 (m, 3H),
7.34-7.43 (m, 3H).
Example 1.127
Preparation of
2-(((1s,4s)-4-((4-(3-Chloro-2-fluorophenyl)-3-methyl-5-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 54)
[0820] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
3-chloro-2-fluorophenylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.97. LCMS m/z=470.1 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.01-1.20 (m, 4H),
1.21-1.39 (m, 4H), 1.54-1.66 (m, 1H), 1.90-2.00 (m, 1H), 2.12 (s,
3H), 3.20 (d, J=6.82 Hz, 2H), 3.91 (s, 2H), 3.94 (d, J=7.58 Hz,
2H), 7.05-7.30 (m, 4H), 7.34-7.53 (m, 4H).
Example 1.128
Preparation of
2-(((1s,4s)-4-((3-Methyl-5-phenyl-4-p-tolyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic Acid (Compound 55)
[0821] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and p-tolylboronic
acid, the title compound (one of the two regioisomers separated)
was obtained using a similar method to the one described in Example
1.97. LCMS m/z=433.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.25-1.50 (m, 8H), 1.68-1.79 (m, 1H),
1.98-2.08 (m, 1H), 2.07 (s, 3H), 2.31 (s, 3H), 3.40 (d, J=7.07 Hz,
2H), 3.98 (s, 2H), 4.06 (d, J=7.58 Hz, 2H), 7.33-7.39 (m, 2H),
7.40-7.47 (m, 4H), 7.77-7.82 (m, 3H).
Example 1.129
Preparation of
2-(((1s,4s)-4-((4-(3-Chloro-4-fluorophenyl)-3-methyl-5-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 56)
[0822] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
3-chloro-4-fluorophenylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.97. LCMS m/z=471.1 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.02-1.18 (m, 4H),
1.21-1.36 (m, 4H), 1.55-1.65 (m, 1H), 1.87-1.98 (m, 1H), 2.23 (s,
3H), 3.20 (d, J=6.82 Hz, 2H), 3.89 (d, J=7.58 Hz, 2H), 3.91 (s,
2H), 7.01-7.08 (m, 1H), 7.18-7.29 (m, 4H), 7.41-7.48 (m, 3H).
Example 1.130
Preparation of
2-(((1s,4s)-4-((4-(3-Chloro-4-fluorophenyl)-5-methyl-3-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 57)
[0823] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
3-chloro-4-fluorophenylboronic acid, the title compound was
obtained using a similar method to the one described in Example
1.97. LCMS m/z=471.1 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.33-1.55 (m, 8H), 1.72-1.83 (m, 1H),
2.05-2.15 (m, 1H), 2.22 (s, 3H), 3.44 (d, J=7.07 Hz, 2H), 4.01 (s,
2H), 4.06 (d, J=7.58 Hz, 2H), 7.10-7.17 (m, 1H), 7.21-7.42 (m,
7H).
Example 1.131
Preparation of
2-(((1s,4s)-4-((4-(4-Methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetic Acid (Compound 58)
[0824] From tert-butyl
2-(((1s,4s)-4-(4-bromo-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy-
)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methox-
y)acetate as a mixture of regioisomers (100 mg, 0.22 mmol) and
4-methoxyphenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.122. LCMS m/z=435.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.26-1.54 (m, 8H),
1.65-1.81 (m, 1H), 2.03-2.19 (m, 1H), 3.40 (d, J=6.82 Hz, 2H), 3.75
(s, 3H), 3.99 (s, 2H), 4.07 (d, J=7.58 Hz, 2H), 6.85-6.92 (m, 2H),
7.11-7.18 (m, 2H), 7.23-7.34 (m, 3H), 7.37-7.43 (m, 2H), 7.84 (s,
1H).
Example 1.132
Preparation of
2-(((1s,4s)-4-((4-(2-Methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetic Acid (Compound 59)
[0825] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methox-
y)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methox-
y)acetate as a mixture of regioisomers and 2-methoxyphenylboronic
acid, the title compound (one of the two regioisomers separated)
was obtained using a similar method to the one described in Example
1.122. LCMS m/z=435.3 [M+H].sup.+; .sup.1H l NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.29-1.52 (m, 8H), 1.69-1.80 (m, 1H),
2.13 (dd, J=6.57, 3.79 Hz, 1H), 3.40 (d, J=6.82 Hz, 2H), 3.52 (s,
3H), 3.99 (s, 2H), 4.09 (d, J=7.58 Hz, 2H), 6.85-6.93 (m, 2H),
7.08-7.13 (m, 2H), 7.18-7.31 (m, 3H), 7.32-7.38 (m, 2H), 7.77 (s,
1H).
Example 1.133
Preparation of
2-(((1s,4s)-4-((3-Phenyl-4-m-tolyl-1H-pyrazol-1-yl)methyl)cyclohexyl)meth-
oxy)acetic Acid (Compound 60)
[0826] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methox-
y)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy-
)acetate as a mixture of regioisomers and m-tolylboronic acid, the
title compound (one of the two regioisomers separated) was obtained
using a similar method to the one described in Example 1.122. LCMS
m/z=419.3 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.29-1.53 (m, 8H), 1.70-1.81 (m, 1H), 2.07-2.18 (m, 1H), 2.25
(s, 3H), 3.40 (d, J=7.07 Hz, 2H), 3.99 (s, 2H), 4.09 (d, J=7.58 Hz,
2H), 6.96-7.08 (m, 2H), 7.09-7.21 (m, 2H), 7.25-7.35 (m, 3H),
7.38-7.44 (m, 2H), 7.90 (s, 1H).
Example 1.134
Preparation of
2-(((1s,4s)-4-(3-Phenyl-4-p-tolyl-1H-pyrazol-1-yl)methyl)cyclohexyl)metho-
xy)acetic Acid (Compound 61)
[0827] From tert-butyl
2-(((1s,4s)-4-(4-bromo-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy-
)acetate and tert-butyl
2-(((1s,4s)-4((4-bromo-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy-
)acetate as a mixture of regioisomers and p-tolylboronic acid, the
title compound (one of the two regioisomers separated) was obtained
using a similar method to the one described in Example 1.122. LCMS
m/z=419.3 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.28-1.51 (m, 8H), 1.70-1.80 (m, 1H), 2.08-2.18 (m, 1H), 2.29
(s, 3H), 3.40 (d, J=7.07 Hz, 2H), 3.99 (s, 2H), 4.08 (d, J=7.58 Hz,
2H), 7.10-7.16 (m, 3H), 7.26-7.36 (m, 3H), 7.37-7.44 (m, 3H), 7.88
(s, 1H).
Example 1.135
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic Acid (Compound 62)
[0828] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methox-
y)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methox-
y)acetate as a mixture of regioisomers and 3-chlorophenylboronic
acid, the title compound (one of the two regioisomers separated)
was obtained using a similar method to the one described in Example
1.122. LCMS m/z=439.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.29-1.53 (m, 8H), 1.70-1.79 (m, 1H),
2.08-2.19 (m, 1H), 3.40 (d, J=7.07 Hz, 2H), 4.00 (s, 2H), 4.10 (d,
J=7.58 Hz, 2H), 7.15-7.19 (m, 1H), 7.25-7.42 (m, 8H), 8.05 (s,
1H).
Example 1.136
Preparation of
2-(((1s,4s)-4-((4-(2-Fluorophenyl)-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic Acid (Compound 63)
[0829] From tert-butyl
2-(((1s,4s)-4-(4-bromo-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy-
)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methox-
y)acetate as a mixture of regioisomers and 2-fluorophenylboronic
acid, the title compound (one of the two regioisomers separated)
was obtained using a similar method to the one described in Example
1.122. LCMS m/z=423.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.29-1.53 (m, 8H), 1.71-1.81 (m, 1H),
2.09-2.20 (m, 1H), 3.41 (d, J=7.07 Hz, 2H), 4.00 (s, 2H), 4.12 (d,
J=7.83 Hz, 2H), 7.13-7.40 (m, 9H), 7.92 (s, 1H).
Example 1.137
Preparation of
2-(((1s,4s)-4-((3-Methyl-4-phenyl-5-m-tolyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic Acid (Compound 64)
[0830] From tert-butyl
2-(((1s,4s)-4-((5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and m-tolylboronic
acid, the title compound (one of the two regioisomers separated)
was obtained using a similar method to the one described in Example
1.107. LCMS m/z=433.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 1.29-1.44 (m, 4H), 1.48 (s, 9H), 1.49-1.60
(m, 4H), 1.81-1.91 (m, 1H), 2.04 (s, 3H), 2.12-2.20 (m, 1H), 3.25
(d, J=6.95 Hz, 2H), 3.87 (s, 2H), 4.02 (d, J=7.58 Hz, 2H),
7.30-7.37 (m, 1H), 7.37-7.49 (m, 3H), 7.84-7.89 (m, 1H).
Example 1.138
Preparation of
2-(((1s,4s)-4-((5-Methyl-4-phenyl-3-m-tolyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic Acid (Compound 65)
[0831] From tert-butyl
2-(((1s,4s)-4-((5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and m-tolylboronic
acid, the title compound was obtained using a similar method to the
one described in Example 1.107. LCMS m/z=433.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.26-1.50 (m, 8H), 1.43 (s,
9H), 1.66-1.78 (m, 1H), 1.97-2.09 (m, 1H), 2.30 (s, 3H), 3.39 (d,
J=6.82 Hz, 2H), 3.94 (s, 2H), 4.06 (d, J=7.58 Hz, 2H), 7.30-7.50
(m, 3H), 7.74-7.85 (m, 2H).
Example 1.139
Preparation of
2-(((1s,4s)-4-((3-(3-Chlorophenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 66)
[0832] From tert-butyl
2-(((1s,4s)-4-((5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
3-chlorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.107. LCMS m/z=453.3 [M+H].sup.+; NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 1.33-1.54 (m, 8H), 1.73-1.81
(m, 1H), 2.06-2.15 (m, 1H), 2.20 (s, 3H), 3.43 (d, J=6.82 Hz, 2H),
4.00 (s, 2H), 4.06 (d, J=7.58 Hz, 2H), 7.16-7.29 (m, 5H), 7.31-7.43
(m, 4H).
Example 1.140
Preparation of
2-(((1s,4s)-4-((5-(3-Fluorophenyl)-3-methyl-4-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 67)
[0833] From tert-butyl
2-(((1s,4s)-4-((5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
3-fluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.107. LCMS m/z=437.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.04-1.20 (m, 4H),
1.22-1.37 (m, 4H), 1.56-1.64 (m, 1H), 1.86-1.96 (m, 1H), 2.21 (s,
3H), 3.22 (d, J=6.82 Hz, 2H), 3.91 (d, J=7.53 Hz, 2H), 3.91 (s,
2H), 7.04-7.29 (m, 7H), 7.41-7.50 (m, 2H).
Example 1.141
Preparation of
2-(((1s,4s)-4-((3-(3-Fluorophenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 68)
[0834] From tert-butyl
2-(((1s,4s)-4-((5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
3-fluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.107. LCMS m/z=437.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.33-1.54 (m, 8H),
1.71-1.81 (m, 1H), 2.05-2.15 (m, 1H), 2.19 (s, 3H), 3.42 (d, J=7.07
Hz, 2H), 4.00 (s, 2H), 4.06 (d, J=7.58 Hz, 2H), 6.99-7.08 (m, 2H),
7.12-7.21 (m, 3H), 7.23-7.44 (m, 4H).
Example 1.142
Preparation of
2-(((1s,4s)-4-((5-(3-Chloro-2-fluorophenyl)-3-methyl-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 69)
[0835] From tert-butyl
2-(((1s,4s)-4-((5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
3-chloro-2-fluorophenylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.107. LCMS m/z=470.1 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.00-1.21 (m, 4H),
1.22-1.37 (m, 4H), 1.55-1.72 (m, 1H), 1.89-2.00 (m, 1H), 2.24 (s,
3H), 3.21 (d, J=6.82 Hz, 2H), 3.67 (d, J=7.58 Hz, 2H), 3.91 (s,
2H), 7.03-7.11 (m, 2H), 7.14-7.39 (m, 6H).
Example 1.143
Preparation of
2-(((1s,4s)-4-((3-(3-Chloro-2-fluorophenyl)-5-methyl-4-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 70)
[0836] From tert-butyl 2-(((1s,4s)-4-((5-bromo-3-methyl-4-pheny
1-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
3-chloro-2-fluorophenylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.107. LCMS m/z=470.1 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.32-1.54 (m, 8H),
1.70-1.81 (m, 1H), 2.04-2.14 (m, 1H), 2.30 (s, 3H), 3.42 (d, J=6.82
Hz, 2H), 3.99 (s, 2H), 4.08 (d, J=7.58 Hz, 2H), 7.05-7.11 (m, 2H),
7.16-7.34 (m, 4H), 7.48-7.56 (m, 2H).
Example 1.144
Preparation of
2-(((1s,4s)-4-((5-(2-Fluorophenyl)-3-methyl-4-phenyl-1H-pyrazol-1-ypmethy-
pcyclohexyl)methoxy)acetic Acid (Compound 71)
[0837] From tert-butyl
2-(((1s,4s)-4-((5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
2-fluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.107. LCMS m/z=437.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.02-1.19 (m, 4H),
1.22-1.35 (m, 4H), 1.88-1.98 (m, 1H), 2.05-2.14 (m, 1H), 2.24 (s,
3H), 3.42 (d, J=7.07 Hz, 2H), 3.99 (s, 2H), 4.07 (d, J=7.58 Hz,
2H), 7.03-7.10 (m, 2H), 7.12-7.39 (m, 6H), 7.43-7.54 (m, 1H).
Example 1.145
Preparation of
2-(((1s,4s)-4-((3-(2-Fluorophenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 72)
[0838] From tert-butyl
2-(((1s,4s)-4-((5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
2-fluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.107. LCMS m/z=437.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.35-1.53 (m, 8H),
1.72-1.80 (m, 1H), 2.04-2.14 (m, 1H), 2.30 (s, 3H), 3.41 (d, J=7.07
Hz, 2H), 3.99 (s, 2H), 4.07 (d, J=7.58 Hz, 2H), 7.03-7.10 (m, 3H),
7.12-7.38 (m, 6H).
Example 1.146
Preparation of
2-(((1s,4s)-4-((5-(2,3-Difluorophenyl)-3-methyl-4-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic Acid (Compound 73)
[0839] From tert-butyl
2-(((1s,4s)-4-((5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
2,3-difluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.107. LCMS m/z=455.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.04-1.22 (m, 4H),
1.24-1.38 (m, 4H), 1.58-1.70 (m, 1H), 1.88-1.98 (m, 1H), 2.24 (s,
3H), 3.23 (d, J=6.82 Hz, 2H), 3.92 (s, 2H), 3.98 (d, J=7.58 Hz,
2H), 7.05-7.39 (m, 8H).
Example 1.147
Preparation of
2-(((1s,4s)-4-((3-(2,3-Difluorophenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic Acid (Compound 74)
[0840] From tert-butyl
2-(((1s,4s)-4-((5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
2,3-difluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.107. LCMS m/z=455.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.33-1.53 (m, 8H),
1.72-1.81 (m, 1H), 2.04-2.14 (m, 1H), 2.29 (s, 3H), 3.42 (d, J=6.82
Hz, 2H), 3.99 (s, 2H), 4.08 (d, J=7.58 Hz, 2H), 7.01-7.35 (m,
8H).
Example 1.148
Preparation of
2-(((1s,4s)-4-(5-Ethoxy-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)me-
thoxy)acetic Acid (Compound 81)
[0841] To a solution of tert-butyl
2-(((1s,4s)-4-((5-ethoxy-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)m-
ethoxy)acetate (100 mg, 0.20 mmol) in dioxane (4 mL) were added
phenylboronic acid (24.0 mg, 0.20 mmol),
tetrakis(triphenylphosphine)palladium (22.8 mg, 0.20 mmol), and
K.sub.2CO.sub.3 (2 M aq., 0.2 mL). The reaction mixture was heated
to 150.degree. C. under microwave for 4 h. The reaction mixture was
filtered and concentrated. The residue was treated with HCl (4 M in
dioxane, 5 mL) at room temperature for 16 h. The mixture was
concentrated and purified by HPLC to give the title compound (one
of the two regioisomers separated) as a white solid. LCMS m/z=449.3
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.15-1.42 (m, 8H), 1.35 (t, J=7.35 Hz, 3H), 1.66-1.75 (m, 1H),
1.87-1.95 (m, 1H), 3.02 (q, J=7.35 Hz, 2H), 3.35 (d, J=6.82 Hz,
2H), 3.99 (s, 2H), 4.08 (d, J=7.58 Hz, 2H), 7.08-7.32 (m, 8H),
7.40-7.48 (m, 2H).
Example 1.149
Preparation of
2-(((1s,4s)-4-((5-(Ethylthio)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)methoxy)acetic Acid (Compound 88)
[0842] To a solution of tert-butyl
2-(((1s,4s)-4-(5-(ethylthio)-4-iodo-3-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-(ethylthio)-4-iodo-5-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate as a mixture of regioisomers (100 mg, 0.18
mmol) in dioxane (4 mL) were added phenylboronic acid (21.9 mg,
0.18 mmol), tetrakis(triphenylphosphine)palladium (22.8 mg, 0.20
mmol), and K.sub.2CO.sub.3 (2 M aq., 0.2 mL). The reaction mixture
was heated to 150.degree. C. under microwave for 4 h. The reaction
mixture was filtered and concentrated. The residue was treated with
HCl (4 M in dioxane, 5 mL) at room temperature for 16 h. The
mixture was concentrated and purified by HPLC to give the title
compound (one of the two regioisomers separated) as white solid.
LCMS m/z=465.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.05-1.36 (m, 8H), 1.24 (t, J=7.33 Hz, 3H), 1.56-1.65
(m, 1H), 1.87-1.99 (m, 1H), 2.92 (q, J=7.33 Hz, 2H), 3.20 (d,
J=6.82 Hz, 2H), 3.91 (s, 2H), 3.94 (d, J=7.58 Hz, 2H), 7.07-7.31
(m, 8H), 7.38-7.45 (m, 2H).
Example 1.150
Preparation of
2-(((1s,4s)-4-((5-(Ethylthio)-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic Acid (Compound 89)
[0843] From tert-butyl
2-(((1s,4s)-4-((5-(ethylthio)-4-iodo-3-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-(ethylthio)-4-iodo-5-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate as a mixture of regioisomers and
3-methoxyphenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.149. LCMS m/z=495.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 0.96 (t, J=7.33 Hz, 3H),
1.32-1.55 (m, 8H), 1.70-1.81 (m, 1H), 2.15-2.25 (m, 1H), 2.53 (q,
J=7.58 Hz, 2H), 3.42 (d, J=7.07 Hz, 2H), 3.70 (s, 3H), 4.00 (s,
2H), 4.28 (d, J=7.58 Hz, 2H), 6.79-6.95 (m, 4H), 7.21-7.32 (m, 3H),
7.33-7.40 (m, 2H).
Example 1.151
Preparation of
2-(((1s,4s)-4-((4-(3-Fluoro-5-methoxyphenyl)-5-(methylthio)-3-phenyl-1H-p-
yrazol-1-ypmethyl)cyclohexyl)methoxy)acetic Acid (Compound 93)
[0844] To a solution of tert-butyl
2-(((1s,4s)-4-(4-iodo-5-(methylthio)-3-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-3-(methylthio)-5-phenyl-1H-pyrazol-1-yl)methyl)cyc-
lohexyl)methoxy)acetate as a mixture of regioisomers (100 mg, 0.18
mmol) in dioxane (3 mL) were added 3-fluoro-5-methoxyphenylboronic
acid (30.6 mg, 0.18 mmol), tetrakis(triphenylphosphine)palladium
(20.8 mg, 0.20 mmol), and K.sub.2CO.sub.3 (2 M aq., 0.2 mL). The
reaction mixture was heated to 150.degree. C. under microwave for 4
h. The reaction mixture was filtered and concentrated. The residue
was treated with HCl (4 M in dioxane, 5 mL) at room temperature for
16 h. The mixture was concentrated and purified by HPLC to give the
title compound (one of the two regioisomers separated) as a white
solid. LCMS m/z=499.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.31-1.56 (m, 8H), 1.62-1.82 (m, 1H),
2.12-2.24 (m, 1H), 2.17 (s, 3H), 3.35 (d, J=6.95 Hz, 2H), 3.54 (s,
2H), 3.72 (s, 3H), 4.27 (d, J=7.58 Hz, 2H), 6.60-6.70 (m, 2H),
6.75-6.87 (m, 2H), 7.19-7.41 (m, 4H).
Example 1.152
Preparation of
2-(((1s,4s)-4-(3-Ethyl-4-(3-methoxyphenyl)-5-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic Acid (Compound 98)
Step A: Preparation of 5-Ethyl-3-phenyl-1H-pyrazole
[0845] To a solution of acetophenone (10 g, 83 mmol) in anhydrous
toluene (10 mL) was added LiHMDS (85.0 mL, 1.0 M in THF, 85.0 mmol)
via syringe at 0.degree. C. under argon. After 5 min, propionyl
chloride (7.70 g, 83 mmol) was added in one portion via syringe.
The ice bath was removed after 10 min and AcOH (2 mL), EtOH (50
mL), and hydrazine hydrate (8.35 g, 116 mmol) was added. The
mixture was refluxed for 2 h. The resulting solution was added to
1.0 M NaOH solution, extracted with EtOAc, washed with brine, dried
over MgSO.sub.4, and concentrated. The residue was purified by
silica gel column chromatography to give the title compound as a
clear yellowish liquid (12.05 g). LCMS m/z=173.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.23 (t, J=7.58 Hz,
3H), 2.64 (q, J=7.07 Hz, 2H), 6.46 (s, 1H), 7.20-7.52 (m, 3H), 7.77
(d, J=6.32 Hz, 2H), 12.55 (s, 1H).
Step B: Preparation of 4-Bromo-5-ethyl-3-phenyl-1H-pyrazole
[0846] To a solution of 5-ethyl-3-phenyl-1H-pyrazole (10.0 g, 58.1
mmol) in DCM (150 mL) was added dropwise bromine (9.28 g, 58.1
mmol) at 0.degree. C. The reaction was stirred at that temperature
for 30 min and continued for 2 h at room temperature before
quenched with aqueous Na.sub.2SO.sub.3 solution (10% wt, 10 mL).
DCM was removed and the residue was extracted with EtOAc, washed
with brine, dried over MgSO.sub.4, and concentrated. The residue
was purified by silica gel column chromatography to give the title
compound as a yellow liquid (9.5 g). LCMS m/z=250.9
[M.sub.+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.22 (t, J=7.58 Hz, 3H), 2.66 (q, J=7.58 Hz, 2H), 7.40-7.56 (m,
3H), 7.82 (d, J=7.58 Hz, 2H), 13.15 (s, 1H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-Bromo-3-ethyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-Butyl
2-(((1s,4s)-4-((4-Bromo-5-ethyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a Mixture of Regioisomers
[0847] To a solution of 4-bromo-5-ethyl-3-phenyl-1H-pyrazole (3.0
g, 11.95 mmol) in DMF (5 mL) was added sodium hydride (0.287 g,
11.95 mmol) followed by tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (4.93 g,
11.95 mmol). The reaction was heated at 45.degree. C. overnight.
After quenched with water (2 mL), the mixture was extracted with
EtOAc, washed with brine, dried over MgSO.sub.4, and concentrated.
The residue was purified by silica gel column chromatography to
give the title compound (a mixture of regioisomers) as a clear
liquid (4.5 g). LCMS m/z=491.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 1.25 (t, J=7.20 Hz, 3H), 1.31-1.43 (m, 4H),
1.49 (s, 9H), 1.51-1.60 (m, 4H), 1.76-1.90 (m, 1H), 2.12-2.24 (m,
1H), 2.72 (q, J=7.75 Hz, 2H), 3.46 (d, J=6.82 Hz, 2H), 3.92 (s,
2H), 4.01 (d, J=7.58 Hz, 2H), 7.31-7.43 (m, 3H), 7.86 (d, J=7.33
Hz, 2H).
Step D: Preparation of
2-(((1s,4s)-4-(3-Ethyl-4-(3-methoxyphenyl)-5-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic Acid
[0848] To a solution of tert-butyl
2-(((1s,4s)-4-((4-bromo-3-ethyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-ethyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers (100 mg, 0.20 mmol)
were added 3-methoxyphenylboronic acid (30.2 mg, 0.20 mmol),
tetrakis(triphenylphosphine)palladium (23.1 mg, 0.20 mmol),
K.sub.2CO.sub.3 (2 M aq., 0.5 mL) and dioxane (3 mL) was heated to
150.degree. C. under microwave for 4 h. The reaction mixture was
filtered and concentrated. The residue was treated with HCl (4 M in
dioxane, 5 mL) at room temperature for 10 h. The mixture was
concentrated and purified by HPLC to give the title compound (one
of the two regioisomers separated) as a white solid (13.5 mg). LCMS
m/z=463.3 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.01-1.18 (m, 4H), 1.12 (t, J=7.58 Hz, 3H), 1.22-1.35 (m, 4H),
1.54-1.68 (m, 1H), 1.87-1.98 (m, 1H), 2.63 (q, J=7.58 Hz, 2H), 3.20
(d, J=6.82 Hz, 2H), 3.58 (s, 3H), 3.90 (d, J=7.32 Hz, 2H), 3.91 (s,
2H), 6.55-6.74 (m, 3H), 7.10-7.17 (m, 2H), 7.22-7.28 (m, 2H),
7.36-7.44 (m, 2H).
Example 1.153
Preparation of
2-(((1s,4s)-4-((3-Ethyl-4,5-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)me-
thoxy)acetic Acid (Compound 100)
[0849] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-ethyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-5-ethyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl-
)methoxy)acetate as a mixture of regioisomers and phenylboronic
acid, the title compound (one of the two regioisomers separated)
was obtained using a similar method to the one described in Example
1.152. LCMS m/z=433.3 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.01-1.16 (m, 4H), 1.11 (t, J=7.58 Hz,
3H), 1.22-1.34 (m, 4H), 1.55-1.66 (m, 1H), 1.83-1.96 (m, 1H), 2.60
(q, J=7.83 Hz, 2H), 3.20 (d, J=6.82 Hz, 2H), 3.90 (s, 2H), 3.94 (d,
J=7.33 Hz, 2H), 7.04-7.26 (m, 5H), 7.35-7.57 (m, 5H).
Example 1.154
Preparation of
2-(((1s,4s)-4-(5-Ethyl-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)met-
hoxy)acetic Acid (Compound 101)
[0850] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-ethyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-ethyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and phenylboronic
acid, the title compound was obtained using a similar method to the
one described in Example 1.152. LCMS m/z=433.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.02 (t, J=7.58 Hz, 3H),
1.30-1.57 (m, 8H), 1.72-1.83 (m, 1H), 2.08-2.18 (m, 1H), 2.59 (q,
J=7.49 Hz, 2H), 3.44 (d, J=7.07 Hz, 2H), 4.00 (s, 2H), 4.03 (d,
J=7.33 Hz, 2H), 7.15-7.25 (m, 4H), 7.28-7.47 (m, 6H).
Example 1.155
Preparation of
2-(((1s,4s)-4-((3-Ethyl-4-(3-fluorophenyl)-5-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic Acid (Compound 102)
[0851] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-ethyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-ethyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
3-fluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.152. LCMS m/z=451.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.00-1.19 (m, 4H), 1.12 (t,
J=7.45 Hz, 3H), 1.21-1.35 (m, 4H), 1.53-1.64 (m, 1H), 1.88-1.98 (m,
1H), 2.64 (q, J=7.58 Hz, 2H), 3.20 (d, J=7.07 Hz, 2H), 3.91 (d,
J=7.33 Hz, 2H), 3.91 (s, 2H), 6.80-7.02 (m, 3H), 7.22-7.46 (m,
6H).
Example 1.156
Preparation of
2-(((1s,4s)-4-((5-Ethyl-4-(3-fluorophenyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic Acid (Compound 103)
[0852] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-ethyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-ethyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
3-fluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.152. LCMS m/z=451.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) S ppm 1.03 (t, J=7.58 Hz, 3H),
1.34-1.56 (m, 8H), 1.74-1.82 (m, 1H), 2.09-2.18 (m, 1H), 2.63 (q,
J=7.58 Hz, 2H), 3.44 (d, J=7.07 Hz, 2H), 4.00 (s, 2H), 4.04 (d,
J=7.33 Hz, 2H), 6.95-7.04 (m, 2H), 7.10-7.18 (m, 1H), 7.18-7.33 (m,
5H), 7.37-7.45 (m, 1H).
Example 1.157
Preparation of
2-(((1s,4s)-4-((3-Ethyl-4-(2-fluoro-3-methoxyphenyl)-5-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 104)
[0853] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-ethyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-ethyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
2-fluoro-3-methoxyphenylboronic acid, the title compound (one of
the two regioisomers separated) was obtained using a similar method
to the one described in Example 1.152. LCMS m/z=481.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.06 (t, J=7.58 Hz,
3H), 1.06-1.19 (m, 4H), 1.26-1.39 (m, 4H), 1.54-1.63 (m, 1H),
1.88-1.98 (m, 1H), 2.64 (q, J=7.41 Hz, 2H), 3.19 (d, J=6.82 Hz,
2H), 3.77 (s, 3H), 3.96 (d, J=7.58 Hz, 2H), 3.99 (s, 2H), 6.95-7.04
(m, 2H), 7.18-7.29 (m, 3H), 7.32-7.42 (m, 3H).
Example 1.158
Preparation of
2-(((1s,4s)-4-((5-Ethyl-4-(2-fluoro-3-methoxyphenyl)-3-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 105)
[0854] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-ethyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-ethyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
2-fluoro-3-methoxyphenylboronic acid, the title compound (one of
the two regioisomers separated) was obtained using a similar method
to the one described in Example 1.152. LCMS m/z=481.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 1.24 (t, J=7.58 Hz,
3H), 1.32-1.70 (m, 8H), 1.85-1.99 (m, 1H), 2.15-2.27 (m, 1H), 2.65
(q, J=7.45 Hz, 2H), 3.53 (d, J=7.07 Hz, 2H), 3.87 (s, 3H), 4.07 (s,
2H), 4.10 (d, J=7.71 Hz, 2H), 6.68-6.74 (m, 1H), 7.04-7.10 (m, 1H),
7.18-7.24 (m, 2H), 7.29-7.38 (m, 2H), 7.45-7.55 (m, 2H).
Example 1.159
Preparation of
2-(((1s,4s)-4-((4-(2,3-Difluorophenyl)-3-ethyl-5-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetic Acid (Compound 106)
[0855] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-ethyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-ethyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
2,3-difluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.152. LCMS m/z=469.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.00 (t, J=7.45 Hz, 3H),
1.03-1.13 (m, 4H), 1.22-1.32 (m, 4H), 1.54-1.65 (m, 1H), 1.81-1.90
(m, 1H), 2.58 (q, J=7.58 Hz, 2H), 3.18 (d, J=6.82 Hz, 2H), 3.90 (s,
2H), 3.95 (d, J=7.83 Hz, 2H), 7.07-7.14 (m, 1H), 7.19-7.32 (m, 3H),
7.36-7.58 (m, 4H).
Example 1.160
Preparation of
2-(((1s,4s)-4-((4-(2,3-Difluorophenyl)-5-ethyl-3-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetic Acid (Compound 107)
[0856] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-ethyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-ethyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
2,3-difluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.152. LCMS m/z=469.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. ppm 1.08 (t, J=7.58 Hz, 3H),
1.38-1.68 (m, 8H), 1.85-1.95 (m, 1H), 2.17-2.27 (m, 1H), 2.66 (q,
J=7.58 Hz, 2H), 3.53 (d, J=7.07 Hz, 2H), 4.08 (s, 2H), 4.12 (d,
J=7.58 Hz, 2H), 6.96-7.02 (m, 1H), 7.11-7.18 (m, 1H), 7.20-7.26 (m,
3H), 7.28-7.33 (m, 3H).
Example 1.161
Preparation of
2-(((1s,4s)-4-((3-Isopropyl-4,5-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetic Acid (Compound 112)
Step A: Preparation of 5-Isopropyl-3-phenyl-1H-pyrazole (15)
[0857] To a solution of acetophenone (1.21 g, 10.07 mmol) in dry
toluene (5 mL) was added LiHMDS (11.0 mL, 1.0 M in THF, 11.0 mmol)
via syringe at 0.degree. C. under argon. After 5 min, isobutyryl
chloride (1.073 g, 10.07 mmol) was added in one portion via
syringe. The ice bath was removed and AcOH (2 mL), EtOH (50 mL) and
THF (5 mL) were added to form a homogeneous mixture. Hydrazine
hydrate (2 mL, 10.07 mmol) was added and the reaction was refluxed
for 2 h. After cooled to room temperature, the reaction was
concentrated and extracted with EtOAc, washed with brine, dried
over MgSO.sub.4, and concentrated. The residue was purified by
silica gel column chromatography to give the title compound as
colorless oil (0.70 g). LCMS m/z=187.3 [M+H].sup.+; .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. ppm 1.33 (d, J=6.82 Hz, 6H),
2.94-3.13 (m, 1H), 6.38 (s, 1H), 7.17-7.45 (m, 5H), 10.14 (bs,
1H).
Step B: Preparation of 4-Iodo-5-isopropyl-3-phenyl-1H-pyrazole
[0858] To a solution of 5-isopropyl-3-phenyl-1H-pyrazole (0.64 g,
3.44 mmol) in THF (20 mL) and water (20.00 mL) were added sodium
iodide (0.515 g, 3.44 mmol), iodine (1.308 g, 5.15 mmol), and
potassium carbonate (0.712 g, 5.15 mmol) at room temperature. The
reaction was refluxed for 2 h, cooled to room temperature and
quenched with 10% aq. Na.sub.2SO.sub.3. The organic solvent was
removed under reduced pressure and the aqueous residue was
extracted with EtOAc. The organic extract was washed with
NaHCO.sub.3 solution, brine, dried over MgSO.sub.4, and
concentrated. The residue was purified by silica gel column
chromatography to give the title compound as a clear liquid (0.42
g). LCMS m/z=313.2 [M+H].sup.+; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 1.17 (d, J=7.07 Hz, 6H), 3.02 (septet, J=7.07 Hz, 1H),
7.23-7.32 (m, 3H), 7.60-7.67 (m, 2H), 11.81 (bs, 1H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-Iodo-5-isopropyl-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate and tert-Butyl
2-(((1s,4s)-4-((4-Iodo-3-isopropyl-5-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate as a Mixture of Regioisomers
[0859] To a solution of 4-iodo-5-isopropyl-3-phenyl-1H-pyrazole
(0.35 g, 1.121 mmol) in DMF (5 mL) was added sodium hydride (0.027
g, 1.121 mmol) at room temperature. The reaction was stirred at
room temperature for 1 h and tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (0.463 g,
1.121 mmol) was added. The reaction was heated at 50.degree. C. for
16 h, cooled to room temperature, and quenched with water (2 mL).
The mixture was extracted with EtOAc. The organic extract was dried
over MgSO.sub.4 and concentrated. The residue was purified by
silica gel column chromatography to give the title compound (a
mixture of two regioisomers) as a clear liquid (0.52 g). LCMS
m/z=553.2 [M+H].sup.+; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
ppm 0.99-1.20 (m, 4H), 1.25-1.42 (m, 4H), 1.46 (d, J=7.20 Hz, 6H),
1.48 (s, 9H), 1.82-1.94 (m, 1H), 2.07-2.19 (m, 1H), 3.16-3.28 (m,
1H), 3.45 (d, J=7.07 Hz, 2H), 3.95 (s, 2H), 4.07 (d, J=7.71 Hz,
2H), 7.30-7.46 (m, 3H), 7.63-7.79 (m, 2H).
Step D: Preparation of
2-(((1s,4s)-4-(3-Isopropyl-4,5-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl-
)methoxy)acetic Acid
[0860] A mixture of phenylboronic acid (21.9 mg, 0.18 mmol),
tert-butyl
2-(((1s,4s)-4-(4-iodo-5-isopropyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-3-isopropyl-5-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate as a mixture of regioisomers (100 mg, 0.18
mmol), tetrakis(triphenylphosphine)palladium (10.0 mg, 0.009 mmol),
K.sub.2CO.sub.3 (2 M aq., 0.2 mL) and dioxane (4 mL) was heated to
150.degree. C. under microwave irradiation for 4 h. The mixture was
filtered and concentrated. The residue was treated with HCl (4 M in
dioxane, 5 mL) at room temperature for 10 h. The mixture was
concentrated and purified by HPLC to give the title compound (one
of the two regioisomers separated) as a white solid (15.5 mg). LCMS
m/z=447.3 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.05-1.15 (m, 4H), 1.17 (d, J=6.82 Hz, 6H), 1.21-1.35 (m, 4H),
1.55-1.63 (m, 1H), 1.84-1.95 (m, 1H), 2.96-3.04 (m, 1H), 3.20 (d,
J=6.82 Hz, 2H), 3.91 (s, 2H), 3.93 (d, J=7.58 Hz, 2H), 7.05-7.10
(m, 2H), 7.12-7.19 (m, 2H), 7.19-7.27 (m, 3H), 7.32-7.40 (m,
3H).
Example 1.162
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-3-ethyl-5-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic Acid (Compound 115)
[0861] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-ethyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-ethyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
3-chlorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.152. LCMS m/z=467.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.08-1.23 (m, 4H), 1.21 (t,
J=7.58 Hz, 3H), 1.27-1.45 (m, 4H), 1.68-1.79 (m, 1H), 1.94-2.04 (m,
1H), 2.77 (q, J=7.54 Hz, 2H), 3.31 (d, J=6.57 Hz, 2H), 4.02 (s,
2H), 4.12 (d, J=7.58 Hz, 2H), 6.88-6.95 (m, 2H), 7.06-7.23 (m, 5H),
7.35-7.44 (m, 2H).
Example 1.163
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-5-ethyl-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic Acid (Compound 116)
[0862] From tert-butyl
2-(((1s,4s)-4-(4-bromo-3-ethyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl-
)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-ethyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
3-chlorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.152. LCMS m/z=467.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.13 (t, J=7.52 Hz, 3H),
1.32-1.46 (m, 4H), 1.48-1.66 (m, 4H), 1.87-1.99 (m, 1H), 2.13-2.26
(m, 1H), 2.66 (q, J=7.58 Hz, 2H), 3.52 (d, J=6.69 Hz, 2H), 4.10 (s,
2H), 4.17 (d, J=7.45 Hz, 2H), 7.02-7.08 (m, 2H), 7.18-7.38 (m,
7H).
Example 1.164
Preparation of
2-(((1s,4s)-4-((4-(2,3-Difluorophenyl)-5-isopropyl-3-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 117)
[0863] From tert-butyl
2-(((1s,4s)-4-((4-iodo-5-isopropyl-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-3-isopropyl-5-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate as a mixture of regioisomers and
2,3-difluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.161. LCMS m/z=483.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.14 (d, J=7.07 Hz, 6H),
1.20-1.36 (m, 8H), 1.56-1.64 (m, 1H), 1.87-1.97 (m, 1H), 2.78-2.88
(m, 1H), 3.20 (d, J=7.07 Hz, 2H), 3.91 (s, 2H), 3.98 (d, J=7.58 Hz,
2H), 6.96-7.14 (m, 2H), 7.19-7.26 (m, 3H), 7.32-7.41 (m, 3H).
Example 1.165
Preparation of
2-(((1s,4s)-4-((5-(Ethylthio)-4-(2-fluorophenyl)-3-phenyl-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methoxy)acetic Acid (Compound 118)
[0864] From tert-butyl
2-(((1s,4s)-4-((5-(ethylthio)-4-iodo-3-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-(ethylthio)-4-iodo-5-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate as a mixture of regioisomers and
3-fluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.149. LCMS m/z=483.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 0.95 (t, J=7.33 Hz, 3H),
1.32-1.56 (m, 8H), 1.72-1.82 (m, 1H), 2.17-2.28 (m, 1H), 2.53 (q,
J=7.33 Hz, 2H), 3.42 (d, J=6.82 Hz, 2H), 4.01 (s, 2H), 4.30 (d,
J=7.58 Hz, 2H), 7.20-7.30 (m, 5H), 7.32-7.39 (m, 2H), 7.40-7.49 (m,
2H).
Example 1.166
Preparation of
2-(((1s,4s)-4-((5-(Ethylthio)-4-(3-fluoro-5-methoxyphenyl)-3-phenyl-1H-py-
razol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 119)
[0865] From tert-butyl
2-(((1s,4s)-4-((5-(ethylthio)-4-iodo-3-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-(ethylthio)-4-iodo-5-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate as a mixture of regioisomers and
3-fluoro-5-methoxyphenylboronic acid, the title compound (one of
the two regioisomers separated) was obtained using a similar method
to the one described in Example 1.149. LCMS m/z=513.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 0.99 (t, J=7.33 Hz,
3H), 1.33-1.56 (m, 8H), 1.72-1.82 (m, 1H), 2.17-2.27 (m, 1H), 2.57
(q, J=7.33 Hz, 2H), 3.42 (d, J=6.82 Hz, 2H), 3.73 (s, 3H), 4.01 (s,
2H), 4.28 (d, J=7.58 Hz, 2H), 6.62-6.70 (m, 2H), 6.76-6.83 (m, 1H),
7.23-7.41 (m, 5H).
Example 1.167
Preparation of
2-(((1s,4s)-4-((5-Cyclopropyl-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic Acid (Compound 120)
Step A: Preparation of 5-Cyclopropyl-3-phenyl-1H-pyrazole
[0866] To a solution of acetophenone (5.0 g, 41.6 mmol) in dry
toluene (5 mL) was added LiHMDS (42.0 mL, 1.0 M in THF, 42.0 mmol)
via syringe at 0.degree. C. under argon. After 5 min,
cyclopropanecarbonyl chloride (4.35 g, 41.6 mmol) was added in one
portion via syringe. The ice bath was removed and AcOH (2 mL), EtOH
(50 mL), and hydrazine hydrate (10 mL, 64% aq., 127.8 mmol) was
added. The mixture was refluxed for 30 min, cooled to room
temperature, and concentrated. The residue was extracted with
EtOAc, washed with brine, dried over MgSO.sub.4, and purified by
silica gel column chromatography to give the title compound as
colorless oil (4.5 g). LCMS m/z=184.7 [M+H].sup.+; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 0.71-0.80 (m, 2H), 0.89-1.00 (m, 2H),
1.81-1.98 (m, 1H), 6.22 (s, 1H), 7.11-7.56 (m, 5H), 10.50 (bs,
1H).
Step B: Preparation of
5-Cyclopropyl-4-iodo-3-phenyl-1H-pyrazole
[0867] To a solution of 5-cyclopropyl-3-phenyl-1H-pyrazole (3.0 g,
16.28 mmol) in THF (20 mL) and water (20 mL) were added sodium
iodide (2.441 g, 16.28 mmol), iodine (6.20 g, 24.43 mmol), and
potassium carbonate (3.38 g, 24.43 mmol) at room temperature. The
reaction was brought to reflux for 2 h at 100.degree. C. The
reaction was cooled to room temperature and quenched with 10% aq.
Na.sub.2SO.sub.3. The organic solvent was removed under reduced
pressure and the aqueous was extracted with EtOAc, washed with
NaHCO.sub.3 solution, brine, dried over MgSO.sub.4, and
concentrated. The residue was purified by silica gel column
chromatography to give the title compound (2.7 g). LCMS m/z=310.8
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
0.75-0.81 (m, 2H), 0.83-0.88 (m, 2H), 2.46-2.56 (m, 1H), 7.33-7.47
(m, 3H), 7.62-7.71 (m, 2H), 12.91 (s, 1H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-(3-Cyclopropyl-4-iodo-5-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate and tert-Butyl
2-(((1s,4s)-4-((5-Cyclopropyl-4-iodo-3-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate as a Mixture of Regioisomers
[0868] A solution of 5-cyclopropyl-4-iodo-3-phenyl-1H-pyrazole (3.5
g, 11.29 mmol) in DMF (5 mL) was treated with sodium hydride (0.271
g, 11.29 mmol) at room temperature for 1 h, then tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (4.66 g,
11.29 mmol) was added. The reaction mixture was heated to
50.degree. C. for 16 h and quenched by water (2 mL). The mixture
was extracted by EtOAc, dried over MgSO.sub.4, and concentrated.
The residue was purified by silica gel column chromatography to
give the title compound (a mixture of two regioisomers) as
colorless oil (4.5 g). LCMS m/z=551.1 [M+H].sup.+; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 1.04-1.19 (m, 4H), 1.33-1.44 (m, 4H),
1.46 (s, 9H), 1.47 (d, J=8.08 Hz, 4H), 1.67-1.77 (m, 1H), 1.85-1.91
(m, 1H), 1.90-1.99 (m, 1H), 3.25 (d, J=7.07 Hz, 2H), 3.87 (s, 2H),
3.91 (d, J=7.58 Hz, 2H), 7.28-7.54 (m, 5H).
Step D: Preparation of
2-(((1s,4s)-4-((5-Cyclopropyl-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexAmethoxy)acetic Acid
[0869] A mixture of 3-methoxyphenylboronic acid (27.4 mg, 0.18
mmol), tert-butyl
2-(((1s,4s)-4-((3-cyclopropyl-4-iodo-5-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-cyclopropyl-4-iodo-3-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate as a mixture of regioisomers (100 mg, 0.18
mmol), tetrakis(triphenylphosphine)palladium (10.0 mg, 0.009 mmol),
K.sub.2CO.sub.3 (2 M aq., 0.2 mL) and dioxane (4 mL) was heated to
150.degree. C. under microwave irradiation for 4 h. The mixture was
filtered and concentrated. The residue was treated with HCl (4 M in
dioxane, 5 mL) at room temperature for 10 h. The mixture was
concentrated and purified by HPLC to give the title compound (one
of the two regioisomers separated) as white solid (23.5 mg). LCMS
m/z=475.3 [M+H].sup.+; .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
ppm 0.35-0.48 (m, 2H), 0.86-0.99 (m, 2H), 1.44-1.80 (m, 8H),
1.83-2.01 (m, 1H), 2.29-2.41 (m, 1H), 2.67-2.76 (m, 1H), 3.57 (d,
J=6.95 Hz, 2H), 3.74 (s, 3H), 4.13 (s, 2H), 4.30 (d, J=7.33 Hz,
2H), 6.70-7.00 (m, 4H), 7.17-7.55 (m, 5H).
Example 1.168
Preparation of
2-(((1s,4s)-4-((5-Cyclopropyl-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)methoxy)acetic Acid (Compound 122)
[0870] From tert-butyl
2-(((1s,4s)-4-(3-cyclopropyl-4-iodo-5-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-cyclopropyl-4-iodo-3-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate as a mixture of regioisomers and
phenylboronic acid, the title compound (one of the two regioisomers
separated) was obtained using a similar method to the one described
in Example 1.167. LCMS m/z=445.4 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 0.20-0.27 (m, 2H), 0.74-0.81 (m, 2H),
1.36-1.56 (m, 8H), 1.70-1.81 (m, 1H), 1.81-1.91 (m, 1H), 2.13-2.28
(m, 1H), 3.42 (d, J=6.95 Hz, 2H), 4.00 (s, 2H), 4.17 (d, J=7.45 Hz,
2H), 7.16-7.25 (m, 5H), 7.25-7.37 (m, 5H).
Example 1.169
Preparation of
2-(((1s,4s)-4-((3-Isopropyl-4-(3-methoxyphenyl)-5-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic Acid (Compound 123)
[0871] From tert-butyl
2-(((1s,4s)-4-((4-iodo-5-isopropyl-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-3-isopropyl-5-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate as a mixture of regioisomers, and
3-methoxyphenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.161. LCMS m/z=477.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. ppm 1.10-1.26 (m, 4H), 1.29 (d,
J=6.95 Hz, 6H), 1.30-1.45 (m, 4H), 1.66-1.76 (m, 1H), 1.95-2.06 (m,
1H), 3.10-3.22 (m, 1H), 3.29 (d, J=6.95 Hz, 2H), 3.66 (s, 3H), 4.00
(s, 2H), 4.10 (d, J=7.71 Hz, 2H), 6.60-6.81 (m, 3H), 7.13-7.31 (m,
3H), 7.33-7.46 (m, 3H).
Example 1.170
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-3-isopropyl-5-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetic Acid (Compound 124)
[0872] From tert-butyl
2-(((1s,4s)-4-((4-iodo-5-isopropyl-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-3-isopropyl-5-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate as a mixture of regioisomers and
3-chlorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.161. LCMS m/z=481.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.18 (d, J=6.82 Hz, 6H),
1.21-1.35 (m, 4H), 1.37-1.56 (m, 4H), 1.83-1.95 (m, 1H), 2.06-2.17
(m, 1H), 2.96-3.06 (m, 1H), 3.20 (d, J=7.07 Hz, 2H), 3.91 (s, 2H),
3.93 (d, J=7.83 Hz, 2H), 7.01-7.09 (m, 1H), 7.15-7.31 (m, 5H),
7.35-7.44 (m, 3H).
Example 1.171
Preparation of
2-(((1s,4s)-4-((4-(2-Fluoro-3-methoxyphenyl)-3-isopropyl-5-phenyl-1H-pyra-
zol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 125)
[0873] From tert-butyl
2-(((1s,4s)-4-(4-iodo-5-isopropyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-3-isopropyl-5-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate as a mixture of regioisomers and
2-fluoro-3-methoxyphenylboronic acid, the title compound (one of
the two regioisomers separated) was obtained using a similar method
to the one described in Example 1.161. LCMS m/z=495.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.24 (d, J=6.82 Hz,
6H), 1.25-1.33 (m, 4H), 1.34-1.43 (m, 4H), 1.72-1.82 (m, 1H),
2.07-2.15 (m, 1H), 2.98-3.08 (m, 1H), 3.42 (d, J=6.82 Hz, 2H), 3.77
(s, 3H), 3.99 (s, 2H), 4.01 (d, J=7.59 Hz, 2H), 6.81-6.88 (m, 1H),
6.96-7.04 (m, 2H), 7.22-7.30 (m, 2H), 7.32-7.40 (m, 3H).
Example 1.172
Preparation of
2-(((1s,4s)-4-((5-Cyclopropyl-4-(2-fluoro-3-methoxyphenyl)-3-phenyl-1H-py-
razol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 126)
[0874] From tert-butyl
2-(((1s,4s)-4-((3-cyclopropyl-4-iodo-5-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(5-cyclopropyl-4-iodo-3-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate as a mixture of regioisomers and
2-fluoro-3-methoxyphenylboronic acid, the title compound was
obtained using a similar method to the one described in Example
1.167. LCMS m/z=493.3 [M+H].sup.+; .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 0.38-0.45 (m, 2H), 0.82-0.90 (m, 2H),
1.49-1.71 (m, 8H), 1.82-1.90 (m, 1H), 1.90-2.00 (m, 1H), 2.29-2.40
(m, 1H), 3.57 (d, J=6.95 Hz, 2H), 3.93 (s, 3H), 4.13 (s, 2H), 4.31
(d, J=7.58 Hz, 2H), 6.66-6.77 (m, 2H), 7.01-7.15 (m, 3H), 7.22-7.39
(m, 3H).
Example 1.173
Preparation of
2-(((1s,4s)-4-((5-Cyclopropyl-4-(2,3-difluorophenyl)-3-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 127)
[0875] From tert-butyl
2-(((1s,4s)-4-((3-cyclopropyl-4-iodo-5-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-cyclopropyl-4-iodo-3-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate as a mixture of regioisomers and
2,3-difluorophenylboronic acid, the title compound was obtained
using a similar method to the one described in Example 1.167. LCMS
m/z=481.2 [M+H].sup.+; .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
ppm 0.36-0.42 (m, 2H), 0.85-0.94 (m, 2H), 1.48-1.72 (m, 8H),
1.84-1.91 (m, 1H), 1.89-1.97 (m, 1H), 2.29-2.40 (m, 1H), 3.56 (d,
J=6.95 Hz, 2H), 4.12 (s, 2H), 4.31 (d, J=7.70 Hz, 2H), 6.92-7.04
(m, 2H), 7.09-7.19 (m, 2H), 7.19-7.40 (m, 4H).
Example 1.174
Preparation of
2-(((1s,4s)-4-((5-Isopropyl-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic Acid (Compound 128)
[0876] From tert-butyl
2-(((1s,4s)-4-((4-iodo-5-isopropyl-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-3-isopropyl-5-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate as a mixture of regioisomers and
3-methoxyphenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.161. LCMS m/z=477.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. ppm 1.23 (d, J=7.07 Hz, 6H),
1.44-1.75 (m, 8H), 1.90-2.00 (m, 1H), 2.17-2.27 (m, 1H), 3.19-3.30
(m, 1H), 3.58 (d, J=7.07 Hz, 2H), 3.78 (s, 3H), 4.13 (s, 2H), 4.17
(d, J=7.58 Hz, 2H), 6.78-6.97 (m, 3H), 7.20-7.25 (m, 3H), 7.27-7.37
(m, 3H).
Example 1.175
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-5-isopropyl-3-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetic Acid (Compound 129)
[0877] From tert-butyl
2-(((1s,4s)-4-((4-iodo-5-isopropyl-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-3-isopropyl-5-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate as a mixture of regioisomers and
3-chlorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.161. LCMS m/z=481.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.09 (d, J=7.07 Hz, 6H),
1.34-1.57 (m, 8H), 1.74-1.83 (m, 1H), 2.06-2.17 (m, 1H), 2.95-3.05
(m, 1H), 3.43 (d, J=7.07 Hz, 2H), 3.99 (s, 2H), 4.07 (d, J=7.33 Hz,
2H), 7.01-7.08 (m, 1H), 7.12-7.27 (m, 4H), 7.32-7.54 (m, 4H).
Example 1.176
Preparation of
2-(((1s,4s)-4-((4-(2-Fluoro-3-methoxyphenyl)-5-isopropyl-3-phenyl-1H-pyra-
zol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 130)
[0878] From tert-butyl
2-(((1s,4s)-4-(4-iodo-5-isopropyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-iodo-3-isopropyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)methoxy)acetate as a mixture of regioisomers and
2-fluoro-3-methoxyphenylboronic acid, the title compound (one of
the two regioisomers separated) was obtained using a similar method
to the one described in Example 1.161. LCMS m/z=495.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.12 (d, J=7.07 Hz,
6H), 1.39-1.55 (m, 8H), 1.70-1.82 (m, 1H), 1.86-1.97 (m, 1H),
2.75-2.85 (m, 1H), 3.20 (d, J=7.07 Hz, 2H), 3.77 (s, 3H), 3.91 (s,
2H), 3.96 (d, J=7.83 Hz, 2H), 6.97-7.05 (m, 1H), 7.13-7.30 (m, 4H),
7.31-7.40 (m, 3H).
Example 1.177
Preparation of Methyl
2-4(1s,4s)-4-((5-(Methylthio)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)Methoxy)acetate (Compound 131)
[0879] From tert-butyl
2-(((1s,4s)-4-((4-iodo-5-(methylthio)-3-phenyl-1H-pyrazol-1-yl)methyl)cyc-
lohexyl)methoxy)acetate and phenylboronic acid, the title compound
(one of the two regioisomers separated) was obtained using a
similar method to the one described in Example 1.151. LCMS
m/z=451.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.32-1.53 (m, 8H), 1.70-1.80 (m, 1H), 2.12 (s, 3H), 2.15-2.25
(m, 1H), 3.39 (d, J=6.95 Hz, 2H), 3.80 (s, 2H), 4.28 (d, J=7.45 Hz,
2H), 7.22-7.29 (m, 5H), 7.30-7.43 (m, 5H).
Example 1.178
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-3-cyclopropyl-5-phenyl-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methoxy)acetic Acid (Compound 132)
[0880] From tert-butyl
2-(((1s,4s)-4-((3-cyclopropyl-4-iodo-5-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-cyclopropyl-4-iodo-3-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate as a mixture of regioisomers and
3-chlorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.167. LCMS m/z=479.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 0.54-0.62 (m, 4H),
0.76-0.92 (m, 4H), 0.95-1.10 (m, 4H), 1.30-1.41 (m, 1H), 1.53-1.60
(m, 1H), 1.60-1.69 (m, 1H), 2.95 (d, J=6.82 Hz, 2H), 3.61 (d,
J=7.33 Hz, 2H), 3.67 (s, 2H), 6.85-6.93 (m, 2H), 6.95-7.07 (m, 4H),
7.08-7.23 (m, 3H).
Example 1.179
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-5-cyclopropyl-3-phenyl-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methoxy)acetic Acid (Compound 133).
[0881] From tert-butyl
2-(((1s,4s)-4-((3-cyclopropyl-4-iodo-5-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(5-cyclopropyl-4-iodo-3-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate as a mixture of regioisomers and
3-chlorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.167. LCMS m/z=479.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. ppm 0.34-0.41 (m, 2H), 0.87-0.95
(m, 2H), 1.37-1.65 (m, 8H), 1.71-1.80 (m, 1H), 1.88-1.97 (m, 1H),
2.23-2.33 (m, 1H), 3.53 (d, J=6.95 Hz, 2H), 4.11 (s, 2H), 4.31 (d,
J=7.58 Hz, 2H), 7.00-7.05 (m, 1H), 7.19-7.30 (m, 6H), 7.30-7.36 (m,
2H).
Example 1.180
Preparation of Methyl
2-(((1s,4s)-4-((4-(3-Methoxyphenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)Methoxy)acetate (Compound 136)
[0882] To a solution of tert-butyl
2-(((1s,4s)-4-(4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers (100 mg, 0.19 mmol)
in dioxane (3 mL) were added 3-methoxyphenylboronic acid (28.9 mg,
0.19 mmol), tetrakis(triphenylphosphine)palladium (22 mg, 0.019
mmol), and K.sub.2CO.sub.3 (2 M aq., 0.2 mL). The reaction was
heated to 150.degree. C. under microwave irradiation for 4 h. The
reaction mixture was filtered and concentrated. The residue was
treated with HCl (4.0 M in dioxane, 5 mL) at room temperature for
10 h. The mixture was concentrated and purified by HPLC to give
2-(((1s,4s)-4-((4-(3-methoxyphenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic acid. The title compound (15.4 mg)
was obtained by treating the above acid with anhydrous methanol for
1 h. LCMS m/z=463.3 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.31-1.53 (m, 8H), 1.69-1.80 (m, 1H),
2.03-2.13 (m, 1H), 2.21 (s, 3H), 3.36 (d, J=7.07 Hz, 2H), 3.56 (s,
3H), 3.68 (s, 3H), 3.82 (s, 2H), 4.04 (d, J=7.45 Hz, 2H), 6.67-6.75
(m, 2H), 6.83-6.88 (m, 1H), 7.20-7.30 (m, 4H), 7.30-7.35 (m,
2H).
Example 1.181
Preparation of
2-(((1s,4s)-4-((3-(4-Fluorophenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 137)
[0883] From tert-butyl
2-(((1s,4s)-4-((5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
4-fluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.107. LCMS m/z=437.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.35-1.53 (m, 8H),
1.72-1.81 (m, 1H), 2.05-2.13 (m, 1H), 2.20 (s, 3H), 3.42 (d, J=6.95
Hz, 2H), 3.99 (s, 2H), 4.05 (d, J=7.58 Hz, 2H), 7.03-7.18 (m, 4H),
7.25-7.42 (m, 5H).
Example 1.182
Preparation of
2-(((1s,4s)-4-((3-(4-Chlorophenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 138)
[0884] From tert-butyl
2-(((1s,4s)-4-((5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
4-chlorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.107. LCMS m/z=453.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.33-1.53 (m, 8H),
1.71-1.82 (m, 1H), 2.03-2.14 (m, 1H), 2.20 (s, 3H), 3.42 (d, J=6.95
Hz, 2H), 3.99 (s, 2H), 4.05 (d, J=7.45 Hz, 2H), 7.13-7.19 (m, 3H),
7.28-7.34 (m, 3H), 7.35-7.41 (m, 3H).
Example 1.183
Preparation of
2-(((1s,4s)-4-((5-Methyl-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic Acid (Compound 139)
[0885] From tert-butyl
2-(((1s,4s)-4-(5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and p-tolylboronic
acid, the title compound (one of the two regioisomers separated)
was obtained using a similar method to the one described in Example
1.107. LCMS m/z=433.3 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.35-1.53 (m, 8H), 1.72-1.80 (m, 1H),
2.04-2.13 (m, 1H), 2.19 (s, 3H), 2.25 (s, 3H), 3.42 (d, J=6.95 Hz,
2H), 3.99 (s, 2H), 4.03 (d, J=7.45 Hz, 2H), 7.00-7.07 (m, 2H),
7.11-7.22 (m, 4H), 7.24-7.40 (m, 3H).
Example 1.184
Preparation of
2-(((1s,4s)-4-((3-(4-Methoxyphenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid (Compound 140)
[0886] From tert-butyl
2-(((1s,4s)-4-((5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
4-methoxyphenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.107. LCMS m/z=449.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.34-1.53 (m, 8H),
1.71-1.80 (m, 1H), 2.04-2.14 (m, 1H), 2.19 (s, 3H), 3.42 (d, J=7.07
Hz, 2H), 3.71 (s, 3H), 3.99 (s, 2H), 4.02 (d, J=7.45 Hz, 2H),
6.77-6.85 (m, 2H), 7.12-7.19 (m, 2H), 7.18-7.41 (m, 5H).
Example 1.185
Preparation of
2-(((1s,4s)-4-((3-(2,4-Difluorophenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic Acid (Compound 141)
[0887] From tert-butyl
2-(((1s,4s)-4-((5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
2,4-difluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.107. LCMS m/z=454.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.31-1.53 (m, 8H),
1.70-1.81 (m, 1H), 2.03-2.14 (m, 1H), 2.29 (s, 3H), 3.41 (d, J=6.95
Hz, 2H), 3.99 (s, 2H), 4.07 (d, J=7.45 Hz, 2H), 7.04-7.08 (m, 2H),
7.08-7.24 (m, 3H), 7.25-7.43 (m, 3H).
Example 1.186
Preparation of
2-4(1s,4s)-4-((4-(2,3-Difluorophenyl)-5-(ethylthio)-3-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 142).
[0888] From tert-butyl
2-(((1s,4s)-4-((5-(ethylthio)-4-iodo-3-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate and 2,3-difluoro-methoxyphenylboronic acid,
the title compound (one of the two regioisomers separated) was
obtained using a similar method to the one described in Example
1.149. LCMS m/z=501.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 0.95 (t, J=7.33 Hz, 3H), 1.30-1.53 (m,
8H), 1.69-1.81 (m, 1H), 2.15-2.27 (m, 1H), 2.56 (q, J=7.33 Hz, 2H),
3.38 (d, J=6.95 Hz, 2H), 3.75 (s, 2H), 4.29 (d, J=7.45 Hz, 2H),
7.14-7.21 (m, 1H), 7.23-7.37 (m, 6H), 7.42-7.52 (m, 1H).
Example 1.187
Preparation of
2-(((1s,4s)-4-((3-(2-Fluoro-4-methoxyphenyl)-5-methyl-4-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 145)
[0889] From tert-butyl
2-(((1s,4s)-4-((5-bromo-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((3-bromo-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
2-fluoro-4-methoxyphenylboronic acid, the title compound (one of
the two regioisomers separated) was obtained using a similar method
to the one described in Example 1.107. LCMS m/z=467.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.34-1.53 (m, 8H),
1.70-1.80 (m, 1H), 2.05-2.14 (m, 1H), 2.29 (s, 3H), 3.42 (d, J=6.82
Hz, 2H), 3.66 (s, 3H), 3.99 (s, 2H), 4.07 (d, J=7.58 Hz, 2H),
6.79-6.91 (m, 2H), 6.97-7.12 (m, 3H), 7.15-7.33 (m, 3H).
Example 1.188
Preparation of
2-(((1s,4s)-4-((4-(5-Fluoropyridin-3-yl)-5-methyl-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic Acid (Compound 147)
[0890] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
5-fluoropyridin-3-ylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.97. LCMS m/z=438.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.30-1.54 (m, 8H),
1.70-1.81 (m, 1H), 2.02-2.14 (m, 1H), 2.27 (s, 3H), 3.42 (d, J=6.95
Hz, 2H), 3.99 (s, 2H), 4.08 (d, J=7.58 Hz, 2H), 7.22-7.32 (m, 3H),
7.33-7.40 (m, 1H), 7.54-7.61 (m, 1H), 7.69-7.74 (m, 1H), 8.18-8.23
(m, 1H), 8.50 (d, J=2.78 Hz, 1H).
Example 1.189
Preparation of
2-(((1s,4s)-4-((5-(Ethylthio)-4-(5-fluoropyridin-3-yl)-3-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 148)
[0891] From tert-butyl
2-(((1s,4s)-4-((5-(ethylthio)-4-iodo-3-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate and 5-fluoropyridin-3-ylboronic acid, the
title compound (one of the two regioisomers separated) was obtained
using a similar method to the one described in Example 1.149. LCMS
m/z=484.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 0.95 (t, J=7.33 Hz, 3H), 1.34-1.54 (m, 8H), 1.70-1.81 (m, 1H),
2.16-2.26 (m, 1H), 2.58 (q, J=7.33 Hz, 2H), 3.41 (d, J=6.95 Hz,
2H), 4.00 (s, 2H), 4.30 (d, J=7.58 Hz, 2H), 7.27-7.35 (m, 5H),
7.65-7.71 (m, 1H), 8.29 (t, J=1.64 Hz, 1H), 8.55 (d, J=2.78 Hz,
1H).
Example 1.190
Preparation of
2-(((1s,4s)-4-((5-Ethyl-4-(5-fluoropyridin-3-yl)-3-phenyl-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methoxy)acetic Acid (Compound 149)
[0892] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-ethyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-ethyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
5-fluoropyridin-3-ylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.152. LCMS m/z=452.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.00-1.07 (m, 3H),
1.35-1.57 (m, 8H), 1.73-1.83 (m, 1H), 2.07-2.19 (m, 1H), 2.66 (q,
J=7.49 Hz, 2H), 3.44 (d, J=7.07 Hz, 2H), 4.00 (s, 2H), 4.06 (d,
J=7.45 Hz, 2H), 7.23-7.31 (m, 5H), 7.57-7.62 (m, 1H), 8.23 (t,
J=1.71 Hz, 1H), 8.53 (d, J=2.78 Hz, 1H).
Example 1.191
Preparation of
2-(((1s,4s)-4-((3,4-Diphenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetic Acid (Compound 151)
Step A: Preparation of 3-Phenyl-5-(trifluoromethyl)-1H-pyrazole
[0893] To a stirred mixture of
4,4,4-trifluoro-1-phenylbutane-1,3-dione (5.0 g, 23.13 mmol) in dry
ethanol (100 mL) was added hydrazine hydrate (1.737 g, 34.7 mmol)
dropwise. The resulting solution was refluxed for 16 h. The
reaction was cooled to room temperature and concentrated. The oil
was diluted with saturated NaHCO.sub.3 solution and extracted with
EtOAc, washed with brine, dried over MgSO.sub.4 and concentrated.
The residue was purified by silica gel column chromatography to
give the title compound as a clear liquid which was crystallized in
hexanes/ethyl acetate (3.25 g). LCMS m/z=213.1 [M+H].sup.+; .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. ppm 6.77 (s, 1H), 7.36-7.51 (m,
3H), 7.53-7.64 (m, 2H), 11.59 (s, 1H).
Step B: Preparation of
4-Iodo-3-phenyl-5-(trifluoromethyl)-1H-pyrazole
[0894] To a mixture of 3-phenyl-5-(trifluoromethyl)-1H-pyrazole
(4.0 g, 18.85 mmol) in THF (50 mL) and water (50 mL) were added
sodium iodide (2.83 g, 18.85 mmol), iodine (7.18 g, 28.3 mmol), and
K.sub.2CO.sub.3 (2.61 g, 18.85 mmol) at room temperature. The
reaction was refluxed for 16 h, quenched with sodium thiosulfite
(2.0 M aq. 10 mL) and concentrated under reduced pressure. The
reaction was extracted with ethyl acetate and washed with
NaHCO.sub.3, brine, dried over MgSO.sub.4 and concentrated under
reduced pressure. The residue was purified by silica gel column
chromatography to give the title compound as white solid (4.0 g).
LCMS m/z=338.8 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 7.39-7.62 (m, 3H), 7.70-7.75 (m, 1H), 7.82-7.88 (m,
1H), 14.11 (s, 1H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-Iodo-5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate and tert-Butyl
2-(((1s,4s)-4-((4-Iodo-3-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate as a Mixture of Regioisomers
[0895] To a solution of
4-iodo-3-phenyl-5-(trifluoromethyl)-1H-pyrazole (2.0 g, 5.92 mmol)
in DMF (6 mL) was added sodium hydride (0.14 g, 5.92 mmol) in
portions at 0.degree. C. The reaction was stirred at that
temperature for 1 h and tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (2.44 g,
5.92 mmol) was added. The reaction was gently heated to 60.degree.
C. for 16 h, quenched with water (2 mL), extracted with ethyl
acetate, dried over MgSO.sub.4, and concentrated. The residue was
purified by silica gel column chromatography to give the title
compound (a mixture of two regioisomers) as a colorless liquid (2.7
g). LCMS m/z=579.1 [M+H].sup.+.
Step D: Preparation of
2-(((1s,4s)-4-(3,4-Diphenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)methyl)cy-
clohexyl)methoxy)acetic Acid
[0896] In a solution of tert-butyl
2-(((1s,4s)-4-(4-iodo-5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-iodo-3-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetate as a mixture of regioisomers (100 mg,
0.17 mmol) in dioxane (3 mL) were added phenylboronic acid (21.0
mg, 0.17 mmol), tetrakis(triphenylphosphine)palladium (22 mg, 0.019
mmol), and K.sub.2CO.sub.3 (2 M aq., 0.2 mL). The reaction was
heated to 150.degree. C. under microwave irradiation for 4 h. The
reaction mixture was filtered and concentrated. The residue was
treated with HCl (4.0 M in dioxane, 4 mL) at room temperature for
10 h. The mixture was concentrated and purified by HPLC to give the
title compound as a white solid (16.4 mg). LCMS m/z=473.2
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.35-1.54 (m, 8H), 1.73-1.82 (m, 1H), 2.13-2.21 (m, 1H), 3.42 (d,
J=7.07 Hz, 2H), 3.99 (s, 2H), 4.27 (d, J=7.45 Hz, 2H), 7.23-7.29
(m, 5H), 7.37-7.43 (m, 5H), 12.30-12.76 (m, 1H).
Example 1.192
Preparation of
2-(((1s,4s)-4-(3-Phenyl-4-p-tolyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid (Compound 152)
[0897] From tert-butyl
2-(((1s,4s)-4-(4-iodo-5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-3-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
p-tolylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.191. LCMS m/z=487.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.34-1.54 (m, 8H),
1.73-1.83 (m, 1H), 2.12-2.21 (m, 1H), 2.34 (s, 3H), 3.42 (d, J=7.07
Hz, 2H), 3.99 (s, 2H), 4.26 (d, J=7.45 Hz, 2H), 7.09-7.15 (m, 2H),
7.18-7.23 (m, 2H), 7.23-7.30 (m, 5H), 12.47 (s, 1H).
Example 1.193
Preparation of
2-(((1s,4s)-4-((4-(3-Methoxyphenyl)-5-phenyl-3-(trifluoromethyl)-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 154)
[0898] From tert-butyl
2-(((1s,4s)-4-((4-iodo-5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-iodo-3-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
3-methoxyphenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.191. LCMS m/z=503.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.01-1.22 (m, 4H),
1.23-1.41 (m, 4H), 1.54-1.70 (m, 1H), 1.86-2.02 (m, 1H), 3.15 (d,
J=6.82 Hz, 2H), 3.49 (s, 2H), 3.62 (s, 3H), 4.03 (d, J=7.07 Hz,
2H), 6.63-6.87 (m, 4H), 7.13-7.24 (m, 2H), 7.29-7.53 (m, 3H).
Example 1.194
Preparation of
2-(((1s,4s)-4-((4-(3-Methoxyphenyl)-3-phenyl-5-(trifluoromethyl)-1H-pyraz-
ol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 155)
[0899] From tert-butyl
2-(((1s,4s)-4-(4-iodo-5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-3-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
3-methoxyphenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.191. LCMS m/z=503.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.34-1.53 (m, 8H),
1.69-1.82 (m, 1H), 2.11-2.19 (m, 1H), 3.35 (d, J=7.58 Hz, 2H), 3.53
(s, 2H), 3.71 (s, 3H), 4.26 (d, J=7.96 Hz, 2H), 6.77-6.83 (m, 2H),
6.94-7.01 (m, 2H), 7.22-7.35 (m, 5H).
Example 1.195
Preparation of
2-(((1s,4s)-4-(5-Ethyl-4-(3-hydroxyphenyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic Acid (Compound 172)
[0900] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-ethyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-ethyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
3-hydroxyphenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.152. LCMS m/z=449.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.03 (t, J=7.45 Hz, 3H),
1.31-1.56 (m, 8H), 1.69-1.83 (m, 1H), 2.03-2.19 (m, 1H), 2.58 (q,
J=7.41 Hz, 2H), 3.40 (d, J=7.07 Hz, 2H), 3.79 (s, 2H), 4.01 (d,
J=7.58 Hz, 2H), 6.54-6.63 (m, 2H), 6.67-6.75 (m, 1H), 7.09-7.38 (m,
6H).
Example 1.196
Preparation of
2-(((1s,4s)-4-((4-(3-Hydroxyphenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 173)
[0901] From tert-butyl
2-(((1s,4s)-4-((4-iodo-5-(methylthio)-3-phenyl-1H-pyrazol-1-yl)methyl)cyc-
lohexyl)methoxy)acetate and phenylboronic acid, the title compound
(one of the two regioisomers separated) was obtained using a
similar method to the one described in Example 1.151. LCMS
m/z=467.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.31-1.53 (m, 8H), 1.70-1.80 (m, 1H), 2.13 (s, 3H), 2.15-2.25
(m, 1H), 3.38 (d, J=7.07 Hz, 2H), 3.80 (s, 2H), 4.26 (d, J=7.33 Hz,
2H), 6.63-6.78 (m, 3H), 7.13-7.20 (m, 1H), 7.21-7.30 (m, 3H),
7.33-7.38 (m, 2H).
Example 1.197
Preparation of
2-(((1s,4s)-4-((5-(Ethylthio)-4-(2-fluoro-3-hydroxyphenyl)-3-phenyl-1H-py-
razol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 174)
[0902] From tert-butyl
2-(((1s,4s)-4-((5-(ethylthio)-4-iodo-3-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate and 2-fluoro-3-hydroxyphenylboronic acid,
the title compound (one of the two regioisomers separated) was
obtained using a similar method to the one described in Example
1.149. LCMS m/z=499.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 0.97 (t, J=7.33 Hz, 3H), 1.31-1.53 (m,
8H), 1.68-1.81 (m, 1H), 2.14-2.25 (m, 1H), 2.54 (q, J=7.33 Hz, 2H),
3.38 (d, J=6.82 Hz, 2H), 3.74 (s, 2H), 4.27 (d, J=7.33 Hz, 2H),
6.64-6.73 (m, 1H), 6.95-7.06 (m, 2H), 7.19-7.30 (m, 2H), 7.34-7.40
(m, 2H), 7.41-7.53 (m, 1H).
Example 1.198
Preparation of
2-(((1s,4s)-4-((5-(Ethylthio)-4-(3-hydroxyphenyl)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic Acid (Compound 177)
[0903] From tert-butyl
2-(((1s,4s)-4-((5-(ethylthio)-4-iodo-3-phenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetate and 3-hydroxyphenylboronic acid, the title
compound (one of the two regioisomers separated) was obtained using
a similar method to the one described in Example 1.149. LCMS
m/z=489.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 0.97 (t, J=7.33 Hz, 3H), 1.31-1.53 (m, 8H), 1.70-1.81 (m, 1H),
2.14-2.25 (m, 1H), 2.53 (q, J=7.33 Hz, 2H), 3.41 (d, J=7.07 Hz,
2H), 4.00 (s, 2H), 4.26 (d, J=7.58 Hz, 2H), 6.63-6.76 (m, 2H),
7.14-7.21 (m, 2H), 7.21-7.30 (m, 3H), 7.32-7.39 (m, 2H).
Example 1.199
Preparation of
2-(((1s,4s)-4-((4-(3-Hydroxyphenyl)-5-(2-methoxyethyl)-3-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 180)
Step A: Preparation of 5-(2-Methoxyethyl)-3-phenyl-1H-pyrazole
[0904] To a solution of acetophenone (3.5 g, 29.1 mmol) in dry
toluene (10 mL) was added LiHMDS (1.0 M in toluene) via syringe at
0.degree. C. under argon. After 5 min, 3-methoxypropanoyl chloride
(3.57 g, 29.1 mmol) was added in one portion via syringe. The ice
bath was removed and AcOH (2 mL), EtOH (100 mL), and hydrazine
hydrate (4.37 g, 87 mmol) were added. The reaction was refluxed for
2 h, cooled to room temperature, and concentrated. The residue was
extracted with EtOAc/H.sub.2O, washed with brine, dried over
MgSO.sub.4, and concentrated. The resulting residue was purified by
silica gel column chromatography to give the title compound as pale
yellow oil (2.0 g). LCMS m/z=203.1 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 2.85 (bs, 2H), 3.27 (s, 3H), 3.59
(t, J=6.82 Hz, 2H), 6.49 (s, 1H), 7.21-7.46 (m, 3H), 7.74 (m, 2H),
12.56 (s, 1H).
Step B: Preparation of
4-Bromo-5-(2-methoxyethyl)-3-phenyl-1H-pyrazole
[0905] To a solution of 5-(2-methoxyethyl)-3-phenyl-1H-pyrazole
(2.0 g, 9.89 mmol) in DCM (100 mL) was added bromine (4.74 g, 29.7
mmol) dropwise at 0.degree. C. The reaction was stirred at that
temperature for 1 h and continued at room temperature for 2 h
before quenched with Na.sub.2SO.sub.3 (10% aq.). The organics were
separated, and the aqueous layer was extracted with DCM (2.times.50
mL). The combined organics were washed with brine, dried over
MgSO.sub.4, and concentrated to give the title compound (2.5 g).
LCMS m/z=281.1 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 2.87 (t, J=6.82 Hz, 2H), 3.27 (s, 3H), 3.62 (t, J=6.82
Hz, 2H), 5.75 (s, 1H), 7.35-7.51 (m, 3H), 7.75-7.82 (m, 2H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-Bromo-5-(2-methoxyethyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate and tert-Butyl
2-(((1s,4s)-4-((4-Bromo-3-(2-methoxyethyl)-5-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate as a Mixture of Regioisomers
[0906] To a solution of
4-bromo-5-(2-methoxyethyl)-3-phenyl-1H-pyrazole (3.0 g, 10.67 mmol)
in DMF (5 mL) was added sodium hydride (0.256 g, 10.67 mmol),
followed by tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (4.40 g,
10.67 mmol). The reaction was gently heated to 45.degree. C.
overnight. After quenched with water (5 mL), the mixture was
extracted with EtOAc, washed with brine, dried over MgSO.sub.4, and
concentrated. The residue was purified by silica gel column
chromatography to give the title compound (a mixture of two
regioisomers, 4.5 g). LCMS m/z=523.4 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 1.69-1.80 (m, 4H), 1.81-1.89 (m,
4H), 1.91 (s, 9H), 2.19-2.30 (m, 2H), 2.90 (s, 3H), 3.46 (t, J=6.63
Hz, 2H), 3.89 (d, J=6.95 Hz, 2H), 4.02 (t, J=6.32 Hz, 2H), 4.43 (s,
2H), 4.56 (d, J=7.45 Hz, 2H), 7.81-7.99 (m, 3H), 8.24-8.32 (m,
2H).
Step D: Preparation of
2-(((1s,4s)-4-((4-(3-Hydroxyphenyl)-5-(2-methoxyethyl)-3-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic Acid
[0907] To a solution of tert-butyl
2-(((1s,4s)-4-(4-bromo-5-(2-methoxyethyl)-3-phenyl-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-3-(2-methoxyethyl)-5-phenyl-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetate as a mixture of regioisomers (100 mg,
0.192 mmol) in dioxane (3 mL) were added 3-hydroxyphenylboronic
acid (26.5 mg, 0.192 mmol), tetrakis(triphenylphosphine)palladium
(22 mg, 0.019 mmol), and K.sub.2CO.sub.3 (2 M aq., 0.2 mL). The
reaction was heated to 150.degree. C. under microwave irradiation
for 4 h. The reaction mixture was filtered and concentrated. The
residue was treated with HCl (4.0 M in dioxane, 5 mL) at room
temperature for 10 h. The mixture was concentrated and purified by
HPLC to give the title compound (one of the two regioisomers
separated) as a white solid (12.8 mg). LCMS m/z=479.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.32-1.57 (m, 8H),
1.73-1.82 (m, 1H), 2.07-2.18 (m, 1H), 2.83 (t, J=6.95 Hz, 2H), 3.15
(s, 3H), 3.35 (t, J=6.95 Hz, 2H), 3.43 (d, J=7.07 Hz, 2H), 4.00 (s,
2H), 4.05 (d, J=7.58 Hz, 2H), 6.56-6.75 (m, 3H), 7.14-7.26 (m, 4H),
7.30-7.37 (m, 2H).
Example 1.200
Preparation of
2-(((1s,4s)-4-((5-(2-Methoxyethyl)-4-(6-methoxypyridin-3-yl)-3-phenyl-1H--
pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
181)
[0908] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-methoxyethyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-methoxyethyl)-5-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
6-methoxypyridin-3-ylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.199. LCMS m/z=494.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.33-1.57 (m, 8H),
1.74-1.84 (m, 1H), 2.09-2.18 (m, 1H), 2.83 (t, J=6.69 Hz, 2H), 3.16
(s, 3H), 3.38 (t, J=6.69 Hz, 2H), 3.43 (d, J=7.07 Hz, 2H), 3.87 (s,
3H), 4.00 (s, 2H), 4.06 (d, J=7.33 Hz, 2H), 6.83 (d, J=8.59 Hz,
1H), 7.19-7.33 (m, 5H), 7.51 (dd, J=8.46, 2.40 Hz, 1H), 8.01 (d,
J=2.02 Hz, 1H).
Example 1.201
Preparation of
2-(((1s,4s)-4-((4-(2-Fluoro-3-hydroxyphenyl)-5-(2-methoxyethyl)-3-phenyl--
1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
182)
[0909] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-methoxyethyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-methoxyethyl)-5-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
2-fluoro-3-hydroxyphenylboronic acid, the title compound (one of
the two regioisomers separated) was obtained using a similar method
to the one described in Example 1.199. LCMS m/z=497.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.31-1.54 (m, 8H),
1.72-1.84 (m, 1H), 2.06-2.19 (m, 1H), 2.79 (t, J=6.32 Hz, 2H), 3.12
(s, 3H), 3.31 (t, J=6.95 Hz, 2H), 3.40 (d, J=6.82 Hz, 2H), 3.68 (s,
2H), 4.07 (d, J=7.07 Hz, 2H), 6.59-6.65 (m, 1H), 6.94-7.04 (m, 2H),
7.16-7.27 (m, 3H), 7.31-7.37 (m, 2H).
Example 1.202
Preparation of
2-(((1s,4s)-4-((4-(2,3-Difluorophenyl)-5-(2-methoxyethyl)-3-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 190)
[0910] From tert-butyl
2-(((1s,4s)-4-(4-bromo-5-(2-methoxyethyl)-3-phenyl-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-methoxyethyl)-5-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
2,3-difluoro-phenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.199. LCMS m/z=499.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.31-1.56 (m, 8H),
1.71-1.83 (m, 1H), 2.07-2.19 (m, 1H), 2.83 (t, J=6.32 Hz, 2H), 3.11
(s, 3H), 3.33 (t, J=6.57 Hz, 2H), 3.39 (d, J=6.82 Hz, 2H), 3.67 (s,
2H), 4.09 (d, J=7.33 Hz, 2H), 7.10-7.18 (m, 1H), 7.19-7.33 (m, 6H),
7.38-7.48 (m, 1H).
Example 1.203
Preparation of
2-(((1s,4s)-4-((4-(3-Chloro-2-fluorophenyl)-5-(2-methoxyethyl)-3-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
191)
[0911] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-methoxyethyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-3-(2-methoxyethyl)-5-phenyl-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
3-chloro-2-fluorophenylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.199. LCMS m/z=515.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.28-1.55 (m, 8H),
1.71-1.85 (m, 1H), 2.07-2.19 (m, 1H), 2.81 (t, J=5.68 Hz, 2H), 3.11
(s, 3H), 3.32 (t, J=6.44 Hz, 2H), 3.40 (d, J=6.82 Hz, 2H), 3.68 (s,
2H), 4.09 (d, J=7.33 Hz, 2H), 7.18-7.34 (m, 6H), 7.55-7.63 (m,
2H).
Example 1.204
Preparation of
2-(((1s,4s)-4-((4-(2-Fluoro-3-methylphenyl)-5-(2-methoxyethyl)-3-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
192)
[0912] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-methoxyethyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-methoxyethyl)-5-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
2-fluoro-3-methylphenylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.199. LCMS m/z=495.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.32-1.56 (m, 8H),
1.72-1.83 (m, 1H), 2.06-2.17 (m, 1H), 2.23 (s, 3H), 2.78 (t, J=5.94
Hz, 2H), 3.11 (s, 3H), 3.30 (t, J=6.06 Hz, 2H), 3.40 (d, J=6.57 Hz,
2H), 3.71 (s, 2H), 4.07 (d, J=6.82 Hz, 2H), 7.05-7.16 (m, 3H),
7.16-7.34 (m, 5H).
Example 1.205
Preparation of
2-(((1s,4s)-4-((5-(2-Methoxyethyl)-3-phenyl-4-m-tolyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid (Compound 193)
[0913] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-methoxyethyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate and tert-butyl
2-(als,4s)-4-(4-bromo-3-(2-methoxyethyl)-5-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate as a mixture of regioisomers and
m-tolylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.199. LCMS m/z=477.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.32-1.54 (m, 8H),
1.72-1.84 (m, 1H), 2.06-2.18 (m, 1H), 2.28 (s, 3H), 2.82 (t, J=6.82
Hz, 2H), 3.14 (s, 3H), 3.35 (t, J=6.82 Hz, 2H), 3.40 (d, J=7.07 Hz,
2H), 3.69 (s, 2H), 4.06 (d, J=7.33 Hz, 2H), 6.97 (d, J=7.58 Hz,
1H), 7.04 (s, 1H), 7.13 (d, J=7.58 Hz, 1H), 7.17-7.35 (m, 6H).
Example 1.206
Preparation of
2-(((1s,4s)-4-((4-(3-Fluorophenyl)-5-(2-methoxyethyl)-3-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 194)
[0914] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-methoxyethyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-methoxyethyl)-5-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
3-fluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.199. LCMS m/z=481.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.32-1.56 (m, 8H),
1.73-1.83 (m, 1H), 2.07-2.18 (m, 1H), 2.87 (t, J=6.69 Hz, 2H), 3.15
(s, 3H), 3.37 (t, J=6.69 Hz, 2H), 3.41 (d, J=7.07 Hz, 2H), 3.83 (s,
2H), 4.07 (d, J=7.33 Hz, 2H), 7.01-7.06 (m, 2H), 7.11-7.18 (m, 1H),
7.19-7.33 (m, 4H), 7.37-7.45 (m, 2H).
Example 1.207
Preparation of
2-(((1s,4s)-4-((4-(2-Methoxypyridin-4-yl)-5-methyl-3-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 195)
[0915] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate as a mixture of regioisomers and
2-methoxypyridin-4-ylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.97. LCMS m/z=450.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.32-1.54 (m, 8H),
1.71-1.80 (m, 1H), 2.04-2.13 (m, 1H), 2.28 (s, 3H), 3.42 (d, J=7.07
Hz, 2H), 3.85 (s, 3H), 3.99 (s, 2H), 4.06 (d, J=7.33 Hz, 2H), 6.62
(s, 1H), 6.74 (dd, J=5.31, 1.26 Hz, 1H), 7.26-7.35 (m, 5H), 8.10
(d, J=5.31 Hz, 1H).
Example 1.208
Preparation of
2-(((1s,4s)-4-((5-Ethyl-4-(2-methoxypyridin-4-yl)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic Acid (Compound 196)
[0916] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-ethyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-ethyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
2-methoxypyridin-4-ylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.152. LCMS m/z=464.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.06 (t, J=7.58 Hz,
3H), 1.32-1.57 (m, 8H), 1.71-1.83 (m, 1H), 2.07-2.18 (m, 1H), 2.67
(q, J=7.49 Hz, 2H), 3.43 (d, J=6.82 Hz, 2H), 3.85 (s, 3H), 4.00 (s,
2H), 4.04 (d, J=7.33 Hz, 2H), 6.61 (s, 1H), 6.76 (dd, J=5.31, 1.26
Hz, 1H), 7.22-7.34 (m, 5H), 8.12 (d, J=5.31 Hz, 1H).
Example 1.209
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-5-(2-methoxyethyl)-3-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 197)
[0917] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-methoxyethyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-methoxyethyl)-5-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
3-chlorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.199. LCMS m/z=497.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.33-1.56 (m, 8H),
1.73-1.84 (m, 1H), 2.06-2.18 (m, 1H), 2.86 (t, J=6.69 Hz, 2H), 3.15
(s, 3H), 3.37 (d, J=6.82 Hz, 2H), 3.39 (t, J=7.07 Hz, 2H), 3.75 (s,
2H), 4.06 (d, J=7.58 Hz, 2H), 7.14-7.19 (m, 1H), 7.20-7.31 (m, 6H),
7.35-7.43 (m, 2H).
Example 1.210
Preparation of
2-4(1s,4s)-4-((5-Ethyl-4-(5-methoxypyridin-3-yl)-3-phenyl-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methoxy)acetic Acid (Compound 201)
[0918] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-ethyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-ethyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers and
5-methoxypyridin-3-ylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.152. LCMS m/z=464.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.05 (t, J=7.52 Hz,
3H), 1.36-1.58 (m, 8H), 1.74-1.83 (m, 1H), 2.10-2.19 (m, 1H), 2.67
(q, J=7.45 Hz, 2H), 3.44 (d, J=7.07 Hz, 2H), 3.84 (s, 3H), 4.00 (s,
2H), 4.07 (d, J=7.45 Hz, 2H), 7.23-7.33 (m, 5H), 7.47 (dd, J=2.65,
1.64 Hz, 1H), 8.09 (d, J=1.64 Hz, 1H), 8.38 (d, J=2.78 Hz, 1H).
Example 1.211
Preparation of
2-(((1s,4s)-4-((4-(2-Fluoro-3-hydroxyphenyl)-5-(2-(methylthio)ethyl)-3-ph-
enyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid
(Compound 213)
Step A: Preparation of
5-(2-(Methylthio)ethyl)-3-phenyl-1H-pyrazole
[0919] To a solution of acetophenone (5.0 g, 41.6 mmol) in dry
toluene (10 mL) was added LiHMDS (1.0 M in toluene, 42 mL, 42 mmol)
via syringe at 0.degree. C. under argon. After 5 min,
3-(methylthio)propanoyl chloride (5.77 g, 41.6 mmol) was added in
one portion via syringe. The ice bath was removed and AcOH (5 mL),
EtOH (100 mL), and hydrazine hydrate (6.25 g, 125 mmol) were added.
The mixture was refluxed for 2 h, cooled to room temperature, and
concentrated. The residue was extracted with EtOAc/H.sub.2O, washed
with brine, dried over MgSO.sub.4, and concentrated. The resulting
residue was purified by silica gel column chromatography to give
the title compound as a pale yellow oil (6.5 g). LCMS m/z=219.2
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 2.09
(s, 3H), 2.77 (t, J=7.71 Hz, 2H), 2.84-2.95 (m, 2H), 6.53 (s, 1H),
7.18-7.50 (m, 3H), 7.63-7.84 (m, 2H), 12.60 (bs, 1H).
Step B: Preparation of
4-Bromo-5-(2-(methylthio)ethyl)-3-phenyl-1H-pyrazole
[0920] To a solution of
5-(2-(methylthio)ethyl)-3-phenyl-1H-pyrazole (4.0 g, 18.32 mmol) in
methanol (20 mL) was added N-bromosuccinimide (3.26 g, 18.32 mmol)
slowly at 0.degree. C. The reaction was stirred at 0.degree. C. for
2 h. The mixture was concentrated and purified by silica gel column
chromatography to give the title compound (3.4 g). LCMS m/z=297.0
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 2.11
(s, 3H), 2.79 (t, J=7.83 Hz, 2H), 2.83-2.97 (m, 2H), 7.32-7.56 (m,
3H), 7.67-7.88 (m, 2H), 13.20 (bs, 1H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-Bromo-5-(2-(methylthio)ethyl)-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetate and tert-Butyl
2-(((1s,4s)-4-((4-Bromo-3-(2-(methylthio)ethyl)-5-phenyl-1H-pyrazol-1-ypm-
ethyl)cyclohexyl)methoxy)acetate as a Mixture of Regioisomers
[0921] To a solution of
4-bromo-5-(2-(methylthio)ethyl)-3-phenyl-1H-pyrazole (3.4 g, 11.44
mmol) in DMF (5 mL) was added sodium hydride (0.275 g, 11.44 mmol)
at room temperature, followed by tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (4.72 g,
11.44 mmol). The reaction was heated to 45.degree. C. overnight,
cooled to room temperature, and quenched with water (5 mL). The
mixture was extracted with EtOAc, washed with brine, dried over
MgSO.sub.4, and concentrated. The residue was purified by silica
gel column chromatography to give the title compound (a mixture of
two regioisomers, 3.5 g). LCMS m/z=539.1 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 1.30-1.40 (m, 4H), 1.43 (s,
9H), 1.44-1.52 (m, 4H), 1.70-1.80 (m, 1H), 2.03-2.11 (m, 1H), 2.14
(s, 3H), 2.72 (t, J=7.07 Hz, 2H), 3.00 (t, J=7.20 Hz, 2H), 3.40 (d,
J=6.95 Hz, 2H), 3.94 (s, 2H), 4.09 (d, J=7.45 Hz, 2H), 7.32-7.51
(m, 3H), 7.75-7.84 (m, 2H).
Step D: Preparation of
2-(((1s,4s)-4-((4-(2-Fluoro-3-hydroxyphenyl)-5-(2-(methylthio)ethyl)-3-ph-
enyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid
[0922] To a solution of tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-(methylthio)ethyl)-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-(methylthio)ethyl)-5-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetate as a mixture of regioisomers (100
mg, 0.19 mmol) in dioxane were added
2-fluoro-3-hydroxyphenylboronic acid (29.6 mg, 0.19 mmol),
tetrakis(triphenylphosphine)palladium (22 mg, 0.019 mmol), and
K.sub.2CO.sub.3 (2 M aq., 0.2 mL). The reaction was heated to
150.degree. C. under microwave irradiation for 4 h. The reaction
mixture was filtered and concentrated. The residue was treated with
HCl (4.0 M in dioxane, 5 mL) at room temperature for 10 h. The
mixture was concentrated and purified by HPLC to give the title
compound (one of the two regioisomers separated) as a white solid
(15.5 mg). LCMS m/z=513.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.32-1.57 (m, 8H), 1.74-1.82 (m, 1H),
1.88 (s, 3H), 2.08-2.18 (m, 1H), 2.46 (t, J=7.71 Hz, 2H), 2.82 (t,
J=7.20 Hz, 2H), 3.43 (d, J=7.07 Hz, 2H), 4.00 (s, 2H), 4.08 (d,
J=7.45 Hz, 2H), 6.65-6.72 (m, 1H), 6.91-7.04 (m, 3H), 7.17-7.28 (m,
3H), 7.31-7.37 (m, 1H).
Example 1.212
Preparation of
2-(((1s,4s)-4-((4-(5-Methoxypyridin-3-yl)-5-methyl-3-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 214)
[0923] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohex-
yl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a mixture of regioisomers, and
5-methoxypyridin-3-ylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.97. LCMS m/z=450.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.35-1.55 (m, 8H),
1.72-1.82 (m, 1H), 2.05-2.15 (m, 1H), 2.27 (s, 3H), 3.42 (d, J=7.07
Hz, 2H), 3.81 (s, 3H), 4.00 (s, 2H), 4.08 (d, J=7.45 Hz, 2H),
7.23-7.33 (m, 5H), 7.39 (dd, J=2.65, 1.64 Hz, 1H), 8.04 (d, J=1.52
Hz, 1H), 8.32 (d, J=2.78 Hz, 1H).
Example 1.213
Preparation of
2-(((1s,4s)-4-((5-(2-(Methylthio)ethyl)-3-phenyl-4-m-tolyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic Acid (Compound 216)
[0924] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-(methylthio)ethyl)-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-(methylthio)ethyl)-5-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
m-tolylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.211. LCMS m/z=493.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.33-1.56 (m, 8H),
1.70-1.82 (m, 1H), 1.89 (s, 3H), 2.07-2.16 (m, 1H), 2.29 (s, 3H),
2.50 (t, J=7.06 Hz, 2H), 2.86 (t, J=7.33 Hz, 2H), 3.40 (d, J=6.80
Hz, 2H), 3.77 (s, 2H), 4.06 (d, J=7.45 Hz, 2H), 6.98 (d, J=7.71 Hz,
1H), 7.07 (s, 1H), 7.13 (d, J=7.58 Hz, 1H), 7.17-7.28 (m, 4H),
7.29-7.35 (m, 2H).
Example 1.214
Preparation of
2-(((1s,4s)-4-((4-(2-Fluoro-3-methylphenyl)-5-(2-(methylthio)ethyl)-3-phe-
nyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
218)
[0925] From tert-butyl
2-(((1s,4s)-4-(4-bromo-5-(2-(methylthio)ethyl)-3-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-(methylthio)ethyl)-5-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
2-fluoro-3-methylphenylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.211. LCMS m/z=511.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.33-1.56 (m, 8H),
1.73-1.81 (m, 1H), 1.85 (s, 3H), 2.09-2.17 (m, 1H), 2.23 (s, 3H),
2.46 (t, J=7.71 Hz, 2H), 2.81 (t, J=7.07 Hz, 2H), 3.41 (d, J=6.95
Hz, 2H), 3.81 (s, 2H), 4.08 (d, J=7.45 Hz, 2H), 7.07-7.14 (m, 2H),
7.18-7.26 (m, 3H), 7.26-7.35 (m, 3H).
Example 1.215
Preparation of
2-(((1s,4s)-4-((4-(3-Chloro-2-tluorophenyl)-5-(2-(methylsulfinyl)ethyl)-3-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid
(Compound 219)
[0926]
2-(((1s,4s)-4-((4-(3-Chloro-2-fluorophenyl-5-(2-(methylthio)ethyl)--
3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid
(16.4 mg, 0.031 mmol) was dissolved in DCM (2 mL) and
3-chloroperbenzoic acid (5.33 mg, 0.031 mmol) was added. After
stirred at room temperature for 30 min, the reaction mixture was
concentrated and purified by HPLC to give the title compound as a
white solid (10.8 mg). LCMS m/z=547.2 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 1.33-1.56 (m, 8H), 1.74-1.82 (m,
1H), 2.10-2.20 (m, 1H), 2.46 (s, 3H), 2.66-2.77 (m, 2H), 2.83-3.00
(m, 2H), 3.43 (d, J=7.07 Hz, 2H), 3.99 (s, 2H), 4.08-4.14 (m, 2H),
7.20-7.30 (m, 6H), 7.30-7.36 (m, 1H), 7.56-7.64 (m, 1H).
Example 1.216
Preparation of
2-(((1s,4s)-4-((5-(2-(Methylsulfinyl)ethyl)-3-phenyl-4-m-tolyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 220)
[0927] To a solution of
2-(((1s,4s)-4-((5-(2-(methylthio)ethyl)-3-phenyl-4-m-tolyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic acid (19.7 mg, 0.040 mmol) in
DCM (2 mL) was added 3-chloroperbenzoic acid (6.9 mg, 0.040 mmol).
After stirred at room temperature for 30 min, the reaction mixture
was concentrated and purified by HPLC to give the title compound as
a white solid (14.2 mg). LCMS m/z=509.2 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 1.31-1.55 (m, 8H), 1.71-1.81
(m, 1H), 2.08-2.18 (m, 1H), 2.27 (s, 3H), 2.44 (s, 3H), 2.68-2.79
(m, 2H), 2.82-2.99 (m, 2H), 3.43 (d, J=7.07 Hz, 2H), 3.98 (s, 2H),
4.04-4.10 (m, 2H), 6.97 (d, J=7.58 Hz, 1H), 7.05 (s, 1H), 7.13 (d,
J=7.58 Hz, 1H), 7.17-7.27 (m, 4H), 7.28-7.33 (m, 2H).
Example 1.217
Preparation of
2-(((1s,4s)-4-((4-(3-Hydroxyphenyl)-5-(2-(methylthio)ethyl)-3-phenyl-1H-p-
yrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
221)
[0928] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-(methylthio)ethyl)-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-3-(2-(methylthio)ethyl)-5-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
3-hydroxyphenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.211. LCMS m/z=495.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.34-1.55 (m, 8H),
1.74-1.82 (m, 1H), 1.91 (s, 3H), 2.09-2.16 (m, 1H), 2.51 (t, J=6.82
Hz, 2H), 2.86 (t, J=7.33 Hz, 2H), 3.43 (d, J=7.07 Hz, 2H), 4.00 (s,
2H), 4.06 (d, J=7.45 Hz, 2H), 6.57-6.75 (m, 3H), 7.15-7.27 (m, 4H),
7.32-7.37 (m, 2H).
Example 1.218
Preparation of
2-(((1s,4s)-4-((4-(3-Fluorophenyl)-5-(2-(methylthio)ethyl)-3-phenyl-1H-py-
razol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 222)
[0929] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-(methylthio)ethyl)-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-3-(2-(methylthio)ethyl)-5-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
3-fluorophenylboronic acid, the title compound was obtained using a
similar method to the one described in Example 1.211. LCMS
m/z=497.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.34-1.59 (m, 8H), 1.74-1.82 (m, 1H), 1.90 (s, 3H), 2.09-2.18
(m, 1H), 2.52 (t, J=6.82 Hz, 2H), 2.91 (t, J=7.33 Hz, 2H), 3.44 (d,
J=6.95 Hz, 2H), 4.00 (s, 2H), 4.08 (d, J=7.45 Hz, 2H), 7.02-7.09
(m, 2H), 7.12-7.19 (m, 1H), 7.19-7.33 (m, 5H), 7.38-7.47 (m,
1H).
Example 1.219
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-5-(2-(methylthio)ethyl)-3-phenyl-1H-py-
razol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 237)
[0930] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-(methylthio)ethyl)-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-3-(2-(methylthio)ethyl)-5-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
3-chlorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.211. LCMS m/z=513.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.35-1.55 (m, 8H),
1.74-1.82 (m, 1H), 1.90 (s, 3H), 2.09-2.17 (m, 1H), 2.53 (t, J=7.20
Hz, 2H), 2.90 (t, J=7.45 Hz, 2H), 3.43 (d, J=7.07 Hz, 2H), 3.96 (s,
2H), 4.07 (d, J=7.45 Hz, 2H), 7.15-7.19 (m, 2H), 7.22-7.32 (m, 5H),
7.37-7.41 (m, 2H).
Example 1.220
Preparation of
2-(((1s,4s)-4-((5-(2-(Methylthio)ethyl)-3,4-diphenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 238)
[0931] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-(methylthio)ethyl)-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-3-(2-(methylthio)ethyl)-5-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
phenylboronic acid, the title compound (one of the two regioisomers
separated) was obtained using a similar method to the one described
in Example 1.211. LCMS m/z=479.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.34-1.56 (m, 8H), 1.73-1.81 (m, 1H),
1.88 (s, 3H), 2.08-2.18 (m, 1H), 2.50 (t, J=7.33 Hz, 2H), 2.87 (t,
J=7.33 Hz, 2H), 3.42 (d, J=7.07 Hz, 2H), 3.88 (s, 2H), 4.07 (d,
J=7.45 Hz, 2H), 7.16-7.25 (m, 5H), 7.28-7.41 (m, 5H).
Example 1.221
Preparation of
2-(((1s,4s)-4-((5-(2-Fluoro-4-methylphenyl)-3-(2-methoxyethyl)-4-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
239)
Step A: Preparation of 5-(2-Methoxyethyl)-4-phenyl-1H-pyrazole
[0932] To a solution of 2-phenylacetaldehyde (4.0 g, 33.3 mmol) in
toluene (10 mL), were added LiHMDS (33.3 mL, 33.3 mmol) at
0.degree. C. After stirring for 10 min, 3-methoxypropanoyl chloride
(4.08 g, 33.3 mmol) was added and continued stirring for 30 min at
0.degree. C. The reaction was quenched with acetic acid (glacial, 2
mL), diluted with ethanol (75 mL), and hydrazine hydrate (5.00 g,
100 mmol) was added. The reaction was brought to reflux for 4 hrs.
After cooling to room temperature, the reaction was concentrated
and extracted with EtOAc, dried over MgSO.sub.4, and purified by
column chromatography to give the title compound as yellowish oil
(2.5 g). LCMS m/z=203.1 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 2.85 (t, J=6.69 Hz, 2H), 3.17 (s, 3H),
3.48 (t, J=6.63 Hz, 2H), 5.75 (s, 1H), 7.31-7.38 (m, 3H), 7.41-7.47
(m, 2H), 13.08 (s, 1H).
Step B: Preparation of
3-Bromo-5-(2-methoxyethyl)-4-phenyl-1H-pyrazole
[0933] To a solution of 5-(2-methoxyethyl)-4-phenyl-1H-pyrazole
(1.0 g, 4.94 mmol) in methanol (20 mL) was added N-bromosuccinimide
(0.880 g, 4.94 mmol) in portions at room temperature. After stirred
at room temperature for 16 h, the reaction was concentrated and
extracted with EtOAc/H.sub.2O, purified by column chromatography to
give the title compound as yellow oil (1.0 g). LCMS m/z=281.3
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 2.97
(t, J=6.63 Hz, 2H), 3.22 (s, 3H), 3.57 (t, J=7.07 Hz, 2H),
7.20-7.27 (m, 2H), 7.35-7.45 (m, 3H), 12.67 (bs, 1H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-((3-Bromo-5-(2-methoxyethyl)-4-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate and tert-Butyl
2-(((1s,4s)-4-(5-Bromo-3-(2-methoxyethyl)-4-phenyl-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetate as a Mixture of Regioisomers
[0934] To a solution of
3-bromo-5-(2-methoxyethyl)-4-phenyl-1H-pyrazole (1.0 g, 3.6 mmol)
in DMF (5 mL) were added cesium carbonate (1.16 g, 3.6 mmol),
followed by tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (1.47 g,
3.6 mmol). The reaction was gently heated to 80.degree. C. for 10
h. After cooled to room temperature, the reaction was quenched with
water (2 mL), extracted with EtOAc, dried over MgSO.sub.4, and
purified by column chromatography to give the title compound as
clear oil. LCMS m/z=521.5 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.33-1.42 (m, 4H), 1.43 (s, 9H),
1.44-1.52 (m, 4H), 1.70-1.81 (m, 1H), 2.04-2.14 (m, 1H), 2.91 (t,
J=6.57 Hz, 2H), 3.14 (s, 3H), 3.41 (d, J=6.95 Hz, 2H), 3.47 (t,
J=7.20 Hz, 2H), 3.95 (s, 2H), 4.04 (d, J=7.07 Hz, 2H), 7.32-7.39
(m, 3H), 7.40-7.50 (m, 2H).
Step D: Preparation of
2-(((1s,4s)-4-((5-(2-Fluoro-4-methylphenyl)-3-(2-methoxyethyl)-4-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid
[0935] To a solution of tert-butyl
2-(((1s,4s)-4-(3-bromo-5-(2-methoxyethyl)-4-phenyl-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(5-bromo-3-(2-methoxyethyl)-4-phenyl-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetate as a mixture of regioisomers (100 mg,
0.19 mmol) in dioxane (3 mL) were added
2-fluoro-4-methylphenylboronic acid (29.3 mg, 0.19 mmol),
tetrakis(triphenylphosphine)palladium (22 mg, 0.019 mmol), and
K.sub.2CO.sub.3 (2 M aq., 0.2 mL). The reaction was heated to
150.degree. C. under microwave irradiation for 4 h. After filtered
and concentrated, the residue was treated with HCl (4.0 M in
dioxane, 5 mL) at room temperature for 10 h. The mixture was
concentrated and purified by HPLC to give the title compound as
white solid (15.6 mg). LCMS m/z=495.4 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 1.05-1.18 (m, 4H), 1.21-1.36 (m,
4H), 1.56-1.67 (m, 1H), 1.85-1.97 (m, 1H), 2.33 (s, 3H), 2.84 (t,
J=7.45 Hz, 2H), 3.18 (s, 3H), 3.19 (d, J=7.07 Hz, 2H), 3.53 (t,
J=7.39 Hz, 2H), 3.74 (s, 2H), 3.81 (d, J=7.83 Hz, 2H), 7.03-7.13
(m, 5H), 7.13-7.20 (m, 2H), 7.22-7.28 (m, 2H).
Example 1.222
Preparation of
2-(((1s,4s)-4-((3-(2-Fluoro-4-methylphenyl)-5-(2-methoxyethyl)-4-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
240)
[0936] From tert-butyl
2-(((1s,4s)-4-((3-bromo-5-(2-methoxyethyl)-4-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-bromo-3-(2-methoxyethyl)-4-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
2-fluoro-4-methylphenylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.221. LCMS m/z=495.4 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.32-1.55 (m, 8H),
1.71-1.82 (m, 1H), 2.04-2.17 (m, 1H), 2.28 (s, 3H), 2.93 (t, J=6.82
Hz, 2H), 3.16 (s, 3H), 3.40 (t, J=6.63 Hz, 2H), 3.41 (d, J=6.69 Hz,
2H), 3.87 (s, 2H), 4.07 (d, J=7.45 Hz, 2H), 6.87-6.98 (m, 2H),
7.07-7.13 (m, 2H), 7.16-7.31 (m, 5H).
Example 1.223
Preparation of
2-(((1s,4s)-4-((4-(2-Fluoro-4-methylphenyl)-5-(2-methoxyethyl)-3-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
241)
[0937] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-methoxyethyl)-3-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-methoxyethyl)-5-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
2-fluoro-4-methylphenylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.199. LCMS m/z=495.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.31-1.57 (m, 8H),
1.73-1.83 (m, 1H), 2.08-2.18 (m, 1H), 2.36 (s, 3H), 2.78 (t, J=6.76
Hz, 2H), 3.12 (s, 3H), 3.30 (t, J=6.82 Hz, 2H), 3.42 (d, J=7.07 Hz,
2H), 3.92 (s, 2H), 4.07 (d, J=7.45 Hz, 2H), 7.03-7.10 (m, 2H),
7.13-7.27 (m, 4H), 7.30-7.34 (m, 2H).
Example 1.224
Preparation of
2-(((1s,4s)-4-((4-(2-Fluoro-4-methylphenyl)-5-(2-(methylthio)ethyl)-3-phe-
nyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
242)
[0938] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-(methylthio)ethyl)-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-3-(2-(methylthio)ethyl)-5-phenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
2-fluoro-4-methylphenylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.211. LCMS m/z=511.1 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.34-1.55 (m, 8H),
1.73-1.82 (m, 1H), 1.88 (s, 3H), 2.08-2.18 (m, 1H), 2.36 (s, 3H),
2.48 (t, J=7.58 Hz, 2H), 2.82 (t, J=7.20 Hz, 2H), 3.43 (d, J=7.07
Hz, 2H), 3.95 (s, 2H), 4.08 (d, J=7.45 Hz, 2H), 7.03-7.11 (m, 2H),
7.15-7.27 (m, 4H), 7.30-7.35 (m, 2H).
Example 1.225
Preparation of
2-(((1s,4s)-4-((4-(3-Methoxyphenyl)-5-(2-(methylthio)ethyl)-3-phenyl-1H-p-
yrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
243)
[0939] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-(methylthio)ethyl)-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-(methylthio)ethyl)-5-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
3-methoxyphenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.211. LCMS m/z=509.7 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.34-1.56 (m, 8H),
1.74-1.82 (m, 1H), 1.91 (s, 3H), 2.09-2.18 (m, 1H), 2.52 (t, J=8.46
Hz, 2H), 2.89 (t, J=8.21 Hz, 2H), 3.43 (d, J=6.95 Hz, 2H), 3.70 (s,
3H), 3.98 (s, 2H), 4.06 (d, J=7.33 Hz, 2H), 6.74-6.80 (m, 2H),
6.87-6.92 (m, 1H), 7.17-7.36 (m, 6H).
Example 1.226
Preparation of
2-(((1s,4s)-4-((4-(2,3-Difluorophenyl)-5-(2-(methylthio)ethyl)-3-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
244)
[0940] From tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-(methylthio)ethyl)-3-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-(methylthio)ethyl)-5-phenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetate as a mixture of regioisomers (100
mg, 0.19 mmol) and 2,3-difluorophenylboronic acid (30.0 mg, 0.19
mmol), the title compound was obtained using a similar method to
the one described in Example 1.211. LCMS m/z=515.4 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.34-1.58 (m, 8H),
1.73-1.82 (m, 1H), 1.86 (s, 3H), 2.09-2.19 (m, 1H), 2.50 (t, J=7.20
Hz, 2H), 2.86 (t, J=7.20 Hz, 2H), 3.42 (d, J=7.07 Hz, 2H), 3.90 (s,
2H), 4.09 (d, J=7.45 Hz, 2H), 7.13-7.20 (m, 1H), 7.20-7.34 (m, 6H),
7.39-7.49 (m, 1H).
Example 1.227
Preparation of
2-(((1s,4s)-4-((3-(2-Methoxyethyl)-5-(3-methoxyphenyl)-4-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 247)
[0941] From tert-butyl
2-(((1s,4s)-4-(3-bromo-5-(2-methoxyethyl)-4-phenyl-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-bromo-3-(2-methoxyethyl)-4-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
3-methoxyphenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.221. LCMS m/z=493.1 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.06-1.20 (m, 4H),
1.22-1.37 (m, 4H), 1.55-1.69 (m, 1H), 1.86-1.99 (m, 1H), 2.82 (t,
J=7.39 Hz, 2H), 3.17 (s, 3H), 3.21 (d, J=6.69 Hz, 2H), 3.51 (t,
J=7.33 Hz, 2H), 3.68 (s, 3H), 3.84 (s, 2H), 3.94 (d, J=7.45 Hz,
2H), 6.74-6.82 (m, 2H), 6.91-6.97 (m, 1H), 7.06-7.34 (m, 6H).
Example 1.228
Preparation of
2-(((1s,4s)-4-((5-(2-Methoxyethyl)-3-(3-methoxyphenyl)-4-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 248)
[0942] From tert-butyl
2-(((1s,4s)-4-((3-bromo-5-(2-methoxyethyl)-4-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((5-bromo-3-(2-methoxyethyl)-4-phenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetate as a mixture of regioisomers and
3-methoxyphenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.221. LCMS m/z=493.1 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.32-1.57 (m, 8H),
1.73-1.83 (m, 1H), 2.05-2.19 (m, 1H), 2.83 (t, J=6.76 Hz, 2H), 3.13
(s, 3H), 3.34 (t, J=6.76 Hz, 2H), 3.43 (d, J=6.95 Hz, 2H), 3.55 (s,
3H), 3.93 (s, 2H), 4.06 (d, J=7.45 Hz, 2H), 6.72-6.81 (m, 2H),
6.90-6.97 (m, 1H), 7.09-7.25 (m, 3H), 7.29-7.42 (m, 3H).
Example 1.229
Preparation of
2-(((1s,4s)-4-((4-(3-Chloro-2-fluorophenyl)-5-(2-(methylsulfonyl)ethyl)-3-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid
(Compound 249)
[0943] To a solution of
2-(((1s,4s)-4-((4-(3-chloro-2-fluorophenyl)-5-(2-(methylthio)ethyl)-3-phe-
nyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid (16.4 mg,
0.031 mmol) in DCM (2 mL) was added 3-chloroperbenzoic acid (16.0
mg, 0.093 mmol) was added. After stirred at room temperature for 30
min, the reaction mixture was concentrated and purified on prep
HPLC to give the title compound as white solid (12.3 mg). LCMS
m/z=563.3 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.34-1.58 (m, 8H), 1.73-1.84 (m, 1H), 2.11-2.23 (m, 1H), 2.95
(s, 3H), 3.01 (t, J=8.02 Hz, 2H), 3.24 (t, J=8.02 Hz, 2H), 3.43 (d,
J=6.95 Hz, 2H), 4.00 (s, 2H), 4.12 (d, J=7.33 Hz, 2H), 7.21-7.32
(m, 6H), 7.32-7.39 (m, 1H), 7.58-7.65 (m, 1H).
Example 1.230
Preparation of
2-(((1s,4s)-4-((3-(2-Cyanoethyl)-4,5-diphenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetic Acid (Compound 259)
Step A: Preparation of
3-(3-Phenyl-1H-pyrazol-5-yl)propanenitrile
[0944] To a solution of acetophenone (5.0 g, 41.6 mmol) in dry
toluene (10 mL) was added LiHMDS (1.0 M in toluene) via syringe at
0.degree. C. under argon. The reaction was allowed to stir at that
temperature for 5 min and 3-cyanopropanoyl chloride (4.89 g, 41.6
mmol) was added via syringe in one portion. The ice bath was
removed and AcOH (glacial, 5 mL), EtOH (100 mL), and hydrazine
hydrate (6.25 g, 125 mmol) were added. The mixture was brought to
reflux for 16 h. After cooled to room temperature, the reaction was
concentrated, extracted with EtOAc, dried over MgSO.sub.4, and
purified by column chromatography to give the title compound as
yellowish oil (2.5 g). LCMS m/z=198.1 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 2.87 (t, J=4.42 Hz, 2H), 2.92 (t,
J=4.04 Hz, 2H), 6.59 (s, 1H), 7.25-7.48 (m, 3H), 7.63-7.81 (m, 2H),
13.06 (bs, 1H).
Step B: Preparation of
3-(4-Bromo-3-phenyl-1H-pyrazol-5-yl)propanenitrile
[0945] To a solution of 3-(3-phenyl-1H-pyrazol-5-yl)propanenitrile
(2.0 g, 10.14 mmol) in methanol (20 mL) was added
N-bromosuccinimide (1.80 g, 10.14 mmol) in portions at room
temperature. After stirred at room temperature for 16 h, the
reaction was concentrated and extracted with EtOAc/H.sub.2O,
purified by column chromatography to give the title compound as
yellow oil (2.4 g). LCMS m/z=276.0 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 2.90 (t, J=4.80 Hz, 2H), 2.92 (t,
J=4.29 Hz, 2H), 7.33-7.59 (m, 3H), 7.76 (d, J=7.07 Hz, 2H), 13.45
(bs, 1H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-(4-Bromo-3-(2-cyanoethyl)-5-phenyl-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetate and tert-Butyl
2-(((1s,4s)-4-((4-Bromo-5-(2-cyanoethyl)-3-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate as a Mixture of Regioisomers
[0946] To a solution of
3-(4-bromo-3-phenyl-1H-pyrazol-5-yl)propanenitrile (2.0 g, 7.24
mmol) in DMF (5 mL) were added cesium carbonate (1.16 g, 3.6 mmol),
followed by tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (2.36 g,
7.24 mmol). The reaction was gently heated to 80.degree. C. for 10
h. After cooled to room temperature, the reaction was quenched with
water (2 mL), extracted with EtOAc, dried over MgSO.sub.4, and
purified by column chromatography to give the title compound as
clear oil (2.4 g) (mixture of two isomers). LCMS m/z=516.2
[M+H].sup.+.
Step D: Preparation of
2-(((1s,4s)-4-((3-(2-Cyanoethyl)-4,5-diphenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetic Acid
[0947] To a solution of tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-cyanoethyl)-5-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-cyanoethyl)-3-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate as a mixture of regioisomers (100 mg,
0.19 mmol) in dioxane (3 mL) were added phenylboronic acid (29.3
mg, 0.19 mmol), tetrakis(triphenylphosphine)palladium (22 mg, 0.019
mmol), and K.sub.2CO.sub.3 (2 M aq., 0.2 mL). The reaction was
heated to 150.degree. C. under microwave irradiation for 4 h. After
filtered and concentrated, the residue was treated with HCl (4.0 M
in dioxane, 5 mL) at room temperature for 10 h. The mixture was
concentrated and purified by HPLC to give the title compound as
white solid (13.5 mg). LCMS m/z=458.3 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 1.03-1.19 (m, 4H), 1.22-1.36 (m,
4H), 1.55-1.66 (m, 1H), 1.88-1.99 (m, 1H), 2.79 (t, J=6.95 Hz, 2H),
2.93 (t, J=7.07 Hz, 2H), 3.20 (d, J=6.95 Hz, 2H), 3.91 (s, 2H),
3.95 (d, J=7.45 Hz, 2H), 7.06-7.13 (m, 2H), 7.15-7.30 (m, 5H),
7.36-7.45 (m, 3H).
Example 1.231
Preparation of
2-(((1s,4s)-4-((5-(2-Cyanoethyl)-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cycl-
ohexyl)methoxy)acetic Acid (Compound 260)
[0948] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-cyanoethyl)-5-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-cyanoethyl)-3-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate as a mixture of regioisomers and
phenylboronic acid, the title compound (one of the two regioisomers
separated) was obtained using a similar method to the one described
in Example 1.230. LCMS m/z=458.3 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.33-1.59 (m, 8H), 1.74-1.84 (m, 1H),
2.06-2.18 (m, 1H), 2.58 (t, J=7.39 Hz, 2H), 2.97 (t, J=7.39 Hz,
2H), 3.45 (d, J=7.07 Hz, 2H), 4.00 (s, 2H), 4.10 (d, J=7.45 Hz,
2H), 7.19-7.27 (m, 5H), 7.28-7.32 (m, 2H), 7.34-7.44 (m, 3H).
Example 1.232
Preparation of
2-(((1s,4s)-4-(3-(2-Cyanoethyl)-4-(3-methoxyphenyl)-5-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 261)
[0949] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-cyanoethyl)-5-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-cyanoethyl)-3-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate as a mixture of regioisomers and
3-methoxyphenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.230. LCMS m/z=488.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.05-1.20 (m, 4H),
1.22-1.36 (m, 4H), 1.56-1.66 (m, 1H), 1.89-2.01 (m, 1H), 2.80 (t,
J=7.20 Hz, 2H), 2.95 (t, J=7.07 Hz, 2H), 3.21 (d, J=6.95 Hz, 2H),
3.60 (s, 3H), 3.91 (s, 2H), 3.94 (d, J=7.45 Hz, 2H), 6.59-6.64 (m,
1H), 6.69 (d, J=7.71 Hz, 1H), 6.75 (dd, J=8.02, 2.21 Hz, 1H), 7.17
(t, J=7.96 Hz, 1H), 7.23-7.30 (m, 2H), 7.38-7.46 (m, 3H).
Example 1.233
Preparation of
2-(((1s,4s)-4-((5-(2-Cyanoethyl)-4-(3-methoxyphenyl)-3-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 262)
[0950] From tert-butyl
2-(((1s,4s)-4-(4-bromo-3-(2-cyanoethyl)-5-phenyl-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-5-(2-cyanoethyl)-3-phenyl-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetate as a mixture of regioisomers and
3-methoxyphenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.230. LCMS m/z=488.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.33-1.59 (m, 8H),
1.76-1.84 (m, 1H), 2.08-2.18 (m, 1H), 2.61 (t, J=7.33 Hz, 2H), 2.99
(t, J=7.33 Hz, 2H), 3.45 (d, J=7.20 Hz, 2H), 3.72 (s, 3H), 4.00 (s,
2H), 4.10 (d, J=7.45 Hz, 2H), 6.79 (s, 1H), 6.80 (d, J=1.64 Hz,
1H), 6.90-6.94 (m, 1H), 7.19-7.27 (m, 3H), 7.28-7.37 (m, 3H).
Example 1.234
Preparation of
2-(((1s,4s)-4-((5-(2-Cyanoethyl)-4-(3-hydroxyphenyl)-3-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 263)
[0951] From tert-butyl
2-(((1s,4s)-4-(4-bromo-3-(2-cyanoethyl)-5-phenyl-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-cyanoethyl)-3-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate as a mixture of regioisomers and
3-hydroxyphenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.230. LCMS m/z=474.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.31-1.59 (m, 8H),
1.73-1.84 (m, 1H), 2.07-2.17 (m, 1H), 2.58 (t, J=7.39 Hz, 2H), 2.97
(t, J=7.39 Hz, 2H), 3.45 (d, J=7.07 Hz, 2H), 4.00 (s, 2H), 4.09 (d,
J=7.45 Hz, 2H), 6.59-6.62 (m, 1H), 6.68 (d, J=7.58 Hz, 1H),
6.73-6.78 (m, 1H), 7.17-7.28 (m, 5H), 7.31-7.37 (m, 1H).
Example 1.235
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-3-(2-cyanoethyl)-5-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 264)
[0952] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-cyanoethyl)-5-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-5-(2-cyanoethyl)-3-phenyl-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetate as a mixture of regioisomers and
3-chlorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.230. LCMS m/z=492.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.04-1.20 (m, 4H),
1.22-1.36 (m, 4H), 1.55-1.66 (m, 1H), 1.90-2.01 (m, 1H), 2.82 (t,
J=6.95 Hz, 2H), 2.95 (t, J=6.95 Hz, 2H), 3.21 (d, J=6.95 Hz, 2H),
3.92 (s, 2H), 3.95 (d, J=7.45 Hz, 2H), 7.04-7.09 (m, 2H), 7.11-7.14
(m, 1H), 7.21-7.32 (m, 4H), 7.40-7.47 (m, 2H).
Example 1.236
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-5-(2-cyanoethyl)-3-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 265)
[0953] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-cyanoethyl)-5-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-5-(2-cyanoethyl)-3-phenyl-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetate as a mixture of regioisomers and
3-chlorophenylboronic acid, the title compound was obtained using a
similar method to the one described in Example 1.230. LCMS
m/z=492.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .sup.8
ppm 1.32-1.60 (m, 8H), 1.76-1.84 (m, 1H), 2.09-2.18 (m, 1H), 2.63
(t, J=7.26 Hz, 2H), 3.00 (t, J=7.33 Hz, 2H), 3.45 (d, J=7.07 Hz,
2H), 4.01 (s, 2H), 4.10 (d, J=7.45 Hz, 2H), 7.19-7.33 (m, 7H),
7.40-7.44 (m, 2H).
Example 1.237
Preparation of
2-(((1s,4s)-4-(3-(2-Cyanoethyl)-4-(3-fluorophenyl)-5-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 266)
[0954] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-cyanoethyl)-5-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-cyanoethyl)-3-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate as a mixture of regioisomers and
3-fluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.230. LCMS m/z=476.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.04-1.22 (m, 4H),
1.23-1.36 (m, 4H), 1.57-1.67 (m, 1H), 1.91-2.00 (m, 1H), 2.82 (t,
J=7.20 Hz, 2H), 2.97 (t, J=7.07 Hz, 2H), 3.22 (d, J=6.82 Hz, 2H),
3.92 (s, 2H), 3.96 (d, J=7.58 Hz, 2H), 6.86-6.96 (m, 2H), 6.97-7.05
(m, 1H), 7.24-7.33 (m, 3H), 7.40-7.46 (m, 3H).
Example 1.238
Preparation of
2-(((1s,4s)-4-((5-(2-Cyanoethyl)-4-(3-fluorophenyl)-3-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 267)
[0955] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-cyanoethyl)-5-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-cyanoethyl)-3-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate as a mixture of regioisomers and
3-fluorophenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.230. LCMS m/z=476.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.33-1.61 (m, 8H),
1.75-1.86 (m, 1H), 2.09-2.19 (m, 1H), 2.62 (t, J=7.33 Hz, 2H), 3.01
(t, J=7.33 Hz, 2H), 3.46 (d, J=7.07 Hz, 2H), 4.01 (s, 2H), 4.11 (d,
J=7.58 Hz, 2H), 7.05-7.11 (m, 2H), 7.14-7.21 (m, 1H), 7.21-7.34 (m,
5H), 7.40-7.48 (m, 1H).
Example 1.239
Preparation of
2-(((1s,4s)-4-((3-(2-Cyanoethyl)-4-(3-hydroxyphenyl)-5-phenyl-1H-pyrazol--
1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 268)
[0956] From tert-butyl
2-(((1s,4s)-4-(4-bromo-3-(2-cyanoethyl)-5-phenyl-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-bromo-5-(2-cyanoethyl)-3-phenyl-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetate as a mixture of regioisomers and
3-hydroxyphenylboronic acid, the title compound (one of the two
regioisomers separated) was obtained using a similar method to the
one described in Example 1.230. LCMS m/z=474.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.03-1.19 (m, 4H),
1.20-1.36 (m, 4H), 1.54-1.67 (m, 1H), 1.87-1.97 (m, 1H), 2.78 (t,
J=7.01 Hz, 2H), 2.91 (t, J=7.01 Hz, 2H), 3.20 (d, J=6.82 Hz, 2H),
3.91 (s, 2H), 3.93 (d, J=8.08 Hz, 2H), 6.46-6.54 (m, 2H), 6.59 (dd,
J=8.15, 1.58 Hz, 1H), 7.04 (t, J=7.83 Hz, 2H), 7.22-7.28 (m, 2H),
7.38-7.46 (m, 2H).
Example 1.240
Preparation of
2-(((1s,4s)-4-((4-(3-Chloro-2-fluorophenyl)-3-(2-cyanoethyl)-5-phenyl-1H--
pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
269)
[0957] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-cyanoethyl)-5-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-cyanoethyl)-3-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate as a mixture of regioisomers and
3-chloro-2-fluorophenylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.230. LCMS m/z=510.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 0.99-1.15 (m, 4H),
1.16-1.34 (m, 4H), 1.55-1.67 (m, 1H), 1.81-1.93 (m, 1H), 2.82-2.94
(m, 4H), 3.16 (d, J=6.95 Hz, 2H), 3.68 (s, 2H), 3.98 (d, J=7.45 Hz,
2H), 7.39-7.46 (m, 3H), 7.48-7.60 (m, 5H).
Example 1.241
Preparation of
2-(((1s,4s)-4-((4-(3-Chloro-2-fluorophenyl)-5-(2-cyanoethyl)-3-phenyl-1H--
pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
270)
[0958] From tert-butyl
2-(((1s,4s)-4-((4-bromo-3-(2-cyanoethyl)-5-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-bromo-5-(2-cyanoethyl)-3-phenyl-1H-pyrazol-1-yl)methyl)-
cyclohexyl)methoxy)acetate as a mixture of regioisomers and
3-chloro-2-fluorophenylboronic acid, the title compound (one of the
two regioisomers separated) was obtained using a similar method to
the one described in Example 1.230. LCMS m/z=510.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.27-1.56 (m, 8H),
1.71-1.83 (m, 1H), 2.00-2.11 (m, 1H), 2.83 (t, J=7.20 Hz, 2H), 3.11
(t, J=7.26 Hz, 2H), 3.41 (d, J=7.20 Hz, 2H), 3.81 (s, 2H), 4.11 (d,
J=7.58 Hz, 2H), 7.35-7.42 (m, 2H), 7.42-7.49 (m, 3H), 7.79-7.85 (m,
3H).
Example 1.242
Preparation of
2-(((1s,4s)-4-((3-(2-Fluoro-4-methylphenyl)-5-(2-hydroxyethyl)-4-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
287)
Step A: Preparation of Ethyl
3-(2-Fluoro-4-methylphenyl)-3-oxo-2-phenylpropanoate
[0959] 2-Fluoro-4-methylbenzoyl chloride was made 2 h before the
reaction by adding oxalyl chloride (3.20 mL, 36.5 mmol) to a
solution of 2-fluoro-4-methylbenzoic acid (4.69 g, 30.5 mmol) in
DCM (5 mL) at room temperature. After stirring for 2 h, the
resulting solution was concentrated to dryness and dissolved in THF
(10 mL), used as it was without further purification.
[0960] The solution of ethyl 2-phenylacetate (5 g, 30.5 mmol) in
THF (20 mL) was cooled to -78.degree. C. and LiHMDS (30.5 mL, 30.5
mmol) was added, followed by prior made solution of
2-fluoro-4-methylbenzoyl chloride in THF (10 mL). The reaction was
allowed to warm to room temperature slowly and stirred for 4 h.
Quenched with AcOH (2 mL), extracted with EtOAc, washed with brine,
dried over MgSO.sub.4, and purified by column chromatography to
give the title compound as clear liquid (7.10 g). LCMS m/z=301.2
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.14
(t, J=7.07 Hz, 3H), 2.32 (s, 3H), 4.22 (q, J=7.07 Hz, 2H), 5.77 (s,
1H), 7.03-7.17 (m, 3H), 7.24-7.40 (m, 4H), 7.82 (t, J=8.21 Hz,
1H).
Step B: Preparation of
1-(2-Fluoro-4-methylphenyl)-2-phenylethanone
[0961] Ethyl 3-(2-fluoro-4-methylphenyl)-3-oxo-2-phenylpropanoate
(8.0 g, 26.6 mmol) was dissolved in THF (20 mL) and hydrogen
chloride (37% wt., 32.0 mL, 400 mmol) was added. The reaction was
brought to reflux overnight. After cooled to room temperature, the
reaction was diluted with H.sub.2O (100 mL) and neutralized to pH 8
with NaOH (4.0 M aq.). The mixture was extracted with EtOAc
(3.times.75 mL), dried over MgSO.sub.4, and purified by column
chromatography to give the title compound as a clear oil (4.81 g).
LCMS m/z=229.1 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 2.36 (s, 3H), 4.28 (s, 2H), 7.11-7.18 (m, 2H),
7.19-7.26 (m, 3H), 7.27-7.34 (m, 2H), 7.77 (t, J=8.21 Hz, 1H).
Step C: Preparation of
1-(1H-Benzo[d][1,2,3]triazol-1-yl)but-3-en-1-one
[0962] Sulfurous dichloride (6.91 g, 58.1 mmol) was added to a
stirred solution of 1H-benzo[d][1,2,3]triazole (27.7 g, 232 mmol)
in anhydrous dichloromethane (100 mL) at room temperature under
argon atmosphere. The mixture was stirred for 30 min and
but-3-enoic acid (5.0 g, 58.1 mmol) was added in one portion and
stirring was continued for 2 h. The resulting suspension was
filtered off and washed with 2.0 M NaOH (3.times.50 mL), dried over
MgSO.sub.4, and purified by column chromatography to give the title
compound as white solid (5.12 g). LCMS m/z=188.1 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 4.24 (d, J=6.57 Hz,
2H), 5.28-5.42 (m, 2H), 6.04-6.19 (m, 1H), 7.61 (t, J=7.71 Hz, 1H),
7.78 (t, J=7.71 Hz, 1H), 8.24 (dd, J=10.61, 8.34 Hz, 2H).
Step D: Preparation of
5-Allyl-3-(2-fluoro-4-methylphenyl)-4-phenyl-1H-pyrazole
[0963] To a solution of
1-(2-fluoro-4-methylphenyl)-2-phenylethanone (1.0 g, 4.38 mmol) in
THF (10 mL) was added LiHMDS (1.0 M in THF) (8.76 mL, 8.76 mmol)
slowly via syringe at 0.degree. C. After stirring for 10 min,
1-(1H-benzo[d][1,2,3]triazol-1-yl)but-3-en-1-one (0.984 g, 5.26
mmol) was added in one portion. The reaction was stirred at
0.degree. C. for 30 min before quenched with AcOH (2 mL). To the
reaction were added EtOH (30 mL), hydrazine hydrate (0.658 g, 13.14
mmol), and heated to reflux for 1 h. After cooled to room
temperature, the reaction was concentrated and extracted with
EtOAc/H.sub.2O, washed with brine, dried over MgSO.sub.4, and
purified by column chromatography to give the title compound as
clear oil (0.50 g). LCMS m/z=293.2 [M+H].sup.+; NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 2.31 (s, 3H), 3.40 (d, J=5.94 Hz, 2H),
4.94-5.08 (m, 2H), 5.88-6.00 (m, 1H), 6.92-7.31 (m, 8H).
Step E: Preparation of
2-(3-(2-Fluoro-4-methylphenyl)-4-phenyl-1H-pyrazol-5-yl)ethanol
[0964] 5-Allyl-3-(2-fluoro-4-methylphenyl)-4-phenyl-1H-pyrazole
(1.0 g, 3.42 mmol) was dissolved in methanol (40 mL) and
dichloromethane (10 mL) and cooled to -78.degree. C. on a
dry-ice/acetone bath. Ozone was bubbled through the solution for
.about.2 h, until the solution appeared light blue. To the reaction
added sodium borohydride (0.129 g, 3.42 mmol) slowly. Upon complete
addition, the reaction was removed from the dry-ice bath and
stirred at room temperature for 1 h. Excess solvent was removed
under reduced pressure and the reaction was extracted with
EtOAc/H.sub.2O, dried over MgSO.sub.4, and purified by column
chromatography to give the title compound as clear oil (0.70 g).
LCMS m/z=297.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 2.30 (s, 3H), 2.79 (t, J=7.20 Hz, 2H), 3.62 (t, J=7.33
Hz, 2H), 6.93-7.00 (m, 1H), 7.09-7.14 (m, 2H), 7.15-7.23 (m, 3H),
7.25-7.31 (m, 2H), 12.86 (bs, 1H).
Step F: Preparation of tert-Butyl
2-(((1s,4s)-4-(3-(2-Fluoro-4-methylphenyl)-5-(2-hydroxyethyl)-4-phenyl-1H-
-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
[0965] To a solution of
2-(3-(2-fluoro-4-methylphenyl)-4-phenyl-1H-pyrazol-5-ypethanol (0.7
g, 2.362 mmol) in DMF (10 mL) were added cesium carbonate (0.770 g,
2.362 mmol) and tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (0.974 g,
2.362 mmol). The reaction was gently heated to 60.degree. C. for 2
h. After cooled to room temperature, the reaction mixture was
extracted with EtOAC/H.sub.2O, dried over MgSO.sub.4, and purified
by column chromatography to give the title compound as a clear oil
(0.75 g). LCMS m/z=537.5 [M+H].sup.+; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 1.14-1.29 (m, 4H), 1.33-1.46 (m, 4H), 1.47
(s, 9H), 1.72-1.81 (m, 1H), 2.00-2.09 (m, 1H), 2.37 (s, 3H), 2.91
(t, J=5.56 Hz, 2H), 3.30 (d, J=7.07 Hz, 2H), 3.89 (s, 2H), 3.90 (d,
J=7.33 Hz, 2H), 3.91 (t, J=5.81 Hz, 2H), 4.68 (s, 1H), 6.89-7.01
(m, 2H), 7.04-7.10 (m, 1H), 7.13-7.27 (m, 5H).
Step G: Preparation of
2-(((1s,4s)-4-((3-(2-Fluoro-4-methylphenyl)-5-(2-hydroxyethyl)-4-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
287)
[0966] tert-Butyl
2-(((1s,4s)-4-((3-(2-fluoro-4-methylphenyl)-5-(2-hydroxyethyl)-4-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate (0.50 g, 0.932
mmol) was dissolved in hydrogen chloride (4.0 M in dioxane) (4.66
mL, 18.63 mmol) and stirred at room temperature for 16 h. The
reaction was concentrated and purified by HPLC to give the title
compound. LCMS m/z=481.6 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.07-1.19 (m, 4H), 1.21-1.41 (m, 4H),
1.55-1.72 (m, 1H), 1.86-1.97 (m, 1H), 2.33 (s, 3H), 3.22 (d, J=6.82
Hz, 2H), 3.59 (t, J=5.81 Hz, 2H), 3.82 (t, J=5.85 Hz, 2H), 3.91 (s,
2H), 3.93 (d, J=7.54 Hz, 2H), 4.55 (s, 1H), 7.03-7.12 (m, 4H),
7.13-7.19 (m, 2H), 7.22-7.27 (m, 2H).
Example 1.243
Preparation of
2-(((1s,4s)-4-((5-(2-fluoro-4-methylphenyl)-3-(2-hydroxyethyl)-4-phenyl-1-
H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
285)
[0967] The title compound was obtained using a similar method to
the one described in Example 1.242. LCMS m/z=481.6 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.32-1.53 (m, 8H),
1.71-1.81 (m, 1H), 2.08-2.17 (m, 1H), 2.28 (s, 3H), 2.84 (t, J=7.07
Hz, 2H), 3.41 (d, J=7.07 Hz, 2H), 3.49 (t, J=7.20 Hz, 2H), 3.93 (s,
2H), 4.08 (d, J=7.58 Hz, 2H), 4.45 (s, 1H), 6.86-6.98 (m, 1H),
7.08-7.13 (m, 2H), 7.16-7.31 (m, 5H).
Example 1.244
Preparation of
2-(((1s,4s)-4-((5-(2-(Methylsulfonyl)ethyl)-4-phenyl-3-p-tolyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 290)
Step A: Preparation of
1-(1H-benzo[d][1,2,3]triazol-1-yl)-3-(methylthio)propan-1-one
[0968] Sulfurous dichloride (4.95 g, 41.6 mmol) was added to a
stirred solution of 1H-benzo[d][1,2,3]triazole (19.83 g, 166 mmol)
in anhydrous dichloromethane (300 mL) at room temperature under
argon. The mixture was stirred for 30 min and
3-(methylthio)propanoic acid (5.0 g, 41.6 mmol) was added in one
portion and stirring was continued for 2 h. The resulting
suspension was filtered off and the filtrated was washed with 2 M
NaOH (3.times.50 mL), dried over MgSO.sub.4, and purified by column
chromatography to give the title compound as clear oil (5.12 g).
LCMS m/z=222.1 [M+H].sup.+; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 2.21 (s, 3H), 3.05 (t, J=7.07 Hz, 2H), 3.74 (t, J=7.07
Hz, 2H), 7.42-7.54 (m, 1H), 7.56-7.69 (m, 1H), 8.08 (d, J=8.34 Hz,
1H), 8.24 (d, J=8.08 Hz, 1H).
Step B: Preparation of
5-(2-(Methylthio)ethyl)-4-phenyl-3-p-tolyl-1H-pyrazole
[0969] To a solution of 2-phenyl-1-p-tolylethanone (2.0 g, 9.51
mmol) in THF (10 mL) was added LiHMDS (1.0 M in THF) (19.02 mL,
19.02 mmol) slowly via syringe at 0.degree. C. After stirring for
10 min,
1-(1H-benzo[d][1,2,3]triazol-1-yl)-3-(methylthio)propan-1-one (2.53
g, 11.41 mmol) was added in one portion. The reaction was stirred
at 0.degree. C. for 30 min before quenched with AcOH (2 mL). To the
reaction were added EtOH (30 mL), hydrazine hydrate (1.428 g, 28.5
mmol), and brought to reflux for 2 h. After cooled to room
temperature, the reaction was concentrated and extracted with
EtOAc/H.sub.2O, washed with brine, dried over MgSO.sub.4, and
purified by column chromatography to give the title compound a as
clear oil (1.50 g). LCMS m/z=309.3 [M+H].sup.+; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 1.96 (s, 3H), 2.29 (s, 3H), 2.66 (t,
J=7.71 Hz, 2H), 2.90 (t, J=7.58 Hz, 2H), 7.01-7.06 (m, 2H),
7.18-7.25 (m, 3H), 7.26-7.37 (m, 3H).
Step C: Preparation of tert-butyl
2-(((1s,4s)-4-((5-(2-(Methylthio)ethyl)-4-phenyl-3-p-tolyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetate
[0970] To a solution of
5-(2-(methylthio)ethyl)-4-phenyl-3-p-tolyl-1H-pyrazole (0.5 g,
1.621 mmol) in DMF (10 mL) were added cesium carbonate (0.528 g,
1.621 mmol) and tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (0.669 g,
1.621 mmol). The reaction was gently heated to 60.degree. C. for 2
h. After cooled to room temperature, the mixture was extracted with
EtOAc/H.sub.2O, dried over MgSO.sub.4, and purified by column
chromatography to give the title compound as a clear oil. LCMS
m/z=549.5 [M+H].sup.+; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
ppm 1.10-1.27 (m, 4H), 1.29-1.45 (m, 4H), 1.46 (s, 9H), 1.53-1.61
(m, 1H), 1.73-1.81 (m, 1H), 2.04 (s, 3H), 2.35 (s, 3H), 2.73 (t,
J=7.58 Hz, 2H), 2.99 (t, J=7.58 Hz, 2H), 3.28 (d, J=6.82 Hz, 2H),
3.88 (s, 2H), 3.96 (d, J=7.58 Hz, 2H), 7.04-7.10 (m, 4H), 7.11-7.18
(m, 3H), 7.18-7.24 (m, 2H).
Step D: Preparation of
2-(((1s,4s)-4-((5-(2-(Methylsulfonyl)ethyl)-4-phenyl-3-p-tolyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 290)
[0971] tert-Butyl
2-(((1s,4s)-4-((5-(2-(methylthio)ethyl)-4-phenyl-3-p-tolyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetate (0.50 g, 0.911 mmol) was
dissolved in hydrogen chloride (4.0 M in dioxane) (4.56 mL, 18.22
mmol) and stirred at room temperature for 16 h. The reaction was
concentrated to dryness and dissolved in dichloromethane (5 mL) and
3-chloroperoxybenzoic acid (0.550 g, 3.19 mmol) was added. After
stirred at room temperature for 1 h, the reaction was concentrated
and purified on HPLC. LCMS m/z=525.4 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 1.08-1.20 (m, 4H), 1.23-1.36 (m,
4H), 1.57-1.68 (m, 1H), 1.90-2.00 (m, 1H), 2.32 (s, 3H), 2.97 (s,
3H), 3.04 (t, J=8.59 Hz, 2H), 3.22 (d, J=6.82 Hz, 2H), 3.41 (t,
J=8.08 Hz, 2H), 3.92 (d, J=7.38 Hz, 2H), 3.92 (s, 2H), 7.08-7.15
(m, 3H), 7.16-7.31 (m, 6H).
Example 1.245
Preparation of
2-(((1s,4s)-4-((3-(2-Fluoro-4-methylphenyl)-5-(2-(methylsulfonypethyl)-4--
phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid
(Compound 291)
Step A: Preparation of
3-(2-Fluoro-4-methylphenyl)-5-(2-(methylthio)ethyl)-4-phenyl-1H-pyrazole
[0972] To a solution of
1-(2-fluoro-4-methylphenyl)-2-phenylethanone (2.0 g, 8.76 mmol) in
THF (10 mL) was added LiHMDS (1.0 M in THF) (17.52 mL, 17.52 mmol)
slowly via syringe at 0.degree. C. After stirring for 10 min,
1-(1H-benzo[d][1,2,3]triazol-1-yl)-3-(methylthio)propan-1-one
(2.327 g, 10.51 mmol) was added in one portion. The reaction was
stirred at 0.degree. C. for 30 min before quenched with AcOH (2
mL). To the reaction were added EtOH (30 mL), hydrazine hydrate
(1.316 g, 26.3 mmol), and brought to reflux for 2 h. After cooled
to room temperature, the reaction was concentrated and extracted
with EtOAc/H.sub.2O, washed with brine, dried over MgSO.sub.4, and
purified by column chromatography to give the title compound as a
clear oil (1.40 g). LCMS m/z=327.2 [M+H].sup.+; .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 1.94 (s, 3H), 2.22 (s, 3H), 2.65 (t,
J=7.33 Hz, 2H), 2.88 (t, J=7.58 Hz, 2H), 6.71 (d, J=7.83 Hz, 1H),
6.80 (d, J=11.87 Hz, 1H), 6.97 (t, J=7.96 Hz, 1H), 7.09-7.29 (m,
5H), 9.64 (bs, 1H).
Step B: Preparation of tert-Butyl
2-(((1s,4s)-4-((3-(2-Fluoro-4-methylphenyl)-5-(2-(methylthio)ethyl)-4-phe-
nyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate
[0973] To a solution of
3-(2-fluoro-4-methylphenyl)-5-(2-(methylthio)ethyl)-4-phenyl-1H-pyrazole
(0.5 g, 1.532 mmol) in DMF (10 mL) were added cesium carbonate
(0.499 g, 1.532 mmol) and tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (0.632 g,
1.532 mmol). The reaction was gently heated to 60.degree. C. for 2
h. After cooled to room temperature, the mixture was extracted with
EtOAc/H.sub.2O, dried over MgSO.sub.4, and purified by column
chromatography to give the title compound as a clear oil. LCMS
m/z=567.5 [M+H].sup.+; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
ppm 1.31-1.44 (m, 4H), 1.46 (s, 9H), 1.52-1.65 (m, 4H), 1.69-1.81
(m, 1H), 1.84-1.92 (m, 1H), 2.04 (s, 3H), 2.35 (s, 3H), 2.55 (t,
J=7.83 Hz, 2H), 2.74 (t, J=7.58 Hz, 2H), 3.47 (d, J=7.07 Hz, 2H),
3.96 (s, 2H), 4.08 (d, J=7.33 Hz, 2H), 6.84-7.01 (m, 2H), 7.06-7.18
(m, 3H), 7.19-7.32 (m, 3H).
Step C: Preparation of
2-(((1s,4s)-4-((3-(2-Fluoro-4-methylphenyl)-5-(2-(methylsulfonyl)ethyl)-4-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid
(Compound 291)
[0974] tert-Butyl
2-(((1s,4s)-4-((3-(2-fluoro-4-methylphenyl)-5-(2-(methylthio)ethyl)-4-phe-
nyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate (0.50 g,
0.882 mmol) was dissolved in hydrogen chloride (4.0 M in dioxane)
(4.41 mL, 17.64 mmol) and stirred at room temperature for 16 h. The
reaction was concentrated and dissolved in DCM (5 mL).
3-Chloroperoxybenzoic acid (0.533 g, 3.09 mmol) was added. After
stirred at room temperature for 1 h, the reaction was concentrated
and the residue was purified by HPLC to give the title compound.
LCMS m/z=543.4 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.05-1.20 (m, 4H), 1.23-1.37 (m, 4H), 1.57-1.69 (m,
1H), 1.89-1.99 (m, 1H), 2.34 (s, 3H), 2.97 (s, 3H), 3.06 (t, J=8.21
Hz, 2H), 3.22 (d, J=6.82 Hz, 2H), 3.43 (t, J=8.21 Hz, 2H), 3.92 (d,
J=7.33 Hz, 2H), 3.91 (s, 2H), 7.05-7.14 (m, 3H), 7.15-7.23 (m, 3H),
7.24-7.31 (m, 2H).
Example 1.246
Preparation of
2-(((1s,4s)-4-((5-(2-Hydroxyethyl)-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid (Compound 292)
Step A: Preparation of 5-Allyl-4-phenyl-3-p-tolyl-1H-pyrazole
[0975] To a solution of 2-phenyl-1-p-tolylethanone (1.0 g, 4.76
mmol) in THF (10 mL) added LiHMDS (1.0 M in THF) (9.51 mL, 9.51
mmol) slowly via syringe at 0.degree. C. After stirring for 10 min,
1-(1H-benzo[d][1,2,3]triazol-1-yl)but-3-en-1-one (1.068 g, 5.71
mmol) was added in one portion. The reaction was stirred at
0.degree. C. for 30 min and then quenched with AcOH (2 mL). EtOH
(30 mL) and hydrazine hydrate (0.714 g, 14.27 mmol) were added, and
the reaction was heated to reflux for 30 min. The reaction was
cooled to room temperature, concentrated and the residue was
extracted with EtOAc/H.sub.2O, washed with brine, dried over
MgSO.sub.4, and purified by column chromatography to give the title
compound as clear oil (0.47 g). LCMS m/z=275.0 [M+H].sup.+; .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. ppm 2.31 (s, 3H), 3.38-3.43 (m,
2H), 5.07-5.14 (m, 2H), 5.90-6.01 (m, 1H), 7.03-7.09 (m, 2H),
7.19-7.30 (m, 5H), 7.30-7.36 (m, 2H).
Step B: Preparation of
2-(4-Phenyl-3-p-tolyl-1H-pyrazol-5-yl)ethanol
[0976] 5-Allyl-4-phenyl-3-p-tolyl-1H-pyrazole (1.0 g, 3.64 mmol)
was dissolved in methanol (40 mL) and dichloromethane (10 mL) and
cooled to -78.degree. C. on a dry-ice/acetone bath. Ozone was
bubbled through the solution for .about.2 h, until the solution
appeared light blue. To the reaction was added sodium borohydride
(0.138 g, 3.64 mmol) and the reaction was removed from the dry-ice
bath and stirred at room temperature for 1 h. Excess solvent was
removed under reduced pressure and the reaction was extracted with
EtOAc/H.sub.2O, dried over MgSO.sub.4, and purified by column
chromatography to give the title compound as white solid (0.54 g).
LCMS m/z=279.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 2.25 (s, 3H), 2.71 (t, J=7.33 Hz, 2H), 3.57 (t, J=7.33
Hz, 2H), 4.65 (bs, 1H), 7.03-7.09 (m, 2H), 7.16-7.23 (m, 3H),
7.24-7.31 (m, 2H), 7.32-7.40 (m, 2H).
Step C: Preparation of tert-Butyl
2-(((1s,4s)-4-((5-(2-Hydroxyethyl)-4-phenyl-3-p-tolyl-1H-pyrazol-1-ypmeth-
yl)cyclohexyl)methoxy)acetate
[0977] To a solution of
2-(4-phenyl-3-p-tolyl-1H-pyrazol-5-yl)ethanol (0.7 g, 2.51 mmol) in
DMF (10 mL) were added cesium carbonate (0.819 g, 2.51 mmol) and
tert-butyl 2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate
(1.037 g, 2.51 mmol). The reaction was gently heated to 60.degree.
C. for 2 h. The reaction was cooled to room temperature and
extracted with EtOAc/H.sub.2O. The organic layer was dried over
MgSO.sub.4 and purified by column chromatography to give the title
compound as clear oil (0.75 g). LCMS m/z=519.5 [M+H].sup.+; .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.34-1.45 (m, 4H), 1.49 (s,
9H), 1.55-1.63 (m, 4H), 1.72-1.80 (m, 1H), 1.85-1.93 (m, 1H), 2.28
(s, 3H), 2.90 (t, J=6.95 Hz, 2H), 3.47 (d, J=7.07 Hz, 2H), 3.66 (t,
J=6.44 Hz, 2H), 3.96 (s, 2H), 4.09 (d, J=7.58 Hz, 2H), 6.98-7.10
(m, 2H), 7.12-7.24 (m, 2H), 7.24-7.37 (m, 5H).
Step D: Preparation of
2-(((1s,4s)-4-((5-(2-Hydroxyethyl)-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid (Compound 292)
[0978] tert-Butyl
2-(((1s,4s)-4-((5-(2-hydroxyethyl)-4-phenyl-3-p-tolyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetate (0.50 g, 0.964 mmol) was dissolved
in hydrogen chloride (4.0 M in dioxane) (4.82 mL, 19.28 mmol) and
stirred at room temperature for 16 h. The reaction was concentrated
and purified by HPLC to give the title compound. LCMS m/z=463.4
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.31-1.57 (m, 8H), 1.73-1.83 (m, 1H), 2.09-2.19 (m, 1H), 2.24 (s,
3H), 2.75 (t, J=7.20 Hz, 2H), 3.44 (t, J=7.20 Hz, 2H), 3.44 (d,
J=6.82 Hz, 2H), 4.00 (s, 2H), 4.07 (d, J=7.33 Hz, 2H), 7.00-7.05
(m, 2H), 7.16-7.22 (m, 4H), 7.27-7.40 (m, 3H).
Example 1.247
Preparation of
2-(((1r,4r)-4-((5-(4-Fluorophenyl)-3-(methylthio)-4-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic Acid (Compound 1)
Step A: Preparation of
3-(4-Fluorophenyl)-5-(methylthio)-4-phenyl-1H-pyrazole
[0979] To a solution of 1-(4-fluorophenyl)-2-phenylethanone (1.0 g,
4.67 mmol) in anhydrous THF (10 mL), was added a solution of 1.0 M
KO-t-Bu in THF (2 mL). The reaction was stirred for 15 min at room
temperature, and then quenched with CS.sub.2 (0.38 g, 5.04 mmol).
After stirring for 30 min, iodomethane (1.45 g, 10.22 mmol) was
added to the reaction over 5 min. The reaction was maintained at
the same temperature for 4 h. The reaction was poured into water
and extracted with ethyl acetate. The extract was dried over
MgSO.sub.4 and concentrated under reduced pressure to give a yellow
solid (1.02 g). To the suspension of the above-mentioned yellow
solid in ethanol (10 mL), hydrazine hydrate (0.70 g, 14.0 mmol) was
added at room temperature. The reaction was refluxed for 4 h. After
cooling to room temperature, the mixture was concentrated under
reduced pressure and extracted with ethyl acetate. The organic
extract was dried over MgSO.sub.4 and concentrated under reduced
pressure. The residue was poured into 10% ethyl acetate in hexane
and the precipitate was filtered and dried in air to give the title
compound (0.69 g) as a white solid. LCMS m/z=285.4 [M+H].sup.+.
Step B: Preparation of
(2-(((1r,4r)-4-((5-(4-Fluorophenyl)-3-(methylthio)-4-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic Acid
[0980] To a solution of
3-(4-fluorophenyl)-5-(methylthio)-4-phenyl-1H-pyrazole (150 mg,
0.528 mmol) and tert-butyl
2-(((1r,4r)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (218 mg,
0.528 mmol) in DMF (3 mL) was added sodium hydride (12.66 mg, 0.528
mmol) at room temperature. The reaction was heated at 60.degree. C.
overnight. After cooling to room temperature, the reaction was
poured into water and extracted with ethyl acetate. The organic
extract was concentrated under reduced pressure and the resulting
residue was purified by HPLC to give the title compound (29 mg).
LCMS m/z=469.8 [M+H].sup.+.
Example 1.248
Preparation of
2-(((1r,4r)-4-((3-(4-Fluorophenyl)-5-(methylthio)-4-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic Acid (Compound 2)
[0981] From 3-(4-fluorophenyl)-5-(methylthio)-4-phenyl-1H-pyrazole
and tert-butyl
2-(((1r,4r)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate, the title
compound was obtained using a similar method to the one described
in Example 1.247, Step B. LCMS m/z=469.5 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 0.95 (m, 2H), 1.15 (m, 2H),
1.56 (m, 1H), 1.74 (m, 2H), 181 (m, 2H), 1.89 (m, 1H), 2.10 (s,
3H), 3.25 (d, J=6.4 Hz, 2H), 3.89 (s, 2H), 4.20 (d, J=7.2 Hz, 2H),
7.12-7.20 (m, 2H), 7.23-7.49 (m, 7H).
Example 1.249
Preparation of
2-4(1r,4r)-4-((4-(3-Methoxyphenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 6)
Step A: Preparation of 3-Methyl-5-phenyl-1H-pyrazole
[0982] To a solution of 1-phenylbutane-1,3-dione (5.0 g, 30.8 mmol)
in ethanol (50 mL), was added hydrazine hydrate (1.54 g, 30.8 mmol)
at ambient temperature. The reaction was refluxed for 5 h. After
cooling, the reaction was concentrated under reduced pressure and
extracted with ethyl acetate. The extract was dried over MgSO.sub.4
and concentrated under reduced pressure. The residue was added 10%
ethyl acetate in hexane. The precipitate was filtered and washed
with hexane. The white solid was dried in air to give the title
compound (3.9 g). LCMS m/z=159.3 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 2.25 (s, 3H), 6.65 (s, 1H), 7.34 (m, 1H),
7.42 (m, 2H), 7.82 (m, 2H).
Step B: Preparation of 4-Iodo-3-methyl-5-phenyl-1H-pyrazole
[0983] To a solution of 5-methyl-3-phenyl-1H-pyrazole (1.5 g, 9.48
mmol) in THF (20 mL) and water (20 mL), were added sodium iodide
(1.42 g, 9.48 mmol), iodine (3.61 g, 14.22 mmol), and
K.sub.2CO.sub.3 (1.96 g, 14.22 mmol) at room temperature. The
reaction was warmed to 100.degree. C. and stirred for 10 h. After
cooling to room temperature, the reaction was poured into water and
extracted with ethyl acetate, which was washed with 2.0 M aq.
sodium thiosulfite and saturated. NaHCO.sub.3 successively. The
extract was dried over MgSO.sub.4 and concentrated under reduced
pressure to give a semi-solid, which was recrystallized from 10%
ethyl acetate in hexane to give the title compound (1.9 g). LCMS
m/z=285.5 [M+H].sup.+.
Step C: Preparation of tert-Butyl
2-(((1r,4r)-4-((4-Iodo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-Butyl
2-(((1r,4r)-4-((4-Iodo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a Mixture of Regioisomers
[0984] To a solution of 4-iodo-5-methyl-3-phenyl-1H-pyrazole (1.0
g, 3.52 mmol) in DMF (10 mL), was added sodium hydride (0.084 g,
3.52 mmol) at ambient temperature. After stirring for 10 min, a
solution of tert-butyl
2-(((1r,4r)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (1.45 g,
3.52 mmol) in DMF (1 mL) was added at room temperature. The
reaction was hea.ted to 45.degree. C. and stirred for 8 h. After
cooling to room temperature, the reaction was poured into H.sub.2O
and extracted with ethyl acetate, which was dried over MgSO.sub.4
and concentrated under reduced pressure. The resulting residue was
purified by silica gel column chromatography to give the title
compound (1.25 g) as a colorless oil. LCMS m/z=525.4
[M+H].sup.+.
Step D: Preparation of
(2-(((1r,4r)-4-(4-(3-Methoxyphenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid
[0985] To a solution of regioisomers, tert-butyl
2-(((1r,4r)-4-((4-iodo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1r,4r)-4-((4-iodo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate (200 mg, 0.381 mmol), in dioxane (2 mL), were
added 3-methoxyphenylboronic acid (58.0 mg, 0.381 mmol),
Pd(PPh.sub.3).sub.4 (22.03 mg, 0.019 mmol), and a 2.0 M aqueous
solution of K.sub.2CO.sub.3 (105 mg, 0.763 mmol) at ambient
temperature. The reaction was irradiated under microwave for 1.5 h
at 150.degree. C. After cooling to room temperature, the reaction
was poured into water, extracted with ethyl acetate, and then dried
over MgSO.sub.4. The extract was concentrated under reduced
pressure and the residue was treated with 4.0 M HCl (5 mL) at room
temperature. After stirring for 10 h, the reaction was concentrated
under reduced pressure and purified by HPLC to give the title
compound (25 mg). LCMS m/z=449.3 [M+H].sup.+.
Example 1.250
Preparation of
2-(((1r,4r)-4-((4-(3-Methoxyphenyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid (Compound 7)
[0986] From a mixture of regioisomers, tert-butyl
2-(((1r,4r)-4-(4-iodo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl-
)methoxy)acetate and tert-butyl
2-(((1r,4r)-4-(4-iodo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl-
)methoxy)acetate, and 3-methoxyphenylboronic acid, the title
compound was obtained using a similar method to the one described
in Example 1.250, Step D. LCMS m/z=449.5 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 0.91 (m, 2H), 1.15 (m, 2H),
1.59 (m, 1H), 1.75 (m, 2H), 1.82 (m, 2H), 1.95 (m, 1H), 2.25 (s,
3H), 2.51 (s, 3H), 3.24 (d, J=6.8 Hz, 2H), 3.75 (s, 2H), 4.01 (d,
J=7.4 Hz, 2H), 6.65-6.89 (m, 3H), 7.26-7.49 (m, 6H).
Example 1.251
Preparation of
2-(((1r,4r)-4-((5-Methyl-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)m-
ethoxy)acetic Acid (Compound 11)
[0987] To a solution of regioisomers, tert-butyl
2-(((1r,4r)-4-((4-iodo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1r,4r)-4-((4-iodo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate (200 mg, 0.381 mmol), in dioxane (2 mL), were
added phenylboronic acid (0.046 g, 0.381 mmol), Pd(PPh.sub.3).sub.4
(0.022 g, 0.019 mmol), and a 2.0 M aqueous solution of
K.sub.2CO.sub.3 (0.105 g, 0.763 mmol) at ambient temperature. The
reaction was irradiated under microwave for 4 h at 150.degree. C.
After cooling to room temperature, the reaction was poured into
water, extracted with ethyl acetate, and then dried over
MgSO.sub.4. The extract was concentrated under reduced pressure and
the residue was treated with 4.0 M HCl (5 mL). After stirring for
10 h, the reaction was concentrated under reduced pressure and
purified by HPLC to give the title compound (0.104 g). LCMS
m/z=419.3 [M+H].sup.+.
Example 1.252
Preparation of
2-(((1s,4s)-4-((5-(4-Fluorophenyl)-3-(methylthio)-4-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic Acid (Compound 12)
[0988] To a solution of
3-(4-fliorophenyl)-5-(methylthio)-4-phenyl-1H-pyrazole (150.0 mg,
0.502 mmol) in DMF (5 mL), was added sodium hydride (12.66 mg,
0.528 mmol) at room temperature. After stirring for 30 min, a
solution of tert-butyl
2-(((1r,4r)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (218 mg,
0.528 mmol) in DMF (1 mL) was added into the reaction at room
temperature. The reaction was heated at 60.degree. C. overnight.
After cooling to room temperature, the reaction was poured into
water and extracted with ethyl acetate. The extract was
concentrated under reduced pressure and the residue was treated
with 4.0 M HCl in dioxane (5 mL). After standing for 10 h, the
reaction was concentrated under reduced pressure and purified by
HPLC to give the title compound (21.0 mg). LCMS m/z=469.5
[M+H].sup.+.
Example 1.253
Preparation of
2-(((1s,4s)-4-((3-(4-Fluorophenyl)-5-(methylthio)-4-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic Acid (Compound 10)
[0989] From 3-(4-fliorophenyl)-5-(methylthio)-4-phenyl-1H-pyrazole
and tert-butyl 2-(((1r,4r)-4-(tosyloxymethyl)cyclohexyl)methoxy),
the title compound was obtained using a similar method to the one
described in Example 1.252. LCMS m/z=496.4 [M+H].sup.+.
Example 1.254
Preparation of
2-(((1s,4s)-4-((4-(3-Methoxyphenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid (Compound 13)
Step A: Preparation of tert-Butyl
2-0(1r,4s)-4-((4-Iodo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl-
)methoxy)acetate and tert-Butyl
2-(((1r,4s)-4-((4-Iodo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate as a Mixture of Regioisomers
[0990] To a solution of 4-iodo-5-methyl-3-phenyl-1H-pyrazole (1.0
g, 3.52 mmol) in DMF (5 mL), was added sodium hydride (0.084 g,
3.52 mmol) at room temperature. After stirring for 30 min, the
reaction was treated with tert-butyl
2-(a1r,4r)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (1.32 g,
0.528 mmol) in DMF (5 mL) at ambient temperature. The reaction was
stirred at 60.degree. C. for 12 h. The reaction was poured into
H.sub.2O and extracted with ethyl acetate. The organic extract was
dried over MgSO.sub.4 and concentrated under reduced pressure. The
residue was purified by column chromatography to give the titled
compounds (1.2 g) as a mixture of regioisomers. LCMS m/z=525.7
[M+H].sup.+.
Step B: Preparation of
(2-(((1s,4s)-4-((4-(3-Methoxyphenyl)-3-methyl-5-phenyl-1H-pyrazol-1-yl)me-
thyl)cyclohexyl)methoxy)acetic Acid
[0991] To a solution of regioisomers, tert-butyl
2-(((1r,4s)-4-((4-iodo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1r,4s)-4-((4-iodo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate (0.2 g, 0.381 mmol), in dioxane (5 mL), were
added 3-methoxyphenylboronic acid (0.058 g, 0.381 mmol),
Pd(PPh.sub.3).sub.4(0.022 g, 0.019 mmol), and a 2.0 M aqueous
solution of K.sub.2CO.sub.3 (0.131 g, 0.952 mmol) at ambient
temperature. The reaction was irradiated under microwave for 4 h at
150.degree. C. After cooling to room temperature, the mixture was
poured into water and extracted with ethyl acetate. The extract was
concentrated under reduced pressure and the residue was treated
with 4.0 M HCl in dioxane (5 mL). After standing for 10 h, the
reaction was concentrated under reduced pressure and purified by
HPLC to give the title compound (0.032 g). LCMS m/z=449.2
[M+H].sup.+.
Example 1.255
Preparation of
(((1s,4s)-4-((5-Methyl-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)met-
hanol
Step A: Preparation of
(E)-1-Benzylidene-2-(((1s,4s)-4-(benzyloxymethyl)cyclohexyl)methyl)hydraz-
ine
[0992] To a solution of tert-butyl
2-(((1s,4s)-4-(benzyloxymethyl)cyclohexyl)methyl)hydrazinecarboxylate
(1.0 g, 2.87 mmol) in dichloromethane (5 mL), was added TFA (5.0
mL) at room temperature. After stirring for 3 h at the same
temperature, the mixture was concentrated under reduced pressure.
The resulting residue was dissolved in THF (10.0 mL) and
benzaldehyde (0.31 g, 2.87 mmol) was added at room temperature.
After stirring for 30 min, the reaction was poured into water and
extracted with ethyl acetate. The organic layer was washed with
sat.NaHCO.sub.3, dried over MgSO.sub.4, and concentrated under
reduced pressure to give the titled compound (0.96 g) without
further purification. LCMS m/z=337.4 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 1.32-1.55 (m, 8H), 1.75-1.85 (m,
2H), 3.11 (m, 2H), 3.31 (d, J=2.5 Hz, 2H), 4.45 (s, 2H), 7.21-7.54
(m, 11H).
Step B: Preparation of
1-(((1s,4s)-4-(Benzyloxymethyl)cyclohexyl)methyl)-5-methyl-3,4-diphenyl-1-
H-pyrazole
[0993] To a solution of
(E)-1-benzylidene-2-(((1s,4s)-4-(benzyloxymethyl)cyclohexyl)methyl)hydraz-
ine (0.77 g, 2.28 mmol) and (E)-(2-nitroprop-1-enyl)benzene (0.37
g, 2.28 mmol) in THF (5 mL) at -78.degree. C., was added potassium
butan-1-olate (0.25 g, 2.28 mmol) dropwise. After stirring for 10
min, TFA (0.35 mL, 4.58 mmol) was added at the same temperature and
maintained for 2 h. After warmed to room temperature, the reaction
was poured into water and extracted with ethyl acetate. The organic
layer was dried over MgSO.sub.4, and concentrated under reduced
pressure. The residue was purified by silica gel to give the title
compound (0.45 g). LCMS m/z=451.3 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 1.29-1.52 (m, 8H), 1.75-1.80 (m,
1H), 2.11-2.15 (m, 1H), 2.22 (s, 3H), 3.30 (s, 2H), 3.42 (d, J=2.5
Hz, 2H), 4.14 (d, J=2.4 Hz, 2H), 7.23-7.42 (m, 15H).
Step C: Preparation of
Ols,4s)-4-((5-Methyl-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)metha-
nol
[0994] To a solution of
1-(((1s,4s)-4-(benzyloxymethyl)cyclohexyl)methyl)-5-methyl-3,4-diphenyl-1-
H-pyrazole (100 mg, 0.22 mmol) in MeOH (5 mL), was added ammonium
formate (280 mg, 4.44 mmol) followed by 10% Pd/C (5 mg). The
reaction was heated to 80.degree. C. for 10 h. The mixture was
filtered. The filtrate was concentrated under reduced pressure to
give the titled compound (78 mg) as a colorless oil. LCMS m/z=361.2
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.34-1.55 (m, 8H), 1.56-1.60 (m, 1H), 2.10-2.15 (m, 1H), 2.21 (s,
3H), 3.31 (d, J=2.5 Hz, 2H), 4.20 (d, J=2.4 Hz, 2H), 7.31-7.54 (m,
10H).
Example 1.256
Preparation of
2-(((1s,4s)-4-((3-Methyl-4,5-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)m-
ethoxy)acetic Acid (Compound 15)
[0995] To a solution of regioisomers, tert-butyl
2-(((1r,4s)-4-((4-iodo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1r,4s)-4-(4-iodo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl-
)methoxy)acetate (0.2 g, 0.381 mmol), in dioxane (5 mL), were added
phenylboronic acid (0.183 g, 1.5 mmol), Pd(PPh.sub.3).sub.4 (86.6
mg, 0.0075 mmol) and a 2.0 M aqueous solution of K.sub.2CO.sub.3
(0.513 g, 3.5 mmol) at ambient temperature. The reaction was
irradiated under microwave for 1.5 h at 150.degree. C. After
cooling to room temperature, the reaction was poured into water and
extracted with ethyl acetate. The organic extract was concentrated
under reduced pressure and the residue was treated with 4.0 M HCl
in dioxane (5 mL). After standing for 10 h, the reaction was
concentrated under reduced pressure and purified by HPLC to give
the title compound (0.075 g). LCMS m/z=419.3 [M+H].sup.+.
Example 1.257
Preparation of
2-(((1s,4s)-4-((5-Methyl-3,4-diphenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)m-
ethoxy)acetic Acid (Compound 16)
[0996] From a mixture of regioisomers, tert-butyl
2-(((1r,4s)-4-((4-iodo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexy-
l)methoxy)acetate and tert-butyl
2-(((1r,4s)-4-(4-iodo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexye-
methoxy)acetate, and phenylboronic acid, the title compound was
obtained using a similar method to the one described in Example
1.256. LCMS m/z=419.4 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.25-1.64 (m, 8H), 1.75 (m, 1H), 2.11 (m,
1H), 2.20 (s, 3H), 3.45 (d, J=7.1 Hz, 2H), 4.05 (s, 2H), 4.12 (d,
J=7.3 Hz, 2H), 7.23-7.46 (m, 10H).
Example 1.258
Preparation of
2-(((1s,4s)-4-((4-(3-Methoxyphenyl)-3-(methylthio)-5-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 30)
Step A: Preparation of
4-(3-Methoxyphenyl)-5-(methylthio)-3-phenyl-1H-pyrazole
[0997] To a solution of 2-(3-methoxyphenyl)-1-phenylethanone (3.0
g, 13.26 mmol) in anhydrous THF (10 mL), was added a solution of
1.0 M KO-t-Bu in THF (13.26 mL, 13.26 mmol). The reaction was
stirred for 15 min at room temperature, and carbon disulfide (1.01
g, 13.26 mmol) was added at 0.degree. C. After 15 min, iodomethane
(4.12 g, 29.0 mmol) was added dropwise and the reaction was
maintained at the same temperature for 4 h. The reaction was poured
into water and extracted with ethyl acetate. The organic extract
was dried over MgSO.sub.4 and concentrated under reduced pressure.
The residue was suspended in ethanol (10 mL) and added hydrazine
hydrate (1.99 g, 39.8 mmol) at room temperature. The reaction was
refluxed for 4 h. After cooling to room temperature, the reaction
was concentrated under reduced pressure and extracted with ethyl
acetate. The organic extract was dried over MgSO.sub.4 and
concentrated under reduced pressure to give a semi-solid, which was
recrystallized from 10% ethyl acetate in hexane to give the title
compound (2.15 g). LCMS m/z=297.5 [M+H].sup.+.
Step B: Preparation of
(2-(((1s,4s)-4-((4-(3-Methoxyphenyl)-3-(methylthio)-5-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic Acid
[0998] To a solution of
4-(3-methoxyphenyl)-5-(methylthio)-3-phenyl-1H-pyrazole (100 mg,
0.337 mmol) in DMF (2 mL), was added sodium hydride (8.10 mg, 0.337
mmol) at ambient temperature. After stirring for 10 min, a solution
of tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (139 mg,
0.337 mmol) in DMF (1 mL) was added at room temperature. The
reaction was heated to 45.degree. C. and stirred for 8 h. After
cooling to room temperature, the reaction was poured into H.sub.2O
and extracted with ethyl acetate, which was dried over MgSO.sub.4
and concentrated under reduced pressure. The resulting residue was
treated with 4.0 M HCl in dioxane and stirred for overnight. The
reaction was concentrated under reduced pressure and the residue
was purified by HPLC to give the title compound (21 mg). LCMS
m/z=481.6 [M.sub.+H].sup.+.
Example 1.259
Preparation of
1-(((1s,4s)-4-(Benzyloxymethyl)cyclohexyl)methyl)-3-(4-fluorophenyl)-5-me-
thyl-4-phenyl-1H-pyrazole
Step A: Preparation of
(E)-1-(((1s,4s)-4-(benzyloxymethyl)cyclohexyl)methyl)-2-(4-fluorobenzylid-
ene)hydrazine
[0999] To a solution of tert-butyl
2-(((1s,4s)-4-(benzyloxymethyl)cyclohexyl)methyl)hydrazinecarboxylate
(1.0 g, 2.87 mmol) in dichloromethane (5 mL), was added TFA (5.0
mL) at room temperature. After stirring for 3 h at the same
temperature, the reaction was concentrated under reduced pressure.
The resulting residue was dissolved in THF (10 mL) and
4-fluorobenzaldehyde (0.36 g, 2.87 mmol) was added at room
temperature. After stirring for 30 min, the reaction was poured
into water and extracted with ethyl acetate. The organic layer was
washed with saturated NaHCO.sub.3, dried over MgSO.sub.4, and then
concentrated under reduced pressure to give the title compound
(0.96 g) without further purification. LCMS m/z=355.3
[M+H].sup.+.
Step B: Preparation of
1-(((1s,4s)-4-(Benzyloxymethyl)cyclohexyl)methyl)-3-(4-fluorophenyl)-5-me-
thyl-4-phenyl-1H-pyrazole
[1000] To a solution of
(E)-1-(((1s,4s)-4-(benzyloxymethyl)cyclohexyl)methyl)-2-(4-fluorobenzylid-
ene)hydrazine (0.97 g, 2.73 mmol) and
(E)-(2-nitroprop-1-enyl)benzene (0.445 g, 2.73 mmol) in THF (5 mL)
at -78.degree. C., was added potassium butan-1-olate (0.31 g, 2.73
mmol) dropwise. After stirring for 10 min, TFA (0.42 mL, 5.45 mmol)
was added and the reaction maintained at -78.degree. C. for 2 h.
After warmed to room temperature, the reaction was poured into
water and extracted with ethyl acetate. The organic layer was dried
over MgSO.sub.4 and concentrated under reduced pressure. The
resulting residue was purified by silica gel column chromatography
to give the title compound (0.2 g). LCMS m/z=469.3.
Example 1.260
Preparation of
2-(((1s,4s)-4-((5-(4-Methoxyphenyl)-3-(methylthio)-4-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 36)
Step A: Preparation of
3-(4-Methoxyphenyl)-5-(methylthio)-4-phenyl-1H-pyrazole
[1001] To a solution of 1-(4-methoxyphenyl)-2-phenylethanone (3.7
g, 16.35 mmol) in anhydrous THF (10 mL), was added a solution of
1.0 M KO-t-Bu in THF at ambient temperature. The reaction was
stirred for 15 min at room temperature, then CS.sub.2 (1.345 g,
17.66 mmol) was added. After 5 min, iodomethane (5.08 g, 35.8 mmol)
was added and the reaction was stirred for 4 h. The reaction was
poured into water and extracted with ethyl acetate. The extract was
dried over MgSO.sub.4 and concentrated under reduced pressure. The
residue was dissolved in ethanol (10 mL) and added hydrazine
hydrate (2.45 g, 49.1 mmol) at room temperature. The reaction was
refluxed for 4 h. After cooling, the reaction was poured into water
and extracted with ethyl acetate. The organic layer was dried over
MgSO.sub.4 and concentrated under reduced pressure. The residue was
purified by column chromatography to give the title compound (3.95
g) as a solid. LCMS m/z=297.4 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 2.41 (s, 3H), 3.72 (s, 3H), 6.72-6.90 (m,
2H), 7.10-7.43 (m, 7H).
Step B: Preparation of
(2-(((1s,4s)-4-((5-(4-Methoxyphenyl)-3-(methylthio)-4-phenyl-1H-pyrazol-1-
-yl)methyl)cyclohexyl)methoxy)acetic Acid
[1002] To a solution of
3-(4-methoxyphenyl)-5-(methylthio)-4-phenyl-1H-pyrazole (100 mg,
0.337 mmol) in DMF (2 mL), was added sodium hydride (8.10 mg, 0.337
mmol) at ambient temperature. After stirring for 10 min, a solution
of tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (139 mg,
0.337 mmol) in DMF (1 mL) was added at room temperature. The
reaction was heated to 45.degree. C. and stirred for 8 h. After
cooling to room temperature, the reaction was poured into H.sub.2O
and extracted with ethyl acetate, which was dried over MgSO.sub.4
and concentrated under reduced pressure. The resulting residue was
treated with 4.0 M HCl in dioxane and stirred for overnight. The
reaction was concentrated under reduced pressure and the residue
was purified by HPLC to give the title compound (31 mg). LCMS
m/z=481.6 [M+H].sup.+.
Example 1.261
Preparation of
2-(((1s,4s)-4-((3-(4-Methoxyphenyl)-5-(methylthio)-4-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 37)
[1003] From 3-(4-methoxyphenyl)-5-(methylthio)-4-phenyl-1H-pyrazole
and tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate, the title
compound was obtained using a similar method to the one described
in Example 1.260, Step B. LCMS m/z=481.5 [M+H].sup.+.
Example 1.262
Preparation of
2-(((1s,4s)-4-((3-(Methylthio)-4,5-diphenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetic Acid (Compound 75)
Step A: Preparation of
3,3-Bis(methylthio)-1,2-diphenylprop-2-en-1-one
[1004] To a solution of 1,2-diphenylethanone (5.0 g, 25.5 mmol) in
anhydrous THF (50 mL), was added a solution of 1.0 M KO-t-Bu in THF
(51.0 mL, 51.0 mmol). The reaction was stirred for 15 min at room
temperature, and then K.sub.2CO.sub.3 (2.095 g, 27.5 mmol) was
added. After 10 min, iodomethane (7.92 g, 55.8 mmol) was added and
the reaction was stirred for 4 h. The reaction was poured into
water and extracted with ethyl acetate. The organic layer was dried
over MgSO.sub.4 and concentrated under reduced pressure to give the
title compound (6.9 g). LCMS m/z=301.3 [M+H].sup.+.
Step B: Preparation of 5-(Methylthio)-3,4-diphenyl-1H-pyrazole
[1005] To a suspension of
3,3-bis(methylthio)-1,2-diphenylprop-2-en-1-one (2.5 g, 8.32 mmol)
in ethanol (20 mL), was added hydrazine hydrate (1.67 g, 33.3 mmol)
at room temperature. The reaction was refluxed for 6 h. After
cooling, the reaction was poured into water and extracted with
ethyl acetate. The organic extract was dried over MgSO.sub.4 and
concentrated under reduced pressure. The residue was purified by
column chromatography to give the title compound (1.98 g). LCMS
m/z=267.0 [M+H].sup.+.
Step C: Preparation of
(2-(((1s,4s)-4-((3-(Methylthio)-4,5-diphenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetic Acid
[1006] To a solution of 5-(methylthio)-3,4-diphenyl-1H-pyrazole
(100 mg, 0.375 mmol) in DMF (3 mL), was added sodium hydride (9.01
mg, 0.375 mmol) at ambient temperature. After stirring for 10 min,
a solution of tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (155 mg,
0.375 mmol) in DMF (1 mL) was added at room temperature. The
reaction was heated to 45.degree. C. and stirred for 8 h. The
reaction was poured into H.sub.2O and extracted with ethyl acetate,
which was dried over MgSO.sub.4 and concentrated under reduced
pressure. The resulting residue was treated with 4.0 M HCl in
dioxane and stirred overnight. The reaction was concentrated under
reduced pressure and purified by HPLC to give the title compound
(19 mg). LCMS m/z=451.6 [M+H].sup.+.
Example 1.263
Preparation of
2-(((1s,4s)-4-((3-(2-Methoxyethylthio)-4,5-diphenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic Acid (Compound 188)
Step A: Preparation of
5-(2-Methoxyethylthio)-3,4-diphenyl-1H-pyrazole
[1007] To a solution of 3,4-diphenyl-1H-pyrazole-5(4H)-thione (0.5
g, 1.981 mmol) in DMF (5 mL), were added 1-bromo-2-methoxyethane
(0.275 g, 1.981 mmol) and K.sub.2CO.sub.3 (0.274 g, 1.981 mmol) at
room temperature. After stirring for 4 h, the reaction was poured
into water and extracted with ethyl acetate. The organic extract
was dried over MgSO.sub.4 and concentrated under reduced pressure.
The resulting residue was purified by column chromatography to give
the title compound (0.45 g). LCMS m/z=311.2 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 3.23 (s, 3H), 3.12-3.54 (m,
4H), 7.22-7.49 (m, 10H), 13.2 (s, 1H).
Step B: Preparation of
(2-(((1s,4s)-4-((3-(2-Methoxyethylthio)-4,5-diphenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid
[1008] To a solution of
5-(2-methoxyethylthio)-3,4-diphenyl-1H-pyrazole (180 mg, 0.580
mmol) in DMF (2 mL), was added sodium hydride (13.92 mg, 0.580
mmol) in 0.degree. C. After stirring for 10 min, tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (239 mg,
0.580 mmol) was added and the reaction was warmed to 40.degree. C.
After stirring for 12 h, the reaction was poured into water and
extracted with ethyl acetate. The organic extract was dried over
MgSO.sub.4 and concentrated under reduced pressure. The residue was
treated with 4.0 M HCl in dioxane (5 mL) and placed for 8 h. The
mixture was concentrated under reduced pressure and purified by
HPLC to give the title compound (32 mg). LCMS m/z=495.7
[M+H].sup.+.
Example 1.264
Preparation of
2-(((1s,4s)-4-((4-(2,5-Difluorophenyl)-3-(methylthio)-5-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 77)
[1009] To a solution of regioisomers, tert-butyl
2-(((1s,4s)-4-((4-iodo-3-methylthio-5-phenyl-1H-pyrazol-1H-yl)methyl)cycl-
ohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-5-methylthio-3-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate (110 mg, 0.198 mmol), in dioxane (2 mL), were
added 2,5-difluorophenylboronic acid (31.2 mg, 0.198 mmol),
Pd(PPh.sub.3).sub.4 (11.42 mg, 9.88 .mu.mol), and a 2.0 M aqueous
solution of K.sub.2CO.sub.3 (54.6 mg, 0.395 mmol) at ambient
temperature. The reaction was irradiated under microwave for 1.5 h
at 150.degree. C. The reaction was filtered and concentrated under
reduced pressure. The residue was treated with 4.0 M HCl (5 mL).
After stirring for 10 h, the reaction was concentrated under
reduced pressure and purified by HPLC to give the title compound
(19 mg). LCMS m/z=487.4 [M+H].sup.+.
Example 1.265
Preparation of
2-(((1s,4s)-4-((4-(2,5-Difluorophenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 78)
[1010] From regioisomers, tert-butyl
2-(((1s,4s)-4-((4-iodo-3-methylthio-5-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-5-methylthio-3-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate, and 2,5-difluorophenylboronic acid, the
title compound was obtained using a similar method to the one
described in Example 1.264. LCMS m/z=487.8 [M+H].sup.+.
Example 1.266
Preparation of
2-(((1s,4s)-4-((4-(2,3-Difluorophenyl)-3-(methylthio)-5-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 82)
[1011] To a mixture of regioisomers, tert-butyl
2-(((1s,4s)-4-(4-iodo-3-methylthio-5-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-5-methylthio-3-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate (110 mg, 0.198 mmol), in dioxane (2 mL), were
added 2,3-difluorophenylboronic acid (31.2 mg, 0.198 mmol),
Pd(PPh.sub.3).sub.4 (11.42 mg, 9.88 .mu.mol), and a 2.0 M aqueous
solution of K.sub.2CO.sub.3 (54.6 mg, 0.395 mmol) at ambient
temperature. The reaction was irradiated under microwave for 1.5 h
at 150.degree. C. After cooling to room temperature, the reaction
was poured into water and extracted with ethyl acetate. The organic
extract was concentrated under reduced pressure and the resulting
residue was treated with 4.0 M HCl in dioxane (5 mL). After
standing for 10 h, the reaction was concentrated under reduced
pressure and purified by HPLC to give the title compound (13 mg).
LCMS m/z=487.4 [M+H].sup.+.
Example 1.267
Preparation of
2-(((1s,4s)-4-((4-(2,3-Difluorophenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 83)
[1012] From a mixture of regioisomers, tert-butyl
2-(((1s,4s)-4-(4-iodo-3-methylthio-5-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate and tert-butyl
2-(((1r,4r)-4-((4-iodo-5-methylthio-3-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate, and 2,3-difluorophenylboronic acid, the
title compound was obtained using a similar method to the one
described in Example 1.266. LCMS m/z=487.4 [M+H].sup.+.
Example 1.268
Preparation of
2-(((1s,4s)-4-((4-(3-Isopropoxyphenyl)-3-(methylthio)-5-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 84)
[1013] To a mixture of regioisomers, tert-butyl
2-(((1s,4s)-4-((4-iodo-3-methylthio-5-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate and tert-butyl
2-(als,4s)-4-(4-iodo-5-methylthio-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)methoxy)acetate (110 mg, 0.198 mmol, 1:3 mixture), in dioxane
(2 mL), were added 3-isopropoxyphenylboronic acid (35.6 mg, 0.198
mmol), Ph(PPh.sub.3).sub.4 (11.42 mg, 9.88 .mu.mol), and a 2.0 M
aqueous solution of K.sub.2CO.sub.3 (54.6 mg, 0.395 mmol) at
ambient temperature. The reaction was irradiated under microwave
for 1.5 h at 150.degree. C. After cooling to room temperature, the
reaction was poured into water and extracted with ethyl acetate.
The extract was concentrated under reduced pressure and the
resulting residue was treated with 4.0 M HCl in dioxane (5 mL).
After standing for 10 h, the reaction was concentrated under
reduced pressure and purified by HPLC to give the title compound
(21 mg). LCMS m/z=509.5 [M+H].sup.+.
Example 1.269
Preparation of
2-(((1s,4s)-4-((4-(3-Isopropoxyphenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 85)
[1014] From a mixture of regioisomers, tert-butyl
2-(((1s,4s)-4-((4-iodo-3-methylthio-5-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate and tert-butyl
2-(((1r,4r)-4-((4-iodo-5-methylthio-3-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate, and 3-isopropoxyphenylboronic acid, the
title compound was obtained using a similar method to the one
described in Example 1.268. LCMS m/z=509.8 [M+H].sup.+.
Example 1.270
Preparation of
2-(((1s,4s)-4-((4-(2,3-Difluorophenyl)-5-(methylsulfonyl)-3-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 86)
[1015] To a solution of
2-(((1s,4s)-4-((4-(2,3-difluorophenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid (10 mg, 0.021 mmol) in
CH.sub.2Cl.sub.2 (2 mL), was added mCPBA (3.55 mg, 0.021 mmol) at
room temperature. The reaction was stirred for 3 h at room
temperature. The reaction was poured into water and extracted with
ethyl acetate. The extract was dried over MgSO.sub.4 and
concentrated under reduced pressure. The resulting residue was
purified by HPLC to give the title compound (9 mg). LCMS m/z=519.7
[M+H].sup.+.
Example 1.271
Preparation of
2-(((1s,4s)-4-((4-(2,5-Difluorophenyl)-5-(methylsulfonyl)-3-phenyl-1H-pyr-
azol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 87)
[1016] To a solution of
2-(((1s,4s)-4-((4-(2,5-difluorophenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-
-1-yl)methyl)cyclohexyl)methoxy)acetic acid (10 mg, 0.021 mmol) in
CH.sub.2Cl.sub.2 (2 mL), was added mCPBA (7.09 mg, 0.041 mmol) at
room temperature. The reaction was stirred for 3 h at room
temperature. The reaction was poured into water and extracted with
ethyl acetate. The extract was dried over MgSO.sub.4 and
concentrated under reduced pressure. The resulting residue was
purified by HPLC to give the title compound (8 mg). LCMS m/z=519.7
[M+H].sup.+.
Example 1.272
Preparation of
2-(((1s,4s)-4-((4-(3-Fluorophenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic Acid (Compound 91)
[1017] To a mixture of regioisomers, tert-butyl
2-(((1s,4s)-4-(4-iodo-3-methylthio-5-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-5-methylthio-3-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate (150 mg, 0.270 mmol), in dioxane (1 mL), were
added 3-fluorophenylboronic acid (37.7 mg, 0.270 mmol),
Pd(PPh.sub.3).sub.4 (1.56 mg, 1.348 gmol) and a 2.0 M aqueous
solution of K.sub.2CO.sub.3 (0.270 mL, 0.539 mmol) at ambient
temperature. The reaction was heated under microwave at 120.degree.
C. for 1.5 h. The reaction was poured into water and extracted with
ethyl acetate. The organic extract was dried over MgSO.sub.4 and
concentrated under reduced pressure. The resulting residue was
treated with hydrogen chloride (3.37 mL, 13.48 mmol) and stirred
for 5 h. The mixture was concentrated under reduced pressure and
purified by HPLC to give the title compound (93 mg). LCMS m/z=469.3
[M+H].sup.+.
Example 1.273
Preparation of
2-(((1s,4s)-4-((4-(2-Fluoro-3-methoxyphenyl)-5-(methylthio)-3-phenyl-1H-p-
yrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 92)
[1018] To a mixture of regioisomers, tert-butyl
2-(((1s,4s)-4-((4-iodo-3-methylthio-5-phenyl-1H-pyrazol-1-yl)methy
1)cyclohexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-5-methylthio-3-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate (150 mg, 0.270 mmol), in dioxane (1 mL), were
added 2-fluoro-3-methoxyphenylboronic acid (45.8 mg, 0.270 mmol),
Pd(PPh.sub.3).sub.4(1.557 mg, 1.348 .mu.mol) and a 2.0 M aqueous
solution of K.sub.2CO.sub.3 (0.270 mL, 0.539 mmol) at ambient
temperature. The reaction was heated under microwave at 120.degree.
C. for 1.5 h. The reaction was poured into water and extracted with
ethyl acetate. The organic extract was dried over MgSO.sub.4 and
concentrated under reduced pressure. The resulting residue was
treated with hydrogen chloride (3.37 mL, 13.48 mmol) and stirred
for 5 h. The reaction was concentrated under reduced pressure and
purified by HPLC to give the title compound (102 mg). LCMS
m/z=499.1 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.34-1.61 (m, 8H), 1.85 (m, 1H), 2.11 (s, 3H), 2.21 (m, 1H),
3.52 (d, J=7.1 Hz, 2H), 3.83 (s, 3H), 3.92 (s, 2H), 4.28 (d, J=7.4
Hz, 2H), 6.80-6.91 (m, 2H), 7.23-7.42 (m, 6H).
Example 1.274
Preparation of
2-(((1s,4s)-4-((4-(4-Fluorophenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic Acid (Compound 94)
[1019] To a mixture of regioisomers, tert-butyl
2-(((1s,4s)-4-((4-iodo-3-methylthio-5-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-(4-iodo-5-methylthio-3-phenyl-1H-pyrazol-1-yl)methyl)cycloh-
exyl)methoxy)acetate (150 mg, 0.270 mmol), in dioxane (1 mL), was
added 4-fluorophenylboronic acid (37.7 mg, 0.270 mmol),
Pd(PPh.sub.3).sub.4 (15.57 mg, 0.013 mmol) and a 2.0 M aqueous
solution of K.sub.2CO.sub.3 (74.5 mg, 0.539 mmol) at ambient
temperature. The reaction was heated under microwave at 120.degree.
C. for 1.5 h. The reaction was poured into water and extracted with
ethyl acetate. The extract was dried over MgSO.sub.4 and
concentrated under reduced pressure. The resulting residue was
treated with hydrogen chloride (3.37 mL, 13.48 mmol) and stirred
for 5 h. The reaction was concentrated under reduced pressure and
purified by HPLC to give the title compound (96 mg). LCMS m/z=469.3
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.20-1.35 (m, 8H) 1.63 (m, 1H), 1.95 (s, 3H), 2.09 (m, 1H), 3.48
(d, J=7.0 Hz, 2H), 3.79 (s, 2H), 4.10 (d, J=7.2 Hz, 2H), 6.94-7.09
(m, 9H).
Example 1.275
Preparation of
2-(((1s,4s)-4-((5-(Methylthio)-3-phenyl-4-(3-(trifluoromethyl)phenyl)-1H--
pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
96)
[1020] To a mixture of regioisomers, tert-butyl
2-(als,4s)-4-(4-iodo-3-methylthio-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohe-
xyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-5-methylthio-3-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate (150 mg, 0.270 mmol), in dioxane (1 mL), was
added 3-(trifluoromethyl)phenylboronic acid (51.2 mg, 0.270 mmol),
Pd(PPh.sub.3).sub.4 (15.57 mg, 0.013 mmol) and a 2.0 M aqueous
solution of K.sub.2CO.sub.3 (74.5 mg, 0.539 mmol) at ambient
temperature. The reaction was heated under microwave at 120.degree.
C. for 1.5 h. The reaction was poured into water and extracted with
ethyl acetate. The extract was dried over MgSO.sub.4 and
concentrated under reduced pressure. The resulting residue was
treated with hydrogen chloride (3.37 mL, 13.48 mmol) and stirred
for 5 h. The reaction was concentrated under reduced pressure and
purified by HPLC to give the title compound (85 mg). LCMS m/z=519.7
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.38-1.59 (m, 8H), 1.85 (m, 1H), 2.10 (s, 3H), 2.25 (m, 1H), 3.52
(d, J=7.0 Hz, 2H), 4.01 (s, 2H), 4.31 (d, J=7.2 Hz, 2H), 7.29-7.65
(m, 9H).
Example 1.276
Preparation of
2-(((1s,4s)-4-((4-(4-Chlorophenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-1-y-
l)methyl)cyclohexyl)methoxy)acetic Acid (Compound 97)
[1021] To a mixture of regioisomers, tert-butyl
2-(((1s,4s)-4-((4-iodo-3-methylthio-5-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-5-methylthio-3-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate (150 mg, 0.270 mmol), in dioxane (1 mL), was
added 4-chlorophenylboronic acid (42.1 mg, 0.270 mmol),
Pd(PPh.sub.3).sub.4 (15.57 mg, 0.013 mmol) and a 2.0 M aqueous
solution of K.sub.2CO.sub.3 (74.5 mg, 0.539 mmol) at ambient
temperature. The reaction was heated under microwave at 120.degree.
C. for 1.5 h. The reaction was poured into water and extracted with
ethyl acetate. The extract was dried over MgSO.sub.4 and
concentrated under reduced pressure. The resulting residue was
treated with hydrogen chloride (3.37 mL, 13.48 mmol) and was
stirred for 5 h. The reaction was concentrated under reduced
pressure and purified by HPLC to give the title compound (98 mg).
LCMS m/z=485.1 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.21-1.45 (m, 8H), 1.68 (m, 1H), 1.99 (s, 3H), 2.10 (m,
1H), 3.35 (d, J=7.1 Hz, 2H), 3.87 (s, 2H), 4.15 (d, J=7.2 Hz, 2H),
7.12-7.38 (m, 9H).
Example 1.277
Preparation of
2-(((1s,4s)-4-((5-(Methylthio)-3-phenyl-4-(thiophen-2-yl)-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methoxy)acetic Acid (Compound 108)
[1022] To a mixture of regioisomers, tert-butyl
2-(((1s,4s)-4-((4-iodo-3-methylthio-5-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-5-methylthio-3-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate (150 mg, 0.270 mmol), in dioxane (1 mL), was
added thiophen-2-ylboronic acid (34.5 mg, 0.270 mmol),
Pd(PPh.sub.3).sub.4(15.57 mg, 0.013 mmol) and a 2.0 M aqueous
solution of K.sub.2CO.sub.3 (74.5 mg, 0.539 mmol) at ambient
temperature. The reaction was heated under microwave at 120.degree.
C. for 1.5 h. The reaction was poured into water and extracted with
ethyl acetate. The extract was dried over MgSO.sub.4 and
concentrated under reduced pressure. The resulting residue was
treated with hydrogen chloride (3.37 mL, 13.48 mmol) and was
stirred for 5 h. The reaction was concentrated under reduced
pressure and purified by HPLC to give the title compound (89 mg).
LCMS m/z=457.1 [M+H].sup.+.
Example 1.278
Preparation of
2-(((1s,4s)-4-((5-(Methylthio)-3-phenyl-4-(thiophen-3-yl)-1H-pyrazol-1-yl-
)methyl)cyclohexyl)methoxy)acetic Acid (Compound 110)
[1023] To a mixture of regioisomers, tert-butyl
2-(((1s,4s)-4-((4-iodo-3-methylthio-5-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-5-methylthio-3-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate (150 mg, 0.270 mmol), in dioxane (1 mL), was
added thiophen-3-ylboronic acid (34.5 mg, 0.270 mmol),
Pd(PPh.sub.3).sub.4 (15.57 mg, 0.013 mmol) and a 2.0 M aqueous
solution of K.sub.2CO.sub.3 (74.5 mg, 0.539 mmol) at ambient
temperature. The reaction was heated under microwave at 120.degree.
C. for 1.5 h. The reaction was poured into water and extracted with
ethyl acetate. The organic extract was dried over MgSO.sub.4 and
concentrated under reduced pressure. The resulting residue was
treated with hydrogen chloride (3.37 mL, 13.48 mmol) and stirred
for 5 h. The mixture was concentrated under reduced pressure and
purified by HPLC to give the title compound (106 mg). LCMS
m/z=457.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.34-1.61 (m, 8H), 1.86 (m, 1H), 1.99 (m, 1H), 2.22 (s, 3H),
3.61 (d, J=7.1 Hz, 2H), 3.99 (s, 2H), 4.24 (d, J=7.4 Hz, 2H),
7.01-7.69 (m, 8H).
Example 1.279
Preparation of
2-(((1s,4s)-4-((4-(3-Methoxyphenyl)-5-(methylsulfinyl)-3-phenyl-1H-pyrazo-
l-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 114)
[1024] To a solution of
2-(((1s,4s)-4-((4-(3-methoxyphenyl)-5-(methylthio)-3-phenyl-1H-pyrazol-1--
yl)methyl)cyclohexyl)methoxy)acetic acid (52 mg, 0.108 mmol) in DCM
(1 mL), was added mCPBA (18.67 mg, 0.108 mmol) portionwise at room
temperature. After stirring for 30 min, the reaction was poured
into water and extracted with ethyl acetate. The extract was dried
over MgSO.sub.4 and concentrated under reduced pressure. The
resulting residue was purified by HPLC to provide the title
compound (40 mg). LCMS m/z=497.2 [M+H].sup.+.
Example 1.280
Preparation of
2-(((1s,4s)-4-((4-(3-Fluoro-5-methylphenyl)-5-(methylthio)-3-phenyl-1H-py-
razol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound 134)
[1025] To a mixture of regioisomers, tert-butyl
2-(((1s,4s)-4-((4-iodo-3-methylthio-5-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate and tert-butyl
2-(((1s,4s)-4-((4-iodo-5-methylthio-3-phenyl-1H-pyrazol-1-yl)methyl)cyclo-
hexyl)methoxy)acetate (500 mg, 0.898 mmol), in dioxane (5 mL), was
added 3-fluoro-5-methylphenylboronic acid (138 mg, 0.898 mmol),
Pd(PPh.sub.3).sub.4 (51.9 mg, 0.045 mmol) and a 2.0 M aqueous
solution of K.sub.2CO.sub.3 (248 mg, 1.797 mmol) at ambient
temperature. The reaction was heated under Microwave at 120.degree.
C. for 1.5 h. The reaction was poured into water and extracted with
ethyl acetate. The extract was dried over MgSO.sub.4 and
concentrated under reduced pressure. The resulting residue was
treated with 4.0 M hydrogen chloride (11.23 mL, 44.9 mmol) in
dioxane and stirred for 5 h. The reaction was concentrated under
reduced pressure and purified by HPLC. The lyophilized solid was
dissolved in acetonitrile (1 mL) and H.sub.2O (2 mL) and added NaOH
(14.6 mg, 0.367 mmol) in H.sub.2O (1 mL). The mixture was dried
under reduced pressure to give the title compound (185 mg). LCMS
m/z=483.4 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.30-1.65 (m, 8H), 1.76 (m, 1H), 2.18 (s, 3H), 2.21 (m, 1H),
2.35 (s, 3H), 3.45 (d, J=7.2 Hz, 2H), 3.98 (s, 2H), 4.28 (d, J=7.4
Hz, 2H), 6.85-7.08 (m, 3H), 7.21-7.35 (m, 5H).
Example 1.281
Preparation of
2-(((1r,4s)-4-(34(S)-3,4-Dihydroxybutyl)-4,5-diphenyl-1H-pyrazol-1-yl)met-
hyl)cyclohexyl)methoxy)acetic Acid (Compound 156)
Step A: Preparation of
(R)-4-(3-phenyl-1H-pyrazol-5-yl)butane-1,2-diol
[1026] To a solution of 5-(but-3-enyl)-3-phenyl-1H-pyrazole (3.0 g,
15.13 mmol) in iso-propanol (20 mL) and H.sub.2O (20 mL), was added
AD-mix-.alpha. (20.0 g) at room temperature. The reaction was
stirred for 48 h at room temperature. The reaction was poured into
saturated Na.sub.2SO.sub.3 (20 mL) and extracted with ethyl acetate
The extract was dried over MgSO.sub.4 and concentrated under
reduced pressure to give the title compound (2.45 g) as an oil,
which was used without further purification. LCMS m/z=232.9
[M+H].sup.+.
Step B: Preparation of
(R)-5-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-3-phenyl-1H-pyrazole
[1027] To a solution of
(R)-4-(3-phenyl-1H-pyrazol-5-yl)butane-1,2-diol (2.5 g, 10.76 mmol)
in acetone (50 mL), were added 2,2-dimethoxypropane (11.21 g, 108
mmol) and PTSA (0.185 g, 1.076 mmol) at room temperature. After
stirring for 3 h, the reaction was concentrated under reduced
pressure. The resulting residue was poured into water and extracted
with ethyl acetate. The extract was dried over MgSO.sub.4 and
concentrated under reduced pressure to give the title compound
without further purification. LCMS m/z=273.4 [M+H].sup.+.
Step C: Preparation of
(R)-4-bromo-5-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-3-phenyl-1H-pyraz-
ole
[1028] To a solution of
(R)-5-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-3-phenyl-1H-pyrazole
(2.3 g, 8.45 mmol) and MP-carbonate (26 g, 84.5 mmol) in
CH.sub.2Cl.sub.2 (100 mL), was added bromine (1.350 g, 8.45 mmol)
dropwise at 0.degree. C. After stirring for 1 h, MP-carbonate was
filtered off and washed with CH.sub.2Cl.sub.2. The combined organic
layer was poured into water, extracted with CH.sub.2Cl.sub.2, dried
over MgSO.sub.4, and then concentrated under reduced pressure. The
resulting residue was purified by column chromatography to give the
title compound (2.81 g) as an oil. LCMS m/z=351.2 [M+H].sup.+.
Step D: Preparation of tert-Butyl
2-(((1s,4s)-4-((4-Bromo-5-(24(R)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-3--
phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate and
tert-Butyl
2-(((1s,4s)-4-((4-Bromo-3-(2-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-5-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate as a
Mixture of Regioisomers.
[1029] To a solution of
(R)-4-bromo-5-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-3-phenyl-1H-pyraz-
ole (1.23 g, 3.50 mmol) in DMF (10 mL), was sodium hydride (0.084
g, 3.50 mmol) added at ambient temperature. After stirring for 30
min, (R)-tert-butyl
2-((4-((4-bromo-3-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-5-phenyl-1H-p-
yrazol-1-yl)methyl)cyclohexyl)methoxy)acetate (1.45 g, 3.50 mmol)
was added and the reaction was heated to 45.degree. C. After
stirring for 12 h, the reaction was poured into H.sub.2O and
extracted with ethyl acetate, which was dried over MgSO.sub.4 and
concentrated under reduced pressure. The resulting residue was
purified by column chromatography to give the title compounds (1.82
g, 1:3 ratio) as a mixture of regioisomers. LCMS m/z=591.7
[M+H].sup.+.
Step E: Preparation of
(2-(((1r,4s)-4-((3-((S)-3,4-dihydroxybutyl)-4,5-diphenyl-1H-pyrazol-1-yl)-
methyl)cyclohexyl)methoxy)acetic Acid
[1030] To a solution of regioisomers, tert-butyl
2-(((1r,4s)-4-((4-bromo-3-(2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-5-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate and
tert-butyl
2-(((1r,4s)-4-((4-bromo-5-(2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-3-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate (150 mg,
0.254 mmol), in dioxane (1 mL), were added phenylboronic acid (30.9
mg, 0.254 mmol), Pd(PPh.sub.3).sub.4 (14.65 mg, 0.013 mmol) and a
2.0 M aqueous solution of K.sub.2CO.sub.3 (70.1 mg, 0.507 mmol) at
ambient temperature. The reaction was heated under microwave at
120.degree. C. for 1.5 h. After cooling to room temperature, the
reaction was poured into water and extracted with ethyl acetate.
The organic extract was dried over MgSO.sub.4 and concentrated
under reduced pressure. The residue was treated with 4.0 M HCl in
dioxane (5 mL). After standing for 10 h, the reaction was
concentrated under reduced pressure and purified by HPLC to give
the title compound (12 mg). LCMS m/z=493.5 [M+H].sup.+
Example 1.282
Preparation of
2-(((1r,4s)-4-((5-((S)-3,4-Dihydroxybutyl)-3,4-diphenyl-1H-pyrazol-1-yl)m-
ethyl)cyclohexyl)methoxy)acetic Acid (Compound 157)
[1031] From a mixture of regioisomers, tert-butyl
2-(((1r,4s)-4-((4-bromo-3-(2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-5-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate and
tert-butyl
2-(((1r,4s)-4-(4-bromo-5-(2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-3--
phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate, and
phenylboronic acid, the title compound was obtained by using a
similar method to the one described in Example 1.281. LCMS
m/z=493.7 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.30-1.78 (m, 10H), 1.86 (m, 1H), 2.10 (s, 1H), 2.63 (m, 1H),
2.71 (m, 1H), 3.10 (m, 2H), 3.12-3.22 (m, 1H), 3.35 (d, J=7.2 Hz,
2H), 3.95 (s, 2H), 4.02 (d, J=7.3 Hz, 2H), 7.02-7.35 (m, 10H).
Example 1.283
Preparation of
2-(((1r,4s)-4-((5-((S)-3,4-Dihydroxybutyl)-4-(3-fluorophenyl)-3-phenyl-1H-
-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
158)
[1032] To a solution of regioisomers, tert-butyl
2-(((1r,4s)-4-((4-bromo-3-(2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-5-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate and
tert-butyl
2-(((1r,4s)-4-((4-bromo-5-(2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-3-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate (150 mg,
0.254 mmol), in dioxane (1 mL), were added 3-fluorophenylboronic
acid (35.5 mg, 0.254 mmol), Pd(PPh.sub.3).sub.4 (14.65 mg, 0.013
mmol) and a 2.0 M aqueous solution of K.sub.2CO.sub.3 (70.1 mg,
0.507 mmol) at ambient temperature. The reaction was heated under
microwave at 120.degree. C. for 1.5 h. The reaction was poured into
water and extracted with ethyl acetate. The extract was dried over
MgSO.sub.4 and concentrated under reduced pressure. The residue was
treated with 4.0 M HCl in dioxane. After stirring for 5 h, the
reaction was concentrated under reduced pressure and purified by
HPLC to give the title compound (45 mg). LCMS m/z=511.5
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.10-1.77 (m, 10H), 1.78 (m, 1H), 1.98 (m, 1H), 2.72 (m, 1H), 2.80
(m, 1H), 3.20-3.40 (m, 3H), 3.38 (d, J=7.2 Hz, 2H), 3.97 (s, 2H),
3.99 (d, J=7.3 Hz, 2H), 7.15-7.38 (m, 9H).
Example 1.284
Preparation of
2-(((1r,4s)-4-((4-(3,4-Difluorophenyl)-3-((S)-3,4-dihydroxybutyl)-5-pheny-
l-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
159)
[1033] To a solution of regioisomers, tert-butyl
2-(((1r,4s)-4-((4-bromo-3-(2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-5-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate and
tert-butyl
2-(((1r,4s)-4-((4-bromo-5-(2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-3-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate (150 mg,
0.254 mmol), in dioxane (1 mL), were added
3,4-difluorophenylboronic acid (40.0 mg, 0.254 mmol),
Pd(PPh.sub.3).sub.4 (14.65 mg, 0.013 mmol) and a 2.0 M aqueous
solution of K.sub.2CO.sub.3 (70.1 mg, 0.507 mmol) at ambient
temperature. The reaction was heated under microwave at 120.degree.
C. for 1.5 h. After cooling to room temperature, the reaction was
poured into water and extracted with ethyl acetate. The extract was
concentrated under reduced pressure and the resulting residue was
treated with 4.0 M HCl in dioxane (5 mL). After standing for 10 h,
the reaction was concentrated under reduced pressure and purified
by HPLC to give the title compound (12 mg). LCMS m/z=529.7
[M+H].sup.+.
Example 1.285
Preparation of
2-(((1r,4s)-4-((4-(3,4-Difluorophenyl)-5-((S)-3,4-dihydroxybutyl)-3-pheny-
l-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
160)
[1034] From regioisomers, tert-butyl
2-(((1r,4s)-4-((4-bromo-3-(2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-5-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate and
tert-butyl
2-(((1r,4s)-4-((4-bromo-5-(2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-3-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate, and
3,4-difluorophenylboronic acid, the title compound was obtained by
using similar method to the one described in Example 1.284. LCMS
m/z=529.5 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.10-1.77 (m, 10H), 1.75 (m, 1H), 2.10 (m, 1H), 2.70 (m, 1H),
2.75 (m, 1H), 3.15 (m, 1H), 3.21 (m, 1H), 3.32 (m, 1H), 3.35 (d,
J=7.2 Hz, 2H), 3.97 (s, 2H), 3.98 (d, J=7.2 Hz, 2H), 6.95 (m, 1H),
7.14-7.41 (m, 7H).
Example 1.286
Preparation of
2-(((1r,4s)-4-((4-(3-Chlorophenyl)-5-((S)-3,4-dihydroxybutyl)-3-phenyl-1H-
-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
162)
[1035] To a solution of regioisomers, tert-butyl
2-(((1r,4s)-4-((4-bromo-3-(2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-5-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate and
tert-butyl
2-(((1r,4s)-4-(4-bromo-5-(2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-3--
phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate (150 mg,
0.254 mmol), in dioxane (1 mL), were added 3-chlorophenylboronic
acid (39.7 mg, 0.254 mmol), Pd(PPh.sub.3).sub.4 (14.65 mg, 0.013
mmol) and a 2.0 M aqueous solution of K.sub.2CO.sub.3 (70.1 mg,
0.507 mmol) at ambient temperature. The reaction was heated under
microwave at 120.degree. C. for 1.5 h. The reaction was poured into
water and extracted with ethyl acetate. The extract was dried over
MgSO.sub.4 and concentrated under reduced pressure. The residue was
treated with 4.0 M HCl in dioxane (5 mL). After stirring for 5 h,
the reaction was concentrated under reduced pressure and purified
by HPLC to give the title compound (65 mg). LCMS m/z=528.3
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.31-1.65 (m, 10H), 1.80 (m, 1H), 2.12 (m, 1H), 2.72 (m, 1H), 2.80
(m, 1H), 3.20 (m, 1H), 3.25 (m, 1H), 3.42 (m, 1H), 3.45 (d, J=7.2
Hz, 2H), 4.00 (s, 2H), 4.05 (d, J=7.2 Hz, 2H), 7.13-7.42 (m,
9H).
Example 1.287
Preparation of
2-(((1s,4s)-4-((5-((R)-3,4-Dihydroxybutyl)-4-(3-fluorophenyl)-3-phenyl-1H-
-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
169)
[1036] To a solution of regioisomers, tert-butyl
2-(((1r,4s)-4-((4-bromo-3-(2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-5-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate and
tert-butyl
2-(((1r,4s)-4-((4-bromo-5-(2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-3-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate (150 mg,
0.254 mmol), in dioxane (1 mL), were added 3-fluorophenylboronic
acid (35.5 mg, 0.254 mmol), Pd(PPh.sub.3).sub.4 (14.65 mg, 0.013
mmol) and a 2.0 M aqueous solution of K.sub.2CO.sub.3 (70.1 mg,
0.507 mmol) at ambient temperature. The reaction was heated under
microwave at 120.degree. C. for 1.5 h. The reaction was poured into
water and extracted with ethyl acetate. The organic extract was
dried over MgSO.sub.4 and concentrated under reduced pressure. The
residue was treated with 4.0 M HCl in dioxane (5 mL). After
stirring for 5 h, the reaction was concentrated under reduced
pressure and purified by HPLC to give the title compound (89 mg).
LCMS m/z=511.4 [M+H].sup.+.
Example 1.288
Preparation of
2-(((1s,4s)-4-((4-(3,4-Difluorophenyl)-5-((R)-3,4-dihydroxybutyl)-3-pheny-
l-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
170)
[1037] To a solution of regioisomers, tert-butyl
2-(((1r,4s)-4-((4-bromo-3-(2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-5-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate and
tert-butyl
2-(((1r,4s)-4-((4-bromo-5-(2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-3-
-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate (150 mg,
0.254 mmol), in dioxane (1 mL), was added 3,4-difluorophenylboronic
acid (40.0 mg, 0.254 mmol), Pd(PPh.sub.3).sub.4 (14.65 mg, 0.013
mmol) and a 2.0 M aqueous solution of K.sub.2CO.sub.3 (70.1 mg,
0.507 mmol) at ambient temperature. The reaction was heated under
microwave at 120.degree. C. for 1.5 h. The reaction was extracted
with ethyl acetate and concentrated under reduced pressure. The
residue was treated with 4.0 M HCl in dioxane and was stirred for 5
h. The reaction was concentrated under reduced pressure and
purified by HPLC to give the title compound (72 mg). LCMS m/z=529.3
[M+H].sup.+.
Example 1.289
Preparation of
2-(((1s,4s)-4-((4-(3-Chlorophenyl)-54(R)-3,4-dihydroxybutyl)-3-phenyl-1H--
pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic Acid (Compound
171)
[1038] To a solution of regioisomers, tert-butyl
2-(((1r,4s)-4-((4-bromo-3-(2-((S)-2,2-dimethyl-1,3-dioxolan-4-yOethyl)-5--
phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate and
tert-butyl
2-(((1r,4s)-4-(4-bromo-5-(24(S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-3-p-
henyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate (150 mg,
0.254 mmol), in dioxane (1 mL), were added 3-chlorophenylboronic
acid (39.7 mg, 0.254 mmol), Pd(PPh.sub.3).sub.4 (14.65 mg, 0.013
mmol) and a 2.0 M aqueous solution of K.sub.2CO.sub.3 (70.1 mg,
0.507 mmol) at ambient temperature. The reaction was heated under
microwave at 120.degree. C. for 1.5 h. The reaction was extracted
with ethyl acetate and concentrated under reduced pressure. The
residue was treated with 4.0 M HCl in dioxane and stirred for 5 h.
The reaction was concentrated under reduced pressure and purified
by HPLC to give the title compound (85 mg). LCMS m/z=528.3
[M+H].sup.+.
Example 1.290
Preparation of
2-(((1s,4s)-4-((3-(Cyanomethylthio)-4,5-diphenyl-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetic Acid (Compound 183)
Step A: Preparation of
2-(3,4-Diphenyl-1H-pyrazol-5-ylthio)acetonitrile
[1039] To a solution of 3,4-diphenyl-1H-pyrazole-5(4H)-thione (0.49
g, 1.981 mmol) in DMF (5 mL), were added 2-bromoacetonitrile (0.253
g, 1.981 mmol) and K.sub.2CO.sub.3 (0.274 g, 1.981 mmol) at room
temperature. After stirring for 2 h, the reaction was poured into
water and extracted with ethyl acetate. The organic extract was
dried over MgSO.sub.4 and concentrated under reduced pressure. The
residue was purified by column chromatography to give the title
compound (0.52 g). LCMS m/z=292.1
Step B: Preparation of
(2-(((1s,4s)-4-(3-(Cyanomethylthio)-4,5-diphenyl-1H-pyrazol-1-yl)methyl)c-
yclohexyl)methoxy)acetic Acid
[1040] To a solution of
2-(3,4-diphenyl-1H-pyrazol-5-ylthio)acetonitrile (330 mg, 1.13
mmol) in DMF (2 mL), was added sodium hydride (27.2 mg, 1.133 mmol)
in 0.degree. C. After stirring for 10 min, tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (467 mg,
1.13 mmol) was added and the reaction was warmed to 40.degree. C.
After stirring for 12 h, the reaction was poured into water and
extracted with ethyl acetate. The extract was dried over
MgSO.sub.4, concentrated under reduced pressure, and then treated
with 4.0 M HCl in dioxane (5 mL). After stirring for 8 h, the
mixture was concentrated under reduced pressure and purified by
HPLC to give the title compound (78 mg). LCMS m/z=476.2
[M+H].sup.+.
Example 1.291
Preparation of
2-(((1s,4s)-4-((5-(2-Methoxyethylthio)-3,4-diphenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic Acid (Compound 189)
[1041] From 5-(2-methoxyethylthio)-3,4-diphenyl-1H-pyrazole and
tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate, the title
compound was obtained by using similar method to the one described
in Example 1.263. LCMS m/z=495.7 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.35-1.52 (m, 8H), 1.85 (m, 1H), 2.31 (m,
1H), 2.43 (t, J=2.5 Hz, 2H), 2.61 (t, J=2.5 Hz, 2H), 3.05 (s, 3H),
3.46 (d, J=7.1 Hz, 2H), 3.98 (s, 2H), 4.31 (d, J=7.2 Hz, 2H),
7.31-7.54 (m, 10H).
Example 1.292
Preparation of
2-(((1s,4s)-4-((3-(2-Ethoxyethylthio)-4,5-diphenyl-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetic Acid (Compound 185)
Step A: Preparation of
5-(2-Ethoxyethylthio)-3,4-diphenyl-1H-pyrazole
[1042] To a solution of 3,4-diphenyl-1H-pyrazole-5(4H)-thione (0.5
g, 1.981 mmol) in DMF (5 mL), were added 1-bromo-2-ethoxyethane
(0.303 g, 1.981 mmol) and K.sub.2CO.sub.3 (0.274 g, 1.981 mmol) at
room temperature. After stirring for 4 h, the reaction was poured
into water and extracted with ethyl acetate, which was dried over
MgSO.sub.4 and concentrated under reduced pressure. The residue was
purified by column chromatography to give the title compound (0.45
g). LCMS m/z=343.5 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.20 (t, J=7.1 Hz, 3H), 3.25 (m, 2H), 3.45 (m, 2H),
4.25 (q, J=7.1 Hz, 2H), 7.25-7.56 (m, 10H), 13.0 (s, 1H).
Step B: Preparation of
(2-(((1s,4s)-4-((3-(2-Ethoxyethylthio)-4,5-diphenyl-1H-pyrazol-1-yl)methy-
l)cyclohexyl)methoxy)acetic Acid
[1043] To a solution of
5-(2-ethoxyethylthio)-3,4-diphenyl-1H-pyrazole (320 mg, 0.986 mmol)
in DMF (2 mL), was added sodium hydride (23.67 mg, 0.986 mmol) at
0.degree. C. After stirring for 10 min, tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate (407 mg,
0.986 mmol) was added and the reaction was warmed to 40.degree. C.
After stirring for 12 h, the reaction was poured into water and
extracted with ethyl acetate. The extract was dried over MgSO.sub.4
and concentrated under reduced pressure. The resulting residue was
treated with 4.0 M HCl in dioxane (5 mL) and stirred for 8 h. The
reaction was concentrated under reduced pressure and purified by
HPLC to give the title compound (70 mg). LCMS m/z=509.5
[M+H].sup.+.
Example 1.293
Preparation of
2-(((1s,4s)-4-((5-(2-Ethoxyethylthio)-3,4-diphenyl-1H-pyrazol-1-yl)methyl-
)cyclohexyl)methoxy)acetic Acid (Compound 186)
[1044] From 5-(2-ethoxyethylthio)-3,4-diphenyl-1H-pyrazole and
tert-butyl
2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate, the title
compound was obtained by using a similar method to the one
described in Example 1.292. LCMS m/z=509.6 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 1.01 (t, J=7.1 Hz, 3H),
1.35-1.52 (m, 8H), 1.85 (m, 1H), 2.25 (m, 1H), 2.41 (q, J=7.1 Hz,
2H), 2.60 (t, J=5.0 Hz, 2H), 3.25 (t, J=5.0 Hz, 2H), 3.45 (d, J=7.1
Hz, 2H), 4.00 (s, 2H), 4.35 (d, J=7.2 Hz, 2H), 7.25-7.53 (m,
10H).
Example 1.294
Preparation of
2-(((1s,4s)-4-((5-(3-Hydroxypropylthio)-3,4-diphenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid (Compound 187)
Step A: Preparation of
3,4-Diphenyl-5-(2-(tetrahydro-2H-pyran-2-yloxy)ethylthio)-1H-pyrazole
[1045] To a solution of
3-(4-bromo-3-phenyl-1H-pyrazol-5-yl)propan-1-ol (1.0 g, 3.56 mmol)
in THF (10 mL), was added 3,4-dihydro-2H-pyran (0.898 g, 10.67
mmol) followed by PTSA (0.061 g, 0.356 mmol) at room temperature.
After stirring for 12 h, the reaction was poured into water and
extracted with ethyl acetate. The extract was dried over MgSO.sub.4
and concentrated under reduced pressure to give the title compound
(1.12 g). LCMS m/z=381.2 [M+H].sup.+.
Step B: Preparation of
(2-(((1s,4s)-4-((5-(2-Hydroxyethylthio)-3,4-diphenyl-1H-pyrazol-1-yl)meth-
yl)cyclohexyl)methoxy)acetic Acid
[1046] To a solution of
3,4-diphenyl-5-(3-(tetrahydro-2H-pyran-2-yloxy)propylthio)-1H-pyrazole
(120 mg, 0.304 mmol) in DMF (2 mL), was added sodium hydride (7.30
mg, 0.304 mmol) at 0.degree. C. After stirring for 10 min,
tert-butyl 2-(((1s,4s)-4-(tosyloxymethyl)cyclohexyl)methoxy)acetate
(125 mg, 0.304 mmol) was added and the reaction was warmed to
40.degree. C. After stirring for 12 h, the reaction was poured into
water and extracted with ethyl acetate. The extract was
concentrated under reduced pressure and treated with 4.0 M HCl
dioxane (5 mL) for 8 h. The mixture was concentrated under reduced
pressure and purified by HPLC to give the title compound (105 mg).
LCMS m/z=495.6 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.35-1.52 (m, 10H), 1.83 (m, 1H), 2.22 (m, 1H), 2.46
(t, J=5.0 Hz, 2H), 3.22 (t, J=5.0 Hz, 2H), 3.50 (d, J=7.1 Hz, 2H),
3.91 (s, 2H), 4.30 (d, J=7.2 Hz, 2H), 7.23-7.50 (m, 10H).
Example 2
Homogeneous Time-Resolved Fluorescence (HTRF.RTM.) Assay For Direct
cAMP Measurement
[1047] Compounds were screened for agonists of the human
prostacyclin (PGI2) receptor using the HTRF.RTM. assay for direct
cAMP measurement (Gabriel et al., ASSAY and Drug Development
Technologies, 1:291-303, 2003) and recombinant CHO-K1 cells stably
transfected with human prostacyclin receptor. CHO-K1 cells were
obtained from ATCC.RTM. (Manassas, Va.; Catalog #CCL-61). An
agonist of the prostacyclin receptor was detected in HTRF.RTM.
assay for direct cAMP measurement as a compound which increased
cAMP concentration. HTRF.RTM. assay also was used to determine
EC.sub.50 values for prostacyclin receptor agonists.
[1048] Principle of the assay: The HTRF.RTM. assay kit was
purchased from Cisbio-US, Inc. (Bedford, Mass.; Catalog #62AM4PEC).
The HTRF.RTM. assay supported by the kit is a competitive
immunoassay between endogenous cAMP produced by the CHO-K1 cells
and tracer cAMP labeled with the dye d2. The tracer binding is
visualized by a monoclonal anti-cAMP antibody labeled with
Cryptate. The specific signal (i.e., fluorescence resonance energy
transfer, FRET) is inversely proportional to the concentration of
unlabeled cAMP in the standard or sample.
[1049] Standard curve: The fluorescence ratio (665 nm/620 nm) of
the standards (0.17 to 712 nM cAMP) included in the assay was
calculated and used to generate a cAMP standard curve according to
the kit manufacturer's instructions. The fluorescence ratio of the
samples (test compound or compound buffer) was calculated and used
to deduce respective cAMP concentrations by reference to the cAMP
standard curve.
[1050] Setup of the assay: The HTRF.RTM. assay was carried out
using a two-step protocol essentially according to the kit
manufacturer's instructions, in 20 .mu.L total volume per well in
384-well plate format (ProxiPlates; PerkinElmer, Fremont, Calif.;
catalog #6008280). To each of the experimental wells was
transferred 3000 recombinant CHO-K1 cells in 5 .mu.L assay buffer
(phosphate buffered saline containing calcium chloride and
magnesium chloride (Invitrogen, Carlsbad, Calif.; catalog #14040)
supplemented with IBMX (100 .mu.M) and rolipram (10 .mu.M)
(phosphodiesterase inhibitors; Sigma-Aldrich, St. Louis, Mo.;
catalog #15879 and catalog #R6520, respectively) and 0.1% bovine
serum albumin (BSA) fraction V (Sigma-Aldrich; catalog #A3059)),
followed by test compound in 5 .mu.L assay buffer or 5 .mu.L assay
buffer. The plate was then incubated at room temperature for 1 h.
To each well was then added 5 .mu.L cAMP-d2 conjugate in lysis
buffer and 5 .mu.L Cryptate conjugate in lysis buffer according to
the kit manufacturer's instructions. The plate was then further
incubated at room temperature for 1 h, after which the assay plate
was read.
[1051] Assay readout: The HTRF.RTM. readout was accomplished using
a PHERAstar (BMG LABTECH Inc., Durham, N.C.) or EnVision.TM.
(PerkinElmer, Fremont Calif.) microplate reader.
[1052] Certain compounds of the present invention and their
corresponding activity values are shown in TABLE B.
TABLE-US-00002 TABLE B human PGI2 receptor Compound No. EC.sub.50
(nM) (HTRF.RTM.) 90 7 111 16 184 11 198 2
[1053] Certain other compounds of the invention had activity values
ranging from about 1.3 nM to about 5 .mu.M in this assay.
Example 3
Human Platelet Aggregation Inhibition Test
[1054] Blood collected from healthy human volunteers in aqueous
trisodium citrate solution was centrifuged at 150 g for 15 min and
the upper layer was recovered to obtain platelet-rich plasma (PRP).
The residual blood was centrifuged at 3000 g for 10 min and the
supernatant was collected as platelet-poor plasma (PPP). Platelet
concentration in the PRP was determined using the Z series Beckman
Coulter particle counter (Beckman, Fullerton, Calif.) and adjusted
to 250,000 platelets/.mu.L using PPP. 480 .mu.L of PRP was
pre-incubated at 37.degree. C. and stirred at 1200 rpm with 10
.mu.L aqueous test compound solution for 1 min prior to induction
of aggregation by the addition of 10 .mu.L of aqueous adenosine
diphosphate (ADP) solution to adjust the final ADP concentration in
the PRP to 1.times.10.sup.-5 M. The maximal amplitude of
aggregation response within 3 min was determined and measured in
triplicate using the Chronolog model 490 aggregometer (Chrono-log
Corp., Havertown, Pa.). Percent inhibition of aggregation was
calculated from the maximum decrease in optical density of the
control (addition of water in place of the test compound solution)
sample and of the samples containing test compound. The test
compound was added to adjust the final concentration to the range
10.sup.-9 to 10.sup.-4 M, and IC.sub.50 values were determined by
inhibition percentage of aggregation at each concentration. The
results are shown in Table C.
TABLE-US-00003 TABLE C Compound No. human PRP IC.sub.50 (nM) 184 20
111 28 146 70 135 220
[1055] Certain other compounds of the invention had activity values
ranging from about 10.3 nM to about 810 nM in this assay.
[1056] It is apparent that the compounds of the present invention
markedly inhibit platelet aggregation in human PRP.
Example 4
Rat Model of Pulmonary Arterial Hypertension
[1057] Animals: Male Wistar rats (100-150 g at start of study)
(Charles River Laboratories, Wilmington, Mass.) were housed two per
cage and maintained in a humidity-(40-60%) and
temperature-(68-72.degree. F.) controlled facility on a 12 hr:12 hr
light/dark cycle (lights on at 6:30 am) with free access to food
(Harlan Teklad, Orange Calif., Rodent Diet 8604) and water. Rats
were allowed one week of habituation to the animal facility before
testing.
[1058] Rat monocrotaline model: The rat monocrotaline (MCT) model
is a standard and well-accepted model of pulmonary arterial
hypertension. MCT induces acute pulmonary endothelial damage
associated with pulmonary vascular inflammation. Subsequently,
pulmonary artery smooth muscle cells proliferate, occluding small
pulmonary vessels and leading to severe pulmonary arterial
hypertension including right ventricular hypertrophy. (See, e.g.,
Schermuly et al., Circ. Res., 2004, 94:1101-1108.)
[1059] Rats were randomly given a single subcutaneous injection of
either 60 mg/kg MCT (Sigma, St. Louis, Mo.) or 0.9% saline (sham)
and assigned to receive oral administration of 20% hydroxypropyl
beta-cyclodextrin (vehicle) or test compound (30 mg/kg; FIGS. 1 and
2). 10-11 rats were used per treatment group. 24 h following MCT
administration, test compound or vehicle was administered by oral
gavage twice a day for 21 consecutive days. Heart chamber weights
were measured on Day 22. Rats were anesthetized with
intraperitoneal pentobarbital (50 mg/kg), the chest cavity was
opened and the heart was excised. The right ventricle was dissected
free from the septum and left ventricle and both parts were
weighed. The ratio of right ventricular (RV) weight to left
ventricle plus septum (LV+S) weight (this ratio is indicated as
"RV/(LV+S)" in FIGS. 1 and 2) was calculated as an index of the
hypertrophic response to the induced pulmonary arterial
hypertension and, as such, as an index of a test compound's
therapeutic efficacy for pulmonary arterial hypertension.
[1060] It is apparent from inspection of FIGS. 1 and 2 that oral
administration of Compounds 14 and 31 inhibited the hypertrophic
response to the induced pulmonary arterial hypertension and, as
such, evidenced therapeutic efficacy for pulmonary arterial
hypertension.
[1061] Those skilled in the art will recognize that various
modifications, additions, substitutions and variations to the
illustrative examples set forth herein can be made without
departing from the spirit of the invention and are, therefore,
considered within the scope of the invention. All documents
referenced above, including, but not limited to, printed
publications and provisional and regular patent applications, are
incorporated herein by reference in their entirety.
* * * * *